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Summary 
 
 
The focus of this PhD thesis is the development of a novel strategy for specific and efficient delivery of 
gene expression systems for targeted genome editing. To mediate efficient transgene expression only 
inside the nuclei of the cells of interest, an optimization of every step along the gene delivery route as 
outlined in the following is absolutely mandatory:  
1. Specific delivery to the target cells  
2. Efficient translocation to the nucleus  
3. Expression and functionality of the gene product 
To structure this comprehensive research project, the thesis is divided into three individually addressed 
work packages according to the delivery route but in a strategic reasonable order.  
First of all, the functionality of the gene expression system must be quantifiable in a robust and simple 
manner to enable optimization of the preceding steps. For the delivery of reporter genes various robust 
methods for quantification exist like GFP expression and its evaluation via flow cytometry for example. 
However, the final goal of this thesis is the delivery of targeted genome editing systems like 
CRISPR/Cas9. Quantification of gene editing is often combined with time consuming assays or is based 
on low overall numbers. To address this bottleneck, an assay for robust quantification of a huge number 
of individual genome editing events has been developed. This assay exploits cell survival and 
subsequent colony formation due to gain of toxin resistance for the quantification of transgene 
integration and homozygous gene inactivation. For transgene integration, puromycin-N-
acetyltransferase gene is the transgene of choice, as integration events can be quantified by cell survival 
and colony formation after puromycin selection. Homozygous gene inactivation is quantified by 
targeting of genes essential for diphthamide synthesis, followed by diphtheria toxin selection and 
quantification of toxin resistant survivor cell colonies. Highlight of this assay is the determination of the 
absolute editing frequencies mediated by CRISPR/Cas9 and the demonstration that CRISPR/Cas9 
editing efficiencies are comparable to the efficiencies of zinc finger nucleases. On the basis of the 
determined frequencies it is reasoned that site specific integration events with an absolute ratio of 0.12% 
are too infrequent for therapeutic application. Homozygous knock out with 6% frequency on the other 
hand might be considered for therapy if not every cell needs to be addressed and is therefore selected in 
this thesis for further development of a targeted gene delivery system. All in all, this assay provides the 
basis for the evaluation of the developed gene delivery system.  
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Specific transgene expression exclusively in the tissue or cells of interest presupposes membrane 
binding and internalization predominantly at the target cells, the focus of the second work package. Such 
discrimination between target and non-target cells can be realized by antibodies or antibody derivatives. 
For flexible coupling of payloads like nucleic acids with ability for intracellular release, bispecific 
hapten binding antibody formats are used. These antibody derivatives comprise specificity against the 
cell surface antigen and a second specificity against a hapten like biotin or digoxigenin. Haptenylation 
of DNA or DNA binding entities generates a flexible platform with ability to compare various antibody 
formats or payloads. The design, production, purification and characterization are the fundamental steps 
for the development of every antibody or antibody derivative and are described with the novel hapten 
binding TriFab format. Furthermore, the broad applicability of the hapten system is demonstrated by 
targeted delivery of various payloads like small molecules, nucleic acids or proteins by the TriFab in 
comparison to the bivalent and bispecific antibody format. The characteristics of the different antibody 
formats and the rationale of particular engineering aspects are discussed.  
After demonstration that the hapten system is suitable for intracellular delivery of various compounds, 
compatibility of this system for gene delivery is investigated. To facilitate nuclear delivery of plasmid 
DNA, this large double stranded circular nucleic acid is organized into plasmid chromatin via histone 
assembly by salt gradient dialysis. The properties favored for efficient and functional translocation of 
plasmid DNA into the nucleus like improved nuclease resistance and charge reduction are demonstrated 
after generation of high quality chromatin. The connection between chromatin and hapten binding 
antibody derivatives was realized by a DNA binding peptide (CPXM2 peptide) derived from human 
carboxypeptidase-like protein X2 (CPXM2 protein). Comparison of TriFab and bivalent bispecific 
antibodies in combination with the haptenylated DNA binding peptide outlined that the latter format has 
greater affinity to DNA most likely due to bivalent peptide / DNA interaction and is therefore chosen 
for further characterization and development. It could be demonstrated that this antibody-peptide 
complex is able to target plasmid DNA and plasmid chromatin with similar efficiency and high 
specificity to the target cells. The impact of histone mediated DNA condensation was pointed out by 
comparison of reporter gene expression. Plasmid DNA targeting did not result in a significant number 
of transgene expressing cells, whereas targeted plasmid chromatin generated high portions of reporter 
gene expressing cells. Finally, the initially developed assay is used to evaluate the compatibility of 
plasmid chromatin targeting with CRISPR/Cas9 genome editing systems. The significant number of cell 
clones with homozygous target gene knock out proves the applicability of this system for efficient 
delivery of targeted genome editing. Moreover, the high specificity of the delivery system to the target 
cells might open up a novel strategy for systemic application of a genome editing system for gene 
therapy. In conclusion, this thesis describes the development of a novel system for specific and efficient 
gene delivery with components exclusively of human or mammalian origin. 
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Zusammenfassung 
 
 
Die vorliegende Doktorarbeit befasst sich mit der Entwicklung eines Systems für die gezielte 
Verabreichung von Transgenen zur spezifischen, therapeutischen Genom-Editierung. Damit ein 
Gentherapeutikum systemisch optimal wirksam ist, müssen drei Schritte gezielt adressiert werden: 
1. Spezifische Aufnahme des Transgens allein durch die Zielzelle 
2. Effiziente Translokation des Transgens in den Nukleus 
3. Expression und Funktionalität des therapeutischen Genprodukts  
Auf diese Weise wurde auch das Forschungsprojekt strukturiert, wodurch drei Arbeitspakete entstanden, 
die nacheinander adressiert werden konnten. Die Reihenfolge der Bearbeitung wurde strategisch so 
gelegt, dass zunächst die Funktionalität des Genprodukts quantitativ bestimmt werden konnte, um 
anschließend die ersten beiden Schritte validieren zu können. Diese Quantifizierung ist im Falle von 
Reportergenen relativ einfach, da viele verschiedene und robuste Methoden etabliert sind. Ein Beispiel 
ist die Expression des GFP Reportergens und die schnelle und präzise Quantifizierung der GFP 
exprimierenden Zellen mittels Durchflusszytometrie. In dieser Arbeit soll final jedoch ein System zur 
Genom-Editierung wie beispielsweise das CRISPR/Cas9 System verwendet werden. Für die 
Quantifzierung von Genom-Editierung sind einfache und robuste Methoden bislang jedoch kaum 
vorhanden. Vielmehr sind die quantitativen Auswertungen der verschiedenen Editierungsereignisse 
meist verbunden mit zeitintensiven Methoden und basieren meist auf eher geringen absoluten Zahlen. 
Um diesen Bedarf zu decken wurde im Zuge dieser Arbeit zunächst eine Methode entwickelt, mit der 
Genom-Editierung basierend auf einer hohen Anzahl an Events robust quantifiziert werden kann. Diese 
Methode basiert auf das Vermitteln von Toxinresistenzen durch Genom-Editierung. Zellen, die durch 
Genom-Editierung Toxin resistent wurden, überleben die Behandlung mit entsprechenden Toxinen und 
wachsen zu Kolonien heran, die am Ende quantifiziert werden können. Für die Quantifizierung der 
Geninaktivierung wurden Genomeditierungssysteme gegen Gene gerichtet, die essentiell für die 
Synthese von Diphthamid sind. Das homozygote Inaktivieren dieser Gene führt zur Resistenz gegen 
Diphtherie Toxin, wodurch diese Editierungsereignisse durch Toxinselektion und Kolonieformierung 
quantifiziert werden können. Die genomische Integration eines Transgens für Puromyzin-N-
Azetyltransferase vermittelt hingegen permanente Resistenz gegen Puromyzin, wodurch 
Integrationsevents duch Puromyzinselektion quantifiziert werden können. Besonders hervorzuheben bei 
dieser Methode ist, dass dadurch ermöglich wird absolute Häufigkeiten der verschiedenen 
Editierungsevents vermittelt durch CRISPR/Cas9 zu bestimmen und auch mit weiteren Systemen wie 
Zinkfinger Nukleasen zu vergleichen. Des Weiteren ist mit dieser Methode gezeigt, dass Zinkfinger 
Nukleasen Genom-Editierung ähnlich effizient vermitteln wie das CRISPR/Cas9 System. Zudem wurde 
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auf Grund dieser Häufigkeiten schnell ersichtlich, dass ortsgerichtete Integration von Transgenen mit 
einer Häufigkeit von 0.12% zu selten auftritt, um therapeutisch Anwendung zu finden. Homozygote 
Geninaktivierung mit einer Wahrscheinlichkeit von 6% hingegen kann durchaus für eine therapeutische 
Anwendung in Erwägung gezogen werden, vor Allem wenn nicht jede Zielzelle erfolgreich editiert 
werden muss um eine therapeutische Wirkung zu erzielen. Auf Grund der beschriebenen Vorteile und 
der umfangreichen Validierung wird diese Methode für die Entwicklung und Charakterisierung eines 
effizienten und gerichteten Gentherapiesystems verwendet.  
Spezifische Transgenexpression durch das Zielgewebe oder die Zielzellen ist hauptsächlich dadurch 
bedingt, dass das Transgen vornehmlich an diesen Zellen bindet und von diesen internalisiert wird. Diese 
Unterscheidung zwischen Ziel- und Nicht-Zielzelle kann durch Antikörper beziehungsweise 
Antikörperderivate ermöglicht werden. Dafür und für die flexible Verbindung von Antikörper und die 
Entität, die spezifisch zur Zielzelle gebracht werden soll, wurden bis-spezifische, Hapten bindende 
Antikörperformate verwendet. Diese Antikörperderivate binden mit einer Spezifität das 
Zelloberflächenantigen und mit einer weiteren Spezifität ein Hapten, beispielsweise Biotin oder 
Digoxigenin. In Kombination mit haptenylierter Nukleinsäure oder haptenylierten DNA bindenden 
Entitäten wurde ein flexibles System generiert, dass ein einfaches Austauschen von Antikörper und 
Nukleinsäure sowie das Vergleichen von beispielsweise verschiedenen Antikörperformaten ermöglicht. 
Anhand des TriFab Antikörperderivats wurden die grundlegenden Schritte der Antikörperentwicklung 
beschrieben, nämlich Design, Produktion, Aufreinigung und Charakterisierung. Die spezifische 
Aufnahme verschiedenster haptenylierter Moleküle, wie niedermolekulare chemische Substanzen, 
Nukleinsäuren oder Proteine durch den TriFab im Vergleich zu bivalenten bis-spezifischen 
Antikörperderivaten zeigt die vielfältigen Anwendungsmöglichkeiten des Hapten-Systems. Des 
Weiteren wurden Charakteristika dieser Antikörperderivate detailliert beschrieben und einzelne 
Entwicklungsaspekte erörtert.  
Im weiteren Verlauf dieser Arbeit wurde untersucht, ob sich das Hapten System eignet, um die 
spezifische Aufnahme von Transgenen zu vermitteln. Für eine effiziente intrazelluläre Aufnahme von 
Plasmid DNA in den Zellkern wurde angenommen, dass ein Verpacken dieser großen doppelsträngigen 
und zirkulären Nukleinsäure von Vorteil ist. Dafür wurde mit plasmid DNA durch Histon 
Assemblierung mittels Salzdialyse plasmid Chromatin rekonstituiert. Eigenschaften, die für die 
effiziente und funktionelle translokation von plasmid DNA in den Nukleus vorteilhaft sind, wie 
verbesserte Nukleaseresistenz und Reduktion der negativen Nettoladung, konnten gezeigt werden 
nachdem qualitativ hochwertiges Plasmid Chromatin generiert wurde. Um chemische Modifikationen 
mit unbekanntem Einfluss zu vermeiden, wurde die Verbindung zwischen plasmid DNA 
beziehungsweise Plasmid Chromatin und Hapten bindendem Antikörperderivat über das DNA bindende 
CPXM2 Peptid hergestellt, welches aus dem Carboxypeptidase-like protein X2 (CPXM2 Protein) 
stammt. Zunächst wurde die Interaktion zwischen TriFab Chromatin über das haptenylierte CPXM2 
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charakterisiert und mit dem bispezifischen bivalenten Antikörperformat verglichen. Da die Affinität 
zwischen bivalentem bispezifischem Antikörperderivat und Chromatin höher ist als die zwischen TriFab 
und Chromatin, vermutlich auf Grund der bivalenten Bindung zwischen Peptid und DNA im Falle des 
bivalenten Antikörperderivats, wurde das bivalente Format für weitere Analysen verwendet. Weiterhin 
konnte gezeigt werden, dass dieses System plasmid DNA und plasmid Chromatin mit nahezu identischer 
Effizienz und hoher Spezifität an die Zielzellen bindet und deren Internalisierung mediiert. Der Einfluss 
der Histon vermittelten plasmid DNA Kompaktierung wurde erst ersichtlich, nachdem der Anteil 
Reportergen-exprimierender Zellen bestimmt und verglichen wurde. Die gezielte Aufnahme 
unverpackter plasmid DNA konnte keine signifikante Anzahl an Reportergen-exprimierenden Zellen 
vermitteln, wohingegen die gezielte Aufnahme an plasmid Chromatin bewirkte, dass ein hoher Anteil 
an Zellen das Reportergen exprimiert. Letztendlich wurde das initial verwendete CRISPR/Cas9 
codierende Plasmid mittels des Antikörper-Chromatin Systems gezielt verabreicht und über die 
eingangs entwickelte Methode validiert. Die signifikante Anzahl an Zellklonen mit homozygoter 
Inaktivierung des Zielgens bewies, dass dieses System übertragbar und anwendbar für gezielte und 
therapeutische Genom-Editierung ist. Darüber hinaus stellt dieses System mit der hohen Spezifität eine 
neue Strategie der Gentherapie dar und könnte eine Möglichkeit eröffnen, therapeutische Genom-
Editierung systemisch zu applizieren. Abschließend soll erwähnt sein, dass diese Arbeit die Entwicklung 
eines neuen und bislang einzigartigen Gentherapieansatzes beschreibt, welches die spezifische und 
effiziente Transgenaufnahme ausschließlich über Proteine bzw. Peptide vermittelt, die identisch zu 
humanen Proteinsequenzen sind.  
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 1 General Introduction 
 
 
 
1.1 Gene therapy 
 
 
Gene therapy is defined by the treatment of disease by transfer of genetic material into cells and is a 
promising approach for the treatment of hereditary diseases, viral infections and cancer for example.1-4 
The possibilities with specific transgene expression are manifold and range from supplementation of 
missing gene products and regulation of gene expression to editing and repair of an altered genome.3-5 
Gene therapy can be applied either in-vivo by local or systemic injection of a gene delivery vehicle or 
ex-vivo by isolating target cells for gene transfer followed by their re-administration.6-8  Today about 
2600 clinical trials are registered to be completed, ongoing or approved since the initial approved 
therapeutic gene supplementation in humans by Michael R. Blaese and William F. Anderson 28 years 
ago.9,10 But how did we get to this point?  
A brief excursion into history of gene therapy highlights the dramatic development with multiple 
milestones but also several drawbacks. One great milestone was reached only 18 years after the 
discovery that genetic material is stored and encoded as DNA by Avery and coworkers in 1944.11,12 This 
milestone was the first successful gene transfer into mammalian cells published by Szybalski in 
1962.5,12,13 Not even ten years later, Rogers and Pfunderer began to collaborate with the goal to treat 
hyperargininemia by virus mediated gene supplementation to regulate the production of arginine.14 As 
they believed that the shope papilloma virus (SPV) encodes the gene responsible for arginase activity, 
they have treated two patients with wildtype SPV.14-16 The experiment failed without useful results as it 
had turned out later that the virus does not express the arginase activity gene as initially expected.15 A 
further drawback in gene therapy occurred in 1980 when Cline established a method to transfect bone 
marrow cells and directly applied it to cure thalassaemia patients by transfection of isolated bone marrow 
cells with the human globin gene followed by re-infusion of the transfected cells.17-19 After the trail, 
Cline was criticized and lost his academic chair and funding not because of the lacking benefit for the 
patients, but because he started the trail without permission of his institution.20-22 This experiment 
provoked a public policy discussion about gene therapy and led to establishment of the human gene 
therapy subcommittee to regulate the use of recombinant DNA in human subjects and to review clinical 
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protocols for this purpose.12 The first approved protocol was handed in by Rosenberg in 1988.23,24 
Rosenberg wanted to track tumor infiltrating blood cells in cancer patients by using gene marking 
techniques.25-27 This study with non-therapeutic purpose was started in 1989 followed by the first gene 
therapy study in 1990 by Blease and Anderson as mentioned above.9,28 After this rather bumpy start, the 
number clinical trials with novel concepts rapidly increased, so that it is worth to highlight different 
disease areas for gene therapy concepts and to point out how to classify gene delivery strategies.10,28-31 
Disease areas for gene therapy application are manifold but with the major interest on cancer, 
monogenic disorders, infectious and cardiovascular diseases.10 The disease area with the fourth most 
applied gene therapies are cardiovascular diseases with almost 7 % of clinical trials according to this 
field.15 Supplementation of growth factors of the vascular endothelial growth factor (VEGF) or 
fibroblast growth factor (FGF) family by recombinant gene expression, for example in ischemic tissue 
to improve angiogenesis, is the most frequent approach in this field.32-42 Gene therapy addressing 
infectious diseases is the third most popular application with about 7% of clinical trials directed against 
infections. One exemplary approach is the transfer of suicide genes into immune cells of HIV patients 
with inducible expression mediated by viral transcription factors.43,44 The consequence is that upon viral 
infection, the suicide gene gets expressed and mediates cell death of the infected cell, preventing 
replication of the virus.44 In addition to this interesting approach, also genetic engineering of immune 
cells to gain viral resistance is a promising gene therapeutic strategy in this field.45,46 Interestingly, 
monogenic diseases were initially the main focus of gene therapy, as the supplementation of a missing 
gene product is the most obvious application but are addressed by only about 10% of the clinical trials. 
One promising approach in this area is the therapy of cystic fibrosis by supplementation of the cystic 
fibrosis transmembrane conductance regulator (CFTR).47,48  In 2015 results of a phase 2b clinical trial 
were published, demonstrating that gene therapy can stabilize lung function of cystic fibrosis patients, 
however, with a need for improvement due to just modest effects.48,49 Finally the most popular research 
area also for gene therapy is cancer with more than 60% of completed clinical trials.10 The most 
prominent gene for treatment of cancer by gene therapy is the p53 tumor suppressor gene with the first 
approved gene therapy product Gendicine (approved by the Chinese State Food and Drug 
Administration).50-52  
The common requirement for all of these approaches is the successful transfer of the genetic material 
into the nucleus of the target cells, irrespective of an ex-vivo (by isolation and treatment of the particular 
cells) or in vivo (by injection of the gene therapeutic) application.8 But what are the strategies behind 
the gene delivery into the target cells or tissue? To address this question, the classes of gene delivery 
strategies are explained in the following.  
Classification of gene delivery strategies in principle requires only two comprehensive categories: 
Recombinant viral and non-viral physico-chemical gene delivery.53,54 About two third of the clinical 
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trials are virus mediated gene therapies, with most of them based on adenovirus.10 The reason for the 
predominance of viral systems in the clinic is their remarkable gene delivery efficiency.55 Viruses are 
the gene delivery experts par excellence, as they have optimized their mechanisms of gene transfer 
during evolution to exploit the host cell gene expression machinery for their own replication.56 This 
means, that viruses have developed certain techniques that mediate the entry of their genetic material 
into the host cell without damaging it before new viruses are successfully replicated.57 In viral gene 
therapy approaches, these mechanisms are now used to transfer therapeutically active genes instead of 
the virulence factors into the target cells.58 The most commonly used viral vectors for therapy are derived 
from retroviruses (RV) for stable integration (ex-vivo application) or adenoviruses (AV) for preferential 
episomal gene delivery.55 In general, viral transduction can lead to stable integration of the genetic 
material into the host cell genome, potentially resulting in a persistent expression of the delivered gene.59 
However, the site of integration into the genome is unpredictable in most cases which links the viral 
approach to severe safety concerns.59 Moreover, systemic application of viral vectors exposes it to the 
immune system linked to a potential response due to the immunogenicity of many viral components.58 
Such an immune response may reduce drug efficacy due to fast, active clearance or may cause severe 
side effects in case of inflammation and immunotoxicity in target organs.58 To address these issues, the 
type of viral vectors nowadays changes from RV towards lentivirus because of a more favorable 
integration profile and from AV to adeno associated virus (AAV), because AAV seems to be quite well 
tolerated after systemic application and its production is more convenient.55,60  
In contrast to viral delivery systems, non-viral (physical or chemical) mechanisms are clearly non-
pathogenic.61 Furthermore, such systems are highly divers, as they exploit various physical and chemical 
mechanisms to transfer DNA over the cell membrane. The vast majority of physical methods are only 
applicable for ex vivo, non-systemic approaches and are therefore not in the focus of this thesis but are 
mentioned for the sake of completeness. Most physical systems are based on the direct transient rupture 
of the cell membrane to allow DNA transfer either via administration of a certain stimulus like an electric 
field (electroporation), ultrasound (sonoporation), laser pulse (photoporation) or via direct mechanical 
force for example with a needle (microinjection) or particle bombardment (gene gun).62-68 Common 
chemical systems consist either of cationic polymers or lipids. Lipid-based DNA vectors use cationic or 
neutral lipids to encapsule DNA by formation of liposomes.69,70 Such lipids consist of three components: 
a hydrophobic tail, a cationic or hydrophilic head group and a linking group to combine head and tail.70  
Due to their cationic head groups, liposomes gain a positively charged surface with the ability to fuse 
with the negatively charged cell membrane, resulting in the release of its DNA content into the 
cytoplasm.71 One major hurdle of this system is the liposome instability and thereby a rather low 
efficacy.54 The second class of chemical vectors is defined by cationic polymers. The most prominent 
polymer is polyethylenimine (PEI) but also branched dendrimers face increased attention as viable 
alternative.54,72  The linear or branched molecules can efficiently bind DNA via charge interaction with 
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the negatively charge DNA phosphate backbone.73 This interaction leads to reduction or even reversion 
of the negative net charge in combination with DNA condensation what facilitates the cellular uptake 
and membrane transfer of these particles.73,74 Mechanistic details and challenges with chemical systems 
for gene therapy are discussed in chapter 1.3.  
In conclusion, both, viral and non-viral strategies are useful tool for gene delivery and comprise 
particular advantages and disadvantages. However, the risk of pathogenicity and immunogenicity 
depicts a strong argument to favor non-viral vectors for systemic application. Subsequent to the 
prevailing delivery strategies, the current focus of DNA functionality hast to be presented. 
The focus of gene therapy shifted over time from gene supplementation to more complex alternatives 
like regulating endogenous gene expression or gene editing and repair.10 For the first approach, a well-
studied mechanism is RNA interference.75 In context of gene therapy, the approach is to transfer a gene 
that expresses oligonucleotides with antisense sequence of a target endogenous RNA. Upon expression 
and maturation of the oligonucleotide, it is able to bind the RNA strand leading to degradation or 
translation inhibition, therefore reducing gene expression by lowering functional RNA levels.75 A 
further gene expression regulating but also transient gene repair approach is the so called antisense 
oligonucleotide-induced exon skipping. With this technology, exon splice sites are masked by directed 
antisense oligonucleotides, e.g. by expression of the antisense RNA with a small nuclear RNA (snRNA) 
for direction to the splice site.76 The masking of the splice site leads to exon skipping during mRNA 
maturation.28,77 This can alter the open reading frame which results either in a nonfunctional gene 
product (reduction of gene expression) or in a functional gene product by skipping deleterious mutations 
for example (gene repair). 76,77 
As already mentioned, not only the level of gene expression can be regulated, also the genome can be 
edited by introduction of therapeutic genes. This approach mediates a persistent genomic alteration, like 
the repair of mutated genes and therefore provides the chance (if it is 100% efficient) to cure a heritable 
disease with one therapy.78 As genome editing is the desired functionality of the gene delivery system 
in this thesis, this topic is introduced in detail in the next chapter. 
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1.2 Genome editing 
 
 
Initial ideas of therapeutic genome editing evoked, when the first tools for targeted gene editing via 
specific introduction of DNA double strand breaks (DSB) were described and became concrete after 
discovery of a breakthrough technology in this area.79,80 The rationale behind the development of tools 
for targeted introduction of DSBs to mediate efficient and directed genome editing was the observation 
that chromosomal DSBs can trigger two different DNA repair mechanisms, leading either to 
mutagenesis or gene replacement.81-84 The first mechanism is the canonical non-homologous end joining 
(c-NHEJ), were the ends of a DNA strand are processed by nucleases and/or polymerases followed by 
ligation of the blunt DNA ends.85-93 As this repair mechanism takes place without DNA template, the 
resulting DNA sequence is often altered due to introduction of deletions, insertions or substitutions.2,94 
Therefore, NHEJ inside the coding sequence of a gene can result in miss-sense or non-sense mutations 
and, as a consequence, may lead to the so called “knock-out” of the gene product.2,95,96 This means that 
targeted DSB introduction could be used to permanently switch off a gene of interest, e.g. an oncogene 
to treat cancer.96,97 The second canonical mechanism for DSB repair is homology directed repair 
(HDR).94,98 The HDR machinery aligns the DNA strand of the homologous chromosome or the sister 
chromatid and initiates DNA repair with the homologous template.94,98-100 This mechanism allows error 
free repair but can result in loss of heterozygosity due to gene conversion.99,100 In addition, if a 
recombinant DNA template is introduced with homologous DNA strands, this repair mechanism can be 
used to integrate or “knock-in” a transgene if it is flanked by the homology arms.2,101-103 For the targeted 
genomic introduction of DSB three technologies are commonly used and are considered for therapeutic 
application.79,104 
The first versatile tool for targeted DNA cleavage was a chimeric fusion protein of the FokI 
endonuclease domain with DNA binding zinc fingers, called zinc finger nuclease (ZFN).105 The basis of 
this tool was the finding that the FokI nuclease has a sequence independent DNA cleavage domain which 
can be separated from the DNA binding domain without losing nuclease activity.106-108 Chandrasegaran 
and coworkers used zinc fingers which specifically bind 3bp of DNA and can be combined in a highly 
modular fashion to generate sequence specificity and fused them to FokI.109 With their fusion protein, 
they observed that FokI introduces double strand brakes with preference to the target gene at high 
concentrations.105,109,110 Great improvement was made when it was recognized that FokI nuclease has to 
dimerize for cleavage with the best results obtained when two ZFNs are designed on neighboring 
sequences therefore achieving close proximity of FokI, which fosters dimerization (Figure 1.2.1).110,111 
One drawback of zinc finger nucleases is the complex design and generation of zinc fingers against new 
DNA sequences with high affinity and specificity as the DNA binding properties of zinc finger motifs 
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are mutually influenced by each other.112-114 However, due to the efficient and specific cleavage of 
optimized ZFNs, they are still frequently used for targeted genome editing.115,116 
A more recently developed example of chimeric proteins with endonuclease and modular DNA binding 
domains are transcription activator-like effector nucleases (TALENs).117-120 Similar to zinc finger 
nucleases, they also comprise the nuclease domain of FokI endonuclease.117-120 However, the DNA 
binding domain is derived from phytopathogenic bacteria of the genus Xanthomonas.121-124 Originally 
these TAL effectors mediate virulence of these pathogens in their host plant cells by induction of 
endogenous genes.125-127 The main characteristic of these effectors is a central domain of tandem repeats. 
Each repeat contains 34 amino acids that are nearly identical except of two amino acids.112,128 These 
hypervariable amino acids mediate sequence specificity of DNA binding.112,128 After deciphering the 
DNA binding code, TAL tandem repeats can be used to direct effector to any DNA sequence.128 With 
fusion to FokI nuclease, an additional genome editing tool was developed with somewhat improved 
modularity in comparison to ZNFs due to single base recognition of one repeat instead of three bases 
for each zinc finger (Figure 1.2.1 B).129 However, the principle of sequence recognition and DNA 
cleavage is quite similar to ZFNs enabling also the combination of both technologies.130  
A novel and completely distinct mechanism for specific DSB introduction into the genome was 
discovered with the understanding how prokaryotes acquire immunity against viruses and plasmids.131 
After exposure to foreign nucleic acids, many bacteria and archaea integrate fragments of the intruder 
nucleic acid into their genome.132-134 These fragments are inserted as spacer region at one end of a 
clustered regularly interspaced short palindromic repeat (CRISPR) that serves as a marker for 
“vaccination”.135,136 Transcription of the CRISPR locus and further processing by nucleases results in 
short CRISPR derived RNAs (crRNA) with complementary sequence to the foreign nucleic acid 
fragment which was integrated after initial exposure.137-139 When challenged by the same bacteriophage 
for example, mature crRNAs direct cas (CRISPR associated) proteins to the complementary loci, finally 
leading to cleavage and elimination of the invader nucleic acid. 137-139 The first characterized 
CRISPR/Cas system comprises the cas9 nuclease with the most extensively studied system derived from 
streptococcus pyogenes.140 The crRNAs of this system are not only complementary to the foreign nucleic 
acid but also contain a complementary stretch in the 3’ region complementary to the 5’ of a trans-
activating crRNA (tracrRNA).141 This crRNA – tracrRNA hybrid forms a ribonuclease complex with 
Cas9 for activation and DSB introduction after crRNA strand invasion and hybridization to the target 
DNA.141,142 This mechanism can be exploited to direct the Cas nuclease to any nucleic acid sequence 
and cutting a DNA strand with single base accuracy by designing just the target DNA complementary 
stretch of crRNA.143 In addition, development of a single guide RNA chimera of crRNA and tracrRNA 
for Cas9 nuclease finally promoted the CRISPR/Cas9 to the major breakthrough technology in the area 
of genome editing.142 The beauty of this system relies in its ease of design and production, as only the 
nucleic acid component has to be designed to direct the system to any genomic DNA sequence.105,142,144-
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146 On the other hand, reports about DSB at other genomic loci than the targeted one (genomic off-target 
effects) and varying numbers of the absolute efficacies make it necessary to further investigate this 
system and to compare it to the protein based methods (ZFN or TALEN).147-150  
 
 
 
Figure 1.2.1 Common genome editing systems.  
A Pair of zinc finger nucleases (ZFN) each with endonuclease (FokI) fused to nucleotide triplet binding 
zinc finger domains; B Pair of transcription activator-like effector nucleases (TALEN) each with 
endonuclease (FokI) fused to single nucleotide binding TAL domains C Cas9/guide RNA 
ribonucleoprotein complex binding by DNA strand invasion via sequence complementary. From: 
Therapeutic gene editing: delivery and regulatory perspectives104 
 
As stated initially, the possibility of specific and directed genome editing also created the chance for 
therapeutic genome editing.151 The opportunity of healing a patient’s genetic disorder by specific repair 
or deletion of genetic mutations generated intense research effort, without being the only application.152-
160 Also approaches for viral protection and supplementation of transgenes via site directed integration 
are promising therapeutic strategies.161-164  
In the context of therapeutic application, not only the editing system also the choice of the right delivery 
strategy is highly critical.165,166 The first consideration has to be that ectopic and persistent expression 
of any genome editing system increases the risk of genomic off-targeting as highlighted above for 
CRISPR/Cas9.166,167 Therefore a transient approach is more appropriate than a stable approach on the 
way to generate a safe drug with a minimized risk for genotoxicity.167 Furthermore, in vivo application 
of a genome editing system is in principle favored over ex vivo application as cost intense cell isolation 
and re-administration is avoided and cells or tissues can be addressed that cannot be isolated. Finally, a 
transient genome editing system might require multiple dosing to achieve a sufficient number of 
successfully edited cells in a patient.167 For this reason also a viral strategy with potential immunogenic 
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components might be a disadvantage over a non-viral approach.168 All in all, the most promising 
approach would be a transient non-viral gene delivery system for in-vivo systemic application. 
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1.3 Transient non-viral gene delivery for systemic application 
 
 
In principle, a systemically applied DNA delivery system has to tackle several barriers until the DNA 
reaches its active site, divided in extracellular and intracellular barriers and with a certain challenge to 
cope with the particular hurdle.169 These hurdles and existing approaches to address them with non-viral 
strategies are explained along the DNA delivery route (Figure 1.3.1). 
 
 
Figure 1.3.1 Subsequent steps of targeted DNA delivery. 
 Step 1 Specific binding at the target cell surface (green); Step 2 Target mediated internalization into 
vesicles (light green or yellow); Step 3 Vesicular escape for DNA translocation into the cytoplasm and 
the nucleus (cyan); Step 4 DNA functionality inside the nucleus. Confocal microscopic image by A. 
Indlekofer, Roche Innovation Center Munich 
 
The first task along this route is to deliver intact DNA efficiently but also specifically to the desired 
tissue or cells (Figure 1.3.1 step1).170 For this aim modern gene delivery systems are equipped with 
targeting domains to direct the nucleic acid delivery system to the tissue or cells of interest.171 Especially 
for systemic application of a gene delivery system (viral as well as non-viral), specific targeting 
1 
2 
3 
4 
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strategies have to be implemented to avoid unspecific uptake in non-target cells or tissues.172-175 Despite 
loss of compound resulting in reduced efficacy and short half-life, cellular off-targeting also provokes 
safety concerns for the gene delivery system.172 This is a common hurdle with synthetic approaches 
(polymers or liposomes) as they readily accumulate in liver or lung after injection.4,175 Promising results 
were obtained especially when antibodies or antibody derivatives with specific binding properties for 
antigens on the target cell surface were fused to synthetic vehicles for directed nucleic acid 
delivery.170,174,176 In general, antibody mediated gene delivery is a viable approach as antibodies display 
high target antigen specificity with proven compatibility for systemic application.177-179 But not only 
specific targeting displays an extracellular hurdle, also serum components can affect efficacy when they 
interact with the gene delivery system.169,180 For example nucleic acids have to be protected from serum 
endonucleases to prevent degradation.169,181 For this reason most delivery systems encapsulate or 
condense their nucleic acids to make them un-accessible for nucleases.169,181 
The second step is, that the specific membrane antigen recognition by the antibody has to trigger 
internalization of the DNA delivery vehicle into the vesicular system (Figure 1.3.1, step 2).169,181 The 
internalization pathway, kinetics and capacity are critical parameters as they define the amount of 
compound available for the downstream events like the vesicular escape.182-186 These parameters are 
influenced by the addressed cell surface target antigen, the antibody as well as their mode of 
interaction.187,188 For example bivalent binding of receptor tyrosine kinases (RTKs) most often mediates 
rapid internalization as a consequence of receptor dimerization, whereas monovalent binding of RTKs 
might result in an dramatically reduced internalization rate.188,189 Finally, the availability of the target 
antigen at the cell surface defines the maximum uptake of the delivery system and here by consequence 
the uptake of DNA.190,191 This is limited on the one hand by the absolute cell surface expression level of 
the target antigen and on the other hand also by its turnover rate, defining how fast the target antigen is 
available at the cell surface again after internalization.192 All these parameters have to be taken into 
consideration because they directly influence the success of the following steps along the delivery 
route.181   
The major hurdle and this is the crux particularly for non-viral nucleic acid delivery is the escape from 
the vesicles into the cytoplasm (Figure 1.3.1, Step 3).62,181,193  Cationic polymers and lipids with 
transfection like properties are the most common endosomal escape mediators for systemic non-viral 
gene delivery.194 Their function is to mediate the release of the internalized nucleic acid out of the 
vesicular system to enable translocation to the right intracellular compartments like the nucleus for 
transgene expression.194 The underlying mechanisms for the nucleic acid transfer are divers.195 For lipid 
based systems, the nucleic acid is encapsulated in micelles.196 After internalization, these DNA 
containing lipid micelles fuse with the lipid bilayer membrane of the vesicular systems and release their 
nucleic acid content into the cytoplasm.196-198 Cationic polymers complex the nucleic acid via charge 
interaction with the phosphate backbone.199 This results in the reduction of the negative net charge and 
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in reduction of the overall size of plasmid DNA, what facilitates the properties of cellular uptake and 
release out of the vesicles.199-201 However, the exact mechanism behind the facilitated endosomal escape 
of DNA/polymer complexes is not well understood.202 One hypothesis existing for years now is the 
‘proton sponge effect’ meaning that after internalization of the polymer/DNA complex, its high 
buffering capacity prevents acidification of the vesicle.203 The increased proton influx and co-influx of 
water leads to vesicular swelling finally results in the release of the internalized content by collapse of 
the vesicle.203  
Independent from the particular mechanism, the challenge is that these reagents have to fulfill 
contradictory requirements as their membrane interaction must be strong enough for a successful escape 
but is only tolerated by the cell to some extent.193 As a result, the membrane interaction of such agent 
has to be well balanced as gene delivery is not successful if the interaction is too weak or too strong and 
moreover must not occur at the cell surface to avoid unspecific uptake by non-target cells.193 Therefore, 
next generation synthetic chemical compounds are designed to address this problem. For example 
branched polymers are described to lead to a higher DNA condensation than linear polymers and 
mediate a more efficient endosomal escape with reduced cytotoxicity.204  
After cytoplasmic localization, DNA has to be transferred into the nucleus for transgene expression.205 
The fact that transfection of naked plasmid DNA (e.g. without fusion of a nuclear localization signal) in 
most cases results in strong transgene expression, leads to the assumption that the DNA transfer from 
the cytoplasm into the nucleus takes place by chance and is therefore not an absolute barrier especially 
in dividing cells.205,206 However, results demonstrate that active nuclear transport is beneficial to increase 
the level of transgene expression.205,207-210  
The functionality of the DNA inside the nucleus represents the final step (Figure 1.3.1, Step 4). 
Optimization of delivery system towards specific and efficient nuclear accumulation is not productive 
for example, if the delivered transgene is not expressed due to chemical modification.211 Furthermore, 
the expression level must be high enough to mediate the therapeutic effect of the transgene. For example 
a target gene knock out can only occur if the editing system is expressed at a sufficient level.212 
As no gene delivery system has been developed to date, that fulfills all the criteria mentioned above 
without adverse effects like un-specificity, cytotoxicity, immunogenicity, the development of novel 
concepts for non-viral gene therapy is highly desired and the major focus of this work..213-215  
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1.4 Aim of the thesis 
 
 
Targeted gene delivery requires optimization of several parameters to create a specific and efficient 
system that can be considered for further development towards an applicable therapy. The major 
parameters that have to be optimized are the targeting domain, the translocation entity and the transgene 
functionality. To enable separate optimization of each parameter, a flexible system is required that 
allows fast and simple exchange of each component. This means that it has to be possible to easily 
exchange the nucleic acid, the targeting domain and the translocation entity.   
 
 
Figure 1.4.1  Strategy of the thesis. 
Division of the project into the single work packages: quantification of transgene functionality, 
characterization of specific targeting domains and development of efficient translocation and nuclear 
entry modules. Individual optimization of each parameter in course of the respective work package and 
final combination shall create an efficient and specific targeted gene delivery system. 
 
Quantification of transgene functionality is the prerequisite for the optimization of a nucleic acid 
delivery system. As the final goal of this thesis is to deliver a genome editing system to pave the way 
for a potential therapeutic application like gene disruption or repair, the first step is assay development 
Targeted 
gene 
delivery
Quantification 
of transgene 
functionality
Specific 
targeting 
domain Efficient 
translocation 
and nuclear 
entry
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to enable determination of DSB frequency and specificity. Because a complex expression system like 
CRISPR/Cas9 has several adjustable parameters along the optimization process (gRNA sequence and 
length or type of Cas9 enzyme for example), a simple and robust method for fast evaluation is absolutely 
mandatory. In addition to the optimization of the knock out system, it should be also possible to 
determine efficiency and specificity of the genome editing mediating DNA delivery system. After the 
characterization and establishment of an assay with the desired properties and therefore providing the 
basis for further development, targeting will be addressed as described in the following. 
Specific targeting domains mediate the initial step of DNA delivery. As highlighted above, antibodies 
have most suitable characteristics for targeted non-viral gene delivery. Therefore, production, 
purification and characterization of different antibody formats are essential steps prior to efficient and 
specific gene delivery and are the focus of the second work package. A further goal of this work package 
is to make use of a flexible system that allows simple exchange of antibody and DNA without the need 
of labor intense conjugation. Such a concept is represented by the hapten binding system, where 
bispecific antibodies are used that are able to simultaneously bind cell surface antigens as well as small 
molecule haptens (like Biotin or Digoxigenin for example).216 Conjugation of a hapten to DNA for 
example allows the non-covalent attachment of DNA to the antibody which enables the release of DNA 
after internalization and further translocation to its site of action, the nucleus.     
Efficient translocation and nuclear entry is the final step for successful DNA delivery and is also the 
final work package of this thesis. As described above, the vast majority of DNA delivery systems 
comprise entities of viral or bacterial origin or synthetic lipids or polymers to facilitate the vesicular 
escape. The ambitious goal of this thesis is to identify entities exclusively of human or mammalian 
origin that mediate vesicular escape and subsequently allow DNA distribution into the nucleus. In 
addition, these entities should be highly efficient, active at a reasonable dose, non-toxic and must not 
interfere with targeting. In the end, the three work packages are combined to evaluate the efficiency and 
specificity of the developed targeted gene editing system.  
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2 Disruption of diphthamide synthesis genes and resulting 
toxin resistance as a robust technology for quantifying and 
optimizing CRISPR/Cas9-mediated gene editing  
 
 
 
2.1 Review 
 
 
2.1.1   Introduction 
 
To validate a system for targeted genome editing towards efficiency and specificity, the ability to 
quantify successful gene delivery is absolutely mandatory. In the context of a therapeutic application, 
‘successful’ can be defined as the introduction of specific double strand brakes mediating the complete, 
homozygous, knock-out of the target gene or, in combination with a donor DNA, its specific integration 
at the target site.167 As targeted genome editing systems comprise several parameters to optimize, robust 
assays with fast and simple readouts are required.151,217,218 Most assays for knock-out quantification are 
based on artificial reporter systems, which do not properly reflect the endogenous situation or labor 
intense sequencing techniques with a low throughput and a low number of analyzed events.219-222 In 
addition the vast majority of these assays do not allow exact determination of the overall editing 
efficiency under endogenous conditions.219-221  
CRISPR/Cas9 is among all other editing systems the most prominent one and still in the focus of 
research due to its ease of design and generation.223,224 Therefore, in past years tremendous research 
effort was made to optimize especially the CRISPR/Cas9 system, ranging from prediction of the optimal 
gRNA sequence and length to protein engineering for Cas9 efficiency and precision.224 In the field of 
gRNA optimization, general design rules for novel gRNAs were developed.225,226 First of all the 
complementary sequence of the gRNA must comprise a protospacer adjacent motif (PAM) at the 3’ end, 
a 3nt sequence (NGG for staphylococcus pyogenes Cas9) that limits the number of potential loci for 
Cas9 targeting.225,226 The second critical parameter is to find a unique sequence to reduce off-
targeting.225,226 Furthermore, the length of the complementary targeting sequence of the gRNA has to be 
at least 16 nucleotides (nt) with an optimum around 20nt.227 In addition to that, another fact that 
influences the gRNA design is the hybridization mechanism of the gRNA with priming at the PAM 
sequence and complete hybridization from 3’ to 5’ in a zipper-like annealing.140 Therefore, a pyrimidine 
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base next to PAM is favored to increase priming efficiency of the gRNA and subsequently cutting 
efficiency.228 As a consequence to the hybridization mechanism, 5’ mismatches are more tolerated than 
3’ mismatches, what has to be considered for the evaluation of potential off-target sequences.229 The 
careful evaluation of off target effects is especially important for conventional CRISPR/Cas9 knock-out 
systems, as one Cas9/gRNA complex is sufficient to introduce a DSB.229  
Beside optimization of individual targeted editing strategies, another reason why quantification assays 
for genome editing are of major importance is the ongoing debate about the absolute efficacy and 
specificity of the existing editing systems.230-232 It is widely accepted that CRISPR/Cas9 editing is highly 
efficient and very specific, therefore on the way being the first choice for therapeutic editing, too.232,233 
But despite the positive facts like ease of design and generation for single guide CRISPR/Cas9 systems, 
reports with varying results about editing efficiency and voiced criticism against the specificity 
necessitate deeper investigation.234-236 In detail, it is claimed that guide RNA mediated Cas9 targeting is 
not as specific as expected.237 Several studies report that off-targeting and therefore introduction of 
random DSBs does not occur in negligible frequencies.237,238 For therapeutic application, random DSBs 
will cause severe safety concerns, as these DSBs could result in genotoxic effects with unpredictable 
consequences.237-239 In contrast to Cas9, in ZFN as well as TALEN systems, the FokI endonuclease has 
to dimerize at the genomic target locus for efficient introduction of a DSB.110,240-242 This potentially 
reduces the risk of off-targeting and might be an advantage of the protein based systems over 
CRISPR/Cas9 and has already been exploited also for CRISPR/Cas9.240-242 The efficiency of specific 
editing is also critical for therapeutic application, as this would influence the intended application.239,243 
For example if it turns out that the editing frequency mediating a homozygous knock out is rather low, 
gain of function strategies, where not every cell has to be addressed would be favored over a loss of 
function strategy, like the oncogene knock-out to inhibit tumor growth were a high “hit-rate” is required 
for a beneficial effect.2 All in all, a comparison of CRISPR/Cas9 with a protein based system is 
mandatory to allow a decision of the best suited editing system for therapy. 
A further, also possible therapeutic, application of targeted genome editing is the site directed integration 
of co-delivered transgenes.2,244 As described in the general introduction, the second canonical repair 
mechanism HDR is exploited for this approach.244 For integration of the transgene, the so called donor 
DNA has to comprise sequences greater 400bp in length that are homologous to the upstream and 
downstream sequence of the targeted genomic locus and flank the transgene.245 This event is rather rare 
because after the DSB has occurred also the homology template has to anneal and HDR has to be 
initiated before the more active NHEJ machinery is recruited.246 As a consequence, various approaches 
exist to enhance HDR, like development of small molecule enhancers or covalent linkage of the donor 
DNA to the nuclease for simultaneous targeting to the genomic locus.222,247,248  
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In the following manuscript a novel method for quantification of genomic editing events is described. 
In addition to outlining the overall knock-out and integration efficiency and specificity of optimized 
editing systems, we also demonstrated exemplarily for some described parameters, how they influence 
editing efficiency. On the one hand the method is validated by confirmation of the main facts of targeted 
genome editing but on the other hand some highly interesting results shed new light on some aspects of 
especially CRISPR/Cas9 mediated genome editing.  
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2.1.2 Summary and discussion 
 
The first step of assay development for endogenous genome editing quantification is the choice of a 
suitable target gene. The successful editing should result in a measurable phenotype, like cell survival 
due the gain of toxin resistance. This principle is already well established for selection of cell clones 
with successful stable gene integration, like selection with antibiotics towards integration of the 
respective resistance gene.249 Several mechanisms exist for this selection strategy, like supplementation 
of hygromycin B or puromycin resistance genes, whereas cell survival for selection of gene knock out 
is not a common tool, as appropriate target genes are rather rare.249-251 The invented assay described in 
this manuscript is based on such a target gene which mediates toxin resistance after successful knock 
out. 
Corynebacterium diphtheriae mediates its pathogenicity through a single protein toxin.252 Diphtheria 
toxin (DT) is one the first discovered toxins and its mode of action are well understood.253 The 63 kDa 
protein consists of two domains, fragment A and fragment B connected by a furin cleavable peptide 
sequence.254-257 Fragment B mediates intracellular delivery of fragment A and consist of a receptor 
binding (R) domain and a translocation (T) domain.258 The R domain binds to the heparin-binding EGF-
like growth factor precursor resulting in cell surface binding and internalization of DT. After endocytosis 
and vesicular trafficking, the T domain forms a small membrane pore after it is activated by furin 
cleavage between fragment A and B.259-261 This mediates membrane translocation of fragment A into 
the cytosol.259-261 Fragment A consist of the catalytic (C) domain of DT which mediates its cytotoxic 
effect by catalyzing the transfer of ADP-ribose from NAD to the elongation factor 2 (EF2).255,258 EF2 is 
a 95kDa GTP-binding protein essential for translation as it mediates polypeptide chain elongation by 
translocating peptidyl-tRNA from the A to the P site on a ribosome.262,263 The ADP-ribosylation 
inactivates EF2 and blocks protein synthesis, leading to cell death.264-267 Bodley and coworkers found 
out that the ADP-ribose is transferred by DT on a post translationally modified histidine.268 The residue 
called diphthamide is unique for EF-2 and is synthesized by a multi-step pathway catalyzed by seven 
enzymes (Dph1-Dph7).268-270 The initial step is the formation of an intermediate with the Diphthamide 
backbone transferred from S-adenosylmethionine (SAM) to EF-2 Histidine 715 (in mammals) by Dph1-
4.271,272 The methyltransferase Dph5 catalyzes the trimethylation of the intermediate resulting in 
generation of diphthine.272 The diphthine intermediate can ADP-ribosylated already by DT.270 The final 
step is the amidation of diphthine to diphthamide by Dph6 and Dph7.273,274 Previous work by Stahl et al. 
demonstrated that homozygous knock-out of Dph1,Dph2, DPh4 and Dph5 results in absolute DT (and 
Pseudomonas exotoxin as it also ADP-ribosylates Diphthamide) resistance, as the point of attack 
(Diphthine or Diphthamide for ADP-ribosylation) is missing.275 In theory also Dph3 should result in 
absolute DT resistance, but no cell line could be established with homozygous knock out of Dph3 (as 
well as Dph6 and Dph7) as it seems to be lethal, in agreement with the fact that it is involved in other 
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essential cellular mechanisms (ranging from transcription regulation to endocytosis).270,275  Homozygous 
knock-out of Dph5 results in reduction of cell growth in contrast to Dph1 Dph2 and Dph4 where viability 
and growth rate was not affected after homo- and heterozygous gene inactivation.275  
Based on these findings, Dph1 and Dph2 were chosen as target for the development of a quantification 
assay for genome editing, whose principle is described in the following. First, MCF7 tumor cells are 
transfected with a targeted editing system, in this manuscript CRISPR/Cas9 or ZFN against either DPH1 
or DPH2. 24h after transfection, transfection efficiency is determined by flow cytometry of the control 
sample transfected with GFP control plasmid instead of a plasmid encoding the editing system. 
Afterwards, a defined cell number is seeded and incubated for 3 days, followed by continuous DT 
exposure. After one week – 1.5 weeks of toxin exposure, colonies formed up by the survivor cells are 
fixed, stained and counted. The number of colonies reflects the number of cell clones, where 
homozygous Dph1 (or Dph2) knock-out occurred. The ratio of colonies from initially seeded cells 
reflects the “success rate” of genome editing and on the one hand allows calculation of the absolute 
number or percentage of targeted gene knock out or on the other hand a direct comparison of different 
parameters which affect knock-out efficiency. In addition, co-transfection of a donor DNA for 
integration of the puromycin N-acetyltransferase gene followed by exposure to puromycin (PM) instead 
or together with DT, enables quantification of integration by HDR mechanism (knock-in) or of both 
events (homozygous knock-out and knock-in). As integration of the transgene is dependent on the 
introduction of DSBs, specificity can be estimated by comparing number of DT and PM resistant 
colonies. For example, if you change a parameter of an editing system that reduces the specificity of 
targeted DSB introduction, this can be detected as the number of DT resistant colonies would decrease 
whereas the number of PM resistant colonies increases due to off target DSB mediated integration. With 
the focus on CRISPR/Cas9, we demonstrated the influence of various parameters on genome editing 
specificity and efficiency, by quantification of DT and PM resistant colonies. First, the portion of 
targeted integration was determined by comparison of targeted (gRNA against Dph1 or 2) with 
untargeted (scrambled gRNA without complementary to the genome) editing (Figure 2.2.3). For the 
scrambled gRNA (scRNA) formation of DT resistant colonies did not occur even though a significant 
number of PM resistant colonies formed. This reflects the integration background caused by off-target 
cleavage or spontaneous integration. Interestingly, the targeted introduction of double strand breaks only 
increased the integration rate by about two-fold, implicating the inefficiency of this mechanism and a 
substantial off target potential. Next, we investigated the dependence of Cas9 genome editing efficiency 
on gRNA length (Figure 2.2.4A). Therefore, we prepared gRNAs with 14 to 26 nt DPH1 complementary 
sequences in increments of two nucleotides. In line with previous observations, gRNAs with a 
complementary sequence shorter 16nt are not functional for specific targeting of Cas9, and we also 
observed no formation of DT resistant colonies.227 The optimal guide RNA length in our system is 20nt, 
with the most frequent introduction of specific DSBs resulting in the highest number of formed DT 
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resistant colonies. To address the question, whether CRISPR/Cas9 is far more efficient in targeted 
editing that ZFN, we compared these two approaches towards DSB introduction and transgene 
integration (Figure 2.2.4B, C). Moreover, we also extended the comparison by a novel engineered Cas9 
variant, the high fidelity spCas9 (spCas9-HF), claimed to be more specific to the target sequence and 
therefore reduced off-target effects.276 Surprisingly, spCas9-HF showed not only a significantly lower 
number of DT resistant colonies compared to wild-type spCas9 but also of double resistant colonies 
whereas the number of PM resistant colonies was only reduced by trend. This demonstrates rather less 
specificity for the Dph1 target gene in addition to the reduced efficiency. In contrast to the widely 
accepted claim that CRISPR/Cas9 would be the far most efficient editing system, comparable numbers 
of colonies (DT as well as PM resistant) for spCas9 and ZFN were achieved. Thus, it was concluded 
that ZFN are a viable alternative to CRISPR/Cas9 also in terms of editing efficiency. The last parameter 
addressed by the developed assay is the influence of small molecules (Figure 2.2.5). Therefore we 
investigated two compounds described to enhance transgene integration either by activating HDR (RS-
1) or by inhibiting NHEJ (SCR7).222,247 We observed a significant increase of PM resistant colonies 
(relative to the DT colony number) of both small molecule compounds with an additive effect for 
simultaneous application. As for most small molecule inhibitors or activators, the addition time-point 
highly influence their efficacy. In this example, if the compounds are added after transfection, no 
increase in HDR mediated integration is observed.  
 Finally, the absolute frequencies of the most efficient editing system (CRISPR/wild-type spCas9) were 
calculated and summarized as displayed in figure 2.2.6. Most obvious is the very low frequency of 
integration with an overall rate of 0.2% if 100% transfection efficiency is achieved with less than two 
third site specific integration. Due to low efficiency and a high rate of random genomic integration, 
stable and site directed gene supplementation is not applicable yet for systemic therapeutic approaches. 
Although 30fold more frequent than integration, homozygous knock out of target genes, this evet is still 
too rare for a therapeutic application with loss off function editing, e.g. to reduce tumor growth. 
However, a gain of function approach where not every cell has to targeted is reasonable, especially if 
heterozygous editing would be sufficient, as overall editing (mono- and bi-allelic) with almost 20% 
frequency (with 100% transfection efficiency) is quite frequent. 
In principle, CRISPR/Cas9 as well as ZFN in theory might be applicable for some therapeutic 
applications based on DSB introduction with efficiencies of the current common technologies. Even for 
these applications, safety concerns like off-targeting and potential immunogenicity for expression of the 
bacterial Cas9 have to be addressed. However, also realization of site directed integration may become 
realized as novel concepts show improvement in efficiency and specificity as already mentioned above 
and demonstrated for small molecule compounds.   
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2.2 Manuscript 
 
 
2.2.1 Abstract 
 
We have devised an effective and robust method for the characterization of gene-editing events. The 
efficacy of editing-mediated mono- and bi-allelic gene inactivation and integration events is quantified 
based on colony counts. The combination of diphtheria toxin (DT) and puromycin (PM) selection 
enables analyses of 10,000-100,000 individual cells, assessing hundreds of clones with inactivated genes 
per experiment. Mono- and bi-allelic gene inactivation is differentiated by DT resistance, which occurs 
only upon bi-allelic inactivation. PM resistance indicates integration. The robustness and 
generalizability of the method were demonstrated by quantifying the frequency of gene inactivation and 
cassette integration under different editing approaches: CRISPR/Cas9-mediated complete inactivation 
was ~30-50-fold more frequent than cassette integration. Mono-allelic inactivation without integration 
occurred >100-fold more frequently than integration. Assessment of gRNA length confirmed 20mers to 
be most effective length for inactivation, while 16-18mers provided the highest overall integration 
efficacy. The overall efficacy was ~2-fold higher for CRISPR/Cas9 than for zinc-finger nuclease and 
was significantly increased upon modulation of non-homologous end joining or homology-directed 
repair. The frequencies and ratios of editing events were similar for two different DPH genes 
(independent of the target sequence or chromosomal location), which indicates that the optimization 
parameters identified with this method can be generalized. 
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2.2.2 Introduction 
 
Gene-editing technologies, which are applicable in science as well as medicine278, include the use of 
zinc-finger nucleases (ZFNs115,279,280), transcription activator-like effector nucleases (TALENs129,280-282) 
and the RNA-guided CRISPR/Cas9 system145,278,283,284. The last approach is a tool that has recently 
emerged as the predominant choice for gene editing. CRISPR/Cas9 technology is highly specific, easy 
to design and generate, and well-suited for application in a variety of cell types and organisms. The 
target gene specificity of the nuclease Cas9 is conferred by small guide RNAs (gRNAs, usually 20mers) 
complementary to the sequence to be edited within the target gene. In contrast, the specificity of ZFNs 
and TALEN is conferred by engineered protein domains that recognize specific target sequences. 
Therapeutic effects can be achieved using genome editing, via the correction or inactivation of 
deleterious mutations, introduction of protective mutations, supplementation of transgenes and/or 
disruption of viral DNA243. The first therapeutic genome editing approach (using ZFN) addressed CCR5 
in autologous CD4 T-cells of HIV patients285,286. The progress of therapeutic gene editing in various 
applications is at the preclinical stage, in addition to one phase 1 trial161,243,286-289.  
Effective and robust methods for the characterization and comparison of editing technologies are 
essential for applications in R&D and the development of editing-based therapies. Such evaluations 
comprise analyses and comparisons of the efficacy as well as the specificity of target gene destruction 
and productive transgene integration. These aspects are particularly crucial for the safe and effective 
clinical translation of editing technologies285. Using first-generation Cas9 editing approaches, off-target 
modifications occur at significant rates147,149,150,237,276,290. Optimization of gene-editing systems is 
therefore desirable to reduce off-target effects while maintaining or enhancing on-target efficiency. 
A prerequisite for optimizing gene editing is the reliable and robust detection and differentiation of 
mono- and bi-allelic gene inactivation as well as nonspecific and targeted integration events. Existing 
methods, such as the determination of phenotypes caused by insertions (e.g., drug resistance) or a lack 
of phenotypes (gene inactivation) or sequencing approaches, frequently do not differentiate mono- and 
bi-allelic inactivation. Moreover, existing technologies rarely address the genetic composition of 
individual cells and may not be based on large numbers of individual gene-edited cells to allow robust 
statistical analyses. 
Here, we describe a simple and robust approach for characterizing gene-editing events. A combination 
of Diphthamide biosynthesis protein encoding gene (DPH) inactivation, diphtheria toxin (DT) treatment 
and puromycin (PM) selection allows the determination of gene-editing efficacy in very large numbers 
of individual cells. The method differentiates mono- and bi-allelic gene inactivation and indicates site-
specific integration. The simplicity and robustness of the method facilitate the optimization of gene-
editing procedures as well as the identification and comparison of gene-editing modulators.  
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2.2.3 Results 
 
2.2.3.1 Determination of target gene inactivation and resistance cassette integration 
via a combination of diphtheria toxin and puromycin selection 
 
DT ADP-ribosylates diphthamide and thereby inactivates eukaryotic translation elongation factor 2 
(eEF2), which irreversibly stalls protein synthesis and kills cells291. Diphthamide is a histidine 
modification placed on eEF2 via diphthamide synthesis gene-encoded enzymes, including DPH1. 
Complete bi-allelic inactivation of DPH1 in MCF7 cells prevents the synthesis of the toxin target 
diphthamide, which renders cells resistant to DT275. Thus, inactivation of all copies of DPH1 generates 
a ‘DT resistance’ (DTr) phenotype. DPH1 gene inactivation as a consequence of DPH1–targeted gene 
editing can occur due to non-homologous end-joining events. In combination with a donor plasmid 
containing a promoter-less expression cassette encoding the enzyme puromycin N-acetyltransferase 
(Pac) flanked by DPH1 homology arms, DPH1 gene inactivation can result from the homology-directed 
repair of DNA double-strand breaks (and pac insertion). Thus, DTr occurs upon inactivation of both 
DPH1 alleles via either mechanism or via a combination of the two. Bi-allelic DPH1 gene inactivation 
combined with homology-directed repair and pac expression cassette (PAC) integration into at least one 
allele leads to DT-PM double resistance (PMr DTr). Pac insertion into one DPH1 allele without 
inactivation of the other generates cells that are PM resistant but DT sensitive (PMr DTs). The same 
phenotype results from cassette integration in off-target positions of the genome that enable pac 
expression (the 5’ homology arm of the DPH1-pac cassette might support transcription even though pac 
lacks its own promoter). Cells with genomic pac insertions at positions that do not enable expression of 
the cassette remain PM sensitive (PMs) and cannot be detected by assessing PM resistance. Figure 
2.2.1A shows possible genomic events leading to the four phenotypes analysed via DT and/or PM 
selection: PMs DTs; PMr DTs; PMs DTr; and PMr DTr.  
 
2.2.3.2 Diphtheria toxin resistance assays and HRM-PCR to quantify and differentiate 
mono- and bi-allelic DPH1 gene inactivation 
 
The frequency of the DTr phenotype can be detected in a robust manner by counting toxin-resistant 
colonies. Exposure of cells (following co-transfection with the CRISPR/Cas9/gRNA-encoding plasmid 
and the pac donor plasmid) to lethal doses (2 nM) of DT eliminates all cells that harbour at least one 
functional copy of the DPH1 gene. Colonies develop only from cells in which both DPH1 genes are 
inactivated (an example is shown in Figure 2.2.1B-D & Suppl. Figure S9.1.2). As the presence of one 
remaining functional DPH1 allele is sufficient for toxin sensitivity, all DPH1 alleles must be knocked 
out in DTr cells. Cells in which only one allele is modified can be identified via high resolution melting 
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(HRM)-PCR assays on clones derived from individual cells (Figure 2.2.1E). This technology is based 
on the amplification of a genomic locus at which sequence alterations are expected, followed by 
recording melting curves. Modified and wild-type amplicons can be discriminated based on their melting 
profiles at the resolution of a single nucleotide exchange, a technology that was originally devised to 
diagnose single nucleotide polymorphisms or detect mutations (see Methods section for details292,293). 
Target sequence modifications consequently also alter the melting temperature of DPH1 PCR fragments 
compared with that of the wild-type fragment, which generates differences in melting temperatures and, 
hence, bi-phasic HRM profiles. Nuclease-mediated gene inactivation events occur independently in 
different alleles and are therefore rarely identical in both alleles. Thus, one would expect not only ‘wild-
type-mutated’ combinations but also cells with complete (bi-allelic) gene inactivation to display bi-
phasic HRM profiles. In fact, all of the DTr colonies that we assessed via HRM-PCR displayed 
deviations of the melting curve shape, which indicates that identical inactivation events in both alleles 
occur infrequently. Determination of the ‘toxin-resistant’ phenotype in cells subjected to HRM-PCR 
therefore differentiates between mono-allelic and bi-allelic (identical and non-identical) DPH1 target 
gene inactivation events. 
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Figure 2.2.1: Determination of DT and/or PM resistance combined with HRM-PCR to quantify 
mono- vs bi-allelic gene inactivation and cassette integration events.  
Determination of DT and/or PM resistance combined with HRM-PCR to quantify mono- vs bi-allelic 
gene inactivation and cassette integration events. (A) Overview of various repair outcomes and 
conferred resistance that can be distinguished by assessing resistance to DT and/or PM. Each box 
indicates 2 DPH1 alleles on the left and ‘other’ undefined chromosomal loci on the right. Crosses 
indicate gene inactivation, and HRM+ reflects detection of mono- or bi-allelic DPH1 sequence 
deviations as described in (E). Cassette insertion events are indicated with a solid ‘PAC-ellipse’, 
inserted either at DPH1 or elsewhere in transcription-enabled locations. Solid PAC-ellipses represent 
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expressed Pac. Open ‘?-ellipses’ represent insertion events at positions that do not enable expression; 
these events cannot be detected by assessing PM resistance. (B-D) MCF7 cells were transfected with a 
CRISPR/Cas9 expression construct and a donor plasmid that integrated the pac resistance cassette in 
DPH1. (B) 48 hours after transfection, cells were exposed to DT at concentrations that are lethal to 
cells carrying functional DPH1. In surviving colonies, all DPH1 gene copies are inactivated. Colonies 
that retain functional DPH1 are killed by DT. DTr colonies emerge only upon treating cells with DPH1 
gRNA without nonspecific background in cells exposed to control guides. (C) 96 hours after transfection, 
cells were exposed to PM at concentrations that are lethal to cells without pac. The surviving colonies 
carry at least one pac expression cassette and emerge in higher numbers in the presence of DPH1 gRNA 
compared with scrambled gRNA. The scramble guide that we applied (20mer, 
GCACTACCAGAGCTAACTCA) does not correspond to any specific human gene. (D) Simultaneous 
PM & DT selection reveals cells in which all DPH1 alleles are inactivated, and at least one pac cassette 
is integrated. (E) MCF7wt, MCF7wtko with one wild-type and one inactivated allele, and cells in which 
both alleles were inactivated were subjected to HRM-PCR spanning the target region. Cells harbouring 
at least one modified allele are differentiated from wt cells based on deviant melting curves. The method 
does not differentiate cells in which one allele is modified from cells carrying modifications on both 
alleles. Curve-shape analyses cannot distinguish between wt-wt and rare events potentially consisting 
of two identical modified alleles. However, without any exceptions, all DT-resistant cells that we 
analysed displayed HRM curve-shape deviations. Thus, identical modifications in both alleles (via 
potential dominance of particular indel types) may occur, but we did not observe any in our analyses, 
indicating that such events are rare under the applied methodology. 
 
2.2.3.3 PM resistance allows detection and differentiation of specific and non-specific 
integration events 
 
The pac integration cassette is flanked by target gene-specific homology arms (Suppl. Figure S9.1.1). 
Integration via homology-directed double-strand break repair results in target gene promoter-driven pac 
expression, conferring PM resistance251. Thus, pac integration is detected and quantified via PM 
resistance assays in a similar manner to that described for DTr colonies: cells that were co-transfected 
with the CRISPR/gRNA-encoding plasmid and the pac donor plasmid were treated with lethal doses 
(500 ng/mL) of PM to eliminate all cells that lack pac expression (Figure 2.2.1C). In contrast to DTr, 
which results only from specific and complete bi-allelic target gene inactivation, PMr may occur 
independent of the position of integration as long as pac integrates into transcription-enabling loci. Pac 
expression may also occur upon integration into loci that, by themselves, are not transcriptionally active 
but may generate promoter activity in combination with the homology arm located upstream of pac (the 
5’-DPH1 arm may contain such sequences; see Suppl. Figure S9.1.1 legend for details). Non-targeted 
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integration at positions that do not support expression will not generate PMr colonies and is not detected 
in our assays. PM- resistance assays therefore provide conservative (underestimated) estimates of non-
gRNA-targeted integration events. The frequency of site-specific versus non-specific transcription-
enabled integration is examined by comparing double-resistant DTr+PMr colonies and PMr colonies 
(Figure 2.2.1D). 
 
2.2.3.4 Comparison of CRISPR-Cas9-mediated DPH1 inactivation and targeted 
integration events 
 
To compare the frequencies of target-specific inactivation and integration and off-target integration, 
plasmids encoding DPH1-specific CRISPR/Cas9 constructs (Suppl. Figure S9.1.1) were transfected into 
MCF7 cells. These cells were subsequently subjected to HRM-PCR and colony count assays to measure 
DT and PM resistance, as described above. The results of these assays are summarized in Figure 2.2.2, 
and individual datasets are available in Suppl. Table S9.1.1. Figure 9.1.2A shows that complete 
inactivation of the DPH1 gene, indicating functional loss of all DPH1 alleles, occurred at a frequency 
of ~6% of all transfected cells (2.5% of all cells, considering a transfection efficiency of 40%, Suppl. 
Table S9.1.1). DPH1 inactivation showed absolute dependency on the matching gRNA sequence: 
scrambled control RNA (scRNA) did not generate any DTr colonies. A comparison of the frequency of 
HRM hits with the occurrence of DTr colonies is shown in Figure 2.2.2B. These analyses revealed that 
mono-allelic gene inactivation (toxin sensitive HRM-hit) occurred twice as frequently as inactivation of 
both alleles (DTr cells). 
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Figure 2.2.2: HRM-PCR and/or DT-selection of MCF7 cells transfected with the DPH1 gene-specific 
CRISPR/Cas9 expression construct and pac donor plasmid.  
Values are displayed as the % transfected cells. (A) DTr colonies occur only when matching DPH1 
gRNA is used; no colonies emerge in untreated cells or in cells that receive scRNA. Mean values +/- 
SEM are shown. (B) HRM-PCR reveals the frequency of cells that harbour DPH1 modifications on one 
or both alleles. Subsequent DT sensitivity assays show that mono-allelic hits (toxin sensitive & HRM 
positive) occur twice as frequently as inactivation of both alleles (HRM positive & toxin resistant). 
 
Figure 2.2.3 shows a comparison of the frequency of DTr and PMr colonies. Inactivation of both DPH1 
alleles (Figure 2.2.3B) occurred with 30-50-fold higher efficacy than cassette integration events that 
enable pac expression and generate PM resistance (Figure 2.2.3B). Compared with DPH1-specific 
gRNA, scRNA generated 2-fold fewer PMr colonies under otherwise identical conditions, which reflects 
integration events that enable pac expression. Integration events in genomic regions that do not lead to 
pac expression cannot be detected by our assay. It is therefore likely that the number of random 
integration events is greater than the number of PMr colonies. The position of pac integration for 
individual clones cannot be determined via mere determination of colony counts. Preferential gRNA-
mediated integration at the gRNA-defined target gene can nevertheless be deduced by comparing the 
frequency of DTr, PMr, and DTr+PMr double-resistant colonies (without the need for normalization to 
the transfection efficacy or scRNA controls): transfection 40,000 cells with Cas9/DPH1-gRNA + pac 
donor DNA results in the generation of 946 (2.4%) DTr colonies and 24 (0.06%) PMr colonies (Suppl. 
Table S9.1.1). If the two events are unrelated, the probability of observing DTr+PMr double-resistant 
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colonies would be 2.4% x 0.06% = 0.00144%, which translates to an expectation of ≤1 DTr+PMr double-
resistant colony among 40,000 cells if gene inactivation and pac integration are unrelated events. Our 
observation of 12 DTr+PMr double-resistant colonies among 40,000 transfected cells therefore indicates 
a high degree of (preferential) targeted integration at the DPH1 locus. Thus, Cas9/DPH1-gRNA-
mediated integration preferentially occurs at the DPH1 gene. In accordance with preferential integration 
in the DPH1 gene, many of the PMr colonies obtained using the DPH1 guide were DT resistant (Figure 
2.2.3A). In contrast, none of the PMr colonies obtained using scRNA were resistant to DT. Thus, Cas9-
mediated gene inactivation (including that of both alleles) occurs highly specifically and with a much 
higher frequency than targeted pac integration (Figure 2.2.3B).  
 
2.2.3.5 The quantification of gene editing works with another target gene, DPH2 
 
Are the results the results obtained thus far a general feature of CRISPR/Cas9-mediated editing or 
specific to the DPH1 gene? To address this question, we applied an identical approach for Cas9-induced 
modification of the DPH2 gene. DPH2 encodes a different enzyme with a different sequence on a 
different chromosome but is also essential for diphthamide synthesis. DPH2 deficiency renders cells 
resistant to DT in the same manner as DPH1 deficiency275. Thus, the assay principles developed to 
characterize DPH1 modification can also be applied to analyse DPH2 modification. The results of 
DPH2 editing followed by the assessment of DT and PM resistance (with a pac insertion cassette that 
contains DPH2 homology arms) are displayed in Figure 2.2.3C: in line with our observations for DPH1, 
bi-allelic DPH2 inactivation events were observed at a higher frequency than integration of the pac 
expression cassette, showing a fold change of a similar magnitude (~90-fold higher inactivation of 
DPH2 than integration of the pac expression cassette). The absolute numbers of editing events were 
reduced for DPH2 compared with DPH1, possibly due to the different sequence composition of the 
gRNA and homologous arms and/or the accessibility of the DPH2 locus. The differences in the absolute 
numbers of PM-resistant colonies between DPH1 and DPH2 editing may also be due to potential 
promoter activity on the 5’ homology arm of the DPH2-pac cassette. The DPH1 5' homology arm 
encompasses the immediate 5' region of the DPH1 gene, making it likely to contain some form of 
minimal promoter. Thus, insertion of the DPH1-pac cassette may lead to pac expression without a strict 
requirement for insertion behind active promoters (legend to Suppl. Figure S9.1.1B). However, the 
relative efficacy (compared with scRNA) was similar for DPH2 and DPH1. Inactivation was strictly 
dependent on the presence of cognate gRNA. Cassette insertion events that enable pac expression 
occurred more frequently when DPH2 gRNA was used than when scRNA was used (comparing the 
frequency of DT vs PM+DT resistance, see calculation above). The similarity of the DPH1 and DPH2 
editing results indicates that the general findings obtained using this assay system will likely also apply 
to other genes.  
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Figure 2.2.3: PM and/or DT selection of MCF7 cells transfected with DPH gene-specific 
CRISPR/Cas9 expression constructs and pac donor plasmids.  
Mean values + SEM are shown (n=4, ***p<0.001). (A) PM selection generates resistant colonies at a 
2-fold higher frequency when DPH1 gRNA is used compared with scRNA. Combining PM selection and 
DT selection reveals the frequency at which the pac cassette becomes integrated in cells in which both 
DPH1 alleles are inactivated. DPH1 gRNA generates clones with PM-DT double resistance. scRNA 
generates only PMr colonies and no DTr colonies. (B) Comparison of the frequency of DTr (both DPH1 
genes inactivated) colonies and PMr (pac integration at DPH1 or at another site) colonies. The position 
or zygosity of pac integration cannot be determined. (C) MCF7 cells transfected with DPH2-specific 
gRNA and donor DNA were subjected to PM and/or to DT selection. The absolute numbers of gRNA- 
as well as scRNA-mediated editing events are reduced for DPH2 compared with DPH1. The efficacy of 
targeted inactivation and integration may be due to differences in the sequence of the gRNA and 
homology arms and/or target gene accessibility. Reduced ‘efficacy’ of scRNA-mediated integration is a 
consequence of sequence features within the different homology arms of the pac cassette, as the scRNA 
was identical in the DPH1 and DPH2 editing experiments. 
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2.2.3.6 Comparison and optimization of the Cas9 gene-targeting complex: gRNA 
length 
 
Because the outcomes of the DPH1 and DPH2 gene-editing experiments were comparable, it can be 
assumed that our method identifies optimized editing parameters that can be generally applied to many 
other genes. Figure 2.2.4 shows how gene inactivation as well as the integration efficacy and specificity 
of Cas9 gRNAs of different lengths can be assessed and compared. All of the applied gRNAs targeted 
the same stretch of sequence within DPH1 but varied in length from 14 to 26 bases (Figure 2.2.4A, 
details of gRNAs in Suppl. Figure S9.1.1). DTr colony numbers were recorded to reflect target gene-
specific complete (bi-allelic) inactivation. Simultaneously, the numbers of PMr and of DTr+PMr double-
resistant colonies were assessed to monitor cassette integration. As expected, gRNA length influenced 
the efficacy of gene inactivation, with 20mers conferring the maximal DPH1 inactivation efficacy. 
Shortening the complementary stretch to 18 or 16 bases or extending it up to 26 bases retained significant 
specific gene inactivation functionality, albeit with a decreased efficacy compared with the 20mer. 
Reducing the complementary stretch within the gRNA to less than 16 bases (14mer) decreased DPH1-
inactivating functionality to below detection levels. The integration efficacy (assessed by counting PMr 
events) was also influenced by gRNA length. Guides smaller than 16mers (14mers) generated few PMr 
colonies, not exceeding scrambled control background levels. Targeted integration was observed for 
16mers, 18mers, 20mers, 22mers, 24mers and 26mers, with an optimum overall insertion efficacy being 
achieved with 16-18mers. No gain in efficacy was achieved for 22-26mer complementary stretches; in 
fact, stretches longer than 20mer gRNAs reduced the overall number of insertion events. The ratio 
between integration events (PMr) and inactivation events (DTr) can be calculated as an ‘indicator’ to 
identify conditions in which integration occurs with the fewest gene inactivation events. Such conditions 
may be favoured if one desires integration without inflicting excessive non-productive target gene 
damage. Low values (e.g., few PMr relative to DTr colonies) reflect inefficient integration in relation to 
simultaneously occurring inactivation events. High values (more PMr and/or relatively decreased 
numbers of DTr colonies) reflect more efficient integration. We observed the highest insertion-per-
inactivation values for 16-18mers (PM/DT 16mer = 0.0431; PM/DT 18mer = 0.0379) and a significant 
drop for guide RNAs containing 20 complementary bases (PM/DT 20mer = 0.018) or more (p-value 
18mer vs. 20mer = 0.0017; unpaired, two-tailed Student’s t-tests), which indicates that 20mers are quite 
efficient for targeted gene inactivation (in agreement with previous observations142,144-146,294. Shorter 
guides increase the frequency of insertion events (PMr colonies) as a consequence of both targeted and 
nonspecific integration. 
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2.2.3.7 Efficacy and specificity of different gene-editing approaches: enzymes 
 
We compared gene inactivation and integration events and the efficacy and specificity of different 
variants of RNA-guided Cas9 as well as ZFN-mediated gene editing. The length and composition of 
gRNA were kept constant (DPH1 20mer), and three different editing enzymes were applied: (i) 
‘SpCas9’ specifies the Cas9 nuclease from Streptococcus pyogenes, which can be considered the current 
standard application278,295; (ii) SpCas9-HF1 is an engineered variant of SpCas9 with reduced nonspecific 
DNA binding and off-target activity and, hence, a proposed higher fidelity and specificity276; and (iii) a 
ZFN-editing entity that recognizes target sequences via designed zinc finger-mediated protein-nucleic 
acid interactions118,296. 
In the same manner as for gRNA analyses, DTr colonies were recorded to reflect targeted gene 
inactivation, and PMr colonies were recorded to monitor cassette integration (Figure 2.2.4B, Suppl. 
Table S9.1.3). In comparisons of the overall efficacy of gene inactivation and cassette integration, the 
highest values for both parameters were observed using CRISPR/SpCas9. CRISPR/SpCas9-HF 
diminished targeted gene inactivation events to less than 20% of the number of DTr colonies compared 
with CRISPR/SpCas9. The frequencies of PMr (integration) and DT-PM double-resistant colonies 
(integration with targeted gene inactivation) were also reduced. Application of ZFN reduced the number 
of DTr colonies under otherwise identical conditions to less than 60% of the events observed using 
CRISPR/SpCas9. The efficacy of ZFN-targeted inactivation was therefore ~2-fold reduced compared 
with SpCas9 and ~2-3 fold better than that of the engineered SpCas9-HF1. The frequency of PMr 
colonies did not significantly differ between CRISPR/SpCas9 and ZFN. Double-resistant colonies 
(cassette integration with simultaneous gene inactivation) were somewhat (30%) reduced using ZFN 
compared with CRISPR/SpCas9. Calculation of the ratio of DTr (target gene inactivation) to DT+PM 
double-resistant (targeted integration) colonies takes overall efficacy out of the equation, indicating that 
CRISPR/SpCas9, CRISPR/Cas9-HF, and ZFN generated the same level (~4x10-3) of targeted 
integration events per bi-allelic gene inactivation event (Figure 2.2.4C). 
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Figure 2.2.4:  Optimization of gene editing: influence of gRNA length and editing enzymes on 
efficacy and specificity.  
(Transfection control shows neither DTr nor PMr colonies.) Mean values + SEM are shown (n=4, 
**p<0.01, ***p<0.001). MCF7 cells transfected with DPH1-specific Cas9 constructs were subjected 
to PM and DT selection using gRNAs of different lengths (A) or different enzymes (B&C). (A) gRNA 
length affects gene inactivation and integration frequencies. Statistical evaluation of the differences was 
performed by setting the gRNA with the maximum value of resistant clones for each group (i.e., DT; 
PM, DT+PM) as a comparator in relation to which the other gRNAs were set. These comparators were 
as follows: 20mer for DT; 16mer for PM, 18mer for DT+PM. a/b: no significant difference to 
comparator value but significant to respective 20mer gRNA value (p<0.01) (B) Total number of DTr, 
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PMr or DTr PMr colonies under DPH1 editing approaches using 20mer gRNA (CRISPR/Cas9) or 
designed ZFN. The values are compared to the SpCas9 treatment of the respective group (DT, PM, 
DT+PM). (C) Ratio of site-specific integration events/total target gene inactivation events (DTr 
PMr)/DTr. 
 
2.2.3.8 Influence of DNA repair modulators on gene-editing efficacy and specificity 
 
Colony assays for quantifying DTr and PMr cells following DPH gene editing can also be used to address 
the influence of compounds that modulate DNA repair. Activators of homology-directed repair (HDR) 
and inhibitors of non-homologous end joining (NHEJ) modulate gene-editing events and increase 
integration efficacy297,298. To demonstrate the suitability of our technology for determining the effect of 
DNA repair modulators on the efficacy and specificity of editing, CRISPR/SpCas9/DPH1gRNA 
(20mer) editing and pac integration assays were combined with such compounds, and the influence was 
quantified. The DNA ligase IV inhibitor SCR7 pyrazine was applied either 4 hrs before transfection 
(‘early addition’) or 18 hrs after transfection (‘late addition’) of the gene-editing constructs, and 
exposure was continued until 96 hrs after transfection. We used the HDR-active pyrazine derivate of 
SCR7 in our experiments (see Methods section). Similarly, the RAD51 modulator RS-1 (RAD51-
stimulatory compound 1) was added to stimulate HDR. Both compounds were applied at doses that had 
no effect on the growth or viability of MCF7 cells (see Methods section): 1 µM for SCR7 pyrazine, 8 
µM for RS-1, and 1 µM+8 µM for SCR7 pyrazine+RS1. Compared with the DMSO-treated control, the 
addition of RS-1 increased the number of PMr colonies ~2-fold (Suppl. Table S9.1.4). To quantify the 
effect on the overall integration efficacy, the percentage of PMr colonies (gene integration) relative to 
DTr colonies (gene inactivation) was calculated (Figure 2.2.5). The addition of RS-1 at an early time 
point led to a significantly higher integration efficacy; however, it did not affect the integration efficacy 
upon late addition (18 hrs after initiation of editing). Thus, choosing the appropriate (early) time point 
for RS1-mediated HDR stimulation is important for the enhancement of productive editing, confirming 
HDR to be a driver of targeted cassette integration. To a similar degree, early application of SCR7 
pyrazine significantly increased the relative number of integrations (Figure 2.2.5 & Suppl. Table S9.1.4), 
which confirms previous observations of enhanced productive gene editing upon SCR7 pyrazine 
administration298. When both compounds were used, the ratio of PMr relative to DTr was 8.1%, 
compared with 6.5% (only SCR7 pyrazine) or 6.9% (only RS-1). However, these differences/increases 
were not significant (p=0.39 vs RS-1 alone), which is in line with previous observations247,299. 
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Figure 2.2.5: Influence of DNA repair-modulating agents on gene editing.  
MCF7 cells were transfected with plasmids encoding 20mer gRNA, SpCas9 and pac as described 
previously. The solvent control (DMSO), HDR-modulating agent RS-1 (8 µM) and NHEJ-modulating 
SCR7 pyrazine (1 µM) were added either 4 hrs before or 18 hrs after transfection. DT or PM selection 
was initiated 72 hrs after transfection. The percentage of PMr colonies (integration) relative to DTr 
colonies (cleavage) is shown. The values are compared to the DMSO control the respective addition 
time-point. Mean values + SEM are shown (n=4, Φp<0.05, ΛΛp<0.01, ΦΦΦp<0.001). 
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2.2.4 Discussion 
 
Genome editing has emerged as a technology of utmost importance for scientific and potential 
therapeutic applications. Its entire potential is, however, still limited by efficacy and specificity issues 
of the currently applied editing approaches. The presented method enables simple and robust 
quantification and comparison of the efficacy and specificity of gene inactivation and donor cassette 
insertion events. The core principle of this method consists of inactivation of the endogenous diploid 
DPH1 or DPH2 genes, which results (provided it occurs on both alleles) in absolute resistance to DT. 
The additional insertion of the pac gene allows the determination of both targeted and non-targeted 
integration via the respective selection methods. Due to the simplicity and robustness of these readouts 
(colony counts), the method allows exact determination of mono- and bi-allelic target gene inactivation 
and nonspecific versus targeted integration events based on large numbers of individual cells (shown in 
Figure 2.2.6). Furthermore (and in contrast to many existing tools295,300-302), mono- and bi-allelic target 
gene inactivation and integration events can be differentiated. Thus, simple colony counts reflect the 
efficacy of and ratios between productive (integration) and destructive gene editing (inactivation without 
integration). The results obtained by applying this method may be of particular importance in the 
development and optimization of gene-editing approaches, such as methods for the generation of 
genetically defined cell lines or organisms, and potentially also for therapeutic gene editing.  
Evidence that the method delivers ‘generalizable’ results was obtained by comparing editing events 
(colony frequency) involving two different DPH genes. DPH1 and DPH2 encode different enzymes, 
both of which are independently essential for diphthamide synthesis. The results revealed comparable 
efficacies, specificities and destruction/integration ratios for the two genes, which indicates that the 
dependencies and parameters obtained via this method are transferrable to optimization of the editing of 
other genes. As a proof of concept and benchmark validation of our method, we addressed and confirmed 
the influence of several previously analysed parameters on gene editing, as listed below. 
The length of gRNA for CRISPR/Cas9-mediated editing influences the efficacy of nonproductive gene 
inactivation as well as productive targeted integration303-305. In line with previous analyses142, our assays 
unambiguously demonstrate that ‘standard’ 20 mer gRNAs are effective for Cas9-mediated gene 
targeting, generating the highest overall gene inactivation frequency. The simplicity of our assay enables 
the simultaneous assessment of gRNAs of diverse lengths, revealing threshold sizes below or above 
which efficacy becomes compromised. One interesting observation within this context was that the best 
ratios between productive and destructive editing events were observed using 16–18 mer guides. Thus, 
20 mers may be the preferred choice for efficient gene inactivation, while 16–18 mers are preferred if 
one desires integration without excessive destructive editing. Fu et al.295, tested <20 mer gRNAs in gene 
inactivation experiments and observed an efficacy comparable to 20 mers, with simultaneously reduced 
off-target effects. Their analyses were based on mono-allelic GFP gene inactivation. As their method 
36 
 
involved only one target gene per cell, it could not address or differentiate between mono- and bi-allelic 
inactivation events in diploid cells and could not compare insertion events. Our approach (based on large 
numbers of cells and inactivation of normal chromosome-encoded human genes) demonstrated that 
20 mers are more efficient mediators of gene inactivation than shorter guides. Shorter guides increase 
the frequency of insertion events (PM-resistant colonies) as a consequence of either targeted or 
nonspecific integration. 
The choice of gene-editing enzymes, such as CRISPR/Cas9/gRNA or protein (e.g., ZFN)-based 
recognition systems and derivatives, is another factor that influences editing efficacy and possibly 
specificity. Our method is not restricted to the standard CRISPR/Cas9 system and can be also applied 
to monitor gene-editing efficacy for other gRNA-targeted Cas9 derivatives or protein-targeted 
approaches, such as those based on ZFN116-118,151,296,306,307. In the comparison of ZFN, CRISPR/Cas9 and 
HF-Cas9 editing, we observed the highest overall efficacy of gene inactivation and cassette integration 
for the ‘original’ CRISPR/SpCas9 system. Compared with this system, reduced efficacy was observed 
for both the ZFN and high-fidelity HF-Cas9 variant systems. In agreement with previous observations276, 
HF-Cas9 dramatically reduced scRNA-mediated (hence, most likely non-specific) integration events to 
below-detection limits.  
The specificity of gene editing was assessed by comparing the frequency of colonies emerging under DT 
selection (bi-allelic target gene inactivation), PM selection (cassette integration) and DT+PM double 
selection (inactivation and integration). Target gene inactivation via CRISPR/spCas9 or HF-Cas9 occurs 
with ‘absolute’ dependence on gRNA specificity, i.e., only when applying cognate gRNAs without any 
scRNA background. In contrast, scRNA background was observed (as expected) when assessing PMr 
colonies. Our colony count assays are not suited to assessing the position of pac integration for 
individual clones, which would require sequencing, involving either many cells in a population (without 
differentiating alleles of individual clones) or defined clones (defined allele compositions of a limited 
number of events). Our approach deduces the probability of targeted integration events according to 
comparison of the frequency of DTr, PMr, and DTr+PMr double-resistant colonies, based on large 
numbers of individual colonies. This approach requires neither normalization of transfection efficacy 
nor scRNA controls, as all data stem from a single editing experiment assessing DTr, PMr and DTr+PMr 
double-resistant colonies. DTr and PMr colony numbers reflect the individual frequency (e.g., in % of 
transfected cells) of gene inactivation or integration, and the frequency of DTr+PMr double-resistant 
colonies indicates whether (and to what degree) the two events are individual events or are ‘linked’. The 
‘extremes’ of these calculations (frequency of DTr+PMr)=(frequency of DTr)x(frequency of PMr) would 
correspond to pac insertion occurring nonspecifically without gRNA involvement or all PMr colonies 
are also being DTr (frequency of DTr+PMr)=(frequency of PMr). In the latter case, all pac insertions 
would occur at the target gene (as the coincidence of double target gene inactivation with non-targeted 
insertion elsewhere is negligibly low). The degree of independence or linkage of DTr and PMr colonies 
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can therefore be regarded as a measure of specificity when comparing different editing approaches or 
editing modulators. 
Compounds that modulate recombination have recently been used to increase the efficacy of productive 
(integration) editing. Examples of such compounds include the ligase IV inhibitor SCR7 pyrazine (see 
Methods section for details of the compounds) for modulation of non-homologous end-joining (NHEJ) 
and the homology-directed repair (HDR) stimulator RS-1297,298. The suitability of our method for 
determining the effect of NHEJ- and HDR-modulating agents on gene editing allows us to compare it 
to available screening approaches described in the literature. The application of our method to editing 
in combination with these compounds confirmed all previous observations of SCR7 pyrazine- and RS-
1-mediated increases in efficacy298. Pinder et al. invented a FACS-based assay that exploits the site-
specific integration of a fluorescent protein. This approach detects integration within single cells, yet 
without addressing zygosity or quantifying off-target integration247. In contrast to their approach, our 
readout is based on the phenotype resulting from endogenous gene modification and allows the 
quantification of NHEJ repair as well as site-specific repair and HDR (via double selection, and the 
probability of co-event comparison, see above). Furthermore, our ‘colony count assays’ recapitulate the 
animal-based results of Song et al.297, demonstrating HR/NHEJ ratios (gene inactivation-to-integration) 
of below 10% as well as RS-1-mediated enhancement of HR and integration. It must be noted that in 
contrast to other assessment technologies247,297, our method permits the assessment of modulators in a 
simple ‘downstream-assay free’ cell culture setting and could serve as a screening or pre-selection 
technology before initiating in vivo studies. Cell-based colony count approaches are high-throughput 
compatible, and death vs survival readouts are very robust. Thus, the method can (in addition to the 
examples above) be used to measure and quantify editing events in the context of various additional 
parameters, which may include the assessment and further characterization of modulating compounds 
and/or the definition of active components of compounds whose activities are under discussion (e.g., 
SCR7 vs SCR7-pyrazine as a DNA ligase I/III and/or IV inhibitor308). It also enables the screening of 
potential additional editing enhancer candidates, collections or libraries (including recombination and 
repair modulators), identification of the most effective mode of delivery for editing entities (mRNA, 
protein or DNA) as well as the composition of the donor cassette (length of insert and homology arms) 
for targeted insertions. 
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Figure 2.2.6: Frequency of CRISPR/Cas9-mediated gene-editing events.  
The average event frequencies obtained via determination of the numbers of PMr, DTr and double-
resistant cells upon CRISPR/Cas9 editing of DPH1 with 20mer gRNA are shown. DT-sensitive mono-
allelic DPH1-edited cells are quantified based on HRM-PCR results indicating a 2:1 ratio of mono- vs 
bi-allelic inactivation events. Site-specific integration can result in DTs PMr colonies (integration at 
DPH1 with the 2nd allele unaltered) as well as double-resistant DTr PMr colonies (integration and bi-
allelic DPH1 inactivation). * PMr colonies occurring following scRNA editing may be due to homology 
arm-mediated integration at the target gene (pac cassette contains homology arms) or to integration at 
transcription-enabling non-target sites. As integration events that do not enable transcription are not 
detected, the overall nonspecific integration frequency, including non-expression-enabling events, is 
expected to be higher than indicated. 
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2.2.5 Materials and Methods 
 
2.2.5.1 Cultivation of MCF7 cells and transfection of plasmids encoding gene-editing 
entities 
 
MCF7 cells309 were originally obtained from the ATCC (Manassas, VA, USA) and maintained in RPMI 
1640 medium supplemented with 10% FCS, 2 mM L-glutamine and penicillin/streptomycin at 37°C and 
85% humidity. Within a set of experiments, we used one batch of cells to ensure that the comparisons 
and conclusions that we made were not affected by variance in the speed of colony formation. Between 
the experimental sets, we thawed new cell batches to ensure that the cells did not develop genomic 
alterations over time. For the transfection of plasmids harbouring gene-editing constructs, 3,000,000 
cells were seeded in a 10 cm-diameter culture dish and cultivated at 37°C in a humidified 5% CO2 
atmosphere. At 24 h after seeding, the cells were transfected with 20 µg of total DNA using jetPEI 
(Polyplus) according to the manufacturer’s protocol, except that an N/P ratio of 6:1 was employed. 
Transfection efficiency was determined 24 h thereafter via flow cytometry (FACSCalibur, BD 
Biosciences) of cells that were transfected with an eGFP expression plasmid310. Plasmids encoding 
CRISPR/Cas9 editing entities targeting DPH1 (gRNA target: CAGGGCGGCCGAGACGGCCC 
derived from RefSeq: NM_001383) and DPH2 (gRNA target: TCGTACACTCCGTCCAGGTC 
derived from RefSeq: NM_001039589, NM_001384), as well as scrambled control RNA (scRNA: 
GCACTACCAGAGCTAACTCA) were obtained from Origene (DPH1# KN221955; DPH2# 
KN201382). This system comprises one plasmid expressing gRNA under the control of a U6 promoter, 
Cas9 nuclease under the control of a CMV promoter, and a donor plasmid with a promoter-less pac 
expression cassette flanked by homologous arms to the target gene (DPH1 or DPH2, see Suppl. Figure 
S9.1.1 for details). Additional DPH1 gRNAs of different sizes (Origene) included the 14mer 
GGCCGAGACGGCCC; 16mer GCGGCCGAGACGGCCC; 18mer GGGCGGCCGAGACGGCCC, 
22mer AGCAGGGCGGCCGAGACGGCCC; 24mer GGAGCAGGGCGGCCGAGACGGCCC and 
26mer GCGGAGCAGGGCGGCCGAGACGGCCC (Suppl. Figure S9.1.1). 
 
2.2.5.2 Quantification of CRISPR/Cas9-mediated bi-allelic DPH1 and DPH2 gene 
inactivation 
 
MCF7 cells in which all chromosomal copies of DPH1 or DPH2 are inactivated are DT resistant275. 
Thus, the occurrence and frequency of toxin-resistant cells/colonies upon gene inactivation provide a 
measure of the efficacy of inactivation of all gene copies. MCF7 cells were transfected as described 
above using (i) a GFP expression plasmid, as a transfection control; (ii) the CRISPR/Cas9 DPH1 or 
DPH2 knock-out/integration system; and (iii) knock-out/integration entities containing scRNA, as a 
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control. After determination of the transfection efficiency, 10,000-40,000 cells were seeded in 6-well 
plates. RPMI medium was exchanged with RPMI medium containing DT (2 nM) 3 days after cell 
seeding. The medium was exchanged every 2–3 days until dead cells became detached. Between day 12 
and day 14 after the initiation of toxin exposure, cells were washed 3 times with PBS and stained with 
ice-cold methylene blue (0.2% in 50% EtOH), followed by gentle washing under running water. Stained 
and fixed colonies were recorded via microscopy counting on 5x5 mm grid foil for orientation. The 
complete raw data (i.e., colony numbers from individual experiments) are provided in the supplementary 
information (Table S9.1.1). 
 
2.2.5.3 Detection of CRISPR/Cas9-mediated mono-allelic DPH gene inactivation 
 
Cells in which only one DPH1 or DPH2 allele is modified are DT sensitive. To identify and quantify 
such events, high-resolution melting (HRM) PCR was applied in a similar manner as previously 
described275: 24 h after transfection, single cells were deposited in 96-well plates through FACS 
(FACSAriaTM, BD Biosciences) and grown to confluency. The cells were washed with PBS and lysed 
by the addition of 40 µL of cell lysis buffer (Roche) per well. After 15 mins of incubation at RT on a 
plate shaker (Titramax 1000, Heidolph) at 750 rpm, the cell lysate was diluted 1:5 with PCR-grade H2O. 
Then, 5 µL of the cell lysate was mixed with HRM master mix (Roche) and primers spanning the gRNA 
target sequence. PCR and HRM were performed on the LC480 II platform (Roche) according the 
manufacturer’s protocol. Clones with edited target genes were identified based on melting curve 
deviations compared with MCF7-wt cells. Cells displaying biphasic melting curves may still possess 
one wt allele, or both alleles may be inactivated. Because nuclease-mediated gene inactivations are 
independent events in different alleles, they are rarely identical in both alleles (in our hands, all DTr 
colonies displayed bi-melting curve-shape deviations. Differentiation between wt and two identical 
modified alleles by HRM is in principle also possible because the melting temperatures of wt and 
mutated alleles differ if only one base is changed (the principle of HRM-mediated SNP-diagnostics 
(ref.292 and293)). We nevertheless suggest ‘abnormal curve shape’ as a readout because this readout is 
simple and robust, is not influenced by potential DNA, salt or buffer content variations in cell extracts 
and, hence, does not require highly standardized procedures for extract preparation. Clones displaying 
melting curve deviations were expanded without DT or PM selection and subjected to viability analyses 
to discriminate between toxin-sensitive mono-allelic and resistant bi-allelic knockout cells. These assays 
were performed in 96-well plates containing 10,000 cells at 37°C in humidified 5% CO2. At 24 hr after 
seeding, the cells were exposed to toxin for 72 h. Metabolic activity was assessed via the CellTiter Glo® 
Luminescent Viability Assay (Promega). 
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2.2.5.4 Identification and quantification of CRISPR/Cas9-induced transgene 
integration 
 
In addition to the Cas9 nuclease and gRNA or scRNA, the applied CRISPR/Cas9 knock-out/integration 
system also contained a pac expression cassette without a promoter to avoid transient expression flanked 
by homologous arms for HDR (donor DNA). Thus, detection of the integration of recombinant 
sequences into the genome was performed via determining the PM sensitivity of cells. The frequency of 
both events (gene inactivation and integration) was detected through the application of DT and PM. 
MCF7 cells were transfected and treated as described for the identification and quantification of gene 
inactivation, applying PM (500 ng/µL) or a combination of PM (500 ng/µL) and DT (2 nM). Complete 
data (i.e., colony numbers from individual experiments) are provided in the supplementary information 
(Table S9.1.1). 
 
2.2.5.5 Identification and quantification of ZFN-mediated DPH1 gene editing 
 
MCF7 cells in which all chromosomal copies of DPH1 are inactivated are DT resistant275. Thus, the 
occurrence and frequency of DTr colonies following ZFN-mediated gene inactivation and/or cassette 
integration provides a measure of the efficacy of inactivation of all gene copies. The ZFN recognition 
sequence (CAGGTGATGGCGGCGCTGGTCGTATCCGGGGCAGCGGAGCAG, cleavage site) is 
derived from NM_001383.3 (DPH1-wt) and was obtained from Sigma. A pac integration cassette for 
this position was obtained from Origene. MCF7 was transfected as described above using (i) a GFP 
expression plasmid, (ii) the plasmid encoding DPH1-targeting ZFN and (iii) the DPH1-targeting pac 
integration cassette. After determination of the transfection efficiency, the cells were seeded in 6-well 
plates. For quantification of bi-allelic knock-out events, (DTr) 20,000 cells were seeded; 40,000 cells 
were seeded for the quantification of integration events (PMr) or double resistance. RPMI medium was 
exchanged with RPMI containing DT, PM or both 3 days after seeding. The medium was changed every 
2–3 days. Between day 12 and day 14 after the initiation of toxin exposure, cells were washed 3 times 
with PBS and stained with ice-cold methylene blue (0.2% in 50% EtOH), followed by gentle washing 
under running water and microscopic determination of colony numbers using 5 mm grid foil. 
 
2.2.5.6 Quantification of the effects of HDR and NHEJ modulators on CRISPR/Cas9-
mediated editing 
 
RAD51-stimulatory compound 1 (RS-1) was applied to modulate homology-directed repair (HDR) 
during gene editing297. RS-1 (Sigma, R9782) was dissolved in DMSO to generate a stock solution of 10 
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mg/mL, which was diluted in RPMI medium just before application to cells. Viability (Promega CTG) 
assays identified a final concentration of 8 µM RS-1 as a dose that does not inflict growth-inhibitory or 
toxic effects on MCF7 cells (viability: 1 µM, 100%; 3.7 µM, 100%; 11 µM, 97%; 33 µM, 61%). The 
DNA ligase IV inhibitor SCR7 pyrazine was applied to modulate non-homologous end joining (NHEJ) 
during gene editing298. SCR7 pyrazine (Sigma, SML1546) was dissolved in DMSO to generate a stock 
solution of 10 mg/mL, which was diluted in RPMI medium just before application to cells. Viability 
(Promega CTG) assays identified a final concentration of 1 µM as a dose that does not inflict growth-
inhibitory or toxic effects on MCF7 cells (viability: 0.37 µM, 100% 1.1 µM, 100%; 3.3 µM, 97%; 10 
µM, 88%). SCR7 pyrazine (1 µM final conc.), RS-1 (8 µM final conc.) or SCR7 pyrazine+RS-1 (1 µM 
+ 8 µM final conc.) was added to MCF7 cells 4 hrs before transfection of the gene-editing constructs in 
the ‘early exposure´ setting. For ‘late exposure’, SCR7 pyrazine (8 µM final conc.) or RS-1 (1 µM final 
conc.) was added to MCF7 cells 18 hrs after transfection. In both settings, the cells were exposed to the 
modulators until 96 hr after transfection, i.e., ‘early exposure’ consisted of treatment for a total of 100 
hrs and ‘late exposure’ for a total of 78 hrs. The system for determining the effects of DNA repair 
modulators consisted of MCF7 cells transfected with the CRISPR/SpCas9 constructs including DPH1 
20mer gRNA and then subjected to DT and PM selection, as described above. The frequencies of DTr, 
PMr, and double-resistant colonies were recorded to reflect gene inactivation and cassette integration 
events. 
 
 
2.2.5.7 Statistics 
 
Unpaired, two-tailed Student’s t-tests were performed for single comparisons between two treatments. 
Multiple comparisons were statistically analysed via a one-way ANOVA, followed by Tukey’s honestly 
different significance (HDS) post hoc test. A significant difference was defined by a p-value of < 0.05. 
The level of significance determined using Student’s t-test or Tukey’s HDS test is indicated in graphs 
by one, two or three symbols (*, Λ or Φ) corresponding to p < 0.05, p < 0.01 and p < 0.001, respectively. 
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3 TriFabs--Trivalent IgG-Shaped Bispecific Antibody 
Derivatives: Design, Generation, Characterization  and 
Application for Targeted Payload Delivery. 
 
 
 
3.1 Review 
 
 
3.1.1   Introduction 
 
Antibodies or antibody derivative mediated targeting has been successfully applied to specifically direct 
compounds across the whole bunch of molecule classes like small chemical compounds, peptides, 
proteins, small nucleic acids or even whole cells to the cells or tissue of interest.177,311 But also many 
novel gene therapeutic approaches make use of antibody mediated delivery to direct nanoparticle 
forming lipids and polymers or even whole capsids to the target tissue.171 According to this variety of 
applications, the landscape of antibody formats is equally diversified.312 As the antibody formats in this 
thesis as well as the majority of recombinant, therapeutic antibodies and antibody derivatives originate 
from immunoglobulin G (IgG) antibodies, the focus is solely on this antibody class, but with mentioning 
that further antibodies classes exist: IgA, IgD, IgE and IgM.313,314  
The general architecture of an IgG antibody for the first instance is a tetramer of about 150kDa with two 
symmetric halves.315,316 Each halve consists of a heavy and light peptide chain (HC and LC respectively, 
figure 3.1.1).315,316 Moreover, the peptide chains HC and LC can be subdivided in variable (VH and VL) 
as well as constant regions (CH1-CH3 and CL) with separate domains.316 In addition, the antibody can 
be dissected in a fragment antigen binding (Fab) and a fragment crystallisable (Fc), with the Fab 
consisting of the light chain and VH and CH1 of the heavy chain and the Fc comprising the dimer of the 
CH2 and CH3 domains.316,317 The two fragments are connected via a flexible hinge region between CH1 
and CH2. Pairing of LC and HC and of the two HCs is stabilized by interchain disulphide bonds.315 For 
all antibody classes, two types of light chains exist, namely kappa and lambda. Finally, the light chains 
can be combined with four different types of IgG heavy chains that define the particular subtype (IgG1-
IgG4).318 The four heavy chains show high similarity and differ mainly in the hinge region with some 
differences in the surface-exposed residues of the constant domains (CH1, CH2 and CH3).314  
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Figure 3.1.1 Antibody structure and nomenclature. 
Schematic depicting the basic structure of an antibody and associated nomenclature:  The light chain 
(shown in brown) consists of a variable (VL) and a constant (CL) domain while the heavy chain (shown 
in grey) consists of a variable (VH) domain and three constant domains (CH1, CH2 and CH3). 
Interchain disulfide bonds within the hinge region stabilize overall antibody structure. The 
complementarity determining regions (CDR, shown as striped lines) determine antigen specificity. The 
glycosylation patterns can also affect function (shown in green). From: Molecular properties of human 
IgG subclasses and their implications for designing therapeutic monoclonal antibodies against 
infectious diseases.313 
 
 
The functional property of an IgG antibody is not only the specific interaction with its antigen, mediated 
by the paratope (the antigen binding site in the variable domains of the Fab).313 Furthermore, the Fc 
region, interacts with a variety of accessory molecules: the Fc gamma receptor (FcγR), the complement 
component C1q and the neonatal Fc receptor (FcRn) (Figure 3.1.2).319-323 Every interaction mediates 
different downstream effector functions like antibody-dependent cellular cytotoxicity (ADCC) mainly 
via FcγRIII interaction or complement dependent cytotoxicity (CDC) via C1q interaction.319-322 In lieu 
of potential cytotoxic downstream effect, interaction with the FcRn prolongs the serum half-life of an 
antibody.323,324 After internalization of an IgG, presence of the FcRn inside the vesicular system can bind 
the antibody and mediate back transport to the cell surface via recycling endosomes instead of lysosomal 
degradation.323 The binding site for FcγR includes parts of CH2 and hinge, the interaction with C1q 
occurs within CH2 and FcRn binds at the junction of CH2 and CH3.325-331 All three interactions can be 
modulated by a conserved glycosylation site at N297 in CH2.332,333   
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Figure 3.1.2 Structure of IgG antibodies with its Fc interaction sites. 
A General structure of an IgG antibody with its LC displayed in brown and HC in grey, Fc binding sites 
are marked with colored dashed circles (FcRn in purple, C1q in turquois, FcγR in pink); B Crystal 
structure of the Fc region with highlighted FcRn, C1q and FcgammaR binding sites with the color code 
in A; Glycosylation at N297 is displayed in green. From: Molecular properties of human IgG subclasses 
and their implications for designing therapeutic monoclonal antibodies against infectious diseases.313 
 
Therapeutic antibodies are engineered for the intended use with deletion of certain features like lack of 
ADCC or CDC if only a conjugated payload has to be delivered.334 Alternatively, an antibody domain 
can be extended by single chain Fabs (scFab) or Fvs (scFv) at the N- or C-terminus of the heavy or light 
chain.179 One opportunity by this approach is to increase the valency (number of antigen binding sites) 
and in case of a cell surface antigen for example, the overall binding strength (avidity).179 On the other 
hand by fusion of scFab or scFv with specific affinity to another antigen, bi- or multispecific antibody 
derivatives are obtained with ability to bind two or more different antigens.335 With the various 
applications of bispecific antibodies and engineering progress realizing recombinant production with 
correct assembly dramatically increased the number of bispecific formats in the past two decades.336  
Examples for such bispecific antibody derivatives are described and characterized in the manuscript 
“TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization 
and Application for Targeted Payload Delivery” that is summarized and discussed in the following.  
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3.1.2 Summary and discussion 
 
The intended application of the antibody or antibody derivative in this thesis is as mentioned the targeted 
delivery of a payload, here a large nucleic acid. As described above, connection between antibody and 
the large DNA payload should have certain features: simple payload coupling in a defined manner, the 
easy switch of payload variants and a non-covalent connection to enable release of payload from the 
antibody. A system with these properties is the so called hapten system.216 The basic principle is that 
bispecific antibodies are generated that bind the cell surface antigen for tissue targeting as well as a 
small molecule like biotin (Bio) or digoxigenin (Dig).216,337-339 This enables the coupling of theoretically 
any molecule or entity that contains the matching hapten. The manuscript on the one hand shows that a 
novel antibody format, the TriFab, is highly compatible to this system and on the other hand 
demonstrates the broad applicability of the hapten binding principle. The key idea behind the TriFab is 
to generate a trivalent, bispecific antibody derivative without massively changing the shape of a 
conventional IgG. To generate trivalent binding properties, a third Fv was inserted instead of the CH2 
domains. Therefore, one CH2 domain was exchanged by a VL and the other CH2 by VH (Figure 3.2.1a). 
To ensure that binding in between the two Fabs is not sterically hindered, the hinge region is replaced 
by linker peptides without disulphide bonds. To enable production of this molecule, several properties 
were considered and implemented. Instead of the hinge region, the stabilization of this molecule is 
realized by introduction of a disulphide bond in the additional Fv region (CysH44 and CysL100) and in 
the CH3 domain (Cys354 and Cys349). All in all, instead of the Fc part as for a conventional IgG, the 
TriFab contains a stem region with VH/VL and CH3 domains. To increase the production efficiency, 
pairing of the right TriFab halves (one comprising VL instead of CH2 with another one comprising VH 
instead of CH2) has to be fostered. To favor this pairing over VH-VH and VL-VL homodimerization, 
the knob-into-hole technology was implemented (Figure 3.2.1b).340 This technology is based on the 
replacement of five amino acids at the interface of the pairing CH3 domains. One CH3-domain contains 
a tryptophane at kabat position 366 and a tyrosine at kabat position 407. As these amino acids contain 
“large” sidechains, this CH3 domain represents the knob side. The CH3-domain of the other antibody 
halve contains serine, alanine and valine at kabat position 366, 368 and 407 respectively. As the side 
chains of these amino acids are rather short, this CH3 domain represents the hole side. As the stem 
region consists of two asymmetric dimers (VH-VL and CH3knob - CH3hole) stabilized by interchain 
disulphides, heterodimerization is strongly favored over respective homodimers (VH-VH/knob-knob 
and VL-VL/hole-hole). In practice, only the right TriFab molecule is obtained after purification without 
detectable homodimers, enabling a straight forward production process. Another aspect of this 
manuscript is the description of recombinant antibody production which is in principle transferable to 
the most recombinant antibodies or antibody derivatives. The major steps of our protocol are the 
transient expression in HEK cells, followed by a two-step chromatographic purification of the 
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supernatant, first by affinity (kappa select or protein A) chromatography and second by size exclusion 
chromatography (Figure 3.2.1c). 
After the appropriate design of the constant part of this TriFab format, the variable regions can be 
exchanged to generate various bispecific formats. In case of the hapten system, formats with either two 
valences against the cell surface antigen (CSA) and one valency against the hapten or with two valencies 
against the hapten and one against the CSA can be generated. As hapten binders, Fvs against Biotin 
(antiBio) and against Digoxigenin (antiDig) were characterized. It could be demonstrated that the hapten 
– antihapten interaction with the Fv in between the stem region has comparable properties to the 
interaction of hapten with the parental IgG regarding specificity and the off-rate binding kinetics, but 
with somehow slower on-rate for the biotin binder most likely due to sterical hindrance. As the 
haptenylated payload is coupled to the antibody by pre-incubation, most applications are not limited by 
a slightly reduced on-rate for hapten binding (Table 3.2). These data were generated with haptenylated 
oligonucleotides, therefore also proving compatibility of the hapten system with nucleic acids. The 
affected on-rate may become more critical if the stem region contains the paratope against the cell 
surface antigen. The sterical hindrance and the reduced avidity due to monovalent binding together may 
result in reduction of targeted delivery efficacy. This is in line with the observation that the fluorescent 
signal is reduced with TriFabs binding monovalent to the cell surface in comparison to the bivalent CSA 
binder. Finally, delivery of large payloads was addressed with haptenylated saporin, a plant toxin 
without unspecific membrane binding domain (Figure 3.2.3).291 It could be demonstrated that the TriFab 
specifically and efficiently mediates toxin delivery, as cell viability only gets reduced with the TriFab 
against the antigen that is expressed on the cell surface (Lewis Y on MCF7 cells). The benchmark 
antibody format used for comparison of targeted payload delivery, is the previously described hapten 
binding 2+2 bispecific antibody (2+2 bsAb) format.6,339 This antibody format consists of a conventional 
IgG against a cell surface antigen that is extended by a scFv against a hapten at the C-terminus of each 
heavy chain. In detail, the fusion molecule comprises a glycine/serine peptide linker at the C-terminus 
of CH3, followed by the variable domains specific for either biotin or digoxigenin binding, that are also 
connected via a glycine/serine peptide linker to generate a scFv. The resulting molecule binds the cell 
surface antigen bivalent like a conventional IgG and is also able to bind two haptens via the HC C-
terminal scFvs. The bivalent CSA binding TriFab demonstrates comparable targeting specificity and 
similar delivery potency compared to the 2+2bsAb. As the monovalent CSA binding TriFab also 
displays reduced efficacy (comparable to fluorophore delivery) in toxin delivery, further development 
of the gene delivery system focusses on monovalent hapten binding TriFab and the 2+2 bsAb format. 
Interesting parameters that might influence gene delivery efficacy and differ between TriFab and 2+2 
bsAb are the valency of Hapten binding, FcRn recycling and geometry. In terms of gene delivery 
efficacy, bivalent Hapten binding might be favored to increase the payload-to-antibody ratio or to 
strengthen the binding of antibody and nucleic acid, if it contains more than one Hapten that can be 
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bound simultaneously by one antibody. Monovalent Hapten binding might be favoured if bivalent 
binding is too strong and therefore preventing release or tends to crosslink payloads resulting in 
aggregation. FcRn recycling might be critical if the serum half-life of the gene delivery system can be 
or has to be prolonged by this mechanism. Finally, the geometry might influence the efficacy of 
membrane translocation mechanisms. For example, if the antibody is designed that CSA binding results 
in a close proximity of payload and cell membrane, membrane interaction and translocation might be 
facilitated. 
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3.2 Manuscript 
 
3.2.1 Abstract 
 
TriFabs are IgG-shaped bispecific antibodies composed of two regular Fab arms fused via flexible linker 
peptides to one asymmetric third Fab-sized binding module. This 3rd module replaces the IgG Fc region 
and is composed of VH fused to CH3 with ‘knob’-mutations, and VL fused to CH3 with matching 
‘holes’. The hinge region does not contain disulfides to facilitate antigen access to the 3rd binding site. 
To compensate the loss of hinge-disulfides between heavy chains, CH3 knob-hole heterodimers are 
linked by S354C-Y349C disulphides, and VH and VL of the stem region may be linked via VH44C-
VL100C disulphides. TriFabs which bind one antigen bivalent in the same manner as IgGs and the 2nd 
antigen monovalent ‘inbetween’ these Fabs can be applied to simultaneously engage two antigens, or 
for targeted delivery of small and large (fluorescent or cytotoxic) payloads. 
 
3.2.2 Introduction 
 
Many different types and formats of bispecific antibodies (bsAbs) have been generated over the past 
years. These combine specificities of two antibodies in one molecule and enable binding of different 
epitopes or antigens342,343. BsAb formats include large Fc-containing molecules 344-346 as well as small 
entities, composed of two or more variable or even smaller binding domains fused to each other347,348. 
A large variety of bsAb formats were designed so far because different formats are required to address 
different therapeutic profiles. Factors that affect the choice and composition of bsAb formats include 
binding geometry and orientation of binding modules to each other (target accessibility, crosslinking), 
valences (avidity effects) and size (distribution and PK). In addition to that, robustness, stability, and 
manufacturing aspects are important points to consider for the development of bsAbs. This work 
describes the design, generation, and characterization of a novel IgG-shaped bispecific trivalent TriFab 
with novel composition and binding region geometry. Functionality of TriFabs is demonstrated by their 
ability to simultaneously bind to two antigens, and by applying TriFabs for bsAb-mediated targeted 
delivery of fluorophores or toxins to tumor cells. 
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3.2.3 Results and Discussion 
3.2.3.1 Design and Generation of TriFabs  
 
The composition of TriFabs and the designed linker regions that connect the individual binding modules 
are shown in Figure 3.2.1a: two regular Fab arms are fused via flexible linker peptides to an asymmetric 
Fab-like entity which replaces the IgG Fc. This entity, which we term “stem region”, is composed of 
VH fused to CH3 with “knob”-mutations, and VL fused to CH3 with matching “holes”. The hinge region 
linker peptides that connect to the Fab arms do not contain interchain disulfides. This facilitates antigen 
access to the third binding site. To compensate the loss of hinge-disulfides between the heavy chains, 
the CH3 knob-hole heterodimer (T366W + T366S, L368A, Y407V according to the Kabat numbering 
scheme349) is linked by additional S354C-Y349C disulphides (Figure 3.2.1b)348,350. In addition, variable 
region of the heavy chain (VH) and variable region of the light chain (VL) of the stem region can be 
linked via additional (H44-L100) interchain disulphides351. This disulphide stabilizes the correct H-
chain heterodimer, but it is not mandatory for heterodimerization to generate functional molecules: CH3 
knob-hole interactions by themselves already provide sufficient heterodimerization, and the VH and VL 
domains that are also part of the stem region provide additional contributions.  
 
A comprehensive description of the design including all fusion points and deviations from normal IgG 
sequences are provided in Figure 3.2.1. TriFabs were designed that address cell surface antigens—LeY, 
CD33, GPC3—and simultaneously bind digoxigenin or biotin- (hapten-)coupled payloads216,337-339,352. 
These TriFabs were produced transiently in HEK293 cells by co-transfection of three plasmids for 
CMV-promoter driven expression345 of the three protein chains that together in a 2 + 1 + 1 ratio comprise 
TriFabs. These components are two light chains, one VH-CH3knob and one VL-CH3hole chain 
(Experimental Section). TriFabs become secreted into culture supernatants in the same manner as IgGs, 
indicating that hinge- and CH2 replacement does not compromise the folding and assembly process353 
of these bsAbs. We observed that TriFabs do not bind to Protein A (see Figure S9.2.1c for experimental 
details) because effective protein A capture of IgG involves the CH2 domain at the CH2-CH3 interface 
which is deleted in TriFabs. Purification is therefore achieved by protein-L followed by size exclusion 
chromatography. This generates TriFabs with yields of 3–20 mg/L (average 8 mg/L without process 
optimization, supplemental data). Due to the combination of the strong dimerizer domain CH3354 with 
four asymmetric hetero-dimerization modules (VH-VL + knob-holes + 2 interchain disulfides), purified 
TriFab preparations contain only desired knob-hole heterodimers without detectable amounts of 
wrongly assembled homo-dimers. 
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Figure 3.2.1: Design and generation of TriFabs.  
(a) TriFabs have the IgG hinge replaced by linker peptides without disulfides, and the CH2 regions by 
VH or VL. Hetero-dimerization is achieved by disulphide-stabilized knob-into-hole CH3, and by 
introducing a H44-L100 disulphide in the Fv. Interchain disulfides that connect light and heavy chains 
and the engineered stem heterodimer are indicated by black bars; (b) Fusion sequences linking CH1 
with VH or VL with CH3. The N-terminus of Dig-VH and GPC3-VH is QVQL, DVQL for LeY-VH, EVQL 
for CD33-VH. The N-terminus of Dig-VL is DIQM, GPC3-VL DVVM, LeY-VL DVLM and CD33-VL 
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DIQL. The N-terminal elbow region of CH3 hole is EIKG for GPC3, LeY and Dig, and EVKG for CD33; 
(c) TriFabs are purified from cell culture supernatants by affinity chromatography with kappa-select 
(left panel, Protein A does not capture our TriFabs). After loading supernatants to the column (left peak 
in Figure 1c), TriFabs were eluted with 100 mM Glycine-buffer (pH 2.5), subsequently adjusted to pH 
6.0–7.5 with 1 M Tris (pH 9.0). This is followed by size exclusion chromatography (middle panel). 
Shaded boxes indicate fractions containing properly folded TriFab. The composition and purity of 
TriFabs obtained by this simple two-step procedure is shown in the SDS PAGE without (n.r.) and with 
(r.) sample reduction (right panel). The purification profiles are exemplarily shown for TriFabs with 
CD33-CD33-Dig specificity. The purification and profiles of other TriFabs are described in the suppl. 
data section. 
 
3.2.3.2 Stability of TriFabs 
 
A problem that is frequently observed for a variety of engineered antibody derivatives is protein 
instability. To assess stability of TriFabs, we measured temperature-induced aggregation and unfolding 
by light scattering and tryptophan fluorescence, respectively (details in the Experimental Section and 
supplemental data). To evaluate stability of the format (independent of the specific binding regions), 
temperature-induced aggregation and unfolding was assessed for TriFabs that bind different cell surface 
antigens (CD33, LeY, GPC3) as well as different haptens (Bio, Dig). The results of these analyses (Table 
3.1 and supplemental Figure S9.2.2) reveal that TriFabs are rather stable molecules with aggregation 
onset temperatures between 51 and 61 °C and denaturation temperatures between 58 and 66 °C for all 
TriFabs that were analysed (CD33-Dig, LeY-Dig, GPC3-Dig, CD33-Bio, LeY-Bio, GPC3-Bio). These 
temperature stability values are in the range of typical antibodies355-357. 
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Table 3.1: Thermal stability of TriFabs.  
Temperature-induced aggregation and unfolding of various TriFabs (hapten-specificity in the stem-Fv) 
was measured by light scattering and tryptophan fluorescence (details in M&M and supplemental data, 
Figure S9.2.2). Listed are aggregation onset temperatures (Tagg) defined as the temperature at which 
the scattered light intensity begins to increase, and denaturation temperatures (Tm) defined as inflection 
points of curves that represent ratios of fluorescence intensities at 350 and 330 nm. 
TriFab Tagg (°C) Tm (°C) 
CD33-CD33-Bio 57 58 
CD33-CD33-Dig 51 66 
GPC3-GPC3-Bio 56 58 
GPC3-GPC3-Dig 61 65 
LeY-LeY-Bio 52 59 
LeY-LeY-Dig 60 66 
 
 
3.2.3.3 TriFabs Retain the Binding Properties of Two Antibodies 
 
TriFabs access one antigen by their two Fab arms with the same affinity, orientation, and the same 
bivalent manner as regular IgGs. Surface resonance (SPR) analyses confirm that the two Fab arms of 
TriFabs bind antigen in the same manner as Fab arms of IgGs from which they were derived (Table 3.2). 
The second antigen is bound by the variable region of the “stem region” (as defined above), which is 
flanked by the Fabs. This Fv binds with the same affinity to digoxigeninylated payloads (antigen is a 
small hapten, payloads are oligonucleotides or fluorophores), or in one case specific but with reduced 
affinity to another biotinylated payload (a biotinylated oligonucleotide). The interspersed Fv also bind 
carbohydrate and protein antigens such as LeY, CD33 or GPC3 with the same specificity and (as shown 
for the CD33 antigen) with the same affinity as monovalent binding entities (Fabs) of their 
corresponding parent antibodies. Table 3.2 and Figure 2c summarize the results of surface plasmon 
resonance (SPR) analyses of the TriFabs with three different cell surface target specificities: The 
bivalent Fab arms of TriFabs bind antigen in the same manner as parent antibodies. The monovalent 
stem Fv (exemplarily shown for CD33 antigen, Biotin and Digoxigenin) has monovalent affinity 
(equivalent to a monovalent Fab fragment in case of CD33). Binding efficacy of the Fv that is part of 
the stem region (VH/VL-CH3) to cell surfaces depends on avidity, epitope accessibility and potential 
steric hindrance (which may explain the reduced affinity of biotin binders). Cell surface antigens CD33, 
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GPC3 or LeY are accessible to Fv in the stem region in a monovalent manner and generate lower cell 
associated signals via fluorescence-activated cell sorting (FACS) analyses compared to bivalent binding 
(Figure 3.2.2). 
 
Table 3.2: Antigen binding properties of TriFabs 
Surface plasmon resonance (Biacore) measurements were applied to compare the affinities of TriFabs 
with those of their parent IgGs (see Figure 3.2.2c). Applied antigens were mono-biotinylated or mono-
digoxigeninylated oligonucleotides, CD33Fc, LeY-BSA or recombinant GPC3 as previously described. 
* Data have been previously describ216,339,352. Because the CD33 antigen is a (dimeric) Fc-fusion 
protein, monovalent binding of the reference molecule was determined with a monovalent Fab to avoid 
avidity effects. 
Format SPR 
LeY  
Arm 
GPC3  
Arm 
CD33  
Arm 
CD33  
Stem 
Dig  
Stem 
Bio  
Stem 
IgG 
ka (1/Ms) 1.5 ×105 8.5 × 104 3.9 × 105 1.9 × 10
5  
(Fab) 6.2 × 10
5 * 2.0 × 107 * 
Kd (1/s) 5.0 × 10−4 2.9 × 10−4 1.7 × 10−3 6.4 × 10
−3  
(Fab) 9.8 × 10
−3 * 1.0 × 10−2 * 
KD (M) 3.3 × 10−9 3.4 × 10−9 4.3 × 10−9 3.4 × 10
−8  
(Fab) 1.6 × 10
−8 * 6.2 × 10−10 * 
TriFab 
ka (1/Ms) 1.5 × 105 8.6 × 104 4.0 × 105 2.4 × 105 5.3 × 105 2.9 × 106 
Kd (1/s) 4.9 × 10−4 2.9 × 10−4 1.6 × 10−3 7.5 × 10−3 5.2 × 10−3 1.5 × 10−2 
KD (M) 3.2 × 10−9 3.4 × 10−9 4.1 × 10−9 3.1 × 10−8 9.8 × 10−9 5.1 × 10−9 
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Figure 3.2.2: TriFab mediated targeted delivery of a small molecule.  
(a) TriFabs specific for glypican3 (GPC3352), CD33 or LeY216 combined with Dig-specificity were tested 
by FACS on LeY+,CD33− MCF7, CD33+,LeY− MOLM13 and GPC3+,Ley−,CD33− HepG2 cells with 
Dig-Cy5 payload216. “+” indicates expression of the listed antigen “−“indicates lack of expression. The 
binding specificities of the Fab arms are represented for each analysed molecule as “numerator” and 
the specificity of the Fv in the stem region as “denominator” with matched colour (except for Dig-Cy5 
only or cells only which are light blue or black, respectively). Specific cell surface and hapten-binding 
is observed for TriFabs that bind cells with Fab arms and hapten in the stem region. Specific cell surface 
and hapten-binding is also observed for TriFabs that bind hapten bivalent with Fab arms and CD33 or 
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GPC3 or LeY monovalent in the stem region; (b) TriFabs that have the Dig-binding moiety replaced by 
Biotin-binding moieties show same functionality when coupled to the payload Bio-Cy5337,338; (c) 
Comparison of the SPR-determined affinities of Biotin-binding TriFabs which bind cell surface antigens 
with their Fab arms (bivalent) and Biotin (monovalent) with their stem-Fv. Listed are the on (ka) and 
off rates (kd) on y- and x-axes, respectively, as well as the resulting KD values (diagonal panels). 
Dashed circle: the Bio-binding of the stem region remains unaltered irrespective of which target antigen 
is addressed by the TriFab. 
 
3.2.3.4 TriFabs enable tumor targeted payload delivery of protein toxins 
 
TriFabs that bind cell surface antigens as well as haptens were generated to evaluate TriFab-mediated 
payload delivery. Specific delivery of small compounds was demonstrated by FACS analyses of cells 
that were simultaneously exposed to digoxigeninylated fluorophores (Dig-Cy5,216), and to TriFabs that 
bind cell surface antigens and digoxigenin. Figure 3.2.2a shows that TriFabs deliver the small 
fluorescent compounds only to cells that express the cognate antigen on their surface: LeY-Dig delivers 
Dig-Cy5 to LeY-expressing MCF7 cells but not to LeY negative HEPG2 or Molm13 cells. Glypican-3 
(GPC3) binding TriFabs deliver specifically to HEPG2 and CD33-binding TriFabs specifically to CD33 
expressing Molm13 cells. Cell surface binding efficacy of TriFabs depends on valences and/or geometry 
of their cell surface binding arms. TriFabs that have their cell surface binding functionalities in bivalent 
Fab arms have higher Cy5-signals than cells that become targeted with TriFabs that bind to cells via 
their monovalent Fv in the stem region. Targeted delivery of small compounds is not restricted to 
TriFabs that bind to digoxigenin and Digoxigenin-containing payloads but works also for TriFabs that 
bind different haptens. Figure 3.2.2b shows that biotin-binding TriFabs can be applied in the same 
manner to deliver biotinylated payloads. 
 
3.2.3.5 TriFabs Enable Tumor Targeted Payload Delivery of Protein Toxins 
 
TriFab-mediated targeted delivery of large molecules was demonstrated with digoxigenin-coupled 
saporin. Saporin is a plant-derived ribosome inactivating protein which becomes cytotoxic upon binding 
to and uptake into cells. By itself, however, saporin does not possess a cell binding functionality291. 
Because of that, only targeted delivery of saporin to and into cells generates cytotoxicity. Figure 3.2.3a 
shows that TriFabs (left panel) can be applied to specifically target Saporin to antigen expressing cells. 
Application of LeY-Dig binding TriFabs and Dig-saporin efficiently kills LeY expressing MCF7 cells. 
In contrast, Dig-Saporin by itself or coupled to TriFabs that recognize CD33 instead of LeY do not 
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induce cytotoxicity in CD33 negative MCF7. Biotinylated saporin becomes specifically delivered to 
target cells in the same manner by Bio-binding TriFabs, however with somewhat reduced potency 
compared to Dig-Saporin (suggesting that the attached hapten may modify payload potency). A 
comparison with targeted delivery of Dig-Saporin by previously described IgG-derived (2 + 2) bsAbs 
(two binding entities for each target,216), or with Fab-derived fusion proteins (one cell surface binding 
entity) revealed that TriFabs retained at the same payload delivery potency than Fc-containing (bivalent 
target addressing) bsAbs and appear to have better potency compared to Fab-derived bsAbs that bind 
the LeY antigen in a monovalent manner (Figure 3.2.3). 
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Figure 3.2.3: TriFab mediated targeted delivery of a large molecule.  
The applied bsAb formats are schematically depicted on the right (cell targeting entities in blue, Dig-
binding entities in red and Bio-binding entities in green colour). (a) TriFab specific for Dig and GPC3 
or CD33 or LeY combined with Dig-Saporin or Bio and GPC3 or CD33 or LeY combined with Bio-
Saporin were applied for targeted delivery of saporin. TriFab-Saporin complexes were generated by a 
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simple and robust charging procedure as previously described for hapten-coupled payloads216,337-339: 
Dig-Saporin and TriFabs are incubated in a 1:1 molar ratio in cell culture medium for at least 15 min, 
followed by subsequent dilution to the concentrations indicated. BrdU incorporation and ATP-content 
(Cell Titer Glo, CTG) assays were applied to measure the viability of cells 48 h after exposure to TriFab 
and Saporin; (b) Targeted delivery of Dig-Saporin with IgG-derived (two antigen binding sites + two 
Dig-binding sites) or Fab-derived (one antigen binding site + two Dig-binding sites) bsAbs of the same 
targeting specificity indicates that TriFabs have at least the same specificity and delivery potential as 
other bsAb Formats (monovalent cell surface targeting with LeY specificity is less potent than bivalent 
(avidity-enhanced) targeting). 
 
3.2.4 Materials and Methods 
3.2.4.1 Expression of TriFabs 
 
TriFabs were produced by co-transfection of three expression plasmids216. One plasmid encodes the L-
chains of desired antibodies, the other two plasmids encode separate modified H chains. The positions 
of mutations and alterations in these H-chains are defined by the Kabat numbering convention349. These 
two H-chains contain linker peptides without disulphides instead of the hinge region, and VHcys44 or 
VLcys100 domains fused to CH3-domains with disulphide-stabilized knobs or holes heterodimer 
(T366W + T366S, L368A, Y407V; + S354C-Y349C disulphide) respectively. The components become 
expressed by CMV promoter driven transcription in HEK293 suspension cells that are grown at 37 °C 
in a humidified 8% CO2 environment. Seven days after transfection, culture supernatants that contain 
the secreted assembled antibody derivatives are sterile filtered and either immediately subjected to 
purification (Figure 3.2.1c), or stored frozen at −80 °C (thawed at room temperature prior to 
purification). 
 
3.2.4.2 Purification of TriFabs 
 
Hi Trap Kappa-select (GE Healthcare, Amersham Place, Little Chalfont, UK) is applied as first 
purification step as the molecules that we generated did not bind to protein A (see supplemental data). 
After loading supernatants to the column (left peak in Figure 3.2.1c) TriFabs were eluted with 100 mM 
Glycine-buffer (pH 2.5), subsequently adjusted to pH 6.0–7.5 with 1M Tris (pH 9.0). Subsequently, 
homogenous TriFab preparations are obtained by applying size exclusion chromatography (SEC, 
Superdex200 HiLoad 16/60, GE Healthcare) equilibrated with 20 mM histidine, 140 mM NaCl, at pH 
6.0 on an Aekta Avant (GE Healthcare) as previously described for IgG-derived bispecific antibodies216. 
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Yields were between 3–20 mg TriFab/L (2LeY-1Dig = 3.0 mg/L, 2Dig-1LeY = 5.7 mg/L, 2CD33-1Dig 
= 20.3 mg/L, 2Dig-1CD33 = 6.9 mg/L 2GPC3-1Dig = 3.5 mg/L, 2Dig-1GPC3 = 8.3 mg/L). 
 
3.2.4.3 Characterization of TriFabs 
 
FACS analyses were applied to assess specific binding of TriFabs to cell surface antigens as well as 
targeted delivery of small compounds. Therefore, cells were exposed to hapten-binding TriFabs 
followed by incubation with haptenylated fluorophores216,337,338. Specific binding is indicated by 
detection of TriFab-mediated fluorophore accumulation on cell. To analyze TriFab mediated targeted 
delivery of protein toxins, cells which either do or do not express the cognate antigen on their surface 
cultured in 96 well plates are exposed to TriFab-Toxin complexes for 48 to 72 h. Subsequently, DNA 
synthesis is determined by BrdU incorporation assays after 48 h. Affinities of recombinant TriFabs were 
determined by Surface Plasmon Resonance measurements as previously described216. 
 
3.2.4.4 Stability Analyses 
 
Thermal stability was assessed using an Optim1000 instrument (Avacta Analytical Inc., Thorp Arch 
Estate, Wetherby, UK) recording light scattering and tryptophan fluorescence simultaneously while 
heating samples with a constant heat rate. Samples were prepared at 0.3–1 mg/mL in 20 mM histidine, 
140 mM NaCl, pH 6.0 and transferred to a 9 µL multi-cuvette array and heated from 30 to 90 °C at a 
constant rate of 0.1 °C/min. The intensity of scattered light and the fluorescence emission spectra was 
recorded after excitation with a 266 nm laser providing a data point approximately every 0.6 °C. Light 
scattering intensities were plotted against temperature and aggregation onset temperature (Tagg) defined 
as the temperature at which the scattered light intensity begins to increase. For the unfolding readout, 
the ratio of the fluorescence intensities at 350 and 330 nm were plotted as a metric for the shift in peak 
position against the temperature. Denaturation temperature (Tm) is defined as the curve inflection point 
(Figure S9.2.2). 
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3.2.5 Conclusions 
 
TriFabs are shaped like IgGs, composed of antibody derived domains, and of sufficient size (150 kDa) 
to avoid renal clearance. In contrast to IgG’s, they lack CH2 domains. These domains, in particular 
residues and structures at the CH2-CH3 interface, are important for binding of IgGs to Fc-interacting 
molecules including Fc-receptors and protein A (PDB:1L6X358,359). Alternative interactions of protein 
A with VH (VH3) domains have also been described (PDB:1DEE360), but those do not enable protein A 
binding of our molecules. In consequence, our TriFabs do not bind to protein A (see supplemental data). 
 
Presence of a functional CH2 and of an intact CH2-CH3 interface region is also required to bind to the 
neonatal Fc receptor (FcRn361,362). Lack of CH2 prevents interaction with FcRn and hence, without that, 
TriFabs will not undergo FcRn mediated recycling. Because of that, it is very likely that TriFabs will 
have pharmacokinetic properties similar to IgG derivatives that are devoid of FcRn binding sites361,362, 
which needs to be confirmed in animal studies. 
 
Removal of CH2 affects not only the pharmacokinetics of TriFabs but renders them also deficient in 
other Fc functionalities. This includes lack of induction of antibody-dependent cell-mediated 
cytotoxicity (ADCC) which is triggered by binding of Fc-Receptors (FcgRIII), involving CH2. ADCC 
is an important contributor to therapeutic efficacy of antibody therapies, in particular for protection from 
viral infections or for ADCC mediated elimination of tumor cells. Obviously, such therapeutic 
approaches in virology or oncology that have ADCC induction (or other Fc mediated functionalities) as 
major efficacy contributors cannot be met by a CH2-deficient TriFab. On the other hand, inability to 
trigger ADCC can be desired if one aims at antibody-mediated neutralization or depletion approaches 
(for example removal of angiogenic ligands or removal of inflammatory stimuli) while avoiding direct 
and potentially damaging cellular effects. 
 
Lack of ADCC competence is of minor concern for bsAb mediated targeted delivery of cytotoxic 
payloads into cells, exemplarily shown in Figure 3.2.3. This principle (ADCs and ADC like molecules) 
requires effective internalization of antibody-payload complexes following target cell binding and is 
hence rather incompatible with ADCC (IgG needs to be surface accessible to trigger ADCC). In contrast 
to most ADCs, tumor-targeting hapten-binding TriFabs are defined entities that have cytotoxic payloads 
coupled to the stem-Fv in a position- and stoichiometry-defined manner. Such TriFabs are therefore well 
suited for payload targeting approaches. 
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Many different antibody formats have been generated since the take-off of the bispecific antibody field 
and its proven applicability for diagnosis and therapy342-348,350,363-366. This includes small Fv-derived 
entities with short serum half-life due to renal filtration (such as BiTEs,361), as well as large Fc containing 
molecules with extended serum half lifes216,337-339. The majority of bsAb formats that have been applied 
so far (and that are in clinical development) are composed of 1 + 1 or 2 + 2 formats, i.e., possess one 
binding site for each different antigen or two binding sites per antigen338,339,342-344,346,347,350,364. Some 
selected examples for previously published 2 + 1 formats (similar to TriFabs with two binding entities 
for one and one entity for another antigen) have been generated by the dock&lock method366, or as knob-
into-hole IgGs fused to disulphide-stabilized Fv’s345. All these 2 + 1 formats differ in “binding 
geometry”, i.e., positioning and special orientation/distance of the binding modules to each other. One 
additional advantage of the TriFab format over other knob-into-hole containing bsAbs is that the fusion 
of additional heterodomerization promoting modules (VH and VL) to the modified CH3 domains results 
in a “super-heterodimerization” entity. Desired heterodimerization of the stem region is thereby 
promoted by two distinct interactions, each of which by itself being already sufficient to drive 
heterodimerization. CH3 knob-hole interactions by themselves are sufficient for heterodimerization, the 
VH and VL domains of the stem region (also independently sufficient) provide additional contributions, 
and the generated stem region is further stabilized by an interchain disulphide between VH and VL. 
 
Valency, orientation or distance between binding modules are parameters that influence the functionality 
of bispecific antibodies, dependent on targets to be addressed and functionalities to be achieved. Because 
of that, there is not one “optimal format” for bsAbs. Instead, different formats may need to be applied 
for different applications. For example, bivalency of binding to cell surface antigens may be desired to 
achieve preferential (avidity mediated) binding to cells with abundant cell surface target expression. On 
the other hand, bivalent engagement of cell surface targets such as receptors may (dependent on the 
addressed targets) also change their internalization, and thereby either promote or attenuate uptake of 
bsAbs and of attached payloads. Other indications such as “bridging approaches” aim at generating tight 
connections between targets or target cells while other applications need rather independent separate 
binding events (e.g., to inactivate two soluble ligands or for targeted payload delivery). 
 
Regarding cell targeting approaches, the binding geometry of TriFabs with two normal Fab arms and 
one interspersed stem-Fv mediates efficient (and avidity enabled) binding of the Fab arms. Monovalent 
binding of the interspersed Fv may also be unrestricted for some accessible and/or flexible cell surface 
antigens (carbohydrates/glycans may be particularly suited as paratope 2 antigens). However, paratope 
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2 binding may also be sterically hindered, depending on the target antigen and epitope in particular for 
large and/or complex antigens. For example, the antigen 2 may need to “squeeze” between the paratope 
1 binding Fab arms, which would affect the on-rate in a similar manner as described in345. Such reduced 
binding affinity to paratope 2 (monovalent and potentially sterically compromised) may, in some cases 
of cell surface targeting approaches, be compensated by the bispecific binding principle: the unrestricted 
bivalent Fab arms keep the TriFab in place and prevent its dissociation from cells. This, in turn, provides 
additional time for the interspersed Fv to bind (or re-bind in case of dissociation due to monovalency), 
compensating for a “bad” on-rate of the interspersed binding module. Thus, the bsAb principle can 
compensate potential affinity deficits of paratope 2 binders on cell surfaces, provided the bsAb geometry 
permits simultaneous binding of both paratopes. Simultaneous binding of two antigens may be applied 
to address “close proximity” requirements, which are necessary for inducing cell to cell contacts, e.g., 
in cancer immune-therapy. 
 
In conclusion, TriFabs can be applied to simultaneously address or crosslink accessible target antigens, 
for imaging, or for targeted (or pre-targeted) delivery of small and large payloads to tumor cells. 
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4  Targeting of chromatin – A novel, fully mammalian 
derived strategy for specific delivery of CRISPR/Cas9 
expression plasmids 
 
 
 
4.1 Review 
 
 
4.1.1   Introduction 
 
Viral systems as well as synthetic polymers and lipids have their advantages for gene delivery as initially 
described but especially for systemic application they also have particular limitations. Safety concerns 
like genotoxicity or potential immunogenicity with inflammatory response or fast clearance are the 
hurdles of a viral delivery system.58,367,368 Moreover also viral systems need specific targeting domains 
to address certain tissues for gene transduction.173 As the production of viral systems in a standardized 
process for a constant quality is quite complex, the extension to the fusion of targeting domains makes 
it highly challenging.59,369 Synthetic systems are in contrast easy to produce but face other hurdles for 
systemic application.62,195,370 These systems in most cases are rather inefficient with a higher risk 
mediating direct cytotoxicity instead of genotoxicity compared to their viral counterparts.62,195,370,371 In 
addition they also need specific targeting domains and even their fusion does not completely abolish 
uptake by non-target tissues/organs predominantly the liver or lung.175,372 Due to these hurdles novel 
systems have to be developed to generate a viable alternative to these systems. As specific targeting to 
the cells of interest can be achieved with antibodies and their derivatives as described in the previous 
chapter, concepts have to be developed that do not interfere with antibody targeting and mediate the 
subsequent steps for successful gene delivery, the vesicular escape and transfer into the nucleus with 
efficient expression of the transgene. As the existing non-viral gene delivery systems highlight, the most 
crucial step is the DNA membrane translocation.62,193 For development of novel concepts in this field, 
the first step is to outline the common features of successful gene delivery vehicles. One of these features 
is the DNA compaction for size and charge reduction.373-375 Viral capsids tightly pack their nucleic acids 
in the inner space of the capsid.374 Similarly, cationic lipids also pack the nucleic into the inner micellar 
space and reduce their charge by electrostatic interaction as it is the principle for cationic polymers, 
too.375  In addition, all these compaction approaches lead to protection of the nucleic acid from 
65 
 
degradation by nucleases.204 Most important all these vehicles interact with the cell membrane most 
often after internalization.197,376,377 Finally, the components of most delivery systems are non-covalently 
associated with its nucleic acids to ensure release into the cytoplasm and functionality inside the 
nucleus.174,378-380 These properties are considered at the beginning of developing a targeted delivery 
system, to avoid implementation of potential bottlenecks. 
On top of this initial consideration, a novel technology should address the limitations or disadvantages 
of the existing systems. The common disadvantage of all currently available efficient DNA delivery 
systems is that they are of non-human or non-mammalian origin and therefore bearing the potential risk 
of being immunogenic.168,213-215  
One mechanism that seems to fit all the requirements is the organization of DNA into chromatin via 
histone assembly. The organization into chromatin is an evolutionary conserved mechanism to compact 
DNA in a highly efficient manner as this mechanism realizes that DNA fibers of about two meters total 
length fit into the nucleus.382 The subunit of a chromatin fiber is called the nucleosome.383 Every 
nucleosome consists of a nucleosome core particle and the linker histone H1.383,384 In genomic 
organization of chromatin this linker histone leads to further compaction of DNA fiber and enable its 
further organization into a compact chromatin fiber.384 The nucleosome core particle consists of a 
histone octamer that is formed by a dimer of a histone H2A, H2B, H3 and H4 hetero tetramer and a 
DNA double strand of 147 base pairs (bp) which is wrapped around the octamer 1.5 times.383-385 Another 
property that in principle matches the initial considerations for development of a gene delivery system 
is that the nucleosomal organization depends on non-covalent charge interaction of the histone subunits, 
which leads to protection from nucleases and does not require chemical modification for DNA binding 
potentially interfering with functionality.385,386 Furthermore, studies suggest that histones contain 
transduction domains that interact with the cellular membrane and enable vesicular release.387-390 
Therefore, the following manuscript exploits this mechanism and demonstrates how chromatin assembly 
can be used for targeted gene delivery. 
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4.1.2 Summary and discussion 
 
Chromatin can be efficiently assembled on supercoiled circular plasmid DNA via salt gradient 
dialysis.391 Slow reduction of the salt concentration mediates binding of histone subunits to DNA and 
assembly of chromatin with cooperative nucleosome formation (binding at DNA adjacent to 
neighboring nucleosomes).392 At a salt concentration below 2 M NaCl, formation of nucleosomes is 
initiated starting with the binding of H3/H4 tetramers to DNA.393 With further reduction of the NaCl 
concentration, H2A/H2B dimers bind at H3/H4 tetramers with completion of Nucleosome assembly at 
0.6 M NaCl.393 The resulting chromatin can be stored at a salt concentration of 0.3 M NaCl or less.393 
The quality of the assembled chromatin can be assessed by partial nuclease digestion.386,391 As the 
associated histones protect the DNA from degradation, an endonuclease can only cut DNA in between 
the linker region of chromatin.386,391 If the chromatin is not assembled efficiently, large linker regions 
exist, that can be cut readily by micrococcal nuclease (MNase) for example. Analysis of the resulting 
fragments by agarose gel electrophoresis would result in a single band of 147 bp (DNA length wrapped 
around one histone octamer) with a subnucleosomal smear below this band. High quality chromatin as 
obtained by an optimized assembly procedure as described in the manuscript (Figure 4.2.1A), results in 
bands of multiples of147 bp without subnucleosomal smear, as the linker regions are rather short (around 
50 bp).  
The next step is the connection to the targeting domain to enable efficient and specific cellular uptake 
of plasmid chromatin. As mentioned above the hapten binding bispecific antibodies are a suitable format 
to couple various payloads. However, to analyze the influence of chromatin assembly and to avoid 
chemical modification of DNA, a system that enables DNA and chromatin association in the same 
manner and with similar efficiency is desired. As chromatin and DNA is negatively charged, one 
possibility is to use nucleic acid binding peptides.394,395 Such peptides are most often amphipathic and 
positively charged and complex nucleic acids via charge interaction with the phosphate backbone.394,395 
One prominent example is a peptide derived from the trans-activator of transcription (tat) protein of 
human immunodeficiency virus type 1 (HIV-1), a well described positively charged peptide that binds 
siRNA or DNA.396 In addition to nucleic acid binding, this peptide can contribute to the vesicular escape 
of nucleic acids (also of other biologics) via its cell penetrating activity, what might be advantageous 
for gene delivery systems, too.396 To stick to entities of human or mammalian origin, alternative peptides 
of this origin are required. Previous work of Haas et al. identified peptides of human origin that are able 
to bind siRNA and can also mediate their intracellular delivery similar to tat.397 CPXM2 has been 
identified as the most potent double stranded DNA binding peptide out of the “best hits” of the screen 
by A. Haas. Therefore, a haptenylated (biotin) version of this peptide is used as a “connector” between 
DNA and a hapten binding bispecific antibody or antibody derivative (Figure 4.2.1B). As described in 
the previous chapter, monovalent hapten-binding TriFabs as well as bivalent hapten-binding 2+2 
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bispecific antibodies are used for this approach. Characterization by microscale thermophoresis revealed 
that bivalent hapten binding 2+2 bsAbs bind with higher affinity to DNA and chromatin probably due 
to avidity effects (Figure 4.2.1C and Supp Figure S9.3.2). As no crosslinking and aggregation effects 
are observed with both antibody formats (Supp Figure 9.3.1), 2+2 bsAbs are preferred over monovalent 
hapten binding TriFabs because of the higher binding affinity. In addition, we could demonstrate by 
FACS analysis that DNA and chromatin is delivered equally efficient by 2+2 bsAbs to MCF7 tumor 
cells (Figure 4.2.2). No unspecific uptake of the untargeted complex or naked chromatin was observed, 
demonstrating that chromatin delivery is solely mediated by the targeting antibody via specific antigen 
binding.  
Next, it was investigated whether targeted delivery results in reporter gene expression and therefore 
DNA transfer into the nucleus (figure 4.2.3). In contrast to unassembled plasmid DNA, targeted delivery 
of plasmid DNA assembled into chromatin resulted in reporter gene expression in about 90% of overall 
treated tumor cells. Moreover, no cytotoxicity was observed with the targeted chromatin system as well 
as with the untargeted system or any component of it. Excited by these results, the intracellular 
distribution of these constructs was further investigated. Confocal microscopic analysis revealed that 
DNA but not antibody is detected in the nucleus after chromatin delivery (Figure 4.2.4). This confirms 
the initial assumption that release from the antibody seems to be important to enable nuclear delivery. 
However, if the intact chromatin accumulates in the nucleus or if the chromatin disassembles along this 
route (inside the vesicles or the cytoplasm) remains unknown. One approach to address this topic might 
be the dual labeling of DNA and histones to identify both molecules inside the nucleus. For this 
approach, modified chromatin competent for specific histone labeling is required and histone labelling 
must not affect the translocation efficacy.  
Finally, plasmid DNA encoding the previously analyzed CRISPR/Cas9 system for Dph1 knock-out was 
assembled into chromatin (Figure 4.2.5A). With this the technologies described in the first two 
manuscripts, the hapten system and the genome editing quantification assay, were combined with the 
here described third technology, the chromatin targeting, to reach the final goal of this thesis: the targeted 
delivery of genome editing systems. After application of this system, almost 4% of the treated cells 
contained a homozygous knock-out (ratio of DT resistant colonies to overall seeded cell number) with 
absolute specificity, as no resistant colonies formed after application of the untargeted system (Figure 
4.2.5B and Table 4.2)). With a knock-out frequency of 2.5% obtained with transfection, the developed 
system has at least comparable potency than transfection but in combination with high cell surface 
antigen specificity. To increase the knock-out frequency, the major focus towards optimization of 
targeted gene editing is not the delivery system but the expressed genome editing system, e.g. 
development of more potent Cas9 enzymes or ZNFs, as discussed in chapter 2.  
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As the delivery system efficiently mediates gene transfer just with human entities, the risk of 
immunogenicity seems to be rather low. However, as chromatin predominantly occurs inside the nucleus 
of a cell, it is usually not exposed to the immune system.398 For this reason, the tolerance of chromatin 
by the immune system has to be addressed. One argument why chromatin might be tolerated by the 
immune system is that in some cases chromatin is present in the blood stream.399,400 For example, 
chromatin is secreted by neutrophils to serve as traps for various bacteria.399,400 Another argument might 
be that chromatin might be shielded by the antibody or antibody-peptide constructs. Another aspect is 
the bio-distribution in-vivo. Despite the high specificity in vitro, the in-vivo distribution has to be 
addressed, to measure off target uptake, e.g. into the liver.  
Independent from these results, various optimization strategies to further improve this novel delivery 
system are conceivable. If it turns out, that intact chromatin is delivered into the nucleus, one strategy is 
to optimize the epigenetic regulation to achieve appropriate expression of the transgene.401,402 The use 
of histones with defined histone tail modifications might enable fine tuning of the expression level.401,402 
For example, acetylation at the lysine 9 of histone 3 tails can be introduced to increase expression level 
by maintaining transcriptionally active chromatin.401,402 In addition to that, histone variants like H2A.Z 
can be used for assembly to further modulate the expression level.403,404 Another strategy is to improve 
the assembly reaction by defining nucleosome positioning for example.405,406 This might influence the 
expression of DNA but also might reduce variances in chromatin activity by definition of the number 
and position of nucleosomes per DNA plasmid.407 
Another aspect is the engineering of the system towards a more defined and covalent construct, as this 
system comprises several non-covalent assemblies, the DNA-histone binding, the peptide DNA 
association and the hapten – anti hapten interaction. But as a targeted gene delivery system requires a 
careful balancing of binding and release, covalent conjugation might require extensive engineering 
effort.204 The results obtained in this thesis suggest that the release of DNA from the antibody after 
internalization is a critical parameter for successful DNA delivery. However, for systemic application, 
the attachment of DNA or chromatin to the antibody has to be stable in circulation to avoid premature 
release.204 This controversial paradigm is the hurdle for most targeted delivery approaches of 
intracellularly active molecules.204 One possibility is the covalent conjugation of DNA or chromatin and 
antibody via cleavable linkers.381,408,409 The progress in design and synthesis of novel linkers allow more 
precise cleavage time-points with higher cleavage efficiency at the right time-point.381,408,409 However, 
choosing the right linker and presupposes to know the right release time-point. For example a cathepsinB 
cleavable linker (Valin-Citrullin) might efficiently release the payload in the late endosomal 
compartments, but if translocation potentially takes place in the early compartments, vesicular escape 
will not take place.381,408,409 Furthermore, a linker might also not be suitable, if the cleavage product 
influences functionality of a gene delivery system (membrane translocation or gene expression).381,408,409 
And finally also the conjugation site matters. For example conjugation of the linker at the targeting 
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domain or DNA payload can influence the functionality of the delivery system (e.g. sterical hindrance 
of cell surface binding) or the accessibility of the cleavage site.381,409 Taken together, all these aspects 
demonstrate that covalent systems might be beneficial, but huge effort has to be made for identification 
of a suitable chemical connection.  
Another strategy is to fine-tune the binding and release of a non-covalent system by implementing 
triggers for dissociation of the payload after internalization. One example is the previously published 
hapten system extended by a disulphide bond (Hap S-S) which fosters release of payload inside the 
vesicular system, as the disulphide bond predominantly gets reduced in the vesicular compartments.337  
Moreover, it has to be outlined, how CPXM2 peptide contributes to the vesicular escape of plasmid 
DNA. With this data, either strategies for direct antibody-chromatin coupling or strategies for integration 
of a cell penetrating peptide (like CPP-histone fusion) might be favored.  
All in all, this thesis led to the development of a novel concept for targeted gene delivery that is distinct 
to the common viral and synthetic strategies. However, despite the advantages of this system (only 
human/mammalian entities, no toxicity, high efficiency and specificity), some parameters have to be 
addressed to check whether this concept is suitable for further drug development (in-vivo distribution 
and activity, pharmacokinetics and immunogenicity).   
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4.2 Manuscript 
 
 
4.2.1 Abstract 
 
We report a novel system for efficient and specific targeted delivery of large nucleic acids to and into 
cells. Plasmid DNA and core histones were assembled to chromatin by salt gradient dialysis and 
subsequently connected to bispecific antibody derivatives (bsAbs) via a nucleic acid binding peptide 
bridge. The resulting reconstituted vehicles termed ‘plasmid-chromatin’ deliver packaged nucleic acids 
to and into cells expressing antigens that are recognized by the bsAb, enabling intracellular functionality 
without detectable cytotoxicity. High efficiency of intracellular nucleic acid delivery is revealed by 
intracellular expression of plasmid encoded genes in most (~90%) target cells to which the vehicles 
were applied under normal growth/medium conditions in nanomolar concentrations. Specific targeting, 
uptake and transgene expression depends on antibody-mediated cell surface binding: plasmid chromatin 
of identical composition but with non-targeting bsAbs or without bsAbs is ineffective. Examples that 
demonstrate applicability, specificity and efficacy of antibody-targeted plasmid chromatin include 
reporter gene constructs as well as plasmids that enable CRISPR/Cas9 mediated genome editing of target 
cells. 
 
4.2.2 Introduction 
 
Addressing acquired or inherited diseases by providing gene products or by modifying the genetic setup 
of patients is the primary concept of gene therapy.1-4 In general, the manifold particular gene therapy 
concepts can be divided in ex vivo or in vivo approaches.6 During an ex vivo gene therapy cells of interest 
are isolated from the patient for subsequent treatment with the therapeutic gene followed by re-
administration of the genetically modified cells. 6-8 The in vivo approach on the contrary is based on 
direct local or systemic injection of a gene delivery system to treat the target cells or tissue.6,246 The 
common goal for both approaches is the efficient transfer of the genetic material over the cell membrane 
and finally into the nucleus.207,410 To mediate successful gene transfer, current clinical trials are 
dominated by two strategies, namely nucleic acid delivery by viral vectors or synthetic chemical 
systems.53,54 Viral gene delivery is highly efficient by nature but safety concerns due to random 
integration of the transgene into the host genome or potential immunogenicity issues limit their 
applicability.55,58,59 In addition a labour and cost intensive manufacturing comprising difficult to 
standardize processes are further issues for drug development.60,411-414 Synthetic chemical systems, most 
often composed of cationic lipids or polymers, are easier to manufacture and face minor concerns of 
biosafety/immunogenicity. Nevertheless, so far viral systems are favoured for the major fraction of 
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current clinical trials, as non-viral systems are less efficient and their mode of action bear the risk for 
toxicity issues.415,416 Both systems, chemical as well as virus-derived entities, are also prone to unspecific 
uptake, i.e. deliver of nucleic acids to non-target cells. This can affect/decrease efficacy because uptake 
into non-target cells increases clearance, it may also elicit  undesired effects in the non-target 
tissues.6,417,418  The significance of these issues is fortified by the fact that to date no systemic gene delivery 
approach succeeded phase III clinical trials to be approved for market access.10 All in all, this emphasizes 
the need for alternative systems for efficient and specific nucleic acid delivery to realize systemic gene 
therapy.  
To develop a gene delivery system that is not aided by viral entities or synthetic transfection reagents, 
important characteristics of these systems have to be pointed out and taken into consideration. One 
common feature of most delivery systems is the protection of DNA to avoid degradation by nucleases.204  
Furthermore, viral as well as synthetic nucleic acid delivery systems condense the large nucleic acid to 
reduce the exposed negative charge and size with the aim to form a compact particle for facilitated 
cellular uptake.373-375,419,420 Moreover, the DNA interaction is most often non-covalent to enable de-
compaction and access of the transcription machinery inside the nucleus and to avoid chemical 
modification influencing gene expression.174,378-380 Finally, every system comprises a particular 
mechanism that enables DNA membrane translocation.197,376,377  
In principle, one mechanism that meets the above mentioned criteria is the assembly of core histones on 
DNA. The assembly into chromatin is a highly conserved mechanism in eukaryotes to organize genomic 
DNA inside the nucleus by reducing its size and charge.382 Furthermore, previous studies demonstrated 
that all four core histone proteins contain protein transduction domains and compatibility of histones for 
gene delivery has been shown by several studies reviewed by Han et al. 387-389,421,422. However, the 
majority of histone based delivery systems comprise unspecific DNA complexation of core histones, 
single histone proteins or domains or peptides derived from them and most often combined with 
synthetic or viral entities 423-430. Wagstaff and co-workers demonstrated that plasmid DNA assembled 
into chromatin can be delivered into the nucleus, using modified histone H2B protein 390.  
The objective of our work was to develop an efficient chromatin-based nucleic acid delivery system that 
does not contain any virus-derived components. In addition, the delivery system shall (in contrast to 
applying histones and/or chromatin for nonspecific DNA delivery) introduce nucleic acids only into 
desired target cells without addressing non-target cells.  To achieve these objectives, we used purified 
histones for packaging DNA into plasmid chromatin (this avoids viral components). In contrast to 
approaches described above, however, these histones were deliberately kept as ‘wildtype proteins’ i.e. 
not mutated/modified and therefore exhibited a very low spontaneous delivery potential 390. We then 
analysed if we can convert such inactive plasmid chromatin to targeted plasmid chromatin with 
intracellular delivery functionality by adding antibody-derived cell surface targeting entities. 
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4.2.3 Materials and Methods 
4.2.3.1 In-vitro chromatin reconstitution of plasmid DNA 
 
Calf thymus histones for assembly were kindly provided by Prof. Dr. Gernot Längst (University of 
Regensburg). A ~4000bp plasmid DNA encoding EGFP (pEGFP) was amplified and used for assembly 
of histones via salt gradient dialysis 431. To set up the assembly reaction we mixed DNA and histones in 
a 1:2 mass ratio in a reaction mix of 2 M NaCL 200 ng/mL BSA and 200 ng/mL BSA, 1 fold low salt 
buffer (10 mM Tris-HCl pH7.6, 50 mM NaCl, 1 mM EDTA, 0.05 % w/v Igepal CA-630), 2 M NaCl 
and histone octamer in a 1 : 2 DNA : histone weight ratio. The reaction mixture was transferred into 3.5 
kDa MWCO mini dialysis devices (Thermo Fisher Scientific) equilibrated for 15min in high salt buffer 
(10 mM Tris-HCl pH7.6, 2 M NaCl, 1 mM EDTA, 0.05 % w/v Igepal CA-630). Afterwards a 4 L beaker 
was prepared with 300 mL high salt buffer containing 1mM beta-mercaptoethanol and a second beaker 
with 3 L 1-fold low salt buffer containing 1 mM beta-mercaptoethanol. A floater with the dialysis 
devices and a magnetic stir bar were added into the beaker with high salt buffer. The salt gradient dialysis 
was performed over night at 4 °C. Therefore, the beaker was placed on a magnetic stirrer to allow slow 
mixing and a peristaltic pump was set to transfer the 3 L of low salt buffer into the beaker containing 
high salt buffer with a velocity of about 300 mL/h. After buffer dilution, chromatin samples were 
purified and buffer was exchanged to PBS via size exclusion chromatography using Sephacryl S-1000 
GE Superfine (Sigma Aldrich) matrix. 
 
4.2.3.2 Antibody Chromatin complex preparation 
 
Hapten binding bispecific antibodies and TriFabs were generated and purified as previously 
described341. Haptenylated CPXM2 peptide was synthesized by Biosynthan GmbH (Berlin). To prepare 
DNA binding antibody constructs, biotinylated peptide and biotin binding antibody was pre-incubated 
in PBS for 30 min in a ratio of two peptides per antibody for the bivalent biotin binding bsAb and one 
peptide per antibody for monovalent biotin binding TriFabs. Subsequently, constructs were added to 
chromatin and incubated for at least 30 min for antibody-peptide association at the DNA backbone.   
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4.2.3.3 Microscale Thermophoresis 
 
Microscale thermophoresis experiments, data processing and determination of KD values was performed 
by 2bind GmbH (Regensburg). Antibody and peptide were diluted in PBS and pre-incubated for 30 mins 
at RT with a 1 : 1 or 1 : 2 molar ratio for TriFab : peptide or 2 + 2 bsAb : peptide, respectively. A serial 
dilution of the ligand was prepared in a way to match the final buffer conditions in the reaction mix (1x 
PBS, 0.05 % Tween-20). 5 μl of each dilution step were mixed with 5 μl of fluorescent labelled plasmid 
chromatin. The final reaction mixture, which was filled in capillaries, contained a respective amount of 
ligand and constant 0.25 nM fluorescent molecule. The samples were analysed on a Monolith NT.115 
Pico at 25 °C, with 10 % LED power and 60 % Laser power. Fluorescence values were normalized and 
data were displayed according the analysed peptide concentration 432. KD values were determined, if 
normalized fluorescence values allowed a proper curve fit. 
 
4.2.3.4 Analytic MNase digestion 
 
For nuclease sensitivity assays, 2 µg of DNA assembled with chromatin was diluted in EX-80 buffer 
(10 mM Tris-HCl pH7.6, 80mM KCl, 10% v/v glycerol, 1.5mM MgCl2, 1mM DTT) and 1 µL BSA to 
a final volume of 50 µL. To stop the reaction, 1.5 mL tubes were prepared with 4 µL stop-buffer (100 
mM EDTA, 4 % w/v sodium dodecyl sulfate). The nuclease reaction was started by addition of 50 µL 
micrococcal nuclease (MNase) mix (6 mM CaCl2, 200 ng/µL BSA and 40 U MNase). After the indicated 
time-points, 30 µL of the reaction mix were transferred to the tubes containing stop-buffer. The DNA 
was de-proteinized by addition of 1 µL Proteinase K and incubation for 1 h at 50 °C. The DNA was 
purified by ethanol precipitation and analysed by agarose gel-electrophoresis. 
 
4.2.3.5 Flow cytometry 
 
To generate fluorescent plasmid DNA and plasmid chromatin, Cy5 fluorescent dye was chemically 
conjugated to plasmid-DNA applying the Label IT® Nucleic Acid Labelling kit (Mirus) according to 
the manufacturer’s specification. To generate fluorescent plasmid chromatin, assembly was performed 
with Cy5 labelled plasmid as described above. Cy3 labelling of antibody was performed via maleimide 
conjugation after partial antibody reduction with TCEP.  
Previous to cell treatment, antibody chromatin complexes were formed as described above. 200,000 
MCF7 cells per well were seeded in 96 well plates and treated with complexes with final concentration 
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1.6 µg/mL plasmid DNA bevor or after chromatin assembly, 50 nM antibody and 100 nM peptide for 1 
h at 37 °C. Single colour flow cytometry with unlabelled antibodies was performed with a FACScanto 
II (BD Biosciences). For dual colour flow cytometry, Cy3 labelled antibodies were used instead of 
unlabelled antibodies. Colour compensation was performed with single stained controls. Dual color flow 
cytometry was performed with an LSRFortessa (BD Biosciences).   
 
4.2.3.6 Reporter gene expression and cytotoxicity assay 
 
80,000 MCF7 cells per well were seeded in 12 well plates for reporter gene expression assays and 10,000 
MCF7 cells per well were seeded in 96-well plates for LDH cytotoxicity assays. 24 h after seeding, cells 
were treated with complexes containing 8 µg/mL plasmid DNA bevor or after chromatin assembly, 250 
nM antibody and 500 nM peptide prepared as described above or single components at the same 
concentration when indicated. The cells were exposed to complexes or single components for 48h in the 
presence of serum. After 48h gene expression or cytotoxicity was analysed. For gene expression analysis 
cells were washed, detached and the ratio of GFP positive cells was determined by flow cytometry with 
a FACScanto II (BD Biosciences). For cytotoxicity analysis, culture supernatant was removed and LDH 
activity was quantified with the Cytotoxicity Detection Kit (LDH) (Sigma-Aldrich) according to the 
manufacturer’s protocol. 
 
4.2.3.7 Confocal microscopy 
 
For live cell imaging, MCF7 cells (NCI) were cultured in phenolred-free RMPI medium supplemented 
with 10 % fetal calf serum (FCS) and 100 U/ml penicillin and 100 µg/ml streptomycin. 20,000 cells/well 
were seeded into 8-well chamber slides (Lab-Tek™, Thermo Fisher Scientific, Braunschweig, 
Germany) and allowed to adhere overnight. Glass surfaces had been coated with 30 µg/ml fibronectin 
in PBS for 1 h at 37 °C. Antibody plasmid DNA-Cy5 and Antibody-plasmid chromatin-Cy5 complexes 
were formed as described in example 7. Samples were added to MCF7 at a final concentration of 4 
µg/mL plasmid DNA, 250 nM peptide and 125 nM antibody. 4 h and 72 h after addition, internalization 
of antibody-chromatin complexes and GFP expression were followed by live cell fluorescence 
microscopy carried out on a Leica SP5 laser scanning confocal microscope using a 63×/ 1.2NA water 
immersion objective lens (Leica, Mannheim, Germany).  Temperature, CO2 level and humidity were 
maintained at 37 °C and 5 % CO2 using a stage-top incubation chamber (Oko-touch, Okolab, Ottaviano, 
Italy). Sequential scans were performed using white light laser excitation at 488 nm, (561 nm) and 633 
nm. Fluorescence emission was detected at 495-548 nm (GFP), 570-628 nm (Cy3) and 647-732 nm 
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(Cy5) using HyD detectors. Images were processed with ImageJ (NIH, Bethesda, MD, USA). 
Immunocytochemistry was performed as previously described 216. 
 
4.2.3.8 CRISPR/Cas9 targeting and knock-out quantification 
 
It has previously been described that gene-editing mediated inactivation of DPH1, combined with 
assessment of cellular sensitivity towards Diphtheria Toxin (DT), can be used to quantify efficacy of 
gene editing 277. Inactivation of all cellular copies of DPH1 (as consequence of gene editing) in turn 
renders cells resistant to DT. This generates a very robust readout which can be quantified by counting 
DT-resistant colonies following gene editing. To prove targeting specificity and efficacy of the delivery 
system with plasmids encoding a therapeutically more relevant gene product, targeted delivery 
complexes were prepared as described above with CISPR/Cas9 ‘plasmid chromatin’ instead of pEGFP 
plasmid chromatin. Afterwards the complexes were added to MCF7 cells seeded in a 12-well plate (4000 
cells/well 24 h before treatment) to a maximal final concentration of 8 µg/mL plasmid DNA assembled 
to Chromatin, 500 nM peptide and 250 nM antibody. After incubation of the complexes in normal serum 
containing cell culture medium for 72h, medium was removed and cells were exposed to the same 
medium containing DT at a final concentration of 4 nM. DT exposure was continued for 2 weeks with 
medium exchange every 3 to 4 days. After this period, cells were stained with methylene blue and 
efficiency of intracellular delivery and expression of the editing components was assessed by 
determination of DT-resistant colonies as previously described. 
 
4.2.3.9 Statistics 
 
Unpaired, two-tailed Student’s t-tests were performed for single comparisons between two treatments. 
Multiple comparisons were statistically analyzed via one-way ANOVA, followed by Tukey’s honestly 
different significance (HDS) post hoc tests. Significant differences were defined by p-values of < 0.05. 
The level of significance determined using Student’s t-test or Tukey’s HDS test is indicated in graphs 
by asterisks. One, two or three asterisks are defined by p < 0.05, p < 0.01 and p < 0.001, respectively. 
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4.2.4 Results 
4.2.4.1 In-vitro chromatin reconstitution of plasmid DNA by salt gradient dialysis 
 
Chromatin can be efficiently reconstituted from DNA and histones by the salt gradient dialysis methods 
391,431,433. Using supercoiled plasmid DNA and purified histone octamers, nucleosomes are formed that 
consist of the histone octamer and 147 bp of DNA wrapped about 1.65 turns around the octamer 434. The 
salt gradient dialysis method gives rise to nucleosomal arrays on DNA that are separated by short DNA 
linkers with a size about 15 bp. Fine titration of histone to DNA ratios results in plasmid chromatin fully 
covered by nucleosomes that are qualitatively evaluated by micrococcal nuclease (MNase) hydrolysis 
of DNA. The endonuclease MNase does preferentially hydrolyse DNA in the linker region between the 
nucleosomes, giving rise to an MNase ladder of DNA when partially hydrolysing chromatin 435. We 
applied this method to generate plasmid chromatin with an eGFP expression plasmid. The quality of the 
reconstituted chromatin was determined by nuclease hydrolysis and subsequent agarose gel-
electrophoresis (Figure 4.2.1A) 431. The partial DNA hydrolysis of assembled chromatin generates DNA 
fragments of multiples of 160 base pairs, suggesting that arrays of nucleosomes were formed on the 
plasmid DNA. Furthermore, the clear pattern of the nucleosomal ladder and the absence of DNA 
fragments shorter than 147 bp (sub-nucleosomal DNA), suggested the efficient reconstitution of the 
plasmid DNA into chromatin (Figure 4.2.1A). 
 
4.2.4.2 Antibody - chromatin complexes with improved nuclease resistance are 
formed via DNA binding peptide CPXM2 
 
To capture plasmid DNA or plasmid chromatin via charge interaction with the negatively charged DNA 
backbone, we used a nucleic acid binding peptide (CPXM2 peptide) identified by Haas et al. and derived 
from human carboxypeptidase-like protein X2 (CPXM2 protein)397. To enable binding of CPXM2 
peptide to antibodies, we used a biotinylated version of CPXM2 peptide (biotin CPXM2 peptide) and 
biotin binding (anti biotin) bispecific antibodies (Figure 4.2.1B). Affinity of antibody-peptide constructs 
to chromatin was determined by microscale thermophoresis (MST). With this method affinity data were 
generated in solution without the need to capture antibody or peptide as this would affect affinity in this 
system due to avidity effects. To identify the most suitable antibody format, we compared monovalent 
biotin binding TriFabs with bivalent biotin binding bispecific antibodies (anti biotin 2+2 bsAb) towards 
affinity and potential aggregation due to crosslinking of the molecules.339,341 Affinity of biotin CPXM2 
peptide ~ anti biotin TriFab constructs to chromatin was in the 3 digits nanomolar range (300nM). The 
biotin CPXM2 peptide ~ anti biotin 2+2 bsAb constructs demonstrated further stabilization (two-digit 
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nM affinity) most likely due to avidity effects as two CPXM2 peptides can be bound by one antibody 
(Figure 4.2.1C). In addition, no aggregation was observed with the biotin CPXM2 peptide ~ anti biotin 
2+2 bsAb construct, indicating that no severe crosslinking occurs with this antibody format (Suppl. 
Figure 9.3.1). Specificity was proven by respective controls without peptide. The MST data set of the 
individual runs (Suppl. Figure 9.3.2) is summarized in Table 4.1. As the strongest interaction was 
observed when the peptide was coupled to anti biotin 2+2 bsAb, we used this antibody format for further 
studies. As the antibody peptide construct interacts with the negatively charged DNA backbone, we 
checked whether this interaction disrupts the nucleosomes, or alters nuclease resistance of plasmid 
chromatin after antibody-peptide assembly. After incubation of chromatin with antibody and peptide 
and subsequent nuclease digestion, the pattern of partially hydrolyzed DNA after 270s was similar to 
the pattern of nuclease treated chromatin alone after 20s (Figure 4.2.1A). This data clearly demonstrates 
that addition of the antibody-peptide reduces the nuclease accessibility, by probably binding to the 
accessible DNA linker, but the nucleosomal arrays remain intact. 
 
Table 4.1: Affinity between chromatin and antibody or antibody-peptide constructs.  
Interaction between chromatin and antibody or antibody-peptide constructs was determined by MST. 
Affinity value for bio-CPXM2 ~ anti biotin 2+2 bsAb refers to biotin-CPXM2 peptide concentration (2-
fold higher than antibody concentration as one antibody can bind two peptides); Affinity values with 
respective SEM were determined by two independent measurements. 
Construct KD (nM) SEM (nM) 
Chromatin + bio-CPXM2 ~ monovalent anti bio bsAb 300.0 36.0 
Chromatin + bio-CPXM2 ~ bivalent anti bio bsAb 73.1 3.4 
Chromatin + monovalent anti bio bsAb only No interaction N.A. 
Chromatin + bivalent anti bio bsAb only No interaction N.A. 
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Figure 4.2.1: MNase digestion of antibody-chromatin complexes and antibody-complexation with 
plasmid-chromatin. 
A Agarose gel electrophoresis of chromatin without (lane 1-3) and in presence of biotin-CPXM2 ~ anti biotin 2+2 
bsAb constructs (lane 4-6) after partial DNA hydrolysis by MNase with increasing incubation time (20s, 80s and 
270s); Chromatin without MNase treatment (lane 7) is shown as control. Mononucleosomal DNA bands (147bp) 
indicate complete digestion in contrast to higher molecular weight bands. In presence of biotin-CPXM2 ~ anti 
biotin 2+2 bsAb constructs, chromatin is more nuclease resistant as the 147bp DNA band only occurs at late time-
points of Nuclease treatment in comparison to the chromatin only sample. B Scheme of antibody-chromatin 
complexes with plasmid DNA reconstituted into nucleosomes and associated antibody-peptide constructs. 
Variable regions against cell surface antigen (blue) faces outwards and anti biotin scFv (green) is bound at biotin-
CPXM2 peptide (purple) associated at the DNA backbone. C MST runs for Chromatin + biotin-CPXM2 ~ anti 
biotin 2+2 bsAb interaction. Ligand concentration refers to biotin-CPXM2 peptide (twice as much as the 
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respective anti biotin 2+2 bsAb concentration). Exp 1 (blue) and Exp 2 (red) are independent experiments of the 
same construct with the respective curve fit for KD determination. 
 
4.2.4.3 DNA as well as chromatin is specifically and efficiently delivered via CPXM2-
antibody constructs 
 
In addition to specific formation and prolonged nuclease resistance of the antibody-chromatin complex, 
we investigated DNA delivery to the cell surface via the associated antibodies. To determine delivery 
efficacy and specificity, anti-biotin 2+2 bsAbs with a second specificity against Lewis Y or CD33 were 
compared on MCF7 cells (LeY+++/CD33-). Furthermore, plasmid DNA labelled with Cy5 fluorophore 
was used to enable quantification of plasmid DNA on cells by flow cytometry 1h after cell treatment. 
To elaborate the influence of chromatin assembly on delivery specificity and efficacy, we applied the 
delivery system for plasmid DNA before and after chromatin assembly. Figure 4.2.2A shows Cy5 signal 
of MCF7 cells after treatment with plasmid DNA before chromatin assembly complexed with anti LeY 
(dotted red) and anti CD33 (dotted blue) antibody. A distinct fluorescence signal was detected after 
treatment with anti LeY-DNA-Cy5 complexes demonstrating that DNA delivery is highly efficient. In 
contrast, application of anti CD33-DNA-Cy5 complexes did not result in Cy5 positive cells (as MCF7 
do not express CD33). This demonstrates that DNA delivery is mediated by the antibody and payload 
is delivered only to cells that express the cognate target antigen. After chromatin assembly, plasmid 
delivery efficacy and specificity was not affected as the same distinct fluorescence signal was observed 
after treatment with anti LeY-chromatin-Cy5 complexes (solid red) and no Cy5 signal was detected with 
anti CD33-chromatin-Cy5 complexes (solid blue) (Figure 4.2.2B). To confirm the presence of the 
antibody in our delivery system, we used anti CD33 and anti LeY antibodies labelled with Cy3 
fluorophore together with Cy5 labelled chromatin. As displayed in figure 4.2.2C, MCF7 cells treated 
with anti CD33-Cy3-chromatin-Cy5 complexes did not show an elevated Cy5 as well as Cy3 signal 
(blue contours) demonstrating that neither antibody nor chromatin is present at the cell surface. In 
contrast, anti LeY-Cy3-chromatin-Cy5 treatment results in distinct fluorescence signals for Cy3 and 
Cy5 (red contours), proving antibody at the cell surface and confirming the successful delivery of 
chromatin (with somehow reduced efficiency compared to unlabelled antibody). Finally, we checked 
the second specificity of our targeting antibody against biotin. Therefore, we compared our targeted 
chromatin delivery system comprising biotinylated-CPXM2 peptide with a targeting system where the 
biotinylated peptide was exchanged against a peptide with the wrong hapten (digoxigenin instead of 
biotin). Figure 4.2.2C highlights that both complexes (blue contours with biotin-CPXM2peptide and 
green contours with digoxigenin-CPXM2 peptide) generate a distinct Cy3 fluorescent signal on MCF7 
cells, whereas Cy5 signal was only detected after treatment with biotin-CPXM2 peptide comprising 
complexes. This clearly demonstrated that despite the cell surface specificity, also the second specificity 
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against the hapten is necessary for chromatin and therefore plasmid DNA delivery without unspecific 
interaction between antibody and peptide/chromatin.  
 
 
Figure 4.2.2: Flow cytometric determination of delivery specificity. 
Binding and uptake of antibody-Cy3 and DNA-Cy5 (before and after chromatin assembly) was analysed by flow 
cytometry after incubation for 1h. A Histogram of MCF7 cells after treatment with targeted (anti LeY; dotted red) 
and untargeted (anti CD33; dotted blue) DNA-Cy5 complexes. Cy5 signal was detected only after treatment with 
the targeted DNA-Cy5 construct. B Histogram of MCF7 cells after treatment with targeted (red) and untargeted 
(blue) chromatin-Cy5 complexes. Results are comparable to results after DNA-Cy5 delivery. C Contours plot of 
MCF7 Cy3 (x-axis) and Cy5 (y-axis) signals after treatment with various antibody chromatin complexes 
comprising Cy3 labelled antibody and Cy5 labelled DNA. Cells were treated with complexes comprising antibody 
without specificity against cell surface antigen but against CPXM2 peptide do neither show Cy3 nor Cy5 signals 
(blue). Cells treated with complexes comprising digoxigenin CPXM2 peptide (instead of biotin CPXM2 peptide) 
display Cy3 signal but no Cy5 signal, demonstrating that antibody but not chromatin is present at the cell surface 
(green). Cells treated with complexes comprising antibody with specificity against the cell surface and CPXM2 
peptide display Cy3 signal and Cy5 signal, demonstrating that antibody as well as chromatin is present at the cell 
surface (red).     
 
4.2.4.4 Targeted chromatin efficiently mediates transgene expression without 
cytotoxicity 
 
After determination of delivery efficiency and specificity to the target cells, we addressed the nuclear 
delivery efficacy by quantifying GFP reporter gene expressing cells via flow cytometry. With this assay 
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we can also directly depict the influence of chromatin assembly on intracellular plasmid DNA delivery 
as on cell DNA delivery is equally efficient with and without chromatin assembly. To address reporter 
gene-expression, we have treated MCF7 cells with different constructs for 48h and subsequently 
identified GFP expressing cells via flow cytometry. The ratio of GFP positive cells was determined by 
comparison with respective vehicle or antibody only control. Incubation of MCF7 cells in presence of 
DNA or chromatin did not generate cells expressing detectable levels of GFP, indicating no unspecific 
nuclear uptake of plasmid DNA before and after chromatin assembly (Figure 4.2.3A). Moreover, 
association of antibody-peptide constructs did not generate GFP positive cells when the antibody does 
not bind the cell surface as shown for anti CD33-DNA as well as anti CD33-chromatin complexes 
(confirming the data of figure 4.2.2 were no unspecific uptake of antibody-DNA and antibody-chromatin 
was detected). Targeting of plasmid DNA by associated antibody-peptide constructs generated single 
GFP positive cells (as observed under the microscope) but not to a significant extent despite efficient 
delivery to the cell surface as shown in figure 4.2.2A. In contrast, antibody-peptide constructs targeting 
chromatin raised the ratio of GFP positive cells from single exceptions to the vast major population 
(more than 90% positive cells). Finally, Lipofection was used as a positive control, resulting in about 
60% reporter gene expressing cells. Next, we addressed the cytotoxicity of the different treatments by 
LDH release relative to vehicle control and complete cell lysis. Lipofection mediated cytotoxicity to a 
certain extent (about 15% to lysis control), usual for most transfection reagents. None of the other 
treatments showed detectable cytotoxic effects (Figure 4.2.3B). 
 
 
Figure 4.2.3: Efficiency and cytotoxicity of gene delivery systems. 
A Delivery efficiency of EGFP expression plasmids was addressed by determination of GFP positive cells via flow 
cytometry 48h after treatment with targeting complexes being present throughout that time. Significant numbers 
of GFP positive cells were achieved with Lipofection and anti LeY-chromatin complexes for MCF7 cells. B 
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Cytotoxicity was addressed by quantification of LDH release. Significant LDH release after 48h was only observed 
with lipofection. Cells were exposed to respective treatment for the whole incubation period in normal (serum 
containing) cell culture medium. Mean values + SEM are shown (n=3); p-values < 0.001 are indicated by three 
asterisks. 
 
4.2.4.5 Chromatin is specifically delivered to target cells by bispecific antibodies 
followed by internalization into the vesicular system 
 
As the impact of chromatin assembly on functional plasmid DNA delivery was surprisingly high, we 
addressed intracellular distribution of antibody and DNA after treatment with different complexes by 
confocal microscopy. Figure 4.2.4A highlights the distribution of antibody-Cy3 (green) and DNA-Cy5 
(red) in living cells 4h after treatment with targeted (LeY-) chromatin, targeted (LeY-) DNA or 
untargeted (CD33-) chromatin. Antibody as well as DNA was present at the cell surface as well as the 
vesicular system after targeting of chromatin (top row of images) as well as DNA (middle row of 
images). Overlay of both fluorescence signals indicates that most of antibody and DNA is co-localized 
and not separated. These data clearly demonstrate that targeted DNA gets delivered to the cell surface 
and internalized via the targeting antibody irrespective of assembled into chromatin or not. Specificity 
of the targeting system was confirmed by confocal microscopy of MCF7 cells after incubation with the 
untargeted chromatin complex, as neither antibody nor DNA was detected at the cell surface as well as 
inside vesicles (bottom row of images). Figure 4.2.4B shows that chromatin targeting does not only 
result in strong DNA accumulation at the cell surface and inside the vesicular system (cyan) but also in 
GFP expression (green). For imaging of GFP signal after 3days, unlabelled antibody was used as 
labelling reduced chromatin delivery efficacy. To image treated cells with higher resolution and in more 
detail, cells were fixed and the antibody was subsequently counterstained with anti-human IgG Cy3 
antibody (Figure 4.2.4C). Confocal microscopy of cells that received targeted plasmid chromatin 
revealed strong above-background signals of the targeting antibodies on cell surfaces and vesicular 
compartments but not in nuclei. Cy5-labeled plasmid payload was found together with the antibody on 
cell surfaces and vesicular compartments but was also clearly detectable in nuclei. These observations 
are in line with previous findings that (i) noncovalent hapten-coupled payloads separate from targeting 
antibodies after internalization and become routed independently from the antibody 339,436 and (ii) that 
most antibodies bind to cells and internalize in an effective manner but by themselves have very low 
propensity to escape from vesicular compartments and enter the cytoplasm or nucleus 437. 
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Figure 4.2.4: Confocal microscopic analysis of antibody mediated plasmid DNA or chromatin 
delivery and intracellular routing. 
A Live cell imaging of MCF7 cells 4h after treatment with targeted (LeY) chromatin (top row), targeted (LeY) 
DNA (middle row) and untargeted (CD33) chromatin (bottom row); Antibody-Cy3 signal is displayed in green 
and DNA-Cy5 level is displayed in red; Overlay of fluorescent images are shown in the “Merge” column and the 
right column shows respective transmission images. B Live cell imaging of MCF7 cells 3 days after treatment with 
targeted (LeY) chromatin complexes comprising unlabelled antibody and Cy5 labelled DNA. Left panel shows 
GFP signal in green, middle panel DNA-Cy5 in cyan and right panel transmission, respectively. C Imaging of 
fixed MCF7 cells 3 days after treatment with targeted (LeY) chromatin. Left panel displays DNA Cy5 signal in 
pseudocolor, middle panel shows antibody signal generated by counterstaining with anti human IgG Cy3 antibody 
in red and the right panel represents the transmission image. Cell surface, vesicular compartments and nuclear 
envelope are marked by yellow contours. Scale bars: 50µm. 
 
4.2.4.6 Targeted chromatin delivery enables specific and efficient CRISPR/Cas9 
mediated genome editing 
 
Next, we addressed if chromatin delivery can be applied with plasmid DNA of larger size and with more 
complex function. Therefore we used a plasmid encoding a CRISPR/Cas9 knock-out system against 
Diphthamide synthesis gene 1 (DPH1) and performed the previously published Diphtheria toxin (DT) 
based assay for quantification of CRISPR/Cas9 mediated gene editing 277. This assay utilizes DT 
resistance mediated by homozygous DPH1 knock-out for identification of cell clones in which gene 
editing by Cas9 was successful. As a result, only homozygous DPH1 knock-out cells survive and display 
colony formation after 2 weeks of continuous DT selection. First of all, we transferred the chromatin 
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assembly on the DPH1 gRNA Cas9 expression plasmid (Figure 4.2.5 A). The delivery system was 
applied for of Cas9 DPH1 gRNA encoding ‘plasmid chromatin’ in the same manner as for GFP encoding 
‘plasmid chromatin’. After treatment of MCF7 cells with targeted (LeY-) Cas9 DPH1 gRNA encoding 
‘plasmid chromatin’, untargeted (CD33-) Cas9 DPH1 gRNA ‘plasmid chromatin’ and targeted (LeY-) 
GFP ‘plasmid chromatin’ and incubation for 3 days, cells were exposed to DT for two weeks. Finally, 
cells were fixed and colonies were counted under the microscope. Representative microscopic images 
are shown in Figure 4.2.5B and the ratio of colony number and number of initially seeded cells are 
summarized in Table 4.2 as percentage of DT resistant colonies and therefore percentage of clones with 
homozygous gene knock-out. Targeted delivery of Cas9 DPH1 gRNA chromatin results in almost 4% 
DT resistant clones whereas targeted delivery of GFP control chromatin does not result in any resistant 
colony, confirming that colony formation can only occur by expression of the CRISPR/Cas9 editing 
system. In line with the specificity of the chromatin targeting system as shown above for GFP, MCF7 
treatment with untargeted (CD33-) Cas9 DPH1 gRNA chromatin does also not result in formation of 
DT resistant colonies. Compared to the absolute CRISPR/Cas9 knock-out frequencies and colony 
numbers from our previous experiments, the determined percentage of DT resistant clones would equal 
to more than 60% of Cas9 expressing cells (Table 4.2). 
 
 
Figure 4.2.5: Antibody-chromatin delivery with plasmid DNA encoding a CRISPR/Cas9 system. 
A Agarose gel electrophoresis of DPH1 gRNA/Cas9 plasmid DNA (lane 1-3) and chromatin (lane 4-6) after partial 
DNA hydrolysis by MNase with increasing incubation time (20s, 80s and 270s); B Representative microscopic 
images of DT resistant MCF7 cell clones after treatment with vehicle (PBS control), targeted control plasmid 
chromatin (LeY-Chromatin (eGFP)), non-targeted Cas9/DPH1 gRNA plasmid chromatin (CD33-Chromatin 
(Cas9/DPH1 gRNA)), targeted Cas9/DPH1 gRNA plasmid chromatin (LeY-Chromatin (Cas9/DPH1 gRNA)); DT 
resistant colonies were only observed after treatment with targeted DPH1 gRNA/Cas9 plasmid chromatin. 
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Table 4.2 Transfection efficiencies with Cas9/DPH1 gRNA expression plasmids based on DPH1 editing 
efficiencies in MCF7 cells. 
Calculated cell transfection efficiencies (a) are based on determined Cas9/DPH1 gRNA mediated homozygous 
DPH1 knock-out (DPH1 k.o.) efficiencies (b) as previously published 277. DT-resistant DPH1 k.o. cells (c) are 
indicated as ratio between counted DT resistant colonies and initially seeded cells. Data of first row are derived 
from previous publication 277; Data of second and third row are based on mean values of colony numbers obtained 
after respective treatments as described in B (n=3). 
 
Treatment 
a 
Transfection efficiency 
(% of seeded cells) 
b 
DPH1 k.o. efficiency of 
Cas9/DPH1 gRNA 
(% transfected cells) 
c 
DT-resisitant DPH1 k.o. 
cells 
(% of seeded cells) 
Lipofection 
(Killian et al. SciRep 2017) 
40 % 
measured 
6.3 % 
calculated c/a 
2.5 % 
measured 
Targeted (LeY) Cas9/gDPH1 
chromatin 
59 % 
calculated c/b 
6.3 % 
same as above 
3.7 % 
measured 
Non-targeted (CD33) 
Cas9/gDPH1 chromatin 
0 % 
calculated c/b 
6.3 % 
same as above 
0 % 
measured 
 
 
4.2.5 Discussion 
 
The development of a targeted gene delivery system faces multiple challenges as it must overcome 
several hurdles and therefore needs well-balanced properties 438,439. For example, a DNA delivery system 
must have affinity to the target cells to efficiently mediate the uptake of DNA but in parallel must not 
interact with serum components or the cell membrane of other cells and tissues to minimize loss of DNA 
and avoid off-target effects along the delivery route 174,176,440. Furthermore, DNA has to be translocated 
over the membrane barrier to enter the cytosol and finally reach the nucleus to enable transgene 
expression 441,442. As a consequence, the required membrane interaction for DNA translocation has to be 
efficient but at the same time gentle enough to avoid cell cytotoxicity. 440.  
Our goal was to generate a highly flexible and modular gene delivery system to outline the influence of 
every component along the gene delivery route. We made use of the hapten- binding bsAb technology 
comprising antibody derivatives that are able to simultaneously bind cell surface antigens and to small 
molecule haptens like biotin or digoxigenin via antibody-antigen interactions 216. This technology 
enables delivery of diverse hapten bearing molecules (payload) to the target cell surface and its broad 
applicability including nucleic acid delivery has already been demonstrated 216,339,341. The fact that 
hapten-binding bsAbs are available in different formats covering various sizes, geometries and 
stoichiometries 341,436,443,444 enhances their versatility as modules for targeted nucleic acid delivery. The 
non-covalent attachment of payload to hapten-binding bsAbs enables separation of payloads from 
targeting vehicles inside vesicular compartments. The latter is important for delivery of molecules with 
intracellular functionality such as nucleic acids. For those, non-covalent hapten coupling is 
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advantageous compared to covalent conjugation strategies were payload release frequently needs to be 
optimized for example by introduction of cleavable linkers 339,436,445.  
Functional plasmid DNA delivery can be observed in about 90% of treated cells without cytotoxicity 
therefore providing a mechanism for efficient but gentle DNA membrane translocation. Such high 
efficacies are comparable to viral gene delivery systems 418,446-450. However, the overall objective of our 
work was not only to achieve high efficacy, but also to combine that with targeting to specific cells. 
Attaching targeting entities to delivery vehicles to selectively address desired cell types is similar to that 
of next-generation viral or virus-like particle (VLP)- based delivery systems. Entities that confer 
targeting specificity can be added to VLPs by conjugating or fusing them to VLPs. Such specificity-
enhancing entities that support enrichment on desired sites can be antibody-based or other protein 
domains or peptide derivatives 451-453. True specificity, however, requires not only addition of specific 
binding entities, but also reduction or elimination of non-targeted transfection activity. Targeted 
plasmid-chromatin described here fulfils targeting requirements and intracellular activity as well as 
reduction of nonspecific uptake without applying any virus-derived modules. 
Hapten-binding bsAbs combined with the DNA binding CPXM2 peptide mediate efficient and specific 
delivery of plasmid chromatin to and into cells. Thus, while other delivery systems show target 
preference 454-457, this novel approach has the potential to reach very high specificity. Moreover, our data 
clearly show that the major component facilitating DNA membrane translocation is the organization of 
plasmid DNA into plasmid chromatin with naturally occurring histones, as we can deliver plasmid DNA 
with and without chromatin assembly to target cells with comparable efficiency and specificity but only 
plasmid chromatin mediates high ratios of transgene expressing cells. In contrast to previous 
observations, we could not observe that histone assembly affects DNA uptake by unspecific membrane 
binding and we could demonstrate that plasmid chromatin facilitates membrane translocation and 
nuclear DNA transport without further engineering of histone proteins 389,390. As we could not observe 
major differences in antibody mediated DNA or chromatin cell surface binding and internalization, DNA 
transduction at the cell surface as well as a specific vesicular escape mechanism cannot be excluded and 
might also not be the only mechanism behind the improved nuclear translocation in line with previous 
suggestions 388-390. Furthermore, DNA compaction and charge reduction may contribute to the facilitated 
DNA membrane translocation and also the transition from the cytoplasm into the nucleus might be 
altered by histones as previously suggested 390,421,458,459. Further studies like measuring the cytoplasmic 
to nuclear transition, as performed for oligonucleotides for example, are necessary to uncover the exact 
role of Histone assembly on plasmid DNA and this modular system can contribute to its further 
understanding 460. 
Beside the fact of being non-toxic and highly specific, the developed gene delivery system exclusively 
consists of proteins and peptides of mammalian origin. Thus, the concerns about safety and the risk of 
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immunogenicity are expected to be rather low. However, one concern of systemic application and 
exposure to the immune system is the chromatin itself. It was shown that plasmid DNA with bacterial 
DNA sequences might be recognized by immune cells via Toll like receptor interaction 458,461. But this 
hurdle might be solved via plasmid DNA engineering like the production of mini-circles or mini-vectors 
containing only a minor portion of bacterial sequences 370. In addition, extracellularly occurring histones 
are elevated in various autoimmune diseases but are also considered in potentially mediating 
inflammatory diseases 462. On the other hand extracellular chromatin release is an active mechanism of 
neutrophils to bind bacteria and therefore serve as a trap for gram positive as well as gram negative 
bacteria 463. Furthermore, in our system histones might not be completely exposed to the immune system 
as they are shielded by the wrapped DNA as well as the associated antibody to some extent. All in all, 
further studies have to be performed to investigate the potential risk of systemic chromatin delivery.  
In conclusion, we have developed a novel system to deliver plasmid DNA with viral-like efficiency, 
high specificity and without cytotoxicity exclusively by mammalian entities. However, further studies 
are necessary for example to understand the exact mechanism of nuclear chromatin and in particular the 
translocation mechanism over the membrane barrier. Nevertheless, antibody mediated chromatin 
targeting is a novel approach for specific gene delivery with the potential of being a viable alternative 
to existing targeted gene delivery systems.   
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5 Abbreviations 
 
 
 
AAV    adeno associated virus 
ADCC     antibody-dependent cellular cytotoxicity 
ADP    adenosine diphosphate 
AV    adenovirus 
Bio    biotin 
bp    basepair 
BSA    bovine serum albumine 
bsAb    bispecific antibody 
Cas    CRISPR associated 
CCR5    C-C chemokine receptor type 5 
CD    cluster of differentiation 
CDC    complement dependent cytotoxicity 
CDR    complementarity determining regions 
CFTR    cystic fibrosis transmembrane conductance regulator 
CMV    cytomegalovirus 
c-NHEJ   canonical non-homologous end joining 
CPP    cell penetrating peptide 
CRISPR   clustered regularly interspaced short palindromic repeat 
crRNA    CRISPR derived RNAs 
CSA    cell surface antigen 
Cy    cyanine 
Dig    digoxigenin 
DNA    deoxyribonucleic acid 
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Dph    diphthamide biosynthesis protein 
DSB    double strand break 
DT    diphtheria toxin 
EF2    elongation factor 2 
Fab    fragment antigen binding 
FACS    fluorescence activated cell sorter 
Fc    fragment crystallisable 
FcRn    neonatal Fc receptor 
FcγR    Fc gamma receptor 
FCS    fetal calf serum 
FGF    fibroblast growth factor 
Fok    flavobacterium okeanokoites 
GFP    green fluorescent protein 
GPC-3    glypican-3 
gRNA    guide RNA 
GTP    guanosine triphosphate 
HC    heavy chain 
HDR    homology directed repair 
HDS    honestly different significance 
HIV-1    human immunodeficiency virus type 1 
HRM    high resolution melting 
Ig    immunoglobulin 
LDH    lactate dehydrogenase 
LeY    lewis Y 
MNase    micrococcal nuclease 
mRNA    messenger ribonucleic acid 
MST    microscale thermophoresis 
MWCO   molecular weight cut-off 
N.A.    not applicable 
90 
 
NAD    nicotinamide adenine dinucleotide 
Pac    puromycin N-acetyltransferase 
PAM    protospacer adjacent motif 
PCR    polymerase chain reaction 
PEI    polyethylenimine 
PM    puromycin 
RNA    ribonucleic acid 
RV    retrovirus 
SAM    S-adenosylmethionine 
scFv    single chain fragment variable 
scRNA    scrambled ribonucleic acid 
siRNA    short interfering ribonucleic acid 
snRNA    small nuclear ribonucleic acid 
SPR    surface plsamon resonance 
SPV    shope papilloma virus 
Tagg    aggregation temperature 
TALEN   transcription activator-like effector nuclease 
Tat    trans-activator of transcription 
Tm    denaturation temperature 
tracrRNA   trans-activating crRNA 
VC    variable chain 
VEGF    vascular endothelial growth factor 
ZFN    zinc finger nuclease 
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9.1 Supplement manuscript 1 
 
 
 
 
Figure S9.1.1: (A) Composition of gRNAs.  
DPH1 RefSeq.: NC_000017.11 (2030137..2043431)  
26mer  GCGGAGCAGGGCGGCCGAGACGGCCC (2030197..2030222) 
24mer    GGAGCAGGGCGGCCGAGACGGCCC (2030199..2030222) 
22mer      AGCAGGGCGGCCGAGACGGCCC (2030201..2030222) 
20mer   CAGGGCGGCCGAGACGGCCC (2030203..2030222) 
18mer     GGGCGGCCGAGACGGCCC (2030205..2030222) 
16mer       GCGGCCGAGACGGCCC (2030207..2030222) 
14mer         GGCCGAGACGGCCC (2030209..2030222) 
 
LHR (2029555..2030154) RHR (2030229..2030828) 
Donor DNA 
gRNA 
DPH2 RefSeq.: NC_000001.11 (43969979..43973371) 
20mer   TCGTACACTCCGTCCAGGTC (43970276..43970257) 
 
LHR (43969576..43970175) 
 
RHR (43970287..43970886) 
 
Donor DNA 
gRNA 
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Sequence, size and exact genomic loci of DPH1 and DPH2 targeting gRNAs according to assembly 
GRCh38.p7 (GCF_000001405.33) for both genes; exact chromosomal position is indicated in brackets; 
LHR: left homologous region and RHR: right homologous region of the integration cassette on the 
donor plasmid. Corresponding mRNA sequences are RefSeq: NM_001383 (DPH1) and RefSeq: 
NM_001039589, NM_001384 (DPH2). Scrambled scRNA applied as control for DPH1 and DPH2 
editing was the 20mer GCACTACCAGAGCTAACTCA which does not address any specific human gene. 
 
 
 
 
 
Figure S9.1.1 (B) Composition of plasmids for PAC insertion  
The integration cassette encoding pac without its own promoter is flanked by sequences homologous to 
DPH1 or DPH2 (numbering according to assembly GRCh38.p7 (GCF_000001405.33). Pac expression 
occurs upon homology-directed insertion into DPH1 or DPH2 loci, respectively. Pac expression may 
also result from insertion into loci different from DPH1 or DPH2 that enable transcription (in 
combination with DPH1 or DPH2 flanking regions).  It has also been brought to our attention by the 
reviewers that the DPH1 5'-homology arm encompasses the immediate 5' region of the DPH1 gene, 
making it likely to contain some form of minimal promoter. Thus, insertion of the DPH1-pac cassette 
may lead to expression without strict requirement of insertion behind active promoters. 
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Figure S9.1.2: Images of colony quantification experiments. 
(A) MCF7 cells were transfected with plasmids encoding CRISPR/Cas9 constructs targeting and 
integrating a pac expression cassette in DPH1. 48 hours after transfection, cells were exposed to DT, 
PM or DT+PM respectively. (B) MCF7 cells were transfected with a plasmid encoding CRISPR/Cas9 
with a scrambled gRNA and the plasmid with the pac expression cassette for integration. 48 hours after 
transfection, cells were exposed DT, PM or DT + PM respectively. Resistant colonies were only 
observed after PM selection. (C) Image of DT resistant (left) and DT sensitive (right) colony. 
 
 
C 
 
 
A 
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Table S9.1.1:  Colony counts & phenotype frequencies of transfected cells 
a)   DPH1 HRM-PCR 
(TF eff  = 38%) 
# of single cells # of HRM+ cells # of DT resistant cells 
92 6 2 
 
b) DPH1 assay (Int vs KO) 
(TF eff  = 38%) 
# of seeded 
cells 
# of DT resistant colonies 
 
# of PM resistant colonies 
 
20mer 
SpCas9 
scRNA 
 
A  
40,000 
0  
0 
17  
12 B 0 13 
C 0 9 
D 0 10 
E  
20,000 
0  
0 
 
11  
9 F 0 7 
G 0 10 
H 0 9 
I  
10,000 
0  
0 
3  
3 J 0 2 
K 0 3 
L 0 4 
 
20mer 
SpCas9 
DPH1 gRNA 
 
A  
40,000 
995  
947 
29  
24 B 942 12 
C 899 30 
D 950 24 
E  
20,000 
364  
472 
18  
13 F 545 13 
G 543 13 
H 435 6 
I  
10,000 
201  
218 
7  
9 
 
J 224 10 
K 219 10 
L 228 29 
 
c) DPH2 assay (Int vs KO)  
(TF eff  = 37%*) 
# of DT resistant colonies 
(40,000 seeded cells) 
# of PM resistant colonies (40,000 
seeded cells) 
 
20mer 
scRNA 
A 0  
0 
2  
0.5 B 0 0 
C 0 0 
D 0 0 
 
20 mer 
SpCas9 DPH2 gRNA 
A 144  
130 
2  
1.5 B 132 2 
C 122 1 
D 122 1 
 
d) DPH1 (Int vs Int+KO) 
(TF eff  = 69*%) 
# of PM resistant colonies 
(40,000 seeded cells) 
# of PM+DT resistant colonies 
(40,000 seeded cells) 
 
20mer 
scRNA 
A 10  
11 
0  
0 B 9 0 
C 10 0 
D 16 0 
 
20 mer 
SpCas9 DPH1 gRNA 
A 25  
24 
 
15  
13 B 22 13 
C 25 11 
D 24 12 
 
‘TF eff.’: Transfection efficiency determined by FACS, monitoring fluorescent cells upon transfection 
with GFP-reporter plasmids (GFP positive cells among all in %). *one assay displayed unusual high 
GFP positivity and unusual FACS pattern. Average transfection efficacy among all assays was 30 -40%. 
‘HRM’: High resolution melting point PCR positive cells display divergent (biphasic) melting curves 
compared to wt. ‘K.O.’ indicates the frequency of cells which carry no functional DPH gene and are 
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hence resistant to DT (DTr). ‘Int.‘ indicates the frequency of cells which harbor the pac expression 
cassette i.e. are PM resistant (PMr). ‘A-D’ are individual results of independent experiments. (a) mono- 
vs bi-allelic DPH inactivation;  (b) seeding density correlates with colony number; (c) DTr and PMr 
upon DPH2 editing; (d) ) DTr and PMr upon DPH1 editing. 
 
Table S9.1.2:    Influence of gRNA length on targeted gene inactivation and cassette integration 
DPH1 (gRNA length)  
(TF eff  = 31%) 
# of DT resistant colonies 
(20,000 seeded cells) 
# of PM resistant colonies 
(40,000 seeded cells) 
# of DT+PM resistant 
colonies (40,000 seeded cells) 
 
20mer 
scRNA 
A 0  
0 
7  
8 
0  
0 B 0 6 0 
C 0 9 0 
D 0 10 0 
 
14 mer 
SpCas9 DPH1 
gRNA 
A 0  
0 
6  
8 
0  
0 B 0 10 0 
C 0 8 0 
D 0 9 0 
 
16 mer 
SpCas9 DPH1 
gRNA 
A 275  
284 
21  
25  
7  
8 B 298 26 9 
C 292 25 10 
D 271 26 9 
 
18 mer 
SpCas9 DPH1 
gRNA 
A 284  
307 
19  
23 
10  
10 B 299 25 12 
C 321 27 7 
D 324 22 11 
 
20 mer 
SpCas9 DPH1 
gRNA 
A 417  
409 
16  
15 
6  
6 B 406 20 5 
C 409 16 7 
D 404 8 7 
 
22 mer 
SpCas9 DPH1 
gRNA 
A 278  
284 
14  
13 
6  
5 B 292 12 5 
C 297 11 4 
D 267 15 5 
 
24 mer 
SpCas9 DPH1 
gRNA 
A 237  
232 
13  
13 
2  
3 B 252 12 4 
C 228 11 3 
D 211 15 3 
 
26 mer 
SpCas9 DPH1 
gRNA 
A 161  
170 
12  
11 
0  
1 B 155 11 1 
C 176 12 0 
D 187 9 1 
 
‘TF eff.’: Transfection efficiency was determined by FACS analyses, monitoring frequencies of 
fluorescent cells upon transfection of MCF7 with GFP-reporter plasmids. Listed are relative numbers of 
GFP positive cells among all cells in %. Cells which carry no functional DPH1 gene copy are resistant 
to DT. Cells which harbor the pac expression cassette are hence resistant to PM. ‘A-D’ indicates 
individual samples of independent experiments. 
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Table S9.1.3:    Phenotype frequencies of MCF7 transfected with different editing entities 
DPH1 editing entities 
(TF eff  = 33%) 
# of DT resistant colonies 
(20,000 seeded cells) 
# of PM resistant colonies 
(40,000 seeded cells) 
DT+PM resistant colonies 
(40,000 seeded cells) 
 
SpCas9  scRNA 
A 0  
0 
4  
4 
0  
0 B 0 3 0 
C 0 5 0 
D 0 4 0 
 
SpCas9 DPH1 
gRNA 
A 476  
477 
14  
11 
5  
4 B 492 11 4 
C 468 9 4 
D 472 10 3 
 
SpCas9-HF 
scRNA 
A 0  
0 
2  
1 
0  
0 B 0 1 0 
C 0 0 0 
D 0 0 0 
 
SpCas9-HF DPH1 
gRNA 
A 60  
65 
9  
8 
1  
0.5 B 70 10 1 
C 66 8 0 
D 62 5 0 
 
ZFN-DPH1 
A 286  
283 
12  
12 
4  
2.5 B 292 13 1 
C 276 10 2 
D 278 11 3 
 
MCF7 cells were transfected with plasmids encoding different genome editing systems (SpCas9, 
SpCas9-HF, ZFN). The SpCas9 construct was as described before. SpCas9-HF includes the 
N497A/R661A/Q695A/Q926A substitutions (Kleinstiver et al. Nature 529, 490-5, 2016). In parallel, 
gRNAs were replaced by scRNAs to address non-specific activity. DPH1-specific ZFN was obtained 
from Sigma Aldrich (CompoZr®). The total amount of plasmid DNA (editing entity and donor) for 
transfection of the initial cell pool of 3x106 cells was as described for the previous experiments. To 
quantify the transfection efficiency (TF eff=%), GFP-reporter plasmids were transfected aside. GFP-
positive cells were counted 24h after transfection by FACS. Defined numbers of cells were seeded and 
treated with DT, PM, or DT+PM 72 hours thereafter. 
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Table S9.1.4:    Phenotypes of MCF-7 exposed to SCR7-pyrazine and/or RS-1 during gene 
editing 
 
Cells transfected with plasmids for SpCas9-mediated DPH1 editing were seeded in defined numbers 
(#seeded cells). DT/PM selection started 72hr after transfection. Values (w,x,y,z) indicate colonies 
obtained in quadruplicate individual experiments. ‘SCR7’ refers to SCR7-pyrazine (see Methods 
section). Influence of the time point of the compounds (RS-1, SCR7-pyrazine and RS-1+SCR7-
pyrazine) addition. Significant difference of PM resistant relative to DT resistant colonies of treated 
samples vs. no compound is indicated with *p<0.05, **p<0.01, ***p<0.001.  
 
  
compound compound addition 
 
mean DTr colonies  
#seeded cells: 40.000 
mean PMr colonies  
#seeded cells: 80.000 
% PMr relative 
to DTr colonies 
- 
 
4 hrs before transfection 200.5  (213;203;194;192) 8.5 (6;11;8;9) 4.2 %    
18 hrs after transfection 515  (522;513;507;518) 20  (20;24;17;19) 3.9 %      
RS-1 (8µM) 4 hrs before transfection 201.5 (196;202;210;198) 14  (11;13;15;17) 6.9 %*    
18 hrs after transfection 512.5 (512;521;506;511) 15.3  (17;15;14;15) 3.0 %      
SCR7 (1µM) 4 hrs before transfection 205.3 (215;193;205;208) 13.3 (11;11;16;15) 6.5 %*    
18 hrs after transfection 488.8 (486;482;491;496) 25 (26;25;27;22) 5.1 %      
RS-1+SCR7 
(8µM +1µM) 
4 hrs before transfection 175 (183;175;177;165) 14.3   (12;14;15;16) 8.1 %***    
18 hrs after transfection 488.3 (492;485;495;481) 10.25 (8;10;6;17) 2.1 %**      
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Purification of TriFabs 
TriFabs are purified from cell culture supernatants by affinity and size exclusion chromatography. Due 
to lack of CH2 domains, TriFabs do not bind to Protein A (Figure S1c: TriFabs pass a Protein A column 
(left panel) while CH2 containing bsAbs [10] bind to and can be eluted from Protein A (right panel)). 
TriFabs are therefore purified by Protein L affinity chromatography followed by size exclusion 
chromatography (Figure S1). Hi Trap Kappa-select (GE Healthcare) is applied as first purification step, 
TriFabs eluted with 100 mM Glycine-buffer (pH 2.5) and adjusted to pH 6.0–7.5 with 1M Tris (pH 9.0) 
are subsequently subjected to SEC on a Superdex200 HiLoad 26/60 (GE Healthcare) equilibrated with 
20 mM histidine, 140 mM NaCl, at pH 6.0 on an Aekta (GE Healthcare). Shaded boxes in Figure S1 
(SEC profiles) indicate fractions containing properly folded TriFab. The composition and purity of 
TriFabs obtained by this simple 2-step procedure is shown in the SDS PAGE without (n.r.) and with (r.) 
sample reduction (right panel). (A) depicts SEC and SDS-PAGE of TriFabs containing the hapten-
binding entity in the stem region; (B) of TriFabs with cell-binding entities in the stem region. 
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Figure S9.2.1. Purification of TriFabs. (a) TriFabs harboring hapten binding entities in their stem 
regions; 
(b) TriFabs harboring hapten cell targeting entities in their stem regions; (c) Fc containing bsAbs 
bind to protein A (left panel) but TriFabs do not bind protein A (right panel). 
 
 
Thermal Stability of TriFabs 
Thermal stability was assessed by recording light scattering and tryptophan fluorescence simultaneously 
while heating samples with a constant heat rate (see Experimental Section for sample preparation and 
experimental details). Samples were heated from 30 to 90 °C at a constant rate of 0.1 °C/min with 
continuous recording of the intensity of scattered light and the fluorescence emission spectra after 
excitation with a 266 nm laser. For the aggregation onset temperature readout, light scattering intensities 
were plotted against the temperature as shown in Figure S2a. The aggregation onset temperature (Tagg) 
is defined as the temperature at which the scattered light intensity begins to increase. For the unfolding 
readout, the ratio of the fluorescence intensities at 350 and 330 nm were plotted as a metric for the shift 
in peak position against the temperature as shown in Figure S2b. The denaturation temperature (Tm) is 
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defined as the inflection point in these curves. Aggregation onset and denaturation curves of TriFabs 
that bind to different cell surface antigens and different haptens are shown in Figure S2: Figure S2a 
demonstrates aggregation onset temperature of TriFabs (scattered light intensity of an incident 266 nm 
laser during continuous heating in an Optim1000 instrument; aggregation onset temperature (Tagg) is 
defined as the temperature at which the scattered light intensity begins to increase). Figure S2b depicts 
denaturation of TriFabs (the ratio of the fluorescence intensities at 350 and 330 nm was recorded during 
the same experiment as in (Figure S2a); denaturation temperature (Tm) is defined as the inflection point 
in these curves). The results of these analyses are summarized in Table 1. These indicate that TriFabs 
are quite stable, with aggregation onset temperatures between 51 and 61 °C and denaturation 
temperatures between 58 and 66 °C. The only (format independent!) variation in stability that we 
observed was that Dig-binder containing TriFabs tolerated even higher melting temperatures (>60 °C) 
than Bio-binders (Table 1). 
 
 
Figure S9.2.2. Stability of TriFabs as determined in thermal denaturation experiments assessing 
aggregation onset (a) or unfolding (b). 
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Figure S9.3.1 MST traces of monovalent anti biotin TriFab and bivalent anti biotin 2+2 bsAb 
constructs and controls. A Chromatin + biotin-CPXM2 ~ anti biotin TriFab interaction. B Chromatin + 
biotin-CPXM2 ~ anti biotin 2+2 bsAb interaction. C-D Antibody only control measurements without biotin-
CPXM2 peptide but with anti biotin TriFab (C) and anti biotin 2+2 bsAb (D); MST traces show no 
aggregation or precipitation effects with anti biotin 2+2 bsAb and just minor aggregation with anti biotin 
TriFab. Area within blue lines determines the fluorescence before activation of the infrared laser and 
area within blue lines determines average fluorescence after activation of the IR-laser. Average values 
were subsequently used for fluorescence normalization.  
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Chromatin + biotin-CPXM2 ~ anti biotin TriFab 
Chromatin + anti biotin TriFab 
Chromatin + biotin-CPXM2 ~ anti biotin 2+2 bsAb 
 
Chromatin + anti biotin 2+2 bsAb 
Chromatin + biotin-CPXM2 ~ anti biotin TriFab 
Chromatin + anti biotin TriFab 
Chromatin + biotin-CPXM2 ~ anti biotin 2+2 bsAb 
 
Chromatin + anti biotin 2+2 bsAb 
A B 
C D 
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Figure S9.3.2 MST runs of monovalent anti biotin TriFab and bivalent anti biotin 2+2 bsAb 
constructs and controls. A Chromatin + biotin-CPXM2 ~ anti biotinTriFab interaction; Ligand 
concentration refers to biotin-CPXM2 peptide (twice as much as the respective anti biotin 2+2 bsAb 
concentration). B Chromatin + biotin-CPXM2 ~ anti biotin  2+2 bsAb interaction; Ligand concentration 
refers to biotin-CPXM2 peptide, but is equal to the respective anti biotin TriFab concentration. C-D 
Antibody only control measurements without biotin-CPXM2 peptide but with anti biotin TriFab (C) and 
anti biotin  2+2 bsAb (D); In contrast to peptide containing constructs, runs with antibody only controls 
did not show a concentration dependent increase in fluorescence, demonstrating that no unspecific 
interaction between antibody and chromatin occurs. Exp 1 (blue) and Exp 2 (red) are independent 
experiments of the same construct with the respective curve fit for KD determination if applicable. 
 
METHODS: Microscale thermophoresis experiments, data processing and determination of KD 
values was performed by 2bind GmbH (Regensburg). Antibody and peptide were diluted in 
PBS and pre-incubated for 30 mins at RT with a 1 : 1 or 1 : 2 molar ratio for TriFab : peptide 
or 2 + 2 bsAb : peptide, respectively. A serial dilution of the ligand was prepared in a way to 
match the final buffer conditions in the reaction mix (1x PBS, 0.05 % Tween-20). 5 μl of each 
dilution step were mixed with 5 μl of fluorescent labelled plasmid chromatin. The final reaction 
mixture, which was filled in capillaries, contained a respective amount of ligand and constant 
0.25 nM fluorescent molecule. The samples were analysed on a Monolith NT.115 Pico at 25 
°C, with 10 % LED power and 60 % Laser power. Fluorescence values were normalized and 
data were displayed according the analysed peptide concentration 432. KD values were 
determined, if normalized fluorescence values allowed a proper curve fit. 
(1) Jerabek-Willemsen, M., André, T., Wanner, R., Roth, H.M., Duhr, S., Baaske, P. and Breitsprecher, D. (2014) 
MicroScale Thermophoresis: Interaction analysis and beyond. Journal of Molecular Structure, 1077, 101-113. 
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Disruption of diphthamide 
synthesis genes and resulting toxin 
resistance as a robust technology 
for quantifying and optimizing 
CRISPR/Cas9-mediated gene 
editing
Tobias Killian, Steffen Dickopf, Alexander K. Haas, Claudia Kirstenpfad, Klaus Mayer &  
Ulrich Brinkmann
We have devised an effective and robust method for the characterization of gene-editing events. The 
efficacy of editing-mediated mono- and bi-allelic gene inactivation and integration events is quantified 
based on colony counts. The combination of diphtheria toxin (DT) and puromycin (PM) selection enables 
analyses of 10,000–100,000 individual cells, assessing hundreds of clones with inactivated genes per 
experiment. Mono- and bi-allelic gene inactivation is differentiated by DT resistance, which occurs only 
upon bi-allelic inactivation. PM resistance indicates integration. The robustness and generalizability 
of the method were demonstrated by quantifying the frequency of gene inactivation and cassette 
integration under different editing approaches: CRISPR/Cas9-mediated complete inactivation was 
~30–50-fold more frequent than cassette integration. Mono-allelic inactivation without integration 
occurred >100-fold more frequently than integration. Assessment of gRNA length confirmed 20mers 
to be most effective length for inactivation, while 16–18mers provided the highest overall integration 
efficacy. The overall efficacy was ~2-fold higher for CRISPR/Cas9 than for zinc-finger nuclease and was 
significantly increased upon modulation of non-homologous end joining or homology-directed repair. 
The frequencies and ratios of editing events were similar for two different DPH genes (independent 
of the target sequence or chromosomal location), which indicates that the optimization parameters 
identified with this method can be generalized.
Gene-editing technologies, which are applicable in science as well as medicine1, include the use of zinc-finger 
nucleases (ZFNs2–4), transcription activator-like effector nucleases (TALENs4–7) and the RNA-guided CRISPR/
Cas9 system1,8–10. The last approach is a tool that has recently emerged as the predominant choice for gene edit-
ing. CRISPR/Cas9 technology is highly specific, easy to design and generate, and well-suited for application in 
a variety of cell types and organisms. The target gene specificity of the nuclease Cas9 is conferred by small guide 
RNAs (gRNAs, usually 20mers) complementary to the sequence to be edited within the target gene. In contrast, 
the specificity of ZFNs and TALEN is conferred by engineered protein domains that recognize specific target 
sequences. Therapeutic effects can be achieved using genome editing, via the correction or inactivation of delete-
rious mutations, introduction of protective mutations, supplementation of transgenes and/or disruption of viral 
DNA11. The first therapeutic genome editing approach (using ZFN) addressed CCR5 in autologous CD4 T-cells 
of HIV patients12,13. The progress of therapeutic gene editing in various applications is at the preclinical stage, in 
addition to one phase 1 trial11,13–17.
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Effective and robust methods for the characterization and comparison of editing technologies are essential 
for applications in R&D and the development of editing-based therapies. Such evaluations comprise analyses 
and comparisons of the efficacy as well as the specificity of target gene destruction and productive transgene 
integration. These aspects are particularly crucial for the safe and effective clinical translation of editing technol-
ogies12. Using first-generation Cas9 editing approaches, off-target modifications occur at significant rates18–23. 
Optimization of gene-editing systems is therefore desirable to reduce off-target effects while maintaining or 
enhancing on-target efficiency.
A prerequisite for optimizing gene editing is the reliable and robust detection and differentiation of mono- and 
bi-allelic gene inactivation as well as nonspecific and targeted integration events. Existing methods, such as the 
determination of phenotypes caused by insertions (e.g., drug resistance) or a lack of phenotypes (gene inacti-
vation) or sequencing approaches, frequently do not differentiate mono- and bi-allelic inactivation. Moreover, 
existing technologies rarely address the genetic composition of individual cells and may not be based on large 
numbers of individual gene-edited cells to allow robust statistical analyses.
Here, we describe a simple and robust approach for characterizing gene-editing events. A combination of 
Diphthamide biosynthesis protein encoding gene (DPH) inactivation, diphtheria toxin (DT) treatment and puro-
mycin (PM) selection allows the determination of gene-editing efficacy in very large numbers of individual cells. 
The method differentiates mono- and bi-allelic gene inactivation and indicates site-specific integration. The sim-
plicity and robustness of the method facilitate the optimization of gene-editing procedures as well as the identifi-
cation and comparison of gene-editing modulators.
Results
Determination of target gene inactivation and resistance cassette integration via a combi-
nation of diphtheria toxin and puromycin selection. DT ADP-ribosylates diphthamide and thereby 
inactivates eukaryotic translation elongation factor 2 (eEF2), which irreversibly stalls protein synthesis and 
kills cells24. Diphthamide is a histidine modification placed on eEF2 via diphthamide synthesis gene-encoded 
enzymes, including DPH1. Complete bi-allelic inactivation of DPH1 in MCF7 cells prevents the synthesis of the 
toxin target diphthamide, which renders cells resistant to DT25. Thus, inactivation of all copies of DPH1 generates 
a ‘DT resistance’ (DTr) phenotype. DPH1 gene inactivation as a consequence of DPH1–targeted gene editing can 
occur due to non-homologous end-joining events. In combination with a donor plasmid containing a promot-
er-less expression cassette encoding the enzyme puromycin N-acetyltransferase (Pac) flanked by DPH1 homology 
arms, DPH1 gene inactivation can result from the homology-directed repair of DNA double-strand breaks (and 
pac insertion). Thus, DTr occurs upon inactivation of both DPH1 alleles via either mechanism or via a combina-
tion of the two. Bi-allelic DPH1 gene inactivation combined with homology-directed repair and pac expression 
cassette (PAC) integration into at least one allele leads to DT-PM double resistance (PMr DTr). Pac insertion into 
one DPH1 allele without inactivation of the other generates cells that are PM resistant but DT sensitive (PMr DTs). 
The same phenotype results from cassette integration in off-target positions of the genome that enable pac expres-
sion (the 5′ homology arm of the DPH1-pac cassette might support transcription even though pac lacks its own 
promoter). Cells with genomic pac insertions at positions that do not enable expression of the cassette remain 
PM sensitive (PMs) and cannot be detected by assessing PM resistance. Figure 1A shows possible genomic events 
leading to the four phenotypes analysed via DT and/or PM selection: PMs DTs; PMr DTs; PMs DTr; and PMr DTr.
Diphtheria toxin resistance assays and HRM-PCR to quantify and differentiate mono- and 
bi-allelic DPH1 gene inactivation. The frequency of the DTr phenotype can be detected in a robust man-
ner by counting toxin-resistant colonies. Exposure of cells (following co-transfection with the CRISPR/Cas9/
gRNA-encoding plasmid and the pac donor plasmid) to lethal doses (2 nM) of DT eliminates all cells that harbour 
at least one functional copy of the DPH1 gene. Colonies develop only from cells in which both DPH1 genes are 
inactivated (an example is shown in Figs 1B–D and S2). As the presence of one remaining functional DPH1 allele 
is sufficient for toxin sensitivity, all DPH1 alleles must be knocked out in DTr cells. Cells in which only one allele 
is modified can be identified via high resolution melting (HRM)-PCR assays on clones derived from individual 
cells (Fig. 1E). This technology is based on the amplification of a genomic locus at which sequence alterations are 
expected, followed by recording melting curves. Modified and wild-type amplicons can be discriminated based 
on their melting profiles at the resolution of a single nucleotide exchange, a technology that was originally devised 
to diagnose single nucleotide polymorphisms or detect mutations (see Methods section for details26,27). Target 
sequence modifications consequently also alter the melting temperature of DPH1 PCR fragments compared with 
that of the wild-type fragment, which generates differences in melting temperatures and, hence, bi-phasic HRM 
profiles. Nuclease-mediated gene inactivation events occur independently in different alleles and are therefore 
rarely identical in both alleles. Thus, one would expect not only ‘wild-type-mutated’ combinations but also cells 
with complete (bi-allelic) gene inactivation to display bi-phasic HRM profiles. In fact, all of the DTr colonies 
that we assessed via HRM-PCR displayed deviations of the melting curve shape, which indicates that identical 
inactivation events in both alleles occur infrequently. Determination of the ‘toxin-resistant’ phenotype in cells 
subjected to HRM-PCR therefore differentiates between mono-allelic and bi-allelic (identical and non-identical) 
DPH1 target gene inactivation events.
PM resistance allows detection and differentiation of specific and non-specific integration 
events. The pac integration cassette is flanked by target gene-specific homology arms (Suppl. Figure S1). 
Integration via homology-directed double-strand break repair results in target gene promoter-driven pac 
expression, conferring PM resistance28. Thus, pac integration is detected and quantified via PM resistance 
assays in a similar manner to that described for DTr colonies: cells that were co-transfected with the CRISPR/
gRNA-encoding plasmid and the pac donor plasmid were treated with lethal doses (500 ng/mL) of PM to 
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Figure 1. Determination of DT and/or PM resistance combined with HRM-PCR to quantify mono- vs bi-
allelic gene inactivation and cassette integration events. (A) Overview of various repair outcomes and conferred 
resistance that can be distinguished by assessing resistance to DT and/or PM. Each box indicates 2 DPH1 alleles 
on the left and ‘other’ undefined chromosomal loci on the right. Crosses indicate gene inactivation, and HRM+ 
reflects detection of mono- or bi-allelic DPH1 sequence deviations as described in (E). Cassette insertion events 
are indicated with a solid ‘PAC-ellipse’, inserted either at DPH1 or elsewhere in transcription-enabled locations. 
Solid PAC-ellipses represent expressed Pac. Open ‘?-ellipses’ represent insertion events at positions that do not 
enable expression; these events cannot be detected by assessing PM resistance. (B–D) MCF7 cells were transfected 
with a CRISPR/Cas9 expression construct and a donor plasmid that integrated the pac resistance cassette in 
DPH1. (B) Cells were exposed to DT at concentrations that are lethal to cells carrying functional DPH1. In 
surviving colonies, all DPH1 gene copies are inactivated. Colonies that retain functional DPH1 are killed by DT. 
DTr colonies emerge only upon treating cells with DPH1 gRNA without nonspecific background in cells exposed 
to control guides. (C) 96 hours after transfection, cells were exposed to PM at concentrations that are lethal to 
cells without pac. The surviving colonies carry at least one pac expression cassette and emerge in higher numbers 
in the presence of DPH1 gRNA compared with scrambled gRNA. The scramble guide that we applied (20mer, 
GCACTACCAGAGCTAACTCA) does not correspond to any specific human gene. (D) Simultaneous PM & 
DT selection reveals cells in which all DPH1 alleles are inactivated, and at least one pac cassette is integrated. 
(E) MCF7wt, MCF7wtko with one wild-type and one inactivated allele, and cells in which both alleles were 
inactivated were subjected to HRM-PCR spanning the target region. Cells harbouring at least one modified allele 
are differentiated from wt cells based on deviant melting curves. The method does not differentiate cells in which 
one allele is modified from cells carrying modifications on both alleles. Curve-shape analyses cannot distinguish 
between wt-wt and rare events potentially consisting of two identical modified alleles. However, without any 
exceptions, all DT-resistant cells that we analysed displayed HRM curve-shape deviations. Thus, identical 
modifications in both alleles (via potential dominance of particular indel types) may occur, but we did not observe 
any in our analyses, indicating that such events are rare under the applied methodology.
www.nature.com/scientificreports/
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eliminate all cells that lack pac expression (Fig. 1C). In contrast to DTr, which results only from specific and 
complete bi-allelic target gene inactivation, PMr may occur independent of the position of integration as long as 
pac integrates into transcription-enabling loci. Pac expression may also occur upon integration into loci that, by 
themselves, are not transcriptionally active but may generate promoter activity in combination with the homol-
ogy arm located upstream of pac (the 5′-DPH1 arm may contain such sequences; see Suppl. Figure S1 legend for 
details). Non-targeted integration at positions that do not support expression will not generate PMr colonies and 
is not detected in our assays. PM- resistance assays therefore provide conservative (underestimated) estimates of 
non-gRNA-targeted integration events. The frequency of site-specific versus non-specific transcription-enabled 
integration is examined by comparing double-resistant DTr+PMr colonies and PMr colonies (Fig. 1D).
Comparison of CRISPR-Cas9-mediated DPH1 inactivation and targeted integration events. To 
compare the frequencies of target-specific inactivation and integration and off-target integration, plasmids 
encoding DPH1-specific CRISPR/Cas9 constructs (Suppl. Figure S1) were transfected into MCF7 cells. These 
cells were subsequently subjected to HRM-PCR and colony count assays to measure DT and PM resistance, as 
described above. The results of these assays are summarized in Fig. 2, and individual datasets are available in 
Suppl. Table S1. Figure 2A shows that complete inactivation of the DPH1 gene, indicating functional loss of all 
DPH1 alleles, occurred at a frequency of ~6% of all transfected cells (2.5% of all cells, considering a transfection 
efficiency of 40%, Suppl. Table S1). DPH1 inactivation showed absolute dependency on the matching gRNA 
sequence: scrambled control RNA (scRNA) did not generate any DTr colonies. A comparison of the frequency 
of HRM hits with the occurrence of DTr colonies is shown in Fig. 2B. These analyses revealed that mono-allelic 
gene inactivation (toxin sensitive HRM-hit) occurred twice as frequently as inactivation of both alleles (DTr cells).
Figure 3 shows a comparison of the frequency of DTr and PMr colonies. Inactivation of both DPH1 alleles 
(Fig. 3B) occurred with 30–50-fold higher efficacy than cassette integration events that enable pac expression and 
generate PM resistance (Fig. 3B). Compared with DPH1-specific gRNA, scRNA generated 2-fold fewer PMr colo-
nies under otherwise identical conditions, which reflects integration events that enable pac expression. Integration 
events in genomic regions that do not lead to pac expression cannot be detected by our assay. It is therefore likely 
that the number of random integration events is greater than the number of PMr colonies. The position of pac 
integration for individual clones cannot be determined via mere determination of colony counts. Preferential 
gRNA-mediated integration at the gRNA-defined target gene can nevertheless be deduced by comparing the 
frequency of DTr, PMr, and DTr+PMr double-resistant colonies (without the need for normalization to the trans-
fection efficacy or scRNA controls): transfection 40,000 cells with Cas9/DPH1-gRNA + pac donor DNA results 
in the generation of 946 (2.4%) DTr colonies and 24 (0.06%) PMr colonies (Suppl. Table S1). If the two events are 
unrelated, the probability of observing DTr+PMr double-resistant colonies would be 2.4% × 0.06% = 0.00144%, 
which translates to an expectation of ≤1 DTr + PMr double-resistant colony among 40,000 cells if gene inactiva-
tion and pac integration are unrelated events. Our observation of 12 DTr + PMr double-resistant colonies among 
40,000 transfected cells therefore indicates a high degree of (preferential) targeted integration at the DPH1 locus. 
Thus, Cas9/DPH1-gRNA-mediated integration preferentially occurs at the DPH1 gene. In accordance with prefer-
ential integration in the DPH1 gene, many of the PMr colonies obtained using the DPH1 guide were DT resistant 
Figure 2. HRM-PCR and/or DT-selection of MCF7 cells transfected with the DPH1 gene-specific CRISPR/Cas9 
expression construct and pac donor plasmid. Values are displayed as the % transfected cells. (A) DTr colonies occur 
only when matching DPH1 gRNA is used; no colonies emerge in untreated cells or in cells that receive scRNA. 
Mean values +/− SEM are shown. (B) HRM-PCR reveals the frequency of cells that harbour DPH1 modifications 
on one or both alleles. Subsequent DT sensitivity assays show that mono-allelic hits (toxin sensitive & HRM 
positive) occur twice as frequently as inactivation of both alleles (HRM positive & toxin resistant).
www.nature.com/scientificreports/
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(Fig. 3A). In contrast, none of the PMr colonies obtained using scRNA were resistant to DT. Thus, Cas9-mediated 
gene inactivation (including that of both alleles) occurs highly specifically and with a much higher frequency than 
targeted pac integration (Fig. 3B).
The quantification of gene editing works with another target gene, DPH2. Are the results 
obtained thus far a general feature of CRISPR/Cas9-mediated editing or specific to the DPH1 gene? To address 
this question, we applied an identical approach for Cas9-induced modification of the DPH2 gene. DPH2 encodes 
a different enzyme with a different sequence on a different chromosome but is also essential for diphthamide 
synthesis. DPH2 deficiency renders cells resistant to DT in the same manner as DPH1 deficiency25. Thus, the 
assay principles developed to characterize DPH1 modification can also be applied to analyse DPH2 modification. 
The results of DPH2 editing followed by the assessment of DT and PM resistance (with a pac insertion cassette 
that contains DPH2 homology arms) are displayed in Fig. 3C: in line with our observations for DPH1, bi-allelic 
DPH2 inactivation events were observed at a higher frequency than integration of the pac expression cassette, 
showing a fold change of a similar magnitude (~90-fold higher inactivation of DPH2 than integration of the 
pac expression cassette). The absolute numbers of editing events were reduced for DPH2 compared with DPH1, 
possibly due to the different sequence composition of the gRNA and homologous arms and/or the accessibility 
of the DPH2 locus. The differences in the absolute numbers of PM-resistant colonies between DPH1 and DPH2 
editing may also be due to potential promoter activity on the 5′ homology arm of the DPH2-pac cassette. The 
DPH1 5′ homology arm encompasses the immediate 5′ region of the DPH1 gene, making it likely to contain some 
form of minimal promoter. Thus, insertion of the DPH1-pac cassette may lead to pac expression without a strict 
requirement for insertion behind active promoters (legend to Suppl. Figure S1B). However, the relative efficacy 
(compared with scRNA) was similar for DPH2 and DPH1. Inactivation was strictly dependent on the presence of 
cognate gRNA. Cassette insertion events that enable pac expression occurred more frequently when DPH2 gRNA 
was used than when scRNA was used (comparing the frequency of DT vs PM + DT resistance, see calculation 
above). The similarity of the DPH1 and DPH2 editing results indicates that the general findings obtained using 
this assay system will likely also apply to other genes.
Comparison and optimization of the Cas9 gene-targeting complex: gRNA length. Because 
the outcomes of the DPH1 and DPH2 gene-editing experiments were comparable, it can be assumed that our 
method identifies optimized editing parameters that can be generally applied to many other genes. Figure 4 shows 
how gene inactivation as well as the integration efficacy and specificity of Cas9 gRNAs of different lengths can 
be assessed and compared. All of the applied gRNAs targeted the same stretch of sequence within DPH1 but 
Figure 3. PM and/or DT selection of MCF7 cells transfected with DPH gene-specific CRISPR/Cas9 expression 
constructs and pac donor plasmids. Mean values + SEM are shown (n = 4, ***p < 0.001). (A) PM selection 
generates resistant colonies at a 2-fold higher frequency when DPH1 gRNA is used compared with scRNA. 
Combining PM selection and DT selection reveals the frequency at which the pac cassette becomes integrated 
in cells in which both DPH1 alleles are inactivated. DPH1 gRNA generates clones with PM-DT double 
resistance. scRNA generates only PMr colonies and no DTr colonies. (B) Comparison of the frequency of DTr 
(both DPH1 genes inactivated) colonies and PMr (pac integration at DPH1 or at another site) colonies. The 
position or zygosity of pac integration cannot be determined. (C) MCF7 cells transfected with DPH2-specific 
gRNA and donor DNA were subjected to PM and/or to DT selection. The absolute numbers of gRNA- as 
well as scRNA-mediated editing events are reduced for DPH2 compared with DPH1. The efficacy of targeted 
inactivation and integration may be due to differences in the sequence of the gRNA and homology arms and/or 
target gene accessibility. Reduced ‘efficacy’ of scRNA-mediated integration is a consequence of sequence features 
within the different homology arms of the pac cassette, as the scRNA was identical in the DPH1 and DPH2 
editing experiments.
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varied in length from 14 to 26 bases (Fig. 4A, details of gRNAs in Suppl. Figure S1). DTr colony numbers were 
recorded to reflect target gene-specific complete (bi-allelic) inactivation. Simultaneously, the numbers of PMr 
and of DTr+PMr double-resistant colonies were assessed to monitor cassette integration. As expected, gRNA 
length influenced the efficacy of gene inactivation, with 20mers conferring the maximal DPH1 inactivation effi-
cacy. Shortening the complementary stretch to 18 or 16 bases or extending it up to 26 bases retained significant 
specific gene inactivation functionality, albeit with a decreased efficacy compared with the 20mer. Reducing the 
complementary stretch within the gRNA to less than 16 bases (14mer) decreased DPH1-inactivating functionality 
to below detection levels. The integration efficacy (assessed by counting PMr events) was also influenced by gRNA 
length. Guides smaller than 16mers (14mers) generated few PMr colonies, not exceeding scrambled control 
background levels. Targeted integration was observed for 16mers, 18mers, 20mers, 22mers, 24mers and 26mers, 
Figure 4. Optimization of gene editing: influence of gRNA length and editing enzymes on efficacy and 
specificity. (Transfection control shows neither DTr nor PMr colonies.) Mean values + SEM are shown (n = 4, 
**p < 0.01, ***p < 0.001). MCF-7 cells transfected with DPH1-specific Cas9 constructs were subjected to PM 
and DT selection using gRNAs of different lengths (A) or different enzymes (B&C). (A) gRNA length affects 
gene inactivation and integration frequencies. Statistical evaluation of the differences was performed by setting 
the gRNA with the maximum value of resistant clones for each group (i.e., DT; PM, DT+PM) as a comparator 
in relation to which the other gRNAs were set. These comparators were as follows: 20mer for DT; 16mer for 
PM, 18mer for DT+PM. a/b: no significant difference to comparator value but significant to respective 20mer 
gRNA value (p < 0.01) (B) Total number of DTr, PMr or DTr PMr colonies under DPH1 editing approaches 
using 20mer gRNA (CRISPR/Cas9) or designed ZFN. The values are compared to the SpCas9 treatment of the 
respective group (DT, PM, DT+PM). (C) Ratio of site-specific integration events/total target gene inactivation 
events (DTr PMr)/DTr.
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with an optimum overall insertion efficacy being achieved with 16–18mers. No gain in efficacy was achieved for 
22–26mer complementary stretches; in fact, stretches longer than 20mer gRNAs reduced the overall number of 
insertion events. The ratio between integration events (PMr) and inactivation events (DTr) can be calculated as 
an ‘indicator’ to identify conditions in which integration occurs with the fewest gene inactivation events. Such 
conditions may be favoured if one desires integration without inflicting excessive non-productive target gene 
damage. Low values (e.g., few PMr relative to DTr colonies) reflect inefficient integration in relation to simultane-
ously occurring inactivation events. High values (more PMr and/or relatively decreased numbers of DTr colonies) 
reflect more efficient integration. We observed the highest insertion-per-inactivation values for 16–18mers (PM/
DT 16mer = 0.0431; PM/DT 18mer = 0.0379) and a significant drop for guide RNAs containing 20 complemen-
tary bases (PM/DT 20mer = 0.018) or more (p-value 18mer vs. 20mer = 0.0017; unpaired, two-tailed Student’s 
t-tests), which indicates that 20mers are quite efficient for targeted gene inactivation (in agreement with previous 
observations8,29–32). Shorter guides increase the frequency of insertion events (PMr colonies) as a consequence of 
both targeted and nonspecific integration.
Efficacy and specificity of different gene-editing approaches: enzymes. We compared gene inac-
tivation and integration events and the efficacy and specificity of different variants of RNA-guided Cas9 as well 
as ZFN-mediated gene editing. The length and composition of gRNA were kept constant (DPH1 20mer), and 
three different editing enzymes were applied: (i) ‘SpCas9’ specifies the Cas9 nuclease from Streptococcus pyo-
genes, which can be considered the current standard application1,33; (ii) SpCas9-HF1 is an engineered variant of 
SpCas9 with reduced nonspecific DNA binding and off-target activity and, hence, a proposed higher fidelity and 
specificity19; and (iii) a ZFN-editing entity that recognizes target sequences via designed zinc finger-mediated 
protein-nucleic acid interactions34,35.
In the same manner as for gRNA analyses, DTr colonies were recorded to reflect targeted gene inactivation, 
and PMr colonies were recorded to monitor cassette integration (Fig. 4B, Suppl. Table S3). In comparisons of the 
overall efficacy of gene inactivation and cassette integration, the highest values for both parameters were observed 
using CRISPR/SpCas9. CRISPR/SpCas9-HF diminished targeted gene inactivation events to less than 20% of 
the number of DTr colonies compared with CRISPR/SpCas9. The frequencies of PMr (integration) and DT-PM 
double-resistant colonies (integration with targeted gene inactivation) were also reduced. Application of ZFN 
reduced the number of DTr colonies under otherwise identical conditions to less than 60% of the events observed 
using CRISPR/SpCas9. The efficacy of ZFN-targeted inactivation was therefore ~2-fold reduced compared with 
SpCas9 and ~2–3 fold better than that of the engineered SpCas9-HF1. The frequency of PMr colonies did not sig-
nificantly differ between CRISPR/SpCas9 and ZFN. Double-resistant colonies (cassette integration with simulta-
neous gene inactivation) were somewhat (30%) reduced using ZFN compared with CRISPR/SpCas9. Calculation 
of the ratio of DTr (target gene inactivation) to DT+PM double-resistant (targeted integration) colonies takes 
overall efficacy out of the equation, indicating that CRISPR/SpCas9, CRISPR/Cas9-HF, and ZFN generated the 
same level (~4 × 10−3) of targeted integration events per bi-allelic gene inactivation event (Fig. 4C).
Influence of DNA repair modulators on gene-editing efficacy and specificity. Colony assays for 
quantifying DTr and PMr cells following DPH gene editing can also be used to address the influence of compounds 
that modulate DNA repair. Activators of homology-directed repair (HDR) and inhibitors of non-homologous 
end joining (NHEJ) modulate gene-editing events and increase integration efficacy36,37. To demonstrate the suit-
ability of our technology for determining the effect of DNA repair modulators on the efficacy and specificity of 
editing, CRISPR/SpCas9/DPH1gRNA (20mer) editing and pac integration assays were combined with such com-
pounds, and the influence was quantified. The DNA ligase IV inhibitor SCR7 pyrazine was applied either 4 hrs 
before transfection (‘early addition’) or 18 hrs after transfection (‘late addition’) of the gene-editing constructs, 
and exposure was continued until 96 hrs after transfection. We used the HDR-active pyrazine derivate of SCR7 
in our experiments (see Methods section). Similarly, the RAD51 modulator RS-1 (RAD51-stimulatory com-
pound 1) was added to stimulate HDR. Both compounds were applied at doses that had no effect on the growth 
or viability of MCF7 cells (see Methods section): 1 µM for SCR7 pyrazine, 8 µM for RS-1, and 1 µM + 8 µM for 
SCR7 pyrazine + RS1. Compared with the DMSO-treated control, the addition of RS-1 increased the number of 
PMr colonies ~2-fold (Suppl. Table S4). To quantify the effect on the overall integration efficacy, the percentage 
of PMr colonies (gene integration) relative to DTr colonies (gene inactivation) was calculated (Fig. 5). The addi-
tion of RS-1 at an early time point led to a significantly higher integration efficacy; however, it did not affect the 
integration efficacy upon late addition (18 hrs after initiation of editing). Thus, choosing the appropriate (early) 
time point for RS1-mediated HDR stimulation is important for the enhancement of productive editing, confirm-
ing HDR to be a driver of targeted cassette integration. To a similar degree, early application of SCR7 pyrazine 
significantly increased the relative number of integrations (Fig. 5 and Suppl. Table S4), which confirms previous 
observations of enhanced productive gene editing upon SCR7 pyrazine administration37. When both compounds 
were used, the ratio of PMr relative to DTr was 8.1%, compared with 6.5% (only SCR7 pyrazine) or 6.9% (only 
RS-1). However, these differences/increases were not significant (p = 0.39 vs RS-1 alone), which is in line with 
previous observations38,39.
Discussion
Genome editing has emerged as a technology of utmost importance for scientific and potential therapeutic appli-
cations. Its entire potential is, however, still limited by efficacy and specificity issues of the currently applied edit-
ing approaches. The presented method enables simple and robust quantification and comparison of the efficacy 
and specificity of gene inactivation and donor cassette insertion events. The core principle of this method consists 
of inactivation of the endogenous diploid DPH1 or DPH2 genes, which results (provided it occurs on both alleles) 
in absolute resistance to DT. The additional insertion of the pac gene allows the determination of both targeted 
www.nature.com/scientificreports/
8SciEnTific RePoRTS | 7: 15480  | DOI:10.1038/s41598-017-15206-x
and non-targeted integration via the respective selection methods. Due to the simplicity and robustness of these 
readouts (colony counts), the method allows exact determination of mono- and bi-allelic target gene inactivation 
and nonspecific versus targeted integration events based on large numbers of individual cells (shown in Fig. 6). 
Furthermore (and in contrast to many existing tools33,40–42), mono- and bi-allelic target gene inactivation and 
integration events can be differentiated. Thus, simple colony counts reflect the efficacy of and ratios between 
productive (integration) and destructive gene editing (inactivation without integration). The results obtained 
by applying this method may be of particular importance in the development and optimization of gene-editing 
approaches, such as methods for the generation of genetically defined cell lines or organisms, and potentially also 
for therapeutic gene editing.
Evidence that the method delivers ‘generalizable’ results was obtained by comparing editing events (colony 
frequency) involving two different DPH genes. DPH1 and DPH2 encode different enzymes, both of which are 
Figure 5. Influence of DNA repair-modulating agents on gene editing. MCF-7 cells were transfected with 
plasmids encoding 20mer gRNA, SpCas9 and pac as described previously. The solvent control (DMSO), HDR-
modulating agent RS-1 (8 µM) and NHEJ-modulating SCR7 pyrazine (1 µM) were added either 4 hrs before or 
18 hrs after transfection. DT or PM selection was initiated 72 hrs after transfection. The percentage of PMr colonies 
(integration) relative to DTr colonies (cleavage) is shown. The values are compared to the DMSO control the 
respective addition time-point. Mean values + SEM are shown (n = 4, Φp < 0.05, ΛΛp < 0.01, ΦΦΦp < 0.001).
Figure 6. Frequency of CRISPR/Cas9-mediated gene-editing events. The average event frequencies obtained 
via determination of the numbers of PMr, DTr and double-resistant cells upon CRISPR/Cas9 editing of DPH1 
with 20mer gRNA are shown. DT-sensitive mono-allelic DPH1-edited cells are quantified based on HRM-PCR 
results indicating a 2:1 ratio of mono- vs bi-allelic inactivation events. Site-specific integration can result in DTs 
PMr colonies (integration at DPH1 with the 2nd allele unaltered) as well as double-resistant DTr PMr colonies 
(integration and bi-allelic DPH1 inactivation). *PMr colonies occurring following scRNA editing may be due to 
homology arm-mediated integration at the target gene (pac cassette contains homology arms) or to integration 
at transcription-enabling non-target sites. As integration events that do not enable transcription are not 
detected, the overall nonspecific integration frequency, including non-expression-enabling events, is expected 
to be higher than indicated.
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independently essential for diphthamide synthesis. The results revealed comparable efficacies, specificities and 
destruction/integration ratios for the two genes, which indicates that the dependencies and parameters obtained 
via this method are transferrable to optimization of the editing of other genes. As a proof of concept and bench-
mark validation of our method, we addressed and confirmed the influence of several previously analysed param-
eters on gene editing, as listed below.
The length of gRNA for CRISPR/Cas9-mediated editing influences the efficacy of nonproductive gene inacti-
vation as well as productive targeted integration43–45. In line with previous analyses30, our assays unambiguously 
demonstrate that ‘standard’ 20 mer gRNAs are effective for Cas9-mediated gene targeting, generating the highest 
overall gene inactivation frequency. The simplicity of our assay enables the simultaneous assessment of gRNAs 
of diverse lengths, revealing threshold sizes below or above which efficacy becomes compromised. One interest-
ing observation within this context was that the best ratios between productive and destructive editing events 
were observed using 16–18 mer guides. Thus, 20 mers may be the preferred choice for efficient gene inactivation, 
while 16–18 mers are preferred if one desires integration without excessive destructive editing. Fu et al.33, tested 
<20 mer gRNAs in gene inactivation experiments and observed an efficacy comparable to 20 mers, with simul-
taneously reduced off-target effects. Their analyses were based on mono-allelic GFP gene inactivation. As their 
method involved only one target gene per cell, it could not address or differentiate between mono- and bi-allelic 
inactivation events in diploid cells and could not compare insertion events. Our approach (based on large num-
bers of cells and inactivation of normal chromosome-encoded human genes) demonstrated that 20 mers are more 
efficient mediators of gene inactivation than shorter guides. Shorter guides increase the frequency of insertion 
events (PM-resistant colonies) as a consequence of either targeted or nonspecific integration.
The choice of gene-editing enzymes, such as CRISPR/Cas9/gRNA or protein (e.g., ZFN)-based recognition 
systems and derivatives, is another factor that influences editing efficacy and possibly specificity. Our method is 
not restricted to the standard CRISPR/Cas9 system and can be also applied to monitor gene-editing efficacy for 
other gRNA-targeted Cas9 derivatives or protein-targeted approaches, such as those based on ZFN34,35,46–50. In the 
comparison of ZFN, CRISPR/Cas9 and HF-Cas9 editing, we observed the highest overall efficacy of gene inac-
tivation and cassette integration for the ‘original’ CRISPR/SpCas9 system. Compared with this system, reduced 
efficacy was observed for both the ZFN and high-fidelity HF-Cas9 variant systems. In agreement with previous 
observations19, HF-Cas9 dramatically reduced scRNA-mediated (hence, most likely non-specific) integration 
events to below-detection limits.
The specificity of gene editing was assessed by comparing the frequency of colonies emerging under DT 
selection (bi-allelic target gene inactivation), PM selection (cassette integration) and DT+PM double selection 
(inactivation and integration). Target gene inactivation via CRISPR/spCas9 or HF-Cas9 occurs with ‘absolute’ 
dependence on gRNA specificity, i.e., only when applying cognate gRNAs without any scRNA background. In 
contrast, scRNA background was observed (as expected) when assessing PMr colonies. Our colony count assays 
are not suited to assessing the position of pac integration for individual clones, which would require sequencing, 
involving either many cells in a population (without differentiating alleles of individual clones) or defined clones 
(defined allele compositions of a limited number of events). Our approach deduces the probability of targeted 
integration events according to comparison of the frequency of DTr, PMr, and DTr+PMr double-resistant col-
onies, based on large numbers of individual colonies. This approach requires neither normalization of trans-
fection efficacy nor scRNA controls, as all data stem from a single editing experiment assessing DTr, PMr and 
DTr+PMr double-resistant colonies. DTr and PMr colony numbers reflect the individual frequency (e.g., in % of 
transfected cells) of gene inactivation or integration, and the frequency of DTr+PMr double-resistant colonies 
indicates whether (and to what degree) the two events are individual events or are ‘linked’. The ‘extremes’ of these 
calculations (frequency of DTr+PMr) = (frequency of DTr) × (frequency of PMr) would correspond to pac inser-
tion occurring nonspecifically without gRNA involvement or all PMr colonies are also being DTr (frequency of 
DTr+PMr) = (frequency of PMr). In the latter case, all pac insertions would occur at the target gene (as the coin-
cidence of double target gene inactivation with non-targeted insertion elsewhere is negligibly low). The degree 
of independence or linkage of DTr and PMr colonies can therefore be regarded as a measure of specificity when 
comparing different editing approaches or editing modulators.
Compounds that modulate recombination have recently been used to increase the efficacy of produc-
tive (integration) editing. Examples of such compounds include the ligase IV inhibitor SCR7 pyrazine (see 
Methods section for details of the compounds) for modulation of non-homologous end-joining (NHEJ) and the 
homology-directed repair (HDR) stimulator RS-136,37. The suitability of our method for determining the effect 
of NHEJ- and HDR-modulating agents on gene editing allows us to compare it to available screening approaches 
described in the literature. The application of our method to editing in combination with these compounds 
confirmed all previous observations of SCR7 pyrazine- and RS-1-mediated increases in efficacy37. Pinder et al. 
invented a FACS-based assay that exploits the site-specific integration of a fluorescent protein. This approach 
detects integration within single cells, yet without addressing zygosity or quantifying off-target integration38. In 
contrast to their approach, our readout is based on the phenotype resulting from endogenous gene modifica-
tion and allows the quantification of NHEJ repair as well as site-specific repair and HDR (via double selection, 
and the probability of co-event comparison, see above). Furthermore, our ‘colony count assays’ recapitulate the 
animal-based results of Song et al.36, demonstrating HR/NHEJ ratios (gene inactivation-to-integration) of below 
10% as well as RS-1-mediated enhancement of HR and integration. It must be noted that in contrast to other 
assessment technologies36,38, our method permits the assessment of modulators in a simple ‘downstream-assay 
free’ cell culture setting and could serve as a screening or pre-selection technology before initiating in vivo studies. 
Cell-based colony count approaches are high-throughput compatible, and death vs survival readouts are very 
robust. Thus, the method can (in addition to the examples above) be used to measure and quantify editing events 
in the context of various additional parameters, which may include the assessment and further characterization 
of modulating compounds and/or the definition of active components of compounds whose activities are under 
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discussion (e.g., SCR7 vs SCR7-pyrazine as a DNA ligase I/III and/or IV inhibitor,51). It also enables the screening 
of potential additional editing enhancer candidates, collections or libraries (including recombination and repair 
modulators), identification of the most effective mode of delivery for editing entities (mRNA, protein or DNA) 
as well as the composition of the donor cassette (length of insert and homology arms) for targeted insertions.
Methods
Cultivation of MCF7 cells and transfection of plasmids encoding gene-editing entities. MCF7 
cells52 were originally obtained from the ATCC (Manassas, VA, USA) and maintained in RPMI 1640 medium 
supplemented with 10% FCS, 2 mM L-glutamine and penicillin/streptomycin at 37 °C and 85% humidity. Within 
a set of experiments, we used one batch of cells to ensure that the comparisons and conclusions that we made 
were not affected by variance in the speed of colony formation. Between the experimental sets, we thawed new 
cell batches to ensure that the cells did not develop genomic alterations over time. For the transfection of plas-
mids harbouring gene-editing constructs, 3,000,000 cells were seeded in a 10 cm-diameter culture dish and 
cultivated at 37 °C in a humidified 5% CO2 atmosphere. At 24 h after seeding, the cells were transfected with 
20 µg of total DNA using jetPEI (Polyplus) according to the manufacturer’s protocol, except that an N/P ratio 
of 6:1 was employed. Transfection efficiency was determined 24 h thereafter via flow cytometry (FACSCalibur, 
BD Biosciences) of cells that were transfected with an eGFP expression plasmid53. Plasmids encoding CRISPR/
Cas9 editing entities targeting DPH1 (gRNA target: CAGGGCGGCCGAGACGGCCC derived from RefSeq: 
NM_001383) and DPH2 (gRNA target: TCGTACACTCCGTCCAGGTC derived from RefSeq: NM_001039589, 
NM_001384), as well as scrambled control RNA (scRNA: GCACTACCAGAGCTAACTCA) were obtained 
from Origene (DPH1# KN221955; DPH2# KN201382). This system comprises one plasmid expressing gRNA 
under the control of a U6 promoter, Cas9 nuclease under the control of a CMV promoter, and a donor plas-
mid with a promoter-less pac expression cassette flanked by homologous arms to the target gene (DPH1 or 
DPH2, see Suppl. Figure S1 for details). Additional DPH1 gRNAs of different sizes (Origene) included the 
14mer GGCCGAGACGGCCC; 16mer GCGGCCGAGACGGCCC; 18mer GGGCGGCCGAGACGGCCC, 
22mer AGCAGGGCGGCCGAGACGGCCC; 24mer GGAGCAGGGCGGCCGAGACGGCCC and 26mer 
GCGGAGCAGGGCGGCCGAGACGGCCC (Suppl. Figure S1).
Quantification of CRISPR/Cas9-mediated bi-allelic DPH1 and DPH2 gene inactivation. MCF7 
cells in which all chromosomal copies of DPH1 or DPH2 are inactivated are DT resistant25. Thus, the occur-
rence and frequency of toxin-resistant cells/colonies upon gene inactivation provide a measure of the efficacy 
of inactivation of all gene copies. MCF7 cells were transfected as described above using (i) a GFP expression 
plasmid, as a transfection control; (ii) the CRISPR/Cas9 DPH1 or DPH2 knock-out/integration system; and (iii) 
knock-out/integration entities containing scRNA, as a control. After determination of the transfection efficiency, 
10,000–40,000 cells were seeded in 6-well plates. RPMI medium was exchanged with RPMI medium containing 
DT (2 nM) 3 days after cell seeding. The medium was exchanged every 2–3 days until dead cells became detached. 
Between day 12 and day 14 after the initiation of toxin exposure, cells were washed 3 times with PBS and stained 
with ice-cold methylene blue (0.2% in 50% EtOH), followed by gentle washing under running water. Stained 
and fixed colonies were recorded via microscopy counting on 5 × 5 mm grid foil for orientation. The complete 
raw data (i.e., colony numbers from individual experiments) are provided in the supplementary information 
(Table S1).
Detection of CRISPR/Cas9-mediated mono-allelic DPH gene inactivation. Cells in which only 
one DPH1 or DPH2 allele is modified are DT sensitive. To identify and quantify such events, high-resolution 
melting (HRM) PCR was applied in a similar manner as previously described25: 24 h after transfection, single 
cells were deposited in 96-well plates through FACS (FACSAriaTM, BD Biosciences) and grown to confluency. The 
cells were washed with PBS and lysed by the addition of 40 µL of cell lysis buffer (Roche) per well. After 15 mins 
of incubation at RT on a plate shaker (Titramax 1000, Heidolph) at 750 rpm, the cell lysate was diluted 1:5 with 
PCR-grade H2O. Then, 5 µL of the cell lysate was mixed with HRM master mix (Roche) and primers spanning the 
gRNA target sequence. PCR and HRM were performed on the LC480 II platform (Roche) according the manu-
facturer’s protocol. Clones with edited target genes were identified based on melting curve deviations compared 
with MCF7-wt cells. Cells displaying biphasic melting curves may still possess one wt allele, or both alleles may 
be inactivated. Because nuclease-mediated gene inactivations are independent events in different alleles, they 
are rarely identical in both alleles (in our hands, all DTr colonies displayed bi-melting curve-shape deviations. 
Differentiation between wt and two identical modified alleles by HRM is in principle also possible because the 
melting temperatures of wt and mutated alleles differ if only one base is changed (the principle of HRM-mediated 
SNP-diagnostics (ref.26 and27)). We nevertheless suggest ‘abnormal curve shape’ as a readout because this readout 
is simple and robust, is not influenced by potential DNA, salt or buffer content variations in cell extracts and, 
hence, does not require highly standardized procedures for extract preparation. Clones displaying melting curve 
deviations were expanded without DT or PM selection and subjected to viability analyses to discriminate between 
toxin-sensitive mono-allelic and resistant bi-allelic knockout cells. These assays were performed in 96-well plates 
containing 10,000 cells at 37 °C in humidified 5% CO2. At 24 hr after seeding, the cells were exposed to toxin for 
72 h. Metabolic activity was assessed via the CellTiter Glo® Luminescent Viability Assay (Promega).
Identification and quantification of CRISPR/Cas9-induced transgene integration. In addition to 
the Cas9 nuclease and gRNA or scRNA, the applied CRISPR/Cas9 knock-out/integration system also contained 
a pac expression cassette without a promoter to avoid transient expression flanked by homologous arms for HDR 
(donor DNA). Thus, detection of the integration of recombinant sequences into the genome was performed via 
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determining the PM sensitivity of cells. The frequency of both events (gene inactivation and integration) was 
detected through the application of DT and PM. MCF7 cells were transfected and treated as described for the 
identification and quantification of gene inactivation, applying PM (500 ng/µL) or a combination of PM (500 ng/
µL) and DT (2 nM). Complete data (i.e., colony numbers from individual experiments) are provided in the sup-
plementary information (Table S1).
Identification and quantification of ZFN-mediated DPH1 gene editing. MCF7 cells in which all chro-
mosomal copies of DPH1 are inactivated are DT resistant25. Thus, the occurrence and frequency of DTr colonies follow-
ing ZFN-mediated gene inactivation and/or cassette integration provides a measure of the efficacy of inactivation of all 
gene copies. The ZFN recognition sequence (CAGGTGATGGCGGCGCTGGTCGTATCCGGGGCAGCGGAGCAG, 
cleavage site) is derived from NM_001383.3 (DPH1-wt) and was obtained from Sigma. A pac integration cassette for 
this position was obtained from Origene. MCF7 was transfected as described above using (i) a GFP expression plas-
mid, (ii) the plasmid encoding DPH1-targeting ZFN and (iii) the DPH1-targeting pac integration cassette. After deter-
mination of the transfection efficiency, the cells were seeded in 6-well plates. For quantification of bi-allelic knock-out 
events, (DTr) 20,000 cells were seeded; 40,000 cells were seeded for the quantification of integration events (PMr) or 
double resistance. RPMI medium was exchanged with RPMI containing DT, PM or both 3 days after seeding. The 
medium was changed every 2–3 days. Between day 12 and day 14 after the initiation of toxin exposure, cells were 
washed 3 times with PBS and stained with ice-cold methylene blue (0.2% in 50% EtOH), followed by gentle washing 
under running water and microscopic determination of colony numbers using 5 mm grid foil.
Quantification of the effects of HDR and NHEJ modulators on CRISPR/Cas9-mediated editing. 
RAD51-stimulatory compound 1 (RS-1) was applied to modulate homology-directed repair (HDR) during gene 
editing36. RS-1 (Sigma, R9782) was dissolved in DMSO to generate a stock solution of 10 mg/mL, which was 
diluted in RPMI medium just before application to cells. Viability (Promega CTG) assays identified a final con-
centration of 8 µM RS-1 as a dose that does not inflict growth-inhibitory or toxic effects on MCF7 cells (viability: 
1 µM, 100%; 3.7 µM, 100%; 11 µM, 97%; 33 µM, 61%). The DNA ligase IV inhibitor SCR7 pyrazine was applied 
to modulate non-homologous end joining (NHEJ) during gene editing37. SCR7 pyrazine (Sigma, SML1546) was 
dissolved in DMSO to generate a stock solution of 10 mg/mL, which was diluted in RPMI medium just before 
application to cells. Viability (Promega CTG) assays identified a final concentration of 1 µM as a dose that does 
not inflict growth-inhibitory or toxic effects on MCF7 cells (viability: 0.37 µM, 100%; 1.1 µM, 100%; 3.3 µM, 97%; 
10 µM, 88%). SCR7 pyrazine (1 µM final conc.), RS-1 (8 µM final conc.) or SCR7 pyrazine + RS-1 (1 µM + 8 µM 
final conc.) was added to MCF7 cells 4 hrs before transfection of the gene-editing constructs in the ‘early exposure’ 
setting. For ‘late exposure’, SCR7 pyrazine (8 µM final conc.) or RS-1 (1 µM final conc.) was added to MCF7 cells 
18 hrs after transfection. In both settings, the cells were exposed to the modulators until 96 hr after transfection, 
i.e., ‘early exposure’ consisted of treatment for a total of 100 hrs and ‘late exposure’ for a total of 78 hrs. The system 
for determining the effects of DNA repair modulators consisted of MCF7 cells transfected with the CRISPR/
SpCas9 constructs including DPH1 20mer gRNA and then subjected to DT and PM selection, as described above. 
The frequencies of DTr, PMr, and double-resistant colonies were recorded to reflect gene inactivation and cassette 
integration events.
Statistics. Unpaired, two-tailed Student’s t-tests were performed for single comparisons between two treat-
ments. Multiple comparisons were statistically analysed via a one-way ANOVA, followed by Tukey’s honestly 
different significance (HDS) post hoc test. A significant difference was defined by a p-value of <0.05. The level 
of significance determined using Student’s t-test or Tukey’s HDS test is indicated in graphs by one, two or three 
symbols (*, Λ or Φ) corresponding to p < 0.05, p < 0.01 and p < 0.001, respectively.
References
 1. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281–2308, https://doi.org/10.1038/
nprot.2013.143 (2013).
 2. Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778–785, 
https://doi.org/10.1038/nbt1319 (2007).
 3. Sander, J. D. et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8, 67–69, 
https://doi.org/10.1038/nmeth.1542 (2011).
 4. Wood, A. J. et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307, https://doi.org/10.1126/
science.1207773 (2011).
 5. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29, 731–734, https://doi.
org/10.1038/nbt.1927 (2011).
 6. Sanjana, N. E. et al. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7, 171–192, https://doi.
org/10.1038/nprot.2011.431 (2012).
 7. Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 
29, 149–153, https://doi.org/10.1038/nbt.1775 (2011).
 8. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. 
Nat Biotechnol 31, 230–232, https://doi.org/10.1038/nbt.2507 (2013).
 9. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823, https://doi.org/10.1126/
science.1231143 (2013).
 10. Makarova, K. S. et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467–477, https://doi.org/10.1038/
nrmicro2577 (2011).
 11. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat Med 21, 121–131, https://doi.
org/10.1038/nm.3793 (2015).
 12. Gori, J. L. et al. Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. Hum Gene Ther 
26, 443–451, https://doi.org/10.1089/hum.2015.074 (2015).
 13. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370, 901–910, https://doi.
org/10.1056/NEJMoa1300662 (2014).
www.nature.com/scientificreports/
1 2SciEnTific RePoRTS | 7: 15480  | DOI:10.1038/s41598-017-15206-x
 14. Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in 
vivo. Nat Biotechnol 28, 839–847, https://doi.org/10.1038/nbt.1663 (2010).
 15. Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217–221, https://doi.
org/10.1038/nature10177 (2011).
 16. Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 
26, 808–816, https://doi.org/10.1038/nbt1410 (2008).
 17. Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32, 551–553, 
https://doi.org/10.1038/nbt.2884 (2014).
 18. Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S. & Yang, S. H. Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. 
Mol Ther Nucleic Acids 4, e264, https://doi.org/10.1038/mtna.2015.37 (2015).
 19. Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495, 
https://doi.org/10.1038/nature16526 (2016).
 20. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24, 
132–141, https://doi.org/10.1101/gr.162339.113 (2014).
 21. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31, 822–826, 
https://doi.org/10.1038/nbt.2623 (2013).
 22. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. 
Nat Biotechnol 31, 833–838, https://doi.org/10.1038/nbt.2675 (2013).
 23. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat 
Biotechnol 31, 839–843, https://doi.org/10.1038/nbt.2673 (2013).
 24. Weidle, U. H. et al. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics 
Proteomics 11, 25–38 (2014).
 25. Stahl, S. et al. Loss of diphthamide pre-activates NF-kappaB and death receptor pathways and renders MCF7 cells hypersensitive to 
tumor necrosis factor. Proc Natl Acad Sci USA 112, 10732–10737, https://doi.org/10.1073/pnas.1512863112 (2015).
 26. Liew, M. et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 50, 
1156–1164, https://doi.org/10.1373/clinchem.2004.032136 (2004).
 27. Liu, Y. P. et al. Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and 
meta-analysis. Sci Rep. 4, 7521, https://doi.org/10.1038/srep07521 (2014).
 28. Vara, J. A., Portela, A., Ortin, J. & Jimenez, A. Expression in mammalian cells of a gene from Streptomyces alboniger conferring 
puromycin resistance. Nucleic Acids Res 14, 4617–4624 (1986).
 29. Bauer, D. E., Canver, M. C. & Orkin, S. H. Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9. J Vis Exp, 
e52118, doi:https://doi.org/10.3791/52118 (2015).
 30. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821, 
https://doi.org/10.1126/science.1225829 (2012).
 31. Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2, e00471, https://doi.org/10.7554/eLife.00471 (2013).
 32. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826, https://doi.org/10.1126/science.1232033 
(2013).
 33. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. 
Nat Biotechnol 32, 279–284, https://doi.org/10.1038/nbt.2808 (2014).
 34. Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143–148, https://doi.org/10.1038/
nbt.1755 (2011).
 35. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat 
Rev Genet 11, 636–646, https://doi.org/10.1038/nrg2842 (2010).
 36. Song, J. et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat Commun 7, 10548, https://doi.
org/10.1038/ncomms10548 (2016).
 37. Ma, Y. et al. Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 
protein. RNA Biol 13, 605–612, https://doi.org/10.1080/15476286.2016.1185591 (2016).
 38. Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain ‘knock-in’ screen for the evaluation and identification of small molecule 
enhancers of CRISPR-based genome editing. Nucleic Acids Res 43, 9379–9392, https://doi.org/10.1093/nar/gkv993 (2015).
 39. Gutschner, T., Haemmerle, M., Genovese, G., Draetta, G. F. & Chin, L. Post-translational Regulation of Cas9 during G1 Enhances 
Homology-Directed Repair. Cell Rep 14, 1555–1566, https://doi.org/10.1016/j.celrep.2016.01.019 (2016).
 40. Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32, 
1262–1267, https://doi.org/10.1038/nbt.3026 (2014).
 41. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end 
joining. Nat Biotechnol 33, 538–542, https://doi.org/10.1038/nbt.3190 (2015).
 42. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87, https://doi.org/10.1126/
science.1247005 (2014).
 43. Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool 
CRISPOR. Genome Biol 17, 148, https://doi.org/10.1186/s13059-016-1012-2 (2016).
 44. Liao, H. K. et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 6, 
6413, https://doi.org/10.1038/ncomms7413 (2015).
 45. Muller, M. et al. Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. Mol Ther 24, 
636–644, https://doi.org/10.1038/mt.2015.218 (2016).
 46. Carroll, D. Genome engineering with zinc-finger nucleases. Genetics 188, 773–782, https://doi.org/10.1534/genetics.111.131433 
(2011).
 47. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761, https://doi.
org/10.1534/genetics.110.120717 (2010).
 48. McMahon, M. A., Rahdar, M. & Porteus, M. Gene editing: not just for translation anymore. Nat Methods 9, 28–31, https://doi.
org/10.1038/nmeth.1811 (2011).
 49. Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends 
Biotechnol 31, 397–405, https://doi.org/10.1016/j.tibtech.2013.04.004 (2013).
 50. Cebrian-Serrano, A & Davies, B. CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of 
genome engineering tools. Mamm Genome Jun 20 (publ. online); doi https://doi.org/10.1007/s00335-017-9697-4, (2017).
 51. Greco, G. E. et al. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV. DNA Repair (Amst) 43, 18–23, https://
doi.org/10.1016/j.dnarep.2016.04.004 (2016).
 52. Brooks, S. C., Locke, E. R. & Soule, H. D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248, 
6251–6253 (1973).
 53. Zhang, G., Gurtu, V. & Kain, S. R. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian 
cells. Biochem Biophys Res Commun 227, 707–711, https://doi.org/10.1006/bbrc.1996.1573 (1996).
www.nature.com/scientificreports/
13SciEnTific RePoRTS | 7: 15480  | DOI:10.1038/s41598-017-15206-x
Author Contributions
U.B. devised the concept, designed experiments & interpreted data. T.K. & S.D. designed and performed 
experiments and analysed/interpreted data. K.M. & C.K. & A.K.H. performed experiments and analysed data. 
T.K., S.D. & U.B. wrote the manuscript. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15206-x.
Competing Interests: The authors are employed by Roche Pharma Research and Early Development. Roche is 
interested in targeted therapies.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
Article
TriFabs—Trivalent IgG-Shaped Bispecific Antibody
Derivatives: Design, Generation, Characterization
and Application for Targeted Payload Delivery
Klaus Mayer †, Anna-Lena Baumann †, Michael Grote, Stefan Seeber, Hubert Kettenberger,
Sebastian Breuer, Tobias Killian, Wolfgang Schäfer and Ulrich Brinkmann *
Received: 12 August 2015 ; Accepted: 5 November 2015 ; Published: 17 November 2015
Academic Editor: Qiang “Shawn” Chen
Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg,
D82377 Penzberg, Germany; klaus.mayer.km1@roche.com (K.M.); annalenabaumann@web.de (A.-L.B.);
michael.grote@roche.com (M.G.); stefan.seeber@roche.com (S.S.); hubert.kettenberger@roche.com (H.K.);
sebastian.breuer@roche.com (S.B.); tobias.killian@roche.com (T.K.); wolfgangschaefer@onlinehome.de (W.S.)
* Correspondence: ulrich.brinkmann@roche.com; Tel.: +49-8856-604753
† These authors contributed equally to this work.
Abstract: TriFabs are IgG-shaped bispecific antibodies (bsAbs) composed of two regular Fab arms
fused via flexible linker peptides to one asymmetric third Fab-sized binding module. This third
module replaces the IgG Fc region and is composed of the variable region of the heavy chain (VH)
fused to CH3 with “knob”-mutations, and the variable region of the light chain (VL) fused to CH3
with matching “holes”. The hinge region does not contain disulfides to facilitate antigen access to
the third binding site. To compensate for the loss of hinge-disulfides between heavy chains, CH3
knob-hole heterodimers are linked by S354C-Y349C disulphides, and VH and VL of the stem region
may be linked via VH44C-VL100C disulphides. TriFabs which bind one antigen bivalent in the
same manner as IgGs and the second antigen monovalent “in between” these Fabs can be applied
to simultaneously engage two antigens, or for targeted delivery of small and large (fluorescent or
cytotoxic) payloads.
Keywords: knob-into-hole; disulfide stabilization; payload delivery; imaging; LeY; GPC3;
CD33; saporin
1. Introduction
Many different types and formats of bispecific antibodies (bsAbs) have been generated over
the past years. These combine specificities of two antibodies in one molecule and enable binding
of different epitopes or antigens [1,2]. BsAb formats include large Fc-containing molecules [3–5] as
well as small entities, composed of two or more variable or even smaller binding domains fused
to each other [6,7]. A large variety of bsAb formats were designed so far because different formats
are required to address different therapeutic profiles. Factors that affect the choice and composition
of bsAb formats include binding geometry and orientation of binding modules to each other (target
accessibility, crosslinking), valences (avidity effects) and size (distribution and PK). In addition to that,
robustness, stability, and manufacturing aspects are important points to consider for the development
of bsAbs. This work describes the design, generation, and characterization of a novel IgG-shaped
bispecific trivalent TriFab with novel composition and binding region geometry. Functionality of
TriFabs is demonstrated by their ability to simultaneously bind to two antigens, and by applying
TriFabs for bsAb-mediated targeted delivery of fluorophores or toxins to tumor cells.
Int. J. Mol. Sci. 2015, 16, 27497–27507; doi:10.3390/ijms161126037 www.mdpi.com/journal/ijms
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2. Results and Discussion
2.1. Design and Generation of TriFabs
The composition of TriFabs and the designed linker regions that connect the individual binding
modules are shown in Figure 1a: two regular Fab arms are fused via flexible linker peptides
to an asymmetric Fab-like entity which replaces the IgG Fc. This entity, which we term “stem
region”, is composed of VH fused to CH3 with “knob”-mutations, and VL fused to CH3 with
matching “holes”. The hinge region linker peptides that connect to the Fab arms do not contain
interchain disulfides. This facilitates antigen access to the third binding site. To compensate the
loss of hinge-disulfides between the heavy chains, the CH3 knob-hole heterodimer (T366W + T366S,
L368A, Y407V according to the Kabat numbering scheme [8]) is linked by additional S354C-Y349C
disulphides (Figure 1b) [7,9]. In addition, variable region of the heavy chain (VH) and variable
region of the light chain (VL) of the stem region can be linked via additional (H44-L100) interchain
disulphides [10]. This disulphide stabilizes the correct H-chain heterodimer, but it is not mandatory
for heterodimerization to generate functional molecules: CH3 knob-hole interactions by themselves
already provide sufficient heterodimerization, and the VH and VL domains that are also part of the
stem region provide additional contributions.
A comprehensive description of the design including all fusion points and deviations from
normal IgG sequences are provided in Figure 1. TriFabs were designed that address cell surface
antigens—LeY, CD33, GPC3—and simultaneously bind digoxigenin or biotin- (hapten-)coupled
payloads [11–15]. These TriFabs were produced transiently in HEK293 cells by co-transfection of
three plasmids for CMV-promoter driven expression [4] of the three protein chains that together in
a 2 + 1 + 1 ratio comprise TriFabs. These components are two light chains, one VH-CH3knob and
one VL-CH3hole chain (Experimental Section). TriFabs become secreted into culture supernatants
in the same manner as IgGs, indicating that hinge- and CH2 replacement does not compromise the
folding and assembly process [16] of these bsAbs. We observed that TriFabs do not bind to Protein
A (see Figure S1c for experimental details) because effective protein A capture of IgG involves the
CH2 domain at the CH2-CH3 interface which is deleted in TriFabs. Purification is therefore achieved
by protein-L followed by size exclusion chromatography. This generates TriFabs with yields of
3–20 mg/L (average 8 mg/L without process optimization, supplemental data). Due to the
combination of the strong dimerizer domain CH3 [17] with four asymmetric hetero-dimerization
modules (VH-VL + knob-holes + 2 interchain disulfides), purified TriFab preparations contain only
desired knob-hole heterodimers without detectable amounts of wrongly assembled homo-dimers.
2.2. Stability of TriFabs
A problem that is frequently observed for a variety of engineered antibody derivatives is
protein instability. To assess stability of TriFabs, we measured temperature-induced aggregation and
unfolding by light scattering and tryptophan fluorescence, respectively (details in the Experimental
Section and supplemental data). To evaluate stability of the format (independent of the specific
binding regions), temperature-induced aggregation and unfolding was assessed for TriFabs that bind
different cell surface antigens (CD33, LeY, GPC3) as well as different haptens (Bio, Dig). The results
of these analyses (Table 1 and supplemental Figure S2) reveal that TriFabs are rather stable molecules
with aggregation onset temperatures between 51 and 61 ˝C and denaturation temperatures between
58 and 66 ˝C for all TriFabs that were analysed (CD33-Dig, LeY-Dig, GPC3-Dig, CD33-Bio, LeY-Bio,
GPC3-Bio). These temperature stability values are in the range of typical antibodies [18–20].
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Figure 1. Design and generation of TriFabs. (a) TriFabs have the IgG hinge replaced by linker  
peptides without disulfides, and the CH2 regions by VH or VL. Hetero-dimerization is achieved by 
disulphide-stabilized knob-into-hole CH3, and by introducing a H44-L100 disulphide in the Fv. 
Interchain disulfides that connect light and heavy chains and the engineered stem heterodimer are 
indicated by black bars; (b) Fusion sequences linking CH1 with VH or VL with CH3. The N-terminus 
of Dig-VH and GPC3-VH is QVQL, DVQL for LeY-VH, EVQL for CD33-VH. The N-terminus of 
Dig-VL is DIQM, GPC3-VL DVVM, LeY-VL DVLM and CD33-VL DIQL. The N-terminal elbow 
region of CH3 hole is EIKG for GPC3, LeY and Dig, and EVKG for CD33; (c) TriFabs are purified 
from cell culture supernatants by affinity chromatography with kappa-select (left panel, Protein A 
does not capture our TriFabs). After loading supernatants to the column (left peak in Figure 1c), 
TriFabs were eluted with 100 mM Glycine-buffer (pH 2.5), subsequently adjusted to pH 6.0–7.5 with 
1 M Tris (pH 9.0). This is followed by size exclusion chromatography (middle panel). Shaded boxes 
indicate fractions containing properly folded TriFab. The composition and purity of TriFabs obtained 
by this simple two-step procedure is shown in the SDS PAGE without (n.r.) and with (r.) sample 
reduction (right panel). The purification profiles are exemplarily shown for TriFabs with 
CD33-CD33-Dig specificity. The purification and profiles of other TriFabs are described in the suppl. 
data section. 
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peptides without disulfides, and the CH2 regions by VH or VL. Hetero-dimerization is achieved
by disulphide-stabilized knob-into-hole CH3, and by introducing a H44-L100 disulphide in the Fv.
Interchain disulfides that connect light and heavy chains and the engineered stem heterodimer are
indicated by black bars; (b) Fusion sequences linking CH1 with VH or VL with CH3. The N-terminus
of Dig-VH and GPC3-VH is QVQL, DVQL for LeY-VH, EVQL for CD33-VH. The N-terminus of
Dig-VL is DIQM, GPC3-VL DVVM, LeY-VL DVLM and CD33-VL DIQL. The N-terminal elbow region
of CH3 hole is EIKG for GPC3, LeY and Dig, and EVKG for CD33; (c) TriFabs are purified from
cell culture supe natants by affinity chromatography with kappa-select (left panel, Protein A does
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Table 1. Thermal stability of of TriFabs. Temperature-induced aggregation and unfolding of
various TriFabs (hapten-specificity in the stem-Fv) was measured by light scattering and tryptophan
fluorescence (details in M&M and supplemental data, Figure S2). Listed are aggregation onset
temperatures (Tagg) defined as the temperature at which the scattered light intensity begins to
increase, and denaturation temperatures (Tm) defined as inflection points of curves that represent
ratios of fluorescence intensities at 350 and 330 nm.
TriFab Tagg (˝C) Tm (˝C)
CD33-CD33-Bio 57 58
CD33-CD33-Dig 51 66
GPC3-GPC3-Bio 56 58
GPC3-GPC3-Dig 61 65
LeY-LeY-Bio 52 59
LeY-LeY-Dig 60 66
2.3. TriFabs Retain the Binding Properties of Two Antibodies
TriFabs access one antigen by their two Fab arms with the same affinity, orientation, and the same
bivalent manner as regular IgGs. Surface resonance (SPR) analyses confirm that the two Fab arms of
TriFabs bind antigen in the same manner as Fab arms of IgGs from which they were derived (Table 2).
The second antigen is bound by the variable region of the “stem region” (as defined above), which is
flanked by the Fabs. This Fv binds with the same affinity to digoxigeninylated payloads (antigen is a
small hapten, payloads are oligonucleotides or fluorophores), or in one case specific but with reduced
affinity to another biotinylated payload (a biotinylated oligonucleotide). The interspersed Fv also
bind carbohydrate and protein antigens such as LeY, CD33 or GPC3 with the same specificity and
(as shown for the CD33 antigen) with the same affinity as monovalent binding entities (Fabs) of their
corresponding parent antibodies. Table 2 and Figure 2c summarize the results of surface plasmon
resonance (SPR) analyses of the TriFabs with three different cell surface target specificities: The
bivalent Fab arms of TriFabs bind antigen in the same manner as parent antibodies. The monovalent
stem Fv (exemplarily shown for CD33 antigen, Biotin and Digoxigenin) has monovalent affinity
(equivalent to a monovalent Fab fragment in case of CD33). Binding efficacy of the Fv that is part of
the stem region (VH/VL-CH3) to cell surfaces depends on avidity, epitope accessibility and potential
steric hindrance (which may explain the reduced affinity of biotin binders). Cell surface antigens
CD33, GPC3 or LeY are accessible to Fv in the stem region in a monovalent manner and generate
lower cell associated signals via fluorescence-activated cell sorting (FACS) analyses compared to
bivalent binding (Figure 2).
Table 2. Antigen binding properties of TriFabs. Surface plasmon resonance (Biacore)
measurements were applied to compare the affinities of TriFabs with those of their parent IgGs (see
Figure 2c). Applied antigens were mono-biotinylated or mono-digoxigeninylated oligonucleotides,
CD33Fc, LeY-BSA or recombinant GPC3 as previously described. * Data have been previously
described [11,12,15]. Because the CD33 antigen is a (dimeric) Fc-fusion protein, monovalent binding
of the reference molecule was determined with a monovalent Fab to avoid avidity effects.
Format SPR LeY Arm GPC3 Arm CD33 Arm CD33 Stem Dig Stem Bio Stem
IgG
ka (1/Ms) 1.5 ˆ 105 8.5 ˆ 104 3.9 ˆ 105 1.9 ˆ 105 (Fab) 6.2 ˆ 105 * 2.0 ˆ 107 *
Kd (1/s) 5.0 ˆ 10´4 2.9 ˆ 10´4 1.7 ˆ 10´3 6.4 ˆ 10´3 (Fab) 9.8 ˆ 10´3 ˆ * 1.0 ˆ 10´2 *
KD (M) 3.3 ˆ 10´9 3.4 ˆ 10´9 4.3 ˆ 10´9 3.4 ˆ 10´8 (Fab) 1.6 ˆ 10´8 ˆ * 6.2 ˆ 10´10 *
TriFab
ka (1/Ms) 1.5 ˆ 105 8.6 ˆ 104 4.0 ˆ 105 2.4 ˆ 105 5.3 ˆ 105 2.9 ˆ 106
Kd (1/s) 4.9 ˆ 10´4 2.9 ˆ 10´4 1.6 ˆ 10´3 7.5 ˆ 10´3 5.2 ˆ 10´3 1.5 ˆ 10´2
KD (M) 3.2 ˆ 10´9 3.4 ˆ 10´9 4.1 ˆ 10´9 3.1 ˆ 10´8 9.8 ˆ 10´9 5.1 ˆ 10´9
27500
Int. J. Mol. Sci. 2015, 16, 27497–27507Int. J. Mol. Sci. 2015, 16, page–page 
5 
 
Figure 2. TriFab mediated targeted delivery of a small molecule. (a) TriFabs specific for glypican3 
(GPC3, [12]), CD33 or LeY [11] combined with Dig-specificity were tested by FACS on LeY+,CD33− 
MCF7, CD33+,LeY− MOLM13 and GPC3+,Ley−,CD33− HepG2 cells with Dig-Cy5 payload [11]. “+” 
indicates expression of the listed antigen “−“indicates lack of expression. The binding specificities of 
the Fab arms are represented for each analysed molecule as “numerator” and the specificity of the Fv 
in the stem region as “denominator” with matched colour (except for Dig-Cy5 only or cells only 
which are light blue or black, respectively). Specific cell surface and hapten-binding is observed for 
TriFabs that bind cells with Fab arms and hapten in the stem region. Specific cell surface and 
hapten-binding is also observed for TriFabs that bind hapten bivalent with Fab arms and CD33 or 
GPC3 or LeY monovalent in the stem region; (b) TriFabs that have the Dig-binding moiety replaced 
by Biotin-binding moieties show same functionality when coupled to the payload Bio-Cy5 [13,14]; (c) 
Comparison of the SPR-determined affinities of Biotin-binding TriFabs which bind cell surface 
antigens with their Fab arms (bivalent) and Biotin (monovalent) with their stem-Fv. Listed are the on 
(ka) and off rates (kd) on y- and x-axes, respectively, as well as the resulting KD values (diagonal 
panels). Dashed circle: the Bio-binding of the stem region remains unaltered irrespective of which 
target antigen is addressed by the TriFab. 
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hapten-binding is also observed for TriFabs that bind hapten bivalent with Fab arms and CD33 or
GPC3 or LeY monovalent in the stem region; (b) TriFabs that have the Dig-binding moiety replaced
by Biotin-binding moieties show same functionality when coupled to the payload Bio-Cy5 [13,14];
(c) Comparison of the SPR-determined affinities of Biotin-binding TriFabs which bind cell surface
antigens with their Fab arms (bivalent) and Biotin (monovalent) with their stem-Fv. Listed are the
on (ka) and off rates (kd) on y- and x-axes, respectively, as well as the resulting KD values (diagonal
panels). Dashed circle: the Bio-binding of the stem region remains unaltered irrespective of which
target antigen is addressed by the TriFab.
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2.4. TriFabs Enable Tumor Targeted Payload Delivery of Small Compounds
TriFabs that bind cell surface antigens as well as haptens were generated to evaluate
TriFab-mediated payload delivery. Specific delivery of small compounds was demonstrated by FACS
analyses of cells that were simultaneously exposed to digoxigeninylated fluorophores (Dig-Cy5, [11]),
and to TriFabs that bind cell surface antigens and digoxigenin. Figure 2a shows that TriFabs deliver
the small fluorescent compounds only to cells that express the cognate antigen on their surface:
LeY-Dig delivers Dig-Cy5 to LeY-expressing MCF7 cells but not to LeY negative HEPG2 or Molm13
cells. Glypican-3 (GPC3) binding TriFabs deliver specifically to HEPG2 and CD33-binding TriFabs
specifically to CD33 expressing Molm13 cells. Cell surface binding efficacy of TriFabs depends on
valences and/or geometry of their cell surface binding arms. TriFabs that have their cell surface
binding functionalities in bivalent Fab arms have higher Cy5-signals than cells that become targeted
with TriFabs that bind to cells via their monovalent Fv in the stem region. Targeted delivery of small
compounds is not restricted to TriFabs that bind to digoxigenin and Digoxigenin-containing payloads
but works also for TriFabs that bind different haptens. Figure 2b shows that biotin-binding TriFabs
can be applied in the same manner to deliver biotinylated payloads.
2.5. TriFabs Enable Tumor Targeted Payload Delivery of Protein Toxins
TriFab-mediated targeted delivery of large molecules was demonstrated with
digoxigenin-coupled saporin. Saporin is a plant-derived ribosome inactivating protein which
becomes cytotoxic upon binding to and uptake into cells. By itself, however, saporin does not
possess a cell binding functionality [21]. Because of that, only targeted delivery of saporin to and into
cells generates cytotoxicity. Figure 3a shows that TriFabs (left panel) can be applied to specifically
target Saporin to antigen expressing cells. Application of LeY-Dig binding TriFabs and Dig-saporin
efficiently kills LeY expressing MCF7 cells. In contrast, Dig-Saporin by itself or coupled to TriFabs
that recognize CD33 instead of LeY do not induce cytotoxicity in CD33 negative MCF7. Biotinylated
saporin becomes specifically delivered to target cells in the same manner by Bio-binding TriFabs,
however with somewhat reduced potency compared to Dig-Saporin (suggesting that the attached
hapten may modify payload potency). A comparison with targeted delivery of Dig-Saporin by
previously described IgG-derived (2 + 2) bsAbs (two binding entities for each target, [11]), or with
Fab-derived fusion proteins (one cell surface binding entity) revealed that TriFabs retained at the
same payload delivery potency than Fc-containing (bivalent target addressing) bsAbs and appear
to have better potency compared to Fab-derived bsAbs that bind the LeY antigen in a monovalent
manner (Figure 3).
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Figure 3. TriFab mediated targeted delivery of a large molecule. The applied bsAb formats are 
schematically depicted on the right (cell targeting entities in blue, Dig-binding entities in red and 
Bio-binding entities in green colour). (a) TriFab specific for Dig and GPC3 or CD33 or LeY combined 
with Dig-Saporin or Bio and GPC3 or CD33 or LeY combined with Bio-Saporin were applied for 
targeted delivery of saporin. TriFab-Saporin complexes were generated by a simple and robust 
charging procedure as previously described for hapten-coupled payloads [11,13–15]: Dig-Saporin 
and TriFabs are incubated in a 1:1 molar ratio in cell culture medium for at least 15 min, followed by 
subsequent dilution to the concentrations indicated. BrdU incorporation and ATP-content (Cell Titer 
Glo, CTG) assays were applied to measure the viability of cells 48 h after exposure to TriFab and 
Saporin; (b) Targeted delivery of Dig-Saporin with IgG-derived (two antigen binding sites + two 
Dig-binding sites) or Fab-derived (one antigen binding site + two Dig-binding sites) bsAbs of the 
same targeting specificity indicates that TriFabs have at least the same specificity and delivery 
potential as other bsAb Formats (monovalent cell surface targeting with LeY specificity is less potent 
than bivalent (avidity-enhanced) targeting). 
3. Experimental Section 
3.1. Expression of TriFabs 
TriFabs were produced by co-transfection of three expression plasmids [11]. One plasmid 
encodes the L-chains of desired antibodies, the other two plasmids encode separate modified H 
chains. The positions of mutations and alterations in these H-chains are defined by the Kabat 
numbering convention [8]. These two H-chains contain linker peptides without disulphides instead 
of the hinge region, and VHcys44 or VLcys100 domains fused to CH3-domains with 
disulphide-stabilized knobs or holes heterodimer (T366W + T366S, L368A, Y407V; + S354C-Y349C 
disulphide) respectively. The components become expressed by CMV promoter driven transcription 
in HEK293 suspension cells that are grown at 37 °C in a humidified 8% CO2 environment. Seven 
days after transfection, culture supernatants that contain the secreted assembled antibody 
derivatives are sterile filtered and either immediately subjected to purification (Figure 1c), or stored 
frozen at −80 °C (thawed at room temperature prior to purification). 
3.2. Purification of TriFabs 
Hi Trap Kappa-select (GE Healthcare, Amersham Place, Little Chalfont, UK) is applied as first 
purification step as the molecules that we generated did not bind to protein A (see supplemental 
data). After loading supernatants to the column (left peak in Figure 1C) TriFabs were eluted with 100 
mM Glycine-buffer (pH 2.5), subsequently adjusted to pH 6.0–7.5 with 1M Tris (pH 9.0). 
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and TriFabs are incubated in a 1:1 molar ratio in cell culture medium for at least 15 min, followed
by subsequent dilution to the concentrations indicated. BrdU incorporation and ATP-content (Cell
Titer Glo, CTG) assays were applied to measure the viability of cells 48 h after exposure to TriFab
and Saporin; (b) Targeted delivery of Dig-Saporin with IgG-derived (two antigen binding sites + two
Dig-binding sites) or Fab-derived (one antigen binding site + two Dig-binding sites) bsAbs of the same
targeting specificity indicates that TriFabs have at least the same specificity and delivery potential as
other bsAb Formats (monovalent cell surface targeting with LeY specificity is less potent than bivalent
(avidity-enhanced) targeting).
3. Experimental Section
3.1. Expression of TriFabs
TriFabs were produced by co-transfection of three expression plasmids [11]. One plasmid
encodes the L-chains of desired antibodies, the other two plasmids encode separate modified H
chains. The positions of mutations and alterations in these H-chains are defined by the Kabat
numbering convention [8]. These two H-chains contain linker peptides without disulphides
instead of the hinge region, and VHcys44 or VLcys100 domains fused to CH3-domains with
disulphide-stabilized knobs or holes heterodimer (T366W + T366S, L368A, Y407V; + S354C-Y349C
disulphide) respectively. The components become expressed by CMV promoter driven transcription
in HEK293 suspension cells that are grown at 37 ˝C in a humidified 8% CO2 environment. Seven days
after transfection, culture supernatants that contain the secreted assembled antibody derivatives are
sterile filtered and either immediately subjected to purification (Figure 1c), or stored frozen at´80 ˝C
(thawed at room temperature prior to purification).
3.2. Purification of TriFabs
Hi Trap Kappa-select (GE Healthcare, Amersham Place, Little Chalfont, UK) is applied
as first purification step as the molecules that we generated did not bind to protein A (see
supplemental data). After loading supernatants to the column (left peak in Figure 1C) TriFabs were
eluted with 100 mM Glycine-buffer (pH 2.5), subsequently adjusted to pH 6.0–7.5 with 1M Tris
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(pH 9.0). Subsequently, homogenous TriFab preparations are obtained by applying size
exclusion chromatography (SEC, Superdex200 HiLoad 16/60, GE Healthcare) equilibrated with
20 mM histidine, 140 mM NaCl, at pH 6.0 on an Aekta Avant (GE Healthcare) as previously
described for IgG-derived bispecific antibodies [11]. Yields were between 3–20 mg TriFab/L
(2LeY-1Dig = 3.0 mg/L, 2Dig-1LeY = 5.7 mg/L, 2CD33-1Dig = 20.3 mg/L, 2Dig-1CD33 = 6.9 mg/L
2GPC3-1Dig = 3.5 mg/L, 2Dig-1GPC3 = 8.3 mg/L).
3.3. Characterization of TriFabs
FACS analyses were applied to assess specific binding of TriFabs to cell surface antigens as well
as targeted delivery of small compounds. Therefore, cells were exposed to hapten-binding TriFabs
followed by incubation with haptenylated fluorophores [11,13,14]. Specific binding is indicated by
detection of TriFab-mediated fluorophore accumulation on cell. To analyze TriFab mediated targeted
delivery of protein toxins, cells which either do or do not express the cognate antigen on their surface
cultured in 96 well plates are exposed to TriFab-Toxin complexes for 48 to 72 h. Subsequently, DNA
synthesis is determined by BrdU incorporation assays after 48 h. Affinities of recombinant TriFabs
were determined by Surface Plasmon Resonance measurements as previously described [11].
3.4. Stability Analyses
Thermal stability was assessed using an Optim1000 instrument (Avacta Analytical Inc., Thorp
Arch Estate, Wetherby, UK) recording light scattering and tryptophan fluorescence simultaneously
while heating samples with a constant heat rate. Samples were prepared at 0.3–1 mg/mL in 20 mM
histidine, 140 mM NaCl, pH 6.0 and transferred to a 9 µL multi-cuvette array and heated from 30 to
90 ˝C at a constant rate of 0.1 ˝C/min. The intensity of scattered light and the fluorescence emission
spectra was recorded after excitation with a 266 nm laser providing a data point approximately
every 0.6 ˝C. Light scattering intensities were plotted against temperature and aggregation onset
temperature (Tagg) defined as the temperature at which the scattered light intensity begins to
increase. For the unfolding readout, the ratio of the fluorescence intensities at 350 and 330 nm were
plotted as a metric for the shift in peak position against the temperature. Denaturation temperature
(Tm) is defined as the curve inflection point (Figure S2).
4. Conclusions
TriFabs are shaped like IgGs, composed of antibody derived domains, and of sufficient size
(150 kDa) to avoid renal clearance. In contrast to IgG’s, they lack CH2 domains. These domains,
in particular residues and structures at the CH2-CH3 interface, are important for binding of IgGs
to Fc-interacting molecules including Fc-receptors and protein A (PDB:1L6X, [22,23]). Alternative
interactions of protein A with VH (VH3) domains have also been described (PDB:1DEE, [24]), but
those do not enable protein A binding of our molecules. In consequence, our TriFabs do not bind to
protein A (see supplemental data).
Presence of a functional CH2 and of an intact CH2-CH3 interface region is also required to bind
to the neonatal Fc receptor (FcRn, [25,26]). Lack of CH2 prevents interaction with FcRn and hence,
without that, TriFabs will not undergo FcRn mediated recycling. Because of that, it is very likely
that TriFabs will have pharmacokinetic properties similar to IgG derivatives that are devoid of FcRn
binding sites [25,26], which needs to be confirmed in animal studies.
Removal of CH2 affects not only the pharmacokinetics of TriFabs but renders them also deficient
in other Fc functionalities. This includes lack of induction of antibody-dependent cell-mediated
cytotoxicity (ADCC) which is triggered by binding of Fc-Receptors (FcgRIII), involving CH2. ADCC
is an important contributor to therapeutic efficacy of antibody therapies, in particular for protection
from viral infections or for ADCC mediated elimination of tumor cells. Obviously, such therapeutic
approaches in virology or oncology that have ADCC induction (or other Fc mediated functionalities)
as major efficacy contributors cannot be met by a CH2-deficient TriFab. On the other hand, inability to
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trigger ADCC can be desired if one aims at antibody-mediated neutralization or depletion approaches
(for example removal of angiogenic ligands or removal of inflammatory stimuli) while avoiding direct
and potentially damaging cellular effects.
Lack of ADCC competence is of minor concern for bsAb mediated targeted delivery of cytotoxic
payloads into cells, exemplarily shown in Figure 3. This principle (ADCs and ADC like molecules)
requires effective internalization of antibody-payload complexes following target cell binding and
is hence rather incompatible with ADCC (IgG needs to be surface accessible to trigger ADCC).
In contrast to most ADCs, tumor-targeting hapten-binding TriFabs are defined entities that have
cytotoxic payloads coupled to the stem-Fv in a position- and stoichiometry-defined manner. Such
TriFabs are therefore well suited for payload targeting approaches.
Many different antibody formats have been generated since the take-off of the bispecific antibody
field and its proven applicability for diagnosis and therapy [1–7,9,27–30]. This includes small
Fv-derived entities with short serum half-life due to renal filtration (such as BiTEs, [25]), as well
as large Fc containing molecules with extended serum half lifes [11,13–15]. The majority of bsAb
formats that have been applied so far (and that are in clinical development) are composed of
1 + 1 or 2 + 2 formats, i.e., possess one binding site for each different antigen or two binding sites per
antigen [1–3,5,6,9,14,15,28]. Some selected examples for previously published 2 + 1 formats (similar
to TriFabs with two binding entities for one and one entity for another antigen) have been generated
by the dock&lock method [30], or as knob-into-hole IgGs fused to disulphide-stabilized Fv’s [4]. All
these 2 + 1 formats differ in “binding geometry”, i.e., positioning and special orientation/distance
of the binding modules to each other. One additional advantage of the TriFab format over other
knob-into-hole containing bsAbs is that the fusion of additional heterodomerization promoting
modules (VH and VL) to the modified CH3 domains results in a “super-heterodimerization” entity.
Desired heterodimerization of the stem region is thereby promoted by two distinct interactions, each
of which by itself being already sufficient to drive heterodimerization. CH3 knob-hole interactions
by themselves are sufficient for heterodimerization, the VH and VL domains of the stem region (also
independently sufficient) provide additional contributions, and the generated stem region is further
stabilized by an interchain disulphide between VH and VL.
Valency, orientation or distance between binding modules are parameters that influence the
functionality of bispecific antibodies, dependent on targets to be addressed and functionalities to
be achieved. Because of that, there is not one “optimal format” for bsAbs. Instead, different formats
may need to be applied for different applications. For example, bivalency of binding to cell surface
antigens may be desired to achieve preferential (avidity mediated) binding to cells with abundant
cell surface target expression. On the other hand, bivalent engagement of cell surface targets such
as receptors may (dependent on the addressed targets) also change their internalization, and thereby
either promote or attenuate uptake of bsAbs and of attached payloads. Other indications such as
“bridging approaches” aim at generating tight connections between targets or target cells while other
applications need rather independent separate binding events (e.g., to inactivate two soluble ligands
or for targeted payload delivery).
Regarding cell targeting approaches, the binding geometry of TriFabs with two normal Fab
arms and one interspersed stem-Fv mediates efficient (and avidity enabled) binding of the Fab
arms. Monovalent binding of the interspersed Fv may also be unrestricted for some accessible
and/or flexible cell surface antigens (carbohydrates/glycans may be particularly suited as paratope
2 antigens). However, paratope 2 binding may also be sterically hindered, depending on the target
antigen and epitope in particular for large and/or complex antigens. For example, the antigen 2
may need to “squeeze” between the paratope 1 binding Fab arms, which would affect the on-rate
in a similar manner as described in [4]. Such reduced binding affinity to paratope 2 (monovalent
and potentially sterically compromised) may, in some cases of cell surface targeting approaches,
be compensated by the bispecific binding principle: the unrestricted bivalent Fab arms keep the
TriFab in place and prevent its dissociation from cells. This, in turn, provides additional time for
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the interspersed Fv to bind (or re-bind in case of dissociation due to monovalency), compensating
for a “bad” on-rate of the interspersed binding module. Thus, the bsAb principle can compensate
potential affinity deficits of paratope 2 binders on cell surfaces, provided the bsAb geometry permits
simultaneous binding of both paratopes. Simultaneous binding of two antigens may be applied to
address “close proximity” requirements, which are necessary for inducing cell to cell contacts, e.g., in
cancer immune-therapy.
In conclusion, TriFabs can be applied to simultaneously address or crosslink accessible target
antigens, for imaging, or for targeted (or pre-targeted) delivery of small and large payloads to
tumor cells.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
16/11/26037/s1.
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ABSTRACT
We report a novel system for efficient and specific
targeted delivery of large nucleic acids to and into
cells. Plasmid DNA and core histones were assem-
bled to chromatin by salt gradient dialysis and sub-
sequently connected to bispecific antibody deriva-
tives (bsAbs) via a nucleic acid binding peptide
bridge. The resulting reconstituted vehicles termed
‘plasmid-chromatin’ deliver packaged nucleic acids
to and into cells expressing antigens that are rec-
ognized by the bsAb, enabling intracellular function-
ality without detectable cytotoxicity. High efficiency
of intracellular nucleic acid delivery is revealed by
intracellular expression of plasmid encoded genes
in most (∼90%) target cells to which the vehicles
were applied under normal growth/medium con-
ditions in nanomolar concentrations. Specific tar-
geting, uptake and transgene expression depends
on antibody-mediated cell surface binding: plasmid
chromatin of identical composition but with non-
targeting bsAbs or without bsAbs is ineffective.
Examples that demonstrate applicability, specificity
and efficacy of antibody-targeted plasmid chromatin
include reporter gene constructs as well as plasmids
that enable CRISPR/Cas9 mediated genome editing
of target cells.
INTRODUCTION
Addressing acquired or inherited diseases by providing gene
products or by modifying the genetic setup of patients is the
primary concept of gene therapy (1–4). In general, the man-
ifold particular gene therapy concepts can be divided in ex
vivo or in vivo approaches (5). During an ex vivo gene ther-
apy cells of interest are isolated from the patient for subse-
quent treatment with the therapeutic gene followed by re-
administration of the genetically modified cells (5–7). The
in vivo approach on the contrary is based on direct local
or systemic injection of a gene delivery system to treat the
target cells or tissue (5,8). The common goal for both ap-
proaches is the efficient transfer of the genetic material over
the cell membrane and finally into the nucleus (9,10). To
mediate successful gene transfer, current clinical trials are
dominated by two strategies, namely nucleic acid delivery
by viral vectors or synthetic chemical systems (11,12). Vi-
ral gene delivery is highly efficient by nature but safety con-
cerns due to random integration of the transgene into the
host genome or potential immunogenicity issues limit their
applicability (13–15). In addition a labour and cost inten-
sive manufacturing comprising difficult to standardize pro-
cesses are further issues for drug development (16–20). Syn-
thetic chemical systems, most often composed of cationic
lipids or polymers, are easier to manufacture and face mi-
nor concerns of biosafety/immunogenicity.Nevertheless, so
far viral systems are favoured for the major fraction of cur-
rent clinical trials, as non-viral systems are less efficient and
their mode of action bear the risk for toxicity issues (21,22).
Both systems, chemical as well as virus-derived entities, are
also prone to unspecific uptake, i.e. deliver of nucleic acids
to non-target cells. This can affect/decrease efficacy because
uptake into non-target cells increases clearance, it may also
elicit undesired effects in the non-target tissues (5,23,24).
The significance of these issues is fortified by the fact that
to date no systemic gene delivery approach succeeded phase
III clinical trials to be approved for market access (25). All
in all, this emphasizes the need for alternative systems for ef-
ficient and specific nucleic acid delivery to realize systemic
gene therapy.
To develop a gene delivery system that is not aided by
viral entities or synthetic transfection reagents, important
characteristics of these systems have to be pointed out and
taken into consideration. One common feature of most de-
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livery systems is the protection of DNA to avoid degrada-
tion by nucleases (26). Furthermore, viral as well as syn-
thetic nucleic acid delivery systems condense the large nu-
cleic acid to reduce the exposed negative charge and size
with the aim to form a compact particle for facilitated cel-
lular uptake (27–31). Moreover, the DNA interaction is
most often non-covalent to enable de-compaction and ac-
cess of the transcription machinery inside the nucleus and
to avoid chemical modification influencing gene expression
(32–35). Finally, every system comprises a particular mech-
anism that enables DNA membrane translocation (36–38).
In principle, one inherent mechanism that meets the
above mentioned criteria is the assembly of core histones on
DNA. The assembly into chromatin is a highly conserved
mechanism in eukaryotes to organize genomic DNA inside
the nucleus by reducing its size and charge (39). Further-
more, previous studies demonstrated that all four core hi-
stone proteins contain protein transduction domains and
compatibility of histones for gene delivery has been shown
by several studies reviewed by Han et al. (40–44). How-
ever, the majority of histone based delivery systems com-
prise unspecific DNA complexation of core histones, sin-
gle histone proteins or domains or peptides derived from
them and most often combined with synthetic or viral en-
tities (45–52). Wagstaff and co-workers demonstrated that
plasmid DNA assembled into chromatin can be delivered
into the nucleus, using modified histone H2B protein (53).
The objective of our work was to develop an efficient
chromatin-based nucleic acid delivery system that does not
contain any virus-derived components. In addition, the de-
livery system shall (in contrast to applying histones and/or
chromatin for nonspecific DNA delivery) introduce nu-
cleic acids only into desired target cells without addressing
non-target cells. To achieve these objectives, we used puri-
fied histones for packaging DNA into plasmid chromatin
(this avoids viral components). In contrast to approaches
described above, however, these histones were deliberately
kept as ‘wildtype proteins’, i.e. not mutated/modified and
therefore exhibited a very low spontaneous delivery poten-
tial (53). We then analysed if we can convert such inac-
tive plasmid chromatin to targeted plasmid chromatin with
intracellular delivery functionality by adding antibody-
derived cell surface targeting entities.
MATERIALS AND METHODS
In-vitro chromatin reconstitution of plasmid DNA
Calf thymus Histones for assembly were kindly provided
by Prof. Dr Gernot La¨ngst (University of Regensburg). A
∼4000 bp plasmid DNA encoding EGFP (pEGFP) was
amplified and used for assembly of histones via salt gradi-
ent dialysis (54). To set up the assembly reaction we mixed
DNA and histones in a 1:2 mass ratio in a reaction mix of
2 M NaCL 200 ng/ml BSA and 200 ng/ml BSA, 1 fold low
salt buffer (10 mM Tris–HCl pH 7.6, 50 mM NaCl, 1 mM
EDTA, 0.05% w/v Igepal CA-630), 2 M NaCl and histone
octamer in a 1:2 DNA:histone weight ratio. The reaction
mixture was transferred into 3.5 kDa MWCO mini dialysis
devices (ThermoFisher Scientific) equilibrated for 15min in
high salt buffer (10 mMTris–HCl pH 7.6, 2MNaCl, 1 mM
EDTA, 0.05% w/v Igepal CA-630). Afterwards a 4 l beaker
was prepared with 300 ml high salt buffer containing 1 mM
beta-mercaptoethanol and a second beaker with 3 l 1-fold
low salt buffer containing 1 mM beta-mercaptoethanol. A
floater with the dialysis devices and a magnetic stir bar were
added into the beaker with high salt buffer. The salt gradi-
ent dialysis was performed over night at 4◦C. Therefore, the
beaker was placed on a magnetic stirrer to allow slow mix-
ing and a peristaltic pump was set to transfer the 3 l of low
salt buffer into the beaker containing high salt buffer with
a velocity of ∼300 ml/h. After buffer dilution, chromatin
samples were purified and buffer was exchanged to PBS via
size exclusion chromatography using Sephacryl S-1000 GE
Superfine (Sigma Aldrich) matrix.
Antibody chromatin complex preparation
Hapten binding bispecific antibodies and TriFabs were
generated and purified as previously described (55). Hap-
tenylated CPXM2 peptide was synthesized by Biosynthan
GmbH (Berlin). To prepare DNA binding antibody con-
structs, biotinylated peptide and biotin binding antibody
was pre-incubated in PBS for 30 min in a ratio of two pep-
tides per antibody for the bivalent biotin binding bsAb and
one peptide per antibody for monovalent biotin binding
TriFabs. Subsequently, constructs were added to chromatin
and incubated for at least 30 min for antibody-peptide as-
sociation at the DNA backbone.
Microscale thermophoresis
Microscale thermophoresis experiments, data processing
and determination of KD values was performed by 2bind
GmbH (Regensburg). Antibody and peptide were diluted
in PBS and pre-incubated for 30 min at RT with a 1:1 or 1:2
molar ratio for TriFab: peptide or 2 + 2 bsAb:peptide, re-
spectively. A serial dilution of the ligand was prepared in a
way to match the final buffer conditions in the reaction mix
(1× PBS, 0.05% Tween-20). 5 l of each dilution step were
mixed with 5 l of fluorescent labelled plasmid chromatin.
The final reaction mixture, which was filled in capillaries,
contained a respective amount of ligand and constant 0.25
nM fluorescent molecule. The samples were analysed on a
Monolith NT.115 Pico at 25◦C, with 10% LED power and
60%Laser power. Fluorescence values were normalized and
data were displayed according the analysed peptide concen-
tration (56). KD values were determined, if normalized flu-
orescence values allowed a proper curve fit.
Analytic MNase digestion
For nuclease sensitivity assays, 2g ofDNAassembledwith
chromatin was diluted in EX-80 buffer (10 mM Tris–HCl
pH 7.6, 80 mM KCl, 10% v/v glycerol, 1.5 mM MgCl2,
1 mM DTT) and 1 l BSA to a final volume of 50 l. To
stop the reaction, 1.5 ml tubes were prepared with 4l stop-
buffer (100 mM EDTA, 4% w/v sodium dodecyl sulfate).
The nuclease reaction was started by addition of 50 l mi-
crococcal nuclease (MNase) mix (6 mM CaCl2, 200 ng/l
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BSA and 40 UMNase). After the indicated time-points, 30
l of the reactionmix were transferred to the tubes contain-
ing stop-buffer. The DNA was de-proteinized by addition
of 1 l Proteinase K and incubation for 1 h at 50◦C. The
DNA was purified by ethanol precipitation and analysed
by agarose gel-electrophoresis.
Flow cytometry
To generate fluorescent plasmid DNA and plasmid chro-
matin, Cy5 fluorescent dye was chemically conjugated to
plasmid–DNA applying the Label IT® Nucleic Acid La-
belling kit (Mirus) according to the manufacturer’s spec-
ification. To generate fluorescent plasmid chromatin, as-
sembly was performed with Cy5 labelled plasmid as de-
scribed above. Cy3 labelling of antibody was performed
via maleimide conjugation after partial antibody reduction
with TCEP.
Previous to cell treatment, antibody chromatin com-
plexes were formed as described above. 200,000MCF7 cells
per well were seeded in 96 well plates and treated with com-
plexes with final concentration 1.6 g/ml plasmid DNA
bevor or after chromatin assembly, 50 nM antibody and
100 nM peptide for 1 h at 37◦C. Single colour flow cytome-
try with unlabelled antibodies was performed with a FAC-
Scanto II (BDBiosciences). For dual colour flow cytometry,
Cy3 labelled antibodies were used instead of unlabelled an-
tibodies. Colour compensation was performed with single
stained controls. Dual color flow cytometry was performed
with an LSRFortessa (BD Biosciences).
Reporter gene expression and cytotoxicity assay
80 000 MCF7 cells per well were seeded in 12-well plates
for reporter gene expression assays and 10 000 MCF7 cells
per well were seeded in 96-well plates for LDH cytotoxic-
ity assays. 24 h after seeding, cells were treated with com-
plexes containing 8 g/ml plasmid DNA bevor or after
chromatin assembly, 250 nM antibody and 500 nM pep-
tide prepared as described above or single components at
the same concentration when indicated. The cells were ex-
posed to complexes or single components for 48 h in the
presence of serum. After 48 h gene expression or cytotox-
icity was analysed. For gene expression analysis cells were
washed, detached and the ratio of GFP positive cells was
determined by flow cytometry with a FACScanto II (BD
Biosciences). For cytotoxicity analysis, culture supernatant
was removed and LDH activity was quantified with the Cy-
totoxicity Detection Kit (LDH) (Sigma-Aldrich) according
to the manufacturer’s protocol.
Confocal microscopy
For live cell imaging, MCF-7 cells (NCI) were cultured
in phenolred-free RMPI medium supplemented with 10%
fetal calf serum (FCS) and 100 U/ml penicillin and 100
g/ml streptomycin. 20 000 cells/well were seeded into 8-
well chamber slides (Lab-Tek™, Thermo Fisher Scientific,
Braunschweig, Germany) and allowed to adhere overnight.
Glass surfaces had been coated with 30 g/ml fibronectin
in PBS for 1 h at 37◦C. Antibody plasmid DNA-Cy5 and
Antibody-plasmid chromatin-Cy5 complexes were formed
as described in example 7. Samples were added to MCF7
at a final concentration of 4 g/ml plasmid DNA, 250
nM peptide and 125 nM antibody. 4 and 72 h after addi-
tion, internalization of antibody–chromatin complexes and
GFP expression were followed by live cell fluorescence mi-
croscopy carried out on a Leica SP5 laser scanning confocal
microscope using a 63×/1.2NA water immersion objective
lens (Leica,Mannheim, Germany). Temperature, CO2 level
and humidity were maintained at 37◦C and 5% CO2 using
a stage-top incubation chamber (Oko-touch, Okolab, Otta-
viano, Italy). Sequential scans were performed using white
light laser excitation at 488 nm, (561 nm) and 633 nm. Fluo-
rescence emission was detected at 495–548 nm (GFP), 570–
628 nm (Cy3) and 647–732 nm (Cy5) using HyD detectors.
Images were processed with ImageJ (NIH, Bethesda, MD,
USA). Immunocytochemistry was performed as previously
described (57).
CRISPR/Cas9 targeting and knock-out quantification
It has previously been described that gene-editing mediated
inactivation of DPH1, combined with assessment of cellu-
lar sensitivity towards Diphtheria Toxin (DT), can be used
to quantify efficacy of gene editing (58). Inactivation of all
cellular copies of DPH1 (as consequence of gene editing)
in turn renders cells resistant to DT. This generates a very
robust readout which can be quantified by counting DT-
resistant colonies following gene editing. To prove targeting
specificity and efficacy of the delivery system with plasmids
encoding a therapeutically more relevant gene product, tar-
geted delivery complexes were prepared as described above
with CISPR/Cas9 ‘plasmid chromatin’ instead of pEGFP
plasmid chromatin. Afterwards the complexes were added
to MCF7 cells seeded in a 12-well plate (4000 cells/well
24 h before treatment) to a maximal final concentration of
8 g/ml plasmid DNA assembled to Chromatin, 500 nM
peptide and 250 nM antibody. After incubation of the com-
plexes in normal serum containing cell culture medium for
72h, medium was removed and cells were exposed to the
same medium containing DT at a final concentration of 4
nM. DT exposure was continued for 2 weeks with medium
exchange every 3 to 4 days. After this period, cells were
stained with methylene blue and efficiency of intracellular
delivery and expression of the editing components was as-
sessed by determination of DT-resistant colonies as previ-
ously described.
Statistics
Unpaired, two-tailed Student’s t-tests were performed for
single comparisons between two treatments. Multiple com-
parisons were statistically analyzed via one-way ANOVA,
followed by Tukey’s honestly different significance (HDS)
post hoc tests. Significant differences were defined by P-
values of < 0.05. The level of significance determined using
Student’s t-test or Tukey’s HDS test is indicated in graphs
by asterisks. One, two or three asterisks are defined by P <
0.05, P < 0.01 and P < 0.001, respectively.
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RESULTS
In-vitro chromatin reconstitution of plasmidDNAby salt gra-
dient dialysis
Chromatin can be efficiently reconstituted from DNA and
histones by the salt gradient dialysis methods (54,59,60).
Using supercoiled plasmid DNA and purified histone oc-
tamers, nucleosomes are formed that consist of the histone
octamer and 147 bp of DNA wrapped ∼1.65 turns around
the octamer (61). The salt gradient dialysis method gives
rise to nucleosomal arrays on DNA that are separated by
short DNA linkers with a size ∼15 bp. Fine titration of
histone to DNA ratios results in plasmid chromatin fully
covered by nucleosomes that are qualitatively evaluated by
micrococcal nuclease (MNase) hydrolysis of DNA. The en-
donuclease MNase does preferentially hydrolyse DNA in
the linker region between the nucleosomes, giving rise to
anMNase ladder of DNAwhen partially hydrolyzing chro-
matin (62). We applied this method to generate plasmid
chromatin with an eGFP expression plasmid. The quality of
the reconstituted chromatin was determined by nuclease hy-
drolysis and subsequent agarose gel-electrophoresis (Figure
1A) (54). The partial DNA hydrolysis of assembled chro-
matin generates DNA fragments of multiples of 160 base
pairs, suggesting that arrays of nucleosomes were formed
on the plasmid DNA. Furthermore, the clear pattern of
the nucleosomal ladder and the absence of DNA fragments
shorter than 147 bp (sub-nucleosomal DNA), suggested the
efficient reconstitution of the plasmid DNA into chromatin
(Figure 1A).
Antibody - chromatin complexes with improved nuclease re-
sistance are formed via DNA binding peptide CPXM2
To capture plasmid DNA or plasmid chromatin via charge
interaction with the negatively charged DNA backbone,
we used a nucleic acid binding peptide (CPXM2 pep-
tide) identified by Haas et al. and derived from human
carboxypeptidase-like protein X2 (CPXM2 protein) (63).
To enable binding of CPXM2peptide to antibodies, we used
a biotinylated version of CPXM2 peptide (biotin CPXM2
peptide) and biotin binding (anti biotin) bispecific antibod-
ies (Figure 1B). Affinity of antibody-peptide constructs to
chromatin was determined by microscale thermophoresis
(MST). With this method affinity data were generated in
solution without the need to capture antibody or peptide
as this would affect affinity in this system due to avidity
effects. To identify the most suitable antibody format, we
compared monovalent biotin binding TriFabs with bivalent
biotin binding bispecific antibodies (anti biotin 2+2 bsAb)
towards affinity and potential aggregation due to crosslink-
ing of the molecules (55,64). Affinity of biotin CPXM2 pep-
tide∼ anti biotin TriFab constructs to chromatin was in the
three digits nanomolar range (300nM). The biotin CPXM2
peptide ∼ anti biotin 2+2 bsAb constructs demonstrated
further stabilization (two-digit nM affinity) most likely due
to avidity effects as two CPXM2 peptides can be bound by
one antibody (Figure 1C). In addition, no aggregation was
observed with the biotin CPXM2 peptide∼ anti biotin 2+2
bsAb construct, indicating that no severe crosslinking oc-
curs with this antibody format (Supplementary Figure S1).
Specificity was proven by respective controls without pep-
tide. The MST data set of the individual runs (Supplemen-
tary Figure S2) is summarized in Table 1. As the strongest
interaction was observed when the peptide was coupled to
anti biotin 2+2 bsAb, we used this antibody format for fur-
ther studies. As the antibody peptide construct interacts
with the negatively charged DNA backbone, we checked
whether this interaction disrupts the nucleosomes, or alters
nuclease resistance of plasmid chromatin after antibody-
peptide assembly. After incubation of chromatin with an-
tibody and peptide and subsequent nuclease digestion, the
pattern of partially hydrolyzed DNA after 270s was similar
to the pattern of nuclease treated chromatin alone after 20s
(Figure 1A). This data clearly demonstrates that addition
of the antibody-peptide reduces the nuclease accessibility,
by probably binding to the accessible DNA linker, but the
nucleosomal arrays remain intact.
DNA as well as chromatin is specifically and efficiently deliv-
ered via CPXM2-antibody constructs
In addition to specific formation and prolonged nuclease
resistance of the antibody–chromatin complex, we investi-
gatedDNAdelivery to the cell surface via the associated an-
tibodies. To determine delivery efficacy and specificity, anti-
biotin 2+2 bsAbs with a second specificity against Lewis Y
orCD33were compared onMCF7 cells (LeY+++/CD33-).
Furthermore, plasmid DNA labelled with Cy5 fluorophore
was used to enable quantification of plasmid DNA on cells
by flow cytometry 1h after cell treatment. To elaborate the
influence of chromatin assembly on delivery specificity and
efficacy, we applied the delivery system for plasmid DNA
before and after chromatin assembly. Figure 2A shows Cy5
signal of MCF7 cells after treatment with plasmid DNA
before chromatin assembly complexed with anti LeY (dot-
ted red) and anti CD33 (dotted blue) antibody. A distinct
fluorescence signal was detected after treatment with anti
LeY–DNA–Cy5 complexes demonstrating that DNA de-
livery is highly efficient. In contrast, application of anti
CD33–DNA–Cy5 complexes did not result in Cy5 posi-
tive cells (as MCF7 do not express CD33). This demon-
strates that DNA delivery is mediated by the antibody and
payload is delivered only to cells that express the cognate
target antigen. After chromatin assembly, plasmid delivery
efficacy and specificity was not affected as the same dis-
tinct fluorescence signal was observed after treatment with
anti LeY-chromatin-Cy5 complexes (solid red) and no Cy5
signal was detected with anti CD33-chromatin-Cy5 com-
plexes (solid blue) (Figure 2B). To confirm the presence of
the antibody in our delivery system, we used anti CD33
and anti LeY antibodies labelled with Cy3 fluorophore to-
gether with Cy5 labelled chromatin. As displayed in figure
2C, MCF7 cells treated with anti CD33–Cy3–chromatin–
Cy5 complexes did not show an elevated Cy5 as well as Cy3
signal (blue contours) demonstrating that neither antibody
nor chromatin is present at the cell surface. In contrast,
anti LeY–Cy3–chromatin–Cy5 treatment results in distinct
fluorescence signals for Cy3 and Cy5 (red contours), prov-
ing antibody at the cell surface and confirming the success-
ful delivery of chromatin (with somehow reduced efficiency
compared to unlabelled antibody). Finally, we checked the
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Figure 1. MNase digestion of antibody–chromatin complexes and antibody-complexation with plasmid-chromatin. (A) Agarose gel electrophoresis of
chromatin without (lane 1–3) and in presence of biotin-CPXM2∼ anti biotin 2+2 bsAb constructs (lane 4–6) after partial DNA hydrolysis byMNase with
increasing incubation time (20s, 80s and 270s); Chromatin without MNase treatment (lane 7) is shown as control. Mononucleosomal DNA bands (147bp)
indicate complete digestion in contrast to higher molecular weight bands. In presence of biotin-CPXM2 ∼ anti biotin 2+2 bsAb constructs, chromatin
is more nuclease resistant as the 147 bp DNA band only occurs at late time-points of Nuclease treatment in comparison to the chromatin only sample.
(B) Scheme of antibody–chromatin complexes with plasmid DNA reconstituted into nucleosomes and associated antibody-peptide constructs. Variable
regions against cell surface antigen (blue) faces outwards and anti biotin scFv (green) is bound at biotin-CPXM2 peptide (purple) associated at the DNA
backbone. (C) MST runs for Chromatin + biotin-CPXM2 ∼ anti biotin 2+2 bsAb interaction. Ligand concentration refers to biotin–CPXM2 peptide
(twice as much as the respective anti biotin 2+2 bsAb concentration). Exp 1 (blue) and Exp 2 (red) are independent experiments of the same construct with
the respective curve fit for KD determination.
Table 1. Affinity between chromatin and antibody or antibody-peptide constructs; Interaction between chromatin and antibody or antibody-peptide con-
structs was determined by MST. Affinity value for bio-CPXM2 ∼ anti biotin 2+2 bsAb refers to biotin-CPXM2 peptide concentration (2-fold higher than
antibody concentration as one antibody can bind two peptides); affinity values with respective SEM were determined by two independent measurements
Construct KD (nM) SEM (nM)
Chromatin + biotin-CPXM2 ∼ anti biotin TriFab 300.0 36.0
Chromatin + biotin-CPXM2 ∼ anti biotin 2+2 bsAb 73.1 3.4
Chromatin + anti biotin TriFab only no interaction n.a.
Chromatin + anti biotin 2+2 bsAb only no interaction n.a.
second specificity of our targeting antibody against biotin.
Therefore, we compared our targeted chromatin delivery
system comprising biotinylated–CPXM2peptidewith a tar-
geting systemwhere the biotinylated peptide was exchanged
against a peptide with the wrong hapten (digoxigenin in-
stead of biotin). Figure 2 C highlights that both complexes
(blue contours with biotin–CPXM2 peptide and green con-
tours with digoxigenin-CPXM2 peptide) generate a distinct
Cy3 fluorescent signal on MCF7 cells, whereas Cy5 signal
was only detected after treatment with biotin–CPXM2 pep-
tide comprising complexes. This clearly demonstrated that
despite the cell surface specificity, also the second specificity
against the hapten is necessary for chromatin and therefore
plasmid DNA delivery without unspecific interaction be-
tween antibody and peptide/chromatin.
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Figure 2. Flow cytometric determination of delivery specificity; Binding and uptake of antibody-Cy3 andDNA-Cy5 (before and after chromatin assembly)
was analysed by flow cytometry after incubation for 1 h. (A) Histogram of MCF7 cells after treatment with targeted (anti LeY; dotted red) and untargeted
(anti CD33; dotted blue)DNA-Cy5 complexes. Cy5 signal was detected only after treatmentwith the targetedDNA-Cy5 construct. (B)HistogramofMCF7
cells after treatment with targeted (red) and untargeted (blue) chromatin-Cy5 complexes. Results are comparable to results after DNA–Cy5 delivery. (C)
Contours plot ofMCF7Cy3 (x-axis) and Cy5 (y-axis) signals after treatment with various antibody chromatin complexes comprising Cy3 labelled antibody
and Cy5 labelled DNA. Cells were treated with complexes comprising antibody without specificity against cell surface antigen but against CPXM2 peptide
do neither show Cy3 nor Cy5 signals (blue). Cells treated with complexes comprising digoxigenin CPXM2 peptide (instead of biotin CPXM2 peptide)
display Cy3 signal but no Cy5 signal, demonstrating that antibody but not chromatin is present at the cell surface (green). Cells treated with complexes
comprising antibody with specificity against the cell surface and CPXM2 peptide display Cy3 signal and Cy5 signal, demonstrating that antibody as well
as chromatin is present at the cell surface (red).
Targeted chromatin efficiently mediates transgene expression
without cytotoxicity
After determination of delivery efficiency and specificity to
the target cells, we addressed the nuclear delivery efficacy
by quantifying GFP reporter gene expressing cells via flow
cytometry. With this assay we can also directly depict the
influence of chromatin assembly on intracellular plasmid
DNA delivery as on cell DNA delivery is equally efficient
with and without chromatin assembly. To address reporter
gene-expression, we have treated MCF7 cells with differ-
ent constructs for 48 h and subsequently identified GFP ex-
pressing cells via flow cytometry. The ratio of GFP positive
cells was determined by comparison with respective vehi-
cle or antibody only control. Incubation of MCF7 cells in
presence of DNA or chromatin did not generate cells ex-
pressing detectable levels of GFP, indicating no unspecific
nuclear uptake of plasmid DNA before and after chromatin
assembly (Figure 3A). Moreover, association of antibody-
peptide constructs did not generate GFP positive cells when
the antibody does not bind the cell surface as shown for anti
CD33–DNA as well as anti CD33–chromatin complexes
(confirming the data of Figure 2 were no unspecific uptake
of antibody-DNA and antibody–chromatin was detected).
Targeting of plasmid DNA by associated antibody–peptide
constructs generated single GFP positive cells (as observed
under the microscope) but not to a significant extent de-
spite efficient delivery to the cell surface as shown in Fig-
ure 2A. In contrast, antibody-peptide constructs targeting
chromatin raised the ratio of GFP positive cells from sin-
gle exceptions to the vast major population (>90% posi-
tive cells). Finally, Lipofection was used as a positive con-
trol, resulting in about 60% reporter gene expressing cells.
Next, we addressed the cytotoxicity of the different treat-
ments by LDH release relative to vehicle control and com-
plete cell lysis. Lipofection mediated cytotoxicity to a cer-
tain extent (∼15% to lysis control), usual for most trans-
fection reagents. None of the other treatments showed de-
tectable cytotoxic effects (Figure 3B).
Chromatin is specifically delivered to target cells by bispecific
antibodies followed by internalization into the vesicular sys-
tem
As the impact of chromatin assembly on functional plas-
mid DNA delivery was surprisingly high, we addressed in-
tracellular distribution of antibody and DNA after treat-
ment with different complexes by confocal microscopy. Fig-
ure 4A highlights the distribution of antibody-Cy3 (green)
and DNA-Cy5 (red) in living cells 4 h after treatment with
targeted (LeY–) chromatin, targeted (LeY–) DNA or un-
targeted (CD33-) chromatin. Antibody as well as DNAwas
present at the cell surface as well as the vesicular system af-
ter targeting of chromatin (top row of images) as well as
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Figure 3. Efficiency and cytotoxicity of gene delivery systems. (A) Delivery efficiency of EGFP expression plasmids was addressed by determination of
GFP positive cells via flow cytometry 48 h after treatment with targeting complexes being present throughout that time. Significant numbers of GFP
positive cells were achieved with Lipofection and anti LeY-chromatin complexes for MCF-7 cells. (B) Cytotoxicity was addressed by quantification of
LDH release. Significant LDH release after 48 h was only observed with lipofection. Cells were exposed to respective treatment for the whole incubation
period in normal (serum containing) cell culture medium. Mean values + SEM are shown (n = 3); P-values < 0.001 are indicated by three asterisks.
Figure 4. Confocal microscopy analysis of antibody mediated plasmid DNA or chromatin delivery and intracellular routing. (A) Live cell imaging of
MCF7 cells 4h after treatment with targeted (LeY) chromatin (top row), targeted (LeY) DNA (middle row) and untargeted (CD33) chromatin (bottom
row); Antibody-Cy3 signal is displayed in green and DNA-Cy5 level is displayed in red; Overlay of fluorescent images are shown in the ‘Merge’ column
and the right column shows respective transmission images. (B) Live cell imaging of MCF7 cells 3 days after treatment with targeted (LeY) chromatin
complexes comprising unlabelled antibody and Cy5 labelled DNA. Left panel shows GFP signal in green, middle panel DNA–Cy5 in cyan and right panel
transmission, respectively. (C) Imaging of fixed MCF7 cells 3 days after treatment with targeted (LeY) chromatin. Left panel displays DNA Cy5 signal in
pseudocolor, middle panel shows antibody signal generated by counterstaining with anti human IgG Cy3 antibody in red and the right panel represents
the transmission image. Cell surface, vesicular compartments and nuclear envelope are marked by yellow contours. Scale bars: 50 m.
DNA (middle row of images). Overlay of both fluorescence
signals indicates that most of antibody and DNA is co-
localized and not separated. These data clearly demonstrate
that targeted DNA gets delivered to the cell surface and in-
ternalized via the targeting antibody irrespective of assem-
bled into chromatin or not. Specificity of the targeting sys-
tem was confirmed by confocal microscopy of MCF7 cells
after incubation with the untargeted chromatin complex, as
neither antibody nor DNA was detected at the cell surface
as well as inside vesicles (bottom row of images). Figure
4B shows that chromatin targeting does not only result in
strong DNA accumulation at the cell surface and inside the
vesicular system (cyan) but also in GFP expression (green).
For imaging of GFP signal after 3days, unlabelled antibody
was used as labelling reduced chromatin delivery efficacy.
To image treated cells with higher resolution and in more
detail, cells were fixed and the antibody was subsequently
counterstained with anti-human IgG Cy3 antibody (Fig-
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Figure 5. Antibody-chromatin delivery with plasmid DNA encoding a CRISPR/Cas9 system. (A) Agarose gel electrophoresis of DPH1 gRNA/Cas9
plasmid DNA (lanes 1–3) and chromatin (lanes 4–6) after partial DNA hydrolysis by MNase with increasing incubation time (20s, 80s and 270s). (B)
Representative microscopic images of DT resistant MCF7 cell clones after treatment with vehicle (PBS control), targeted control plasmid chromatin (LeY-
Chromatin (eGFP)), non-targeted Cas9/DPH1 gRNAplasmid chromatin (CD33-Chromatin (Cas9/DPH1 gRNA)), targeted Cas9/DPH1 gRNAplasmid
chromatin (LeY-Chromatin (Cas9/DPH1 gRNA)); DT resistant colonies were only observed after treatment with targeted DPH1 gRNA/Cas9 plasmid
chromatin.
Table 2. Transfection efficiencies with Cas9/DPH1 gRNA expression plasmids based on DPH1 editing efficiencies in MCF7 cells; Calculated cell trans-
fection efficiencies (a) are based on determined Cas9/DPH1 gRNA mediated homozygous DPH1 knock-out (DPH1 k.o.) efficiencies (b) as previously
published (58). DT-resistant DPH1 k.o. cells (c) are indicated as ratio between counted DT resistant colonies and initially seeded cells. Data of first row
are derived from previous publication (58); data of second and third row are based on mean values of colony numbers obtained after respective treatments
as described in B (n = 3)
Treatment
a Transfection
efficiency (% of
seeded cells)
b DPH1 k.o.
efficiency of
Cas9/DPH1 gRNA
(% transfected cells)
c DT-resisitant DPH1
k.o. cells (% of seeded
cells)
Lipofection (Killian et al. SciRep 2017) 40% measured 6.3% calculated c/a 2.5% measured
Targeted (LeY) Cas9/gDPH1 chromatin 59% calculated c/b 6.3% same as above 3.7% measured
Non-targeted (CD33) Cas9/gDPH1 chromatin 0% calculated c/b 6.3% same as above 0% measured
ure 4C). Confocal microscopy of cells that received targeted
plasmid chromatin revealed strong above-background sig-
nals of the targeting antibodies on cell surfaces and vesic-
ular compartments but not in nuclei. Cy5-labeled plasmid
payload was found together with the antibody on cell sur-
faces and vesicular compartments but was also clearly de-
tectable in nuclei. These observations are in line with previ-
ous findings that (i) noncovalent hapten-coupled payloads
separate from targeting antibodies after internalization and
become routed independently from the antibody (64,65)
and (ii) that most antibodies bind to cells and internal-
ize in an effective manner but by themselves have very low
propensity to escape from vesicular compartments and en-
ter the cytoplasm or nucleus (66).
Targeted chromatin delivery enables specific and efficient
CRISPR/Cas9 mediated genome editing
Next, we addressed if chromatin delivery can be applied
with plasmid DNA of larger size and with more com-
plex function. Therefore we used a plasmid encoding
a CRISPR/Cas9 knock-out system against Diphthamide
synthesis gene 1 (DPH1) and performed the previously pub-
lished Diphtheria toxin (DT) based assay for quantifica-
tion of CRISPR/Cas9 mediated gene editing (58). This as-
say utilizes DT resistance mediated by homozygous DPH1
knock-out for identification of cell clones in which gene
editing by Cas9 was successful. As a result, only homozy-
gous DPH1 knock-out cells survive and display colony for-
mation after 2 weeks of continuous DT selection. First of
all, we transferred the chromatin assembly on the DPH1
gRNA Cas9 expression plasmid (Figure 5A). The deliv-
ery system was applied for of Cas9 DPH1 gRNA encod-
ing ‘plasmid chromatin’ in the same manner as for GFP en-
coding ‘plasmid chromatin’. After treatment of MCF7 cells
with targeted (LeY–) Cas9DPH1 gRNA encoding ‘plasmid
chromatin’, untargeted (CD33-) Cas9 DPH1 gRNA ‘plas-
mid chromatin’ and targeted (LeY–) GFP ‘plasmid chro-
matin’ and incubation for 3 days, cells were exposed to DT
for two weeks. Finally, cells were fixed and colonies were
counted under the microscope. Representative microscopic
images are shown in Figure 5B and the ratio of colony num-
ber and number of initially seeded cells are summarized in
Table 2 as percentage of DT resistant colonies and there-
fore percentage of clones with homozygous gene knock-out.
Targeted delivery of Cas9 DPH1 gRNA chromatin results
in almost 4% DT resistant clones whereas targeted delivery
of GFP control chromatin does not result in any resistant
colony, confirming that colony formation can only occur by
expression of theCRISPR/Cas9 editing system. In line with
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the specificity of the chromatin targeting system as shown
above for GFP, MCF7 treatment with untargeted (CD33–)
Cas9 DPH1 gRNA chromatin does also not result in for-
mation of DT resistant colonies. Compared to the absolute
CRISPR/Cas9 knock-out frequencies and colony numbers
from our previous experiments, the determined percentage
of DT resistant clones would equal to >60% of Cas9 ex-
pressing cells (Table 2).
DISCUSSION
The development of a targeted gene delivery system faces
multiple challenges as it must overcome several hurdles and
therefore needs well-balanced properties (67,68). For exam-
ple, a DNA delivery system must have affinity to the tar-
get cells to efficiently mediate the uptake of DNA but in
parallel must not interact with serum components or the
cell membrane of other cells and tissues to minimize loss of
DNA and avoid off-target effects along the delivery route
(34,69,70). Furthermore, DNA has to be translocated over
the membrane barrier to enter the cytosol and finally reach
the nucleus to enable transgene expression (71,72). As a
consequence, the required membrane interaction for DNA
translocation has to be efficient but at the same time gentle
enough to avoid cell cytotoxicity (70).
Our goal was to generate a highly flexible and modu-
lar gene delivery system to outline the influence of every
component along the gene delivery route. We made use of
the hapten-binding bsAb technology comprising antibody
derivatives that are able to simultaneously bind cell sur-
face antigens and to small molecule haptens like biotin or
digoxigenin via antibody-antigen interactions57. This tech-
nology enables delivery of diverse hapten bearing molecules
(payload) to the target cell surface and its broad applicabil-
ity including nucleic acid delivery has already been demon-
strated. The fact that hapten-binding bsAbs are available in
different formats covering various sizes, geometries and sto-
ichiometries (55,65,73,74) enhances their versatility asmod-
ules for targeted nucleic acid delivery. The non-covalent at-
tachment of payload to hapten-binding bsAbs enables sep-
aration of payloads from targeting vehicles inside vesicu-
lar compartments. The latter is important for delivery of
molecules with intracellular functionality such as nucleic
acids. For those, non-covalent hapten coupling is advan-
tageous compared to covalent conjugation strategies were
payload release frequently needs to be optimized for exam-
ple by introduction of cleavable linkers (64,65,75).
Functional plasmid DNA delivery can be observed in
about 90% of treated cells without cytotoxicity therefore
providing a mechanism for efficient but gentle DNA mem-
brane translocation. Such high efficacies are comparable to
viral gene delivery systems (24,76–80). However, the over-
all objective of our work was not only to achieve high ef-
ficacy, but also to combine that with targeting to specific
cells. Attaching targeting entities to delivery vehicles to se-
lectively address desired cell types is similar to that of next-
generation viral or virus-like particle (VLP)- based deliv-
ery systems. Entities that confer targeting specificity can
be added to VLPs by conjugating or fusing them to VLPs.
Such specificity-enhancing entities that support enrichment
on desired sites can be antibody-based or other protein do-
mains or peptide derivatives (81–83). True specificity, how-
ever, requires not only addition of specific binding entities,
but also reduction or elimination of non-targeted trans-
fection activity. Targeted plasmid-chromatin described here
fulfils targeting requirements and intracellular activity as
well as reduction of nonspecific uptake without applying
any virus-derived modules.
Hapten-binding bsAbs combined with the DNA bind-
ing CPXM2 peptide mediate efficient and specific delivery
of plasmid chromatin to and into cells. Thus, while other
delivery systems show target preference (84–87), this novel
approach has the potential to reach very high specificity.
Moreover, our data clearly show that the major component
facilitating DNA membrane translocation is the organiza-
tion of plasmid DNA into plasmid chromatin with natu-
rally occurring histones, as we can deliver plasmid DNA
with and without chromatin assembly to target cells with
comparable efficiency and specificity but only plasmid chro-
matin mediates high ratios of transgene expressing cells.
In contrast to previous observations, we could not observe
that histone assembly affects DNA uptake by unspecific
membrane binding and we could demonstrate that plasmid
chromatin facilitates membrane translocation and nuclear
DNA transport without further engineering of histone pro-
teins (42,53). As we could not observe major differences in
antibody mediated DNA or chromatin cell surface bind-
ing and internalization, DNA transduction at the cell sur-
face as well as a specific vesicular escape mechanism can-
not be excluded and might also not be the only mecha-
nism behind the improved nuclear translocation in line with
previous suggestions (41,42,53). Furthermore, DNA com-
paction and charge reduction may contribute to the facili-
tated DNAmembrane translocation and also the transition
from the cytoplasm into the nucleus might be altered by hi-
stones as previously suggested (88,53,89,90). Further stud-
ies like measuring the cytoplasmic to nuclear transition, as
performed for oligonucleotides for example, are necessary
to uncover the exact role of Histone assembly on plasmid
DNA and this modular system can contribute to its further
understanding (91).
Beside the fact of being non-toxic and highly specific,
the developed gene delivery system exclusively consists of
proteins and peptides of mammalian origin. Thus, the con-
cerns about safety and the risk of immunogenicity are ex-
pected to be rather low. However, one concern of systemic
application and exposure to the immune system is the chro-
matin itself. It was shown that plasmid DNA with bacterial
DNA sequences might be recognized by immune cells via
Toll like receptor interaction (89,92). But this hurdle might
be solved via plasmid DNA engineering like the production
of mini-circles or mini-vectors containing only a minor por-
tion of bacterial sequences (93). In addition, extracellularly
occurring histones are elevated in various autoimmune dis-
eases but are also considered in potentially mediating in-
flammatory diseases (94). On the other hand extracellular
chromatin release is an active mechanism of neutrophils to
bind bacteria and therefore serve as a trap for gram posi-
tive as well as gram negative bacteria (95). Furthermore, in
our system histones might not be completely exposed to the
immune system as they are shielded by the wrapped DNA
as well as the associated antibody to some extent. All in all,
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further studies have to be performed to investigate the po-
tential risk of systemic chromatin delivery.
In conclusion, we have developed a novel system to de-
liver plasmid DNAwith viral-like efficiency, high specificity
andwithout cytotoxicity exclusively bymammalian entities.
However, further studies are necessary for example to un-
derstand the exact mechanism of nuclear chromatin and in
particular the translocation mechanism over the membrane
barrier. Nevertheless, antibody mediated chromatin target-
ing is a novel approach for specific gene delivery with the
potential of being a viable alternative to existing targeted
gene delivery systems.
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ABSTRACT
Locked nucleic acid based antisense oligonu-
cleotides (LNA-ASOs) can reach their intracellular
RNA targets without delivery modules. Functional
cellular uptake involves vesicular accumulation fol-
lowed by translocation to the cytosol and nucleus.
However, it is yet unknown how many LNA-ASO
molecules need to be delivered to achieve target
knock down. Here we show by quantitative fluores-
cence imaging combined with LNA-ASO microinjec-
tion into the cytosol or unassisted uptake that ∼105
molecules produce >50% knock down of their tar-
gets, indicating that a substantial amount of LNA-
ASO escapes from endosomes. Microinjected LNA-
ASOs redistributed within minutes from the cytosol
to the nucleus and remained bound to nuclear com-
ponents. Together with the fact that RNA levels for
a given target are several orders of magnitude lower
than the amounts of LNA-ASO, our data indicate that
only a minor fraction is available for RNase H1 me-
diated reduction of target RNA. When non-specific
binding sites were blocked by co-administration of
non-related LNA-ASOs, the amount of target LNA-
ASO required was reduced by an order of magnitude.
Therefore, dynamic processes within the nucleus ap-
pear to influence the distribution and activity of LNA-
ASOs and may represent important parameters for
improving their efficacy and potency.
INTRODUCTION
Antisense technologies have experienced significant inter-
est in academia and industry both as research tools and
therapeutic agents. As drugs, oligonucleotide basedmodali-
ties have shown great promise because of their superior tar-
get selectivity and potency against otherwise undruggable
RNA targets. They can suppress gene expression, modu-
late mRNA splicing or target non-coding RNAs (ncRNAs)
involved in transcriptional and epigenetic regulation (1–5).
To reach their intracellular sites of action, oligonucleotides
need to overcome cellular membrane barriers such as the
plasma membrane and/or the limiting membrane of endo-
somes (6).Whereas their size and negative charges have long
prevented oligonucleotides from crossing lipid membranes
(7), introducing chemical modifications has significantly
improved their delivery to the cytosol and nucleus. Unas-
sisted uptake of nucleic acid therapeutics has been shown
for certain cell types (8,9). The term gymnosis (from greek
gymnos: naked) was coined for locked nucleic acid based an-
tisense oligonucleotides (LNA-ASOs) (10). It refers to an
in vitro culturing process where unformulated, not further
modified or conjugated ‘naked’ LNA-ASOs are taken up
with concomitant efficient cytoplasmic or nuclear activity.
Gymnosis alleviates the need for transfection reagents and
IC50 values are typically found in the micromolar to sub-
micromolar range (10–13).
LNA-ASOs are normally designed as short single
stranded 13- to 20-mers containing three structural units:
LNA nucleotides, DNA nucleotides and a fully phospho-
rothioated backbone (14–16). Besides their high resistance
to nucleases, they are characterized by their high bind-
ing affinity to RNA. Depending on the desired mechanism
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of action, different oligonucleotide designs have been de-
veloped (17,18). In most applications, LNAs are designed
as gapmers containing a central DNA nucleotide region
flanked at both ends by LNA nucleotides. When hybridized
to a complementary RNA target, the DNA/RNA het-
ero duplex will recruit RNase H1 that cleaves RNA (19).
The recruitment of RNase H1 and subsequent RNase H1-
mediated cleavage of the target RNA increase the degrada-
tion rate of the target RNA by 2- to 4-fold compared with
the intrinsic rate of cellular RNA degradation (20,21). The
internucleoside phosphorothioate is essential for antisense
activity and mediates resistance against nucleolytic degra-
dation. The lipophilic nature of phosphorothioates drives
protein binding, binding to cellular membranes and stimu-
lates cellular uptake.
The mechanisms by which LNA oligonucleotides are
functionally internalized in cells remain incompletely un-
derstood, however there is agreement that multiple en-
docytotic pathways can be exploited depending on cell
type, physiological state or applied LNA-ASO concen-
tration (22–25). The uptake route also appears to affect
the activity of internalized oligonucleotides. In primary
hepatocytes, functional uptake of unconjugated oligonu-
cleotides has been described to follow a caveolin- and
clathrin-independent pathway, which, however, requires the
clathrin adaptor AP2 (22), whereas conjugation to N-
acetyl galactosamine (GalNAc) triggers uptake via classi-
cal receptor-mediated endocytosis (26). Following internal-
ization, oligonucleotides traffic through early endosomes,
late endosomes and lysosomes with a large fraction being
trapped inside late endosomes or lysosomes (23). Appar-
ently, internalized LNA molecules are able to escape from
membrane-enclosed vesicles to some extent and reach the
cytosol and the nucleus to act on their targets. There is
evidence that endosomal release may occur from late en-
dosomes, possibly via membrane fusion processes or con-
formational changes of the oligonucleotides upon protein
binding (27,28).
The subcellular distribution of LNAoligonucleotides has
been studied by fluorescence microscopy which allows vi-
sualizing fluorescently labelled LNA oligonucleotides in-
side intact cells. However, due to limited sensitivity, only
sites with relatively high accumulation have been detected
(22,27–29). Upon unassisted cellular uptake, strong fluo-
rescence signals originating from vesicular structures inside
the cells have been observed, whereas functionally relevant
LNA-ASO located elsewhere in the cell might have been
missed (23).
While RNase H1 is present in mitochondria and in the
nucleus (30,31), it is generally assumed that RNase H1 me-
diated cleavage of mRNA predominantly takes place in the
nucleus (32). Delivery into the nucleus is thought to corre-
late with activity due to nuclear accumulation of fluores-
cently labelled oligonucleotides after transfection (33,34).
The notion of nuclear activity of LNA-ASO is further sup-
ported by the fact that antisense oligonucleotides have been
shown to efficiently target non-codingRNAs retained in the
nucleus (35). However, nuclear LNA-ASO signals have not
been detected after gymnotic delivery, which has led to the
conclusion that LNA oligonucleotides can efficiently knock
down their targets even at very low nuclear concentrations.
So far, quantitative information on the cellular distribution
of LNA-ASOs (including nuclear content) is not available
and the crucial question - how many LNA-ASO molecules
need to be present at their site of action - has yet remained
unanswered.
In the present study, we have applied quantitative and
highly sensitive fluorescence microscopy to measure intra-
cellular LNA-ASO concentrations down to the nanomo-
lar range. The goal of this work was to determine the ab-
solute number of LNA-ASO molecules required for func-
tional knock down of a target RNA. To this end, we deliv-
ered a defined amount of LNA-ASO directly into the cy-
tosol via microinjection, thereby circumventing the plasma
membrane and endosomal barriers and confirmed the re-
sults by gymnotic uptake experiments. The number of in-
jected LNA-ASO molecules was correlated with the degree
of functional knock down via quantitative image analysis at
the single cell level. In addition, the mobility and diffusion
coefficients of nuclear LNA-ASO were measured by fluo-
rescence recovery after photobleaching (FRAP) analysis.
In summary, our studies demonstrate that approximately
105 of the LNA-ASO molecules tested are required to effi-
ciently suppress gene expression of the selected target genes.
This was found irrespectively of the route of delivery ei-
ther by LNA-ASO microinjection into the cytosol or gym-
notic LNA-ASO uptake. Following microinjection, LNA-
ASOs rapidly translocated into the nucleus where a major
fraction appeared immobilized to nuclear components not
available for functional knock down. Upon gymnotic up-
take of LNA-ASOs via endocytosis a significant amount
of LNA-ASOs reached the cytosol/nucleus most likely by
endosomal escape. Therefore, improving targeted accumu-
lation at desired tissues/cells and dynamic processes within
the nucleus represent important parameters for extending
the therapeutic applications of LNA-ASOs.
MATERIALS AND METHODS
Oligonuncleotides and antibodies
MALAT1: GAGttacttgccaACT
MALAT1-AF488: GAGttacttgccaACT-AF488-3′
HIF1A: GCaagcatcctGT
FAM-HIF1A: 5′-FAMS1GCaagcatcctGT
AF647-HIF1A: 5′-AF647-GCaagcatcctGT
AF594-HIF1A: 5′-AF594-GCaagcatcctGT
Atto647N-HIF1A: 5′-Atto647N-GCaagcatcctGT
Unrelated: CcAAAtcttataataACtAC
The MALAT1 ASO sequence was previously published
(36), the HIF1A sequence was published in the patent
US20100249219A1, SEQ IDNO: 14. Single-stranded LNA
oligonucleotides were synthesized using standard phos-
phoramidite chemistry. Upper case denotes LNA, lower
case DNA. All sequences are full phosphorthioate. DNA
phosphoramidites and Atto647N N-hydroxy succinimidyl
(NHS) ester were purchased fromSigma-Aldrich (St. Louis,
MO), and LNA phosphoramidites were produced in house
(LNA phosphoramidites are also commercially available
fromQIAGEN [Hilden, Germany]). 5′-aminolinker C6 and
FAM phosphoramidite was purchased from Link Tech-
nologies (Bellshill, Scotland). 3′-aminolinker C6 CPG was
purchased from Chemgenes (Wilmington, MA, USA).
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Alexa Fluor (AF488, AF594 and AF647) N-hydroxy suc-
cinimidyl (NHS) esters were purchased from Fisher Scien-
tific (Slangerup, Denmark)
Unconjugated and amino linker oligonucleotides were
synthesized onNittoPhaseHLUnyLinker 350 support (Ki-
novate, Oceanside, CA, USA) on a MerMade 12 synthe-
sizer (Bioautomation, Irving TXmark) at 20 mol scale.
After synthesis, the oligonucleotides were cleaved from the
support using aqueous ammonia at 65◦C overnight. The
oligonucleotides were purified by ion exchange on SuperQ-
5PW gel (Tosoh Bioscience, Griesheim, Germany) and de-
salted using a Millipore membrane. After lyophilization,
the oligonucleotide was characterized by LC–MS (reverse
phase and electrospray ionization-mass spectrometry).
Alexa Fluor (AF488, AF594 and AF647) and Atto647N
labelled oligonucleotides were synthesized by conjuga-
tion of 4 equivalents of the corresponding Alexa Fluor
N-hydroxy succinimidyl (NHS) ester with a 5′- or 3′-
aminolinker oligonucleotide in 20 mM aqueous sodium
hydrogen carbonate. After 5–16 h, the reaction mixture
was applied directly to reversed-phase HPLC purification
(XBridge Peptide BEH C18 OBD Prep, 300A, 10 m, 10 ×
150 mm column and 0.1M ammonium acetate and acetoni-
trile as eluent). Pooled fractions were lyophilized and pre-
cipitated from 300mM sodium acetate and ethanol to ob-
tain the sodium salt. The oligonucleotide was characterized
by LC–MS.
Primary antibody: HIF1A (Clone 54, 610958, BD Bio-
science). Secondary antibody: anti-mouse-AF594 (115-585-
164, Jackson)
Cell culture
MCF-7 cells (NCI) were grown in Roswell Park Memo-
rial Institute (RPMI) medium supplemented with 10% fe-
tal calf serum (FCS) and 100U/ml penicillin and 100g/ml
streptomycin. The cell linewas verified as pathogen-free and
identity was verified by STR-PCR analysis before use. Cells
were subcultured every 2–3 days and incubated at 37◦C in a
humidified atmosphere containing 5% CO2.
Microinjection
Formicroinjection,MCF-7 cells were either seeded onto 35-
mm -dishes with glass bottom grid (-ibidi, Martinsried,
Germany) or 35-mmWillCo dishes (WillCoWells B.V., Am-
sterdam, Netherlands) containing glass coverslips with grid
(Celllocate, Eppendorf, Hamburg, Germany). Glass sur-
faces had been coated with 30 g/ml fibronectin in PBS for
1 h at 37◦C. Microinjection was performed using a Fem-
toJet Microinjector (Eppendorf, Hamburg, Germany) with
sterile Femtotips® I capillaries with a 0.5 m inner diame-
ter and 1 m outer diameter. Injected material was diluted
in injection buffer containing 48 mM K2HPO4; 4.5 mM
KH2PO4; 14 mM NaH2PO4; pH 7.2.The following injec-
tion parameters were applied: Injection pressure pi: 120 hP,
compensation pressure pc: 5 hP, injection time ti: 0.2 s.
Calibration of microinjection via photon counting imaging
In order to calibrate the number of molecules injected into
the cell, intracellular concentrations of tracer molecules
after microinjection were measured by photon counting
imaging. One day prior to the experiment 1 × 105 MCF-
7 cells were seeded into 35-mm -dishes with glass bot-
tom grid (ibidi, Martinsried, Germany) which had been
coated with 30 g/ml fibronectin. On the next day, cells
were injected with 10 kDa, anionic, fixable dextran-AF488
and dextran-AF647 (ThermoFisher) using the injection pa-
rameters described above. Injection buffer containing 5
M dextran-AF647 + 1 M/0.5 M/0.1 M dextran-
AF488 was centrifuged at 13 200 g for 3 min and son-
icated before injection. Concentrations of injection so-
lutions were confirmed by absorption measurements us-
ing a Nanodrop spectrophotometer based on the pub-
lished molar extinction coefficient (ε) for Alexa Fluor 488
(73 000 cm−1 M−1; www.aatbio.com/resources/extinction-
coefficient/Alexa Fluor 488). Conjugation to dextran did
not measurably affect the spectral properties of the Alex-
aFluor 488 dye as confirmed by excitation and emis-
sion spectra. For every experimental condition, 10 in-
jected cells were analyzed on a Leica SP5X confocal mi-
croscope directly after injection. Intracellular tracer con-
centrations were measured using hybrid detectors (HyD) in
photon countingmode. Imaging conditions were as follows:
63×/1.2 NA water immersion lens, white light laser exci-
tation at 488 and 647 nm, emission band pass at 495–550
and 656–758 nm, pinhole AU = 1.0, pixel size 72.9 nm and
8-bit resolution. For quantification, solutions with defined
concentrations of dextran-AF488 and dextran-AF647 were
measured and a calibration curve was established. For ev-
ery image pixel, photon counts were translated into abso-
lute concentrations of dextran-AF488 and dextran-AF647,
respectively. Image segmentation was carried out to identify
injected cells using an analysis pipeline built in CellProfiler.
Calibration of microinjection via fluorescence correlation
spectroscopy
In parallel to photon counting imaging, intracellular tracer
concentrations were measured using fluorescence correla-
tion spectroscopy (FCS) within the same cells. For FCS,
temporal intensity fluctuations within the confocal volume
were recorded and concentrations were calculated from the
amplitude of the autocorrelation of the time-resolved sig-
nal. FCS measurements were carried out on a Leica SP5X
confocal microscope equipped with external APD detectors
and TCSPC electronics (PicoHarp300, PicoQuant, Berlin)
at 37◦C. As excitation source, a pulsed white light laser with
a repetition rate of 80 MHz was used at emission wave-
lengths set to 488 and 633 nm.
The light was focused onto the sample via a 63×/1.2 NA
water immersion objective lens and the resulting fluores-
cence was collected through the same objective. Emission
light originating from AF488 and AF647 were divided via
a HC BS 560 beamsplitter (Semrock), separated from the
laser light by 535/70 ET bandpass and 685/70 ET bandpass
filters (both from Chroma), and focused onto an avalanche
photodiode detector (MPD micro photon devices, Pico-
Quant) operated in single photon counting mode. All mea-
surements and data analysis were performed using the Sym-
PhoTime software integrated into the FCS wizard of the
Leica LAS acquisition software. Guided by the FCS wiz-
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ards, the following acquisition steps were carried out: First,
the motorized correction collar was adjusted to correct for
the thickness of the glass surface of the chamber slide. The
excitation laser power was adjusted such that the dye was
not oversaturated which would lead to an overestimation of
the confocal volume. To performpointmeasurements inside
the injected cells, single cells were centered above the ob-
jective and imaged by scanning in the xz-dimension. Imag-
ing scans allowed positioning of the confocal volume at lo-
cations suitable for FCS measurements. Intensity fluctua-
tions within the confocal volume were recorded for 30 sec
on every spot and three spots were analyzed per cell. Auto-
correlation curves were calculated from the recorded time
traces and fit to a 2D-diffusive model with a triplet term as-
suming a triplet lifetime of 4 s (37). The average number
of molecules present in the confocal volume was obtained
from the fit and translated into concentrations by calibrat-
ing the confocal volume (38). Solutions of Atto488-NHS
and AF647-NHS were routinely used to calibrate the in-
strument prior to measurements. Knowing the diffusion co-
efficient of both dyes, the effective volume was determined
analytically from the FCS fit of the samples (400 and 330
m2/s, respectively (39).
Immunofluorescence and FISH
For detection of MALAT1 RNA fluorescence in situ hy-
bridization (FISH) was performed using Stellaris FISH
probes according to the manufacturer’s protocol (LGC
Biosearch, Steinach, Germany). In brief, treated cells were
fixed with 4% para-formaldehyde (PFA) for 20 min, washed
two times with PBS and incubated for at least 4 h in 70%
ethanol at 4◦C. Samples were stored in ethanol at 4◦C for up
to 1 week. After one washing step with the provided wash-
ing buffer A, samples were incubated over night at 37◦C in
a humidified chamber with hybridization buffer containing
12.5 nM Quasar®570-labelled probes (MALAT1: SMF-
2035-1, GAPDH: SMF-2026-1) and dimethylformamide.
Samples were then washed with washing buffer A for 30
min at 37◦C, and nuclei were stained with DAPI (5 ng/ml
in washing buffer A) for 30 min at 37◦C. Subsequently,
samples were washed for 5 min with washing buffer B and
mounted using Vectashield mounting medium (Vectorlabs,
Burlingame, CA, USA). Samples were allowed to dry for 1
h and imaged on the same day.
For detection of proteins by immunofluorescence, sam-
ples were prepared as described (40). In brief, PFA-fixed
samples were washed with PBS with increasing salt con-
centration and incubated for 30 min with goat serum dilu-
tion buffer (GSDB; 0.45MNaCl, 20 mMphosphate buffer,
0.3% Triton X-100, 17% goat serum) in order to perme-
abilize membranes and block nonspecific antibody binding
sites. Cells were next incubated for 1 h with primary anti-
bodies prepared in GSDB (HIF1A: 5 g/ml). Following
three washes with high-salt PBS, cells were incubated for 30
to 90 min with fluorescent secondary antibodies prepared
inGSDB (1:100). Cells were washed with PBSwith decreas-
ing salt concentration and nuclei were counterstained with
DAPI at 1 g/ml for 5 min before mounting the coverslips
onto glass slides using freshly prepared mounting solution
containing 70% glycerol in PBS.
Quantitative analysis of target gene knock down in single
cells
Single cell analysis of target knock down was carried out
on a Leica SP5X confocal microscope using a 40×/1.25NA
oil immersion objective lens. Injected cells were located with
the help of the Celllocate grid on the glass cover slide. Se-
quential scans were performed using white light laser ex-
citation at 405 nm, 488 nm, 561 nm or 594 nm. Fluores-
cence emission was detected at 415–480 nm (DAPI), 495–
530 nm (AF488), 550–560 nm (Quasar® 570) or 600–700
nm (AF594) using HyD detectors. Image format: 512× 512
pixel, image size: 193.75× 193.75 m2. Acquisition param-
eters were kept constant within the experiment to ensure
comparable signal levels. Images were segmented and nu-
clear mean fluorescence intensities (grey values) were cal-
culated using an automated image analysis pipeline im-
plemented in Cellprofiler. Nuclei were identified using the
DAPI channel, estimating a typical object diameter of 20–
150 pixel and discarding objects outside the diameter range.
Three-classes thresholding was performed using the Otsu
method minimizing the weighted variance. The middle in-
tensity class was assigned to background. According to
their shape, touching objects were automatically separated
using dividing lines. Nuclear mean intensities of tracer and
target signals were calculated as percentage of maximal in-
tensity (255 grey values). Target vs tracer intensity was visu-
alized on a scatter plot to manually define a tracer intensity
threshold for identification of injected cells. Statistical anal-
ysis was performed using GraphPad Prism (La Jolla, CA,
USA).
Live cell imaging of nuclear LNA-ASO accumulation
MCF-7 cells were grown in 35-mm -dishes with glass bot-
tom grid (-ibidi, Martinsried, Germany) to 50–70% con-
fluency and co-injected either with 5 M dextran-AF488
(10 kDa) + 5 M AF647-HIF1A LNA or 5 M dextran-
TMR (70kDa) + 5MAF488-MALAT1 LNA-ASO as de-
scribed above. Immediately after injection, cells were trans-
ferred to a Leica SP8X confocal microscope equipped with
a stage-top incubator to maintain temperature, CO2 and
humidity (Oko-touch, Okolab, Ottaviano, Italy). Acquisi-
tion of time series was started approximately two minutes
after injection using a 63×/1.2 NA water immersion objec-
tive lens and HyD detectors under adaptive focus control
with a frame interval of 10 s. For ATP depletion, cells were
transferred to starvation conditions over night (DMEM
with 1%FCS and 0.1% glucose, PANBiotech, Cat.No. P04-
03556). 45min prior to injection, cells were incubatedwith 6
mM deoxyglucose and 10 mM sodium azide in phenolred-
free medium and kept therein during injection and image
acquisition.
Staining of RNA via click-chemistry
Freshly synthesized RNA was labelled using the Click-iT™
RNAAlexa Fluor™ 594 ImagingKit (ThermoFisher) as de-
scribed by the manufacturer. In brief, MCF-7 cells were in-
cubated with 1 mM 5-ethynyl uridine (EU) for 1 h. After
fixation with 4% PFA for 20 min, cells were washed once
with PBS and permeabilized by incubating for 15 min with
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GSDB.Afterwashingwith PBS, cells were incubated 30min
at room temperature with the Click-iT™ reaction cocktail
containing CuSO4 and AF594-azide. Subsequently, cells
were washed twice with PBS before mounting the coverslips
onto glass slides using ProLong™Gold AntifadeMountant
(ThermoFisher).
Fluorescence recovery after photobleaching
In order to measure intracellular diffusion coefficients of
LNA, fluorescence recovery after photo bleaching (FRAP)
experiments were performed with microinjected cells. To
this end,MCF-7 cells were injectedwith 20MstockFAM-
LNA, incubated for 30 min at 37◦C and 5% CO2 and ana-
lyzed on Leica SP5X confocal microscope using a 63×/1.2
NA water immersion objective lens. FRAP experiments
were conducted using the in-built FRAP wizard. An Ar-
gon laser set to maximum intensity (emission: 488 nm) was
used to bleach the fluorophore within a circular region of
interest with 4 m diameter (1 frame, 97 ms) and the recov-
ery of the fluorescence intensity within the bleached area
was recorded over time (70 frames, 97 ms). Ten frames were
acquired before photobleaching for the region of interest
(ROI). The following imaging parameters were chosen for
fast acquisition of the recovery: Scan speed: 1400 Hz, bidi-
rectional scan, format: 256 × 256 pixel, image size: 30.75
× 30.75 m2, AOTF setting: 5%, emission detection range:
496–600 nm. Fluorescence intensities within the bleached
area (ROI1), an unbleached area within the nucleus (ROI2)
and background area (ROI3) were measured using the ROI
manager tool implemented in ImageJ (NIH, Bethesda,MD,
USA). Recovery curves were background subtracted, cor-
rected for photobleaching and normalized either to pre-
bleach intensities (for representation of immobile/mobile
fractions) or to postbleach intensity at infinity (for calcula-
tion of diffusion coefficients). In the latter case, normalized
recovery curves were fitted to an exponential model: F(t) =
a(1 – exp(1/ )) + c using the Matlab software environment
(Mathworks, MA, USA). Diffusion coefficients were calcu-
lated from the half-life of the recovery using the following
relationship: D = 0.88r2/4t1/2 with t1/2 =  ln(2).
FRAP measurements in solution were carried out in 8-
well chamber slides (Nunc™ Lab-Tek™, ThermoFisher) us-
ing 5 M solutions of FAM-HIF1A LNA-ASO at 20 m
distance from the glass surface. Acquisition parameters
were the same as for cellular measurements except that the
diameter of the bleached area was adjusted to 10 m to ac-
count for faster recovery kinetics.
Gymnotic cultures
MCF-7 cells (7500 cells/well) were seeded into 8-well cham-
ber slides (Nunc™ Lab-Tek™, ThermoFisher) and allowed
to adhere overnight. Cells were incubated with AF594-
HIF1A-LNA-ASO for 24 h/48 h/72 h and a heat map of
intracellular LNA-ASO concentrations was generated by
photon counting imaging of living cells. Therefore, cells
werewashed three timeswith PBS and imaged in phenolred-
free medium using a Leica SP5X confocal microscope
equipped with a humidified and temperature controlled
stage-top incubator (INU, Tokai hit, Fujinomiya, Japan).
Intracellular tracer concentrations were determined using
hybrid detectors (HyD) in photon counting mode. Imag-
ing conditions were as follows: 63×/1.2 NA water immer-
sion lens, white light laser excitation at 594 nm, emission
band pass at 600–700 nm, pinhole AU = 2.0, pixel size
300 nm, scan speed 400 lines/s and 12-bit resolution. 10–
15 image frames were accumulated to collect enough pho-
tons from dim cellular structures. This acquisition proce-
dure allowed displaying the whole dynamic range including
bright vesicular and dim nuclear signals. For quantification,
a dilution series of LNA-AF594 ranging from 0.1 to 1 M
were measured using the same imaging conditions to estab-
lish a calibration curve. Photon counts were then translated
into concentrations and displayed as pseudo colour inten-
sity heat map using a logarithmic colour bar such that dif-
ferences in the low concentration range could be visualized.
To quantify nuclear and vesicular concentrations, vesicles
were detected using an analysis pipeline built in CellPro-
filer whereas nuclei were identified manually using trans-
mission images such that signal contamination originating
from vesicular structures was prevented. The number of
vesicles/cell was determined from maximum projections of
3D volumes of 328 analyzed cells using the image analysis
pipeline implemented in CellProfiler for 2D images.
Knock down analysis-qPCR
Cells were seeded in 96-well plates at a density of 3500
cells/well and allowed to adhere overnight. LNA-ASO so-
lutions were diluted in phosphate buffered saline and added
to the cells at the indicated concentrations. After 72 h of
LNA-ASO exposure, medium was removed and gene ex-
pression levels were analyzed by RNA isolation and real-
time qPCR. Total RNA was isolated with the PureLink™
Pro 96 total RNA Purification Kit (Thermo Fisher Scien-
tific; Waltham, MA, USA) according to the manufacturer’s
protocol. Real-time PCRs were prepared as 10 l reac-
tions containing 10-fold diluted total RNA, qScript XLT 1-
Step RT-qPCRToughMix (Quantabio; Beverly,MA,USA)
and TaqMan gene expression assays (Assay ID HIF1A:
Hs00936368; Assay ID MALAT1: 00273907; Assay ID
GAPDH control: Hs99999905; Thermo Fisher Scientific;
Waltham, MA, USA). 1-Step RT-qPCR was performed in
386-well plates with a LightCycler 480 II (RocheMolecular
Systems; Pleasanton, CA). Target and reference gene ex-
pression were analyzed in the same reaction by multiplex
PCR with a FAM labelled probe for the target gene and
a VIC labelled probe for the reference gene. Relative gene
expression levels were determined by the standard curve
method. PCRs were performed in duplicates.
RESULTS
Quantification of the number of microinjected LNA-ASO
molecules required for gene knock down
To address the question how many LNA-ASO molecules
are required for effective gene knock down we followed first
a single-cell analysis approach, combining microinjection
of LNA-ASO with quantitative confocal fluorescence mi-
croscopy (Figure 1A). Microinjection enables the direct de-
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Figure 1. Delivery of LNA-ASOs by microinjection and single cell knock down analysis. The number of LNA-ASO molecules required for target knock
down was determined by delivering a defined amount of LNA-ASOs into the cytosol via microinjection and subsequent single cell knock down analysis
in injected cells (A). Calibration experiments were performed to determine the number of injected molecules. The fluorescence signal of a tracer molecule
was used to measure intracellular concentrations via fluorescence correlation spectroscopy (FCS) and photon counting imaging (B). Target knock down
was detected in injected cells on RNA and protein level by fluorescence in-situ hybridization and immunofluorescence, respectively. RNA and protein levels
were assessed by quantitative image analysis. Using an automated analysis pipeline, cell nuclei were first identified by image segmentation. Thereafter, mean
fluorescence intensities of tracer and target signals in the segmented cell nuclei were calculated. Injected cells were distinguished from non-injected cells
using the tracer signal (C).
livery of LNA-ASO molecules into the cytosol, thereby by-
passing the cellular membrane and uptake into endosomes
and avoiding transfection-based reagents that may compro-
mise membrane integrity.
Calibration. We calibrated the experimental setup by de-
livering a defined amount of LNA-ASO directly into the cy-
tosol via microinjection. We then analyzed the efficacy of
target knock down in the injected cells either on the RNA
or on the protein levels via quantitative fluorescence imag-
ing of single cells. The amount of LNA-ASO injected into
the cells cannot specifically be calculated, as the injection
volume depends on both, the applied injection pressure and
on time. To measure the actual injection volume, we deter-
mined the concentrations of labelled molecules inside liv-
ing cells by quantitative confocal imaging using HyD de-
tectors set to photon counting mode, which directly trans-
lates into the effectively delivered amount of substance (Fig-
ure 1B). Fluorescently labelled dextran molecules were mi-
croinjected into the cells at different concentrations ranging
from 100 nM to 5 M (Supplementary Figure S1). Intra-
cellular concentrations obtained from confocal imaging in
photon counting mode were validated by fluorescence cor-
relation spectroscopy (FCS), a technique that measures in-
tensity fluctuations within the focal volume depending on
the fluorophore concentration (Supplementary Figure S2)
(41). We were able to detect fluorescently labelled dextrans
at intracellular concentrations down to 1 nM correspond-
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ing to roughly 1/10 (0.079 ± 0.008, mean ± SD) of the
injected concentrations. For example, injection of a 1 M
stock solution resulted in an average intracellular concen-
tration of ∼100 nM (114 ± 36 nM, mean ± SD). Assuming
an average cellular volume of 2000 fl (42), the injected vol-
ume was roughly 200 fl containing∼105 (1.37± 0.43× 105,
mean± SD)molecules. These data verified that quantitative
confocal fluorescence microscopy at the single cell level al-
lows determining the total number of injected fluorescent
molecules.
Knock down analysis at RNA level. Having successfully
calibrated the conditions for microinjection, we determined
the efficiency of target RNA knock down following deliv-
ery of a defined amount of LNA-ASO into the cells. Long
non-coding MALAT1 RNA was used as a model as this
RNA is retained within the nucleus (43). Knock down of
RNA within injected cells was detected by fluorescence in
situ hybridization using a mixture of fluorescently labelled
MALAT1 probes designed to specifically hybridize to com-
plementary regions of the MALAT1 RNA sequence (Sup-
plementary Figure S3). We verified that the presence of
LNA-ASO did not interfere with the target hybridization of
the probe (Supplementary Figure S4). To analyze the time
course of target RNA suppression, MALAT1 RNA levels
were determined at different time points after co-injection
of defined concentrations of unlabelled MALAT1 LNA-
ASO and a fluorescent tracer (Supplementary Figure S5).
Already 2 h post-injection the MALAT1 RNA signal was
clearly reduced in the injected cells. Knock down of the tar-
get RNA persisted to 24 h, the latest observed time point.
Based on these data we decided to analyze knock down ef-
ficiencies 4 h post-injection in all subsequent experiments.
To determine the number of LNA-ASO molecules re-
quired for efficient suppression of MALAT1 RNA, the
LNA-ASO injection concentrationwas adjusted from1M
to 10 nM (Figure 2). The MALAT1 RNA signal was virtu-
ally eliminated in all cells injected with a 1 M LNA-ASO
solution (corresponding to ∼105 intracellular LNA-ASO
molecules). In contrast, MALAT1 RNA signals remained
detectable in cells injected with lower LNA-ASO concentra-
tions and in all non-injected cells (Figure 2A). To determine
the efficacy of knock down quantitatively, we injected a
large number of cells and performed automated image anal-
ysis to measure RNA levels in injected vs non-injected cells
(Figure 1C): Using the DAPI channel, cell nuclei were iden-
tified via image segmentation. Subsequently, nuclear mean
fluorescence intensities of the tracer and the target RNA
signals were determined. Injected cells were distinguished
from non-injected cells by defining a threshold based on
the intensity of the tracer. Statistical analysis revealed that
RNA levels were significantly reduced by more than 50%
in cells treated with an average number of ∼105 LNA-ASO
molecules (Figure 2B). An average amount of ∼104 LNA-
ASO molecules resulted in a minor reduction of MALAT1
RNA levels, whereas ∼103 LNA-ASO molecules did not
yield any measurable knock down. Microinjection of non-
targeting LNA-ASO into the cytoplasm had no effect on
target RNA levels (Figure 3). In a competition experiment
in which the target LNA-ASOwas co-injected together with
an excess of unrelated LNA-ASO, the presence of unre-
lated non-targeting LNA-ASO significantly decreased the
number of target LNA oligonucleotides required for knock
down to 104 molecules (Figure 3).
Knock down analysis at protein level. Proteins are, on aver-
age, about 2,800 times more abundant and five times more
stable than their corresponding transcripts (44). The time
course of protein knock down is more complex as it is de-
termined as a function of transcription and translation rate
and protein half-life. Depending on those parameters, de-
pletion of target proteins is usually detected at much later
time points compared to RNA (10,45). To determine the
number of LNA-ASOmolecules required for protein knock
down we analyzed the levels of the short-lived transcription
factor HIF1A. While HIF1A mRNA is constitutively ex-
pressed and transcribed, HIF1A protein exhibits a half-life
of less than 5 min in the presence of oxygen (46), but is sta-
bilized under conditions of hypoxia. Indeed, treatment of
cells with 100 M deferoxamine, simulating hypoxic condi-
tions, resulted in bright nuclear HIF1A protein staining af-
ter 48 h incubation (Figure 4A). Deferoxamine-treated cells
were co-injected with 1 M or 0.1 M unlabelled LNA-
ASO targeting HIF1A and 10 M of dextran-AF488 as
a fluorescent tracer. Injection of 1 M LNA-ASO led to
a substantial reduction of HIF1A immunoreactivity, while
injection of 0.1 M LNA-ASO was insufficient (Figure
4A+B). Statistical analysis of several hundred injected cells
confirmed that ∼105 LNA-ASO molecules were required
to induce functional HIF1A protein knock down (Figure
4B+C). This effect was specific for HIF1A as the RNA lev-
els of the house-keeping geneGAPDHwere unaltered in in-
jected cells (Supplementary Figure S6). These results show
that similarly high numbers of LNA-ASOmolecules (∼105)
are required for efficient knockdown of target RNA and
protein.
Nuclear accumulation and limited diffusion of LNA-ASO
within the nucleus
Rapid nuclear accumulation of microinjected LNA. Having
found that a high number of ∼105 LNA-ASO molecules
needed to be injected into the cytosol for efficient target
knock down, we applied fluorescence microscopy to vi-
sualize how the bulk of injected LNA-ASO became dis-
tributed inside cells following microinjection (Figure 5A).
To exclude the possibility that the integrity of the nuclear
membrane was affected by microinjection, we co-injected
a high molecular weight TMR-labelled dextran (70 kDa)
into the cytosol, which cannot diffuse freely through nu-
clear pores. Directly after injection, both LNA-ASO and
dextran were detected in the cytosol. While the high molec-
ular weight dextran did not passage through the nuclear
membrane, the smaller LNA-ASO was rapidly distributed
throughout the whole cell. Within less than five minutes, we
observed a strong accumulation of LNA-ASO inside the nu-
cleus. Similar data were obtained for another LNA-ASO
compound carrying a different fluorophore (Supplemen-
tary Figure S7). Depletion of the intracellular ATP pool
by treatment with 6 mM deoxyglucose and 10 mM sodium
azide did not significantly affect nuclear translocation of
LNA-ASO (Figure 5B), indicating that the nuclear accumu-
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Figure 2. MALAT1 RNA knock down in microinjected cells. MCF-7 cells were microinjected with a solution of 10 M dextran-AF488 as tracer + 1000
nM/100 nM/10 nM unlabelledMALAT1 LNA-ASOs. Cells were incubated for 4 h, and fixed with 4% PFA.MALAT1RNAwas detected via fluorescence
in situ hybridization. Fluorescence microscopy revealed knock down of MALAT1 RNA in injected cells at high LNA-ASO concentrations. White arrows
indicate injected cells. Scale bars: 50 m (A). The cellular fluorescence signal originating from MALAT1 RNA staining was quantified. Injected and
non-injected cells were distinguished by defining a threshold of the tracer signal (B). Intracellular concentrations of LNA-ASOs after microinjection were
estimated from calibration experiments. Mean values ± standard error of the mean (SEM) of cellular MALAT1 RNA levels are depicted. 20 000–200 000
LNA-ASO molecules need to be injected into the cells to observe significant knock down of MALAT1 RNA. Statistical significance was assessed with a
two-way ANOVA and Tukey posttest. The degree of significance is ****P < 0.0001.
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Figure 3. Competition experiment using unrelated LNA-ASOs. MCF-7 cells were microinjected with a solution of 10 M dextran-AF488 as tracer +
target LNA-ASOs (MALAT1) + unrelated LNA-ASOs at the indicated concentrations. After microinjection, cells were incubated for 4 h, and fixed with
4% PFA. MALAT1 RNA was detected via fluorescence in situ hybridization. White arrows indicate injected cells. Scale bars: 50 m (A). Knock down
of target RNA was assessed by quantitative image analysis. Scatter plot representation of relative MALAT1 RNA levels versus relative tracer signals (B).
Mean values ± standard error of the mean (SEM) of cellular MALAT1 RNA levels are depicted (C).
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Figure 4. HIF1A protein knock down inmicroinjected cell. MCF-7 cells were microinjected with a solution of 10Mdextran-AF488 as tracer + 1/0.1M
unlabelled HIF1A LNA-ASOs. Cells were incubated with 100Mdeferoxamine for 48 h, and fixed with 4% PFA. HIF1A protein was detected via HIF1A-
antibody immunocytochemistry. Fluorescencemicroscopy revealed knock downofHIF1Aprotein in injected cells at highLNA-ASOconcentrations.White
arrows indicate injected cells. Scale bars: 50 m (A). Knock down analysis in injected cells was performed using quantitative image analysis. The cellular
fluorescence signal originating fromHIF1A protein staining was quantified. Injected cells were distinguished from non-injected cells using the tracer signal
(B).Mean values± standard error of themean (SEM) of cellular HIF1A protein levels in injected and non-injected cells are depicted. Statistical significance
was assessed with a two-way ANOVA and Tukey posttest. The degree of significance is ****P < 0.0001 (C).
lation did not require active transport. Given that oligonu-
cleotides are small enough to pass through nuclear pore
complexes, LNA-ASO s can rapidly translocate into the
nucleus via passive diffusion, which leads to an even cel-
lular distribution, but does not explain nuclear accumula-
tion. Consistently, a freely diffusible tracer (small molec-
ular weight dextran at 10 kDa) co-injected together with
LNA-ASO, was found evenly distributed throughout the
cell with no visible nuclear accumulation (Supplementary
Figure S7). The finding that LNA-ASOs rapidly accumu-
lated inside the nucleus following passive diffusion indicates
that they must be retained inside the nucleus by binding
to nuclear components, according to the diffuse and bind
model (47).
Fluorescence recovery after photobleaching. As a result
of binding to nuclear components, nuclear LNA-ASO
may exhibit limited diffusion. To investigate whether LNA
oligonucleotides can diffuse freely or are bound or com-
partmentalized inside the nucleus we analyzed LNA-ASO
mobility within the nucleus via fluorescence recovery af-
ter photobleaching (FRAP) (48). Fluorescent LNA-ASO
molecules were delivered to the cytoplasm via microinjec-
tion and cells were incubated for 20 min to allow for com-
plete nuclear accumulation of the LNA-ASO. A circular re-
gion within the nucleus with 4 m diameter size was photo-
bleached using a high intensity laser pulse and the recovery
of the fluorescence signal in the bleached area was recorded
over time (Figure 6A). Analysis of the recovery curve pro-
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Figure 5. Rapid nuclear accumulation of LNA-ASOs after microinjection. MCF-7 cells were co-injected with 5 MTMR-dextran (70 kDa) as tracer + 5
MMALAT1 LNA-AF488 (LNA-ASO-AF488). Directly after injection confocal time lapse imaging was started. LNA rapidly accumulates in the nucleus
whereas the tracer remains in the cytosol. Scale bar: 20 m (A). To assess the influence of active transport on nuclear accumulation, cellular ATP pools
were depleted before injection. Cells were kept under starvation conditions over night and incubated with 6 mM deoxyglucose and 10 mM sodium azide
for 45 min prior to injection. Scale bar: 20 m (B).
vides information about the apparent diffusion rate of the
labelled molecule. As the nuclear architecture is character-
ized by different compartments, obtained diffusion rates
represent an average value originating from different mi-
croenvironments. We observed that LNA oligonucleotides
accumulated within nuclear foci and were absent in nucle-
oli. These sites of ribosomal RNA synthesis accounting for
80% of cellular RNA were visualized by incubation with
5-ethynyl uridine (EU) which is incorporated into freshly
synthesized RNA (Figure 6C). Therefore, nucleoli were ex-
cluded from the analysis. The effective diffusion coefficient
of labelled LNA-ASO molecules inside the nucleus was de-
termined from the half-time of the recovery curve as 0.7 ±
0.2 m2/s (mean ± SD) (Figure 6B). The fluorescence sig-
nal did not completely recover to pre-bleached levels indi-
cating a fraction of approximately 29% immobilemolecules.
In contrast, complete recovery was observed in aqueous so-
lution where the free diffusion of LNA-ASO is character-
ized by a diffusion coefficient of 107 ± 10 m2/s (mean
± SD) which is by two orders of magnitude higher com-
pared to the nuclear environment (Figure 6D). The dramat-
ically restricted nuclear diffusion of LNA-ASO even when
injected as large excess is a strong indication for substantial
binding to macromolecular complexes and consistent with
its stable accumulation within the nucleus.
Knock down of LNA-ASO delivered by gymnosis
Our microinjection studies showed LNA-ASO numbers in
the range of 105 molecules need to be delivered into the cy-
tosol to achieve knock down of the target genes. However,
as biomedical applications of LNA-ASO cannot rely onmi-
croinjection techniques, we assessed the amount of LNA-
ASO reaching the nucleus following gymnotic delivery, i.e.
uptake of single-stranded oligonucleotides by living cells
without the use of any transfection reagents (10). MCF-7
cells were incubated in cell culturemedium containing 5M
fluorescently labelled LNA-ASO for 24, 48 and 72 h. At
this extracellular concentration, HIF1A RNA levels were
decreased by 50% as determined by qPCR (Supplementary
Figure S8). Comparing unlabelled and labelled LNA-ASO
side by side, we did not observe any difference in potency, in-
dicating that the fluorescent label does not interfere with up-
take, routing and mechanism of knock down (Supplemen-
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Figure 6. Restricted diffusion of LNA-ASOs inside the nucleus. Fluorescence recovery after photobleaching (FRAP) experiments were performed in
microinjected cells using FAM-HIF1A-LNA-ASOs. MCF-7 cells were injected with a solution of 20 M FAM-LNA-ASOs and incubated for 30 min.
Diffusion of the labelled oligonucleotides was assessed by photobleaching a defined region of interest and monitoring the recovery of fluorescence signal
within the photobleached area. Scale bars: 10m (A). The time trace of fluorescence intensity within the photobleached area was recorded, normalized and
fit to an exponential model (see Material and Methods). Mean diffusion coefficient ± SD was calculated from the half-life time of fluorescence recovery.
Three independent experiments were performed and 30 cells were analyzed in total (B). Nucleoli were identified via incubation with 1 mM EU for 1 h,
which is incorporated into freshly synthesized RNA. EU-treated cells were injected with a solution of 5 M LNA-ATTO647N (LNA-ASO-ATTO647).
Cells were fixed 20 min after injection and incorporated EU was detected via Click-reaction with AF594-N3. Scale bar: 5 m (C). Diffusion of FAM-
HIF1A-LNA-ASOs was assessed in aqueous solution performing FRAP experiments under similar conditions as in the nuclear environment. To account
for faster recovery kinetics, the radius of the bleached area was increased (D).
tary Figure S8). As fixation of cells has been observed to in-
duce artificial nuclear localization (49), we analyzed living
cells by confocal imaging in photon countingmode allowing
the generation of quantitative false-colour heat maps of in-
tracellular LNA-ASO concentrations. As expected, the ma-
jority of intracellular LNA-ASOwas contained in the endo-
lysosomal compartment (Figure 7A). Using image segmen-
tation and calibration of grey values, we calculated the av-
erage vesicular concentrations as 11.3 ± 4.5, 13.3 ± 5.8 and
19.8 ± 4.7 MLNA-ASO after 24, 48 and 72 h incubation,
respectively (mean± SD) (Figure 7B). From image segmen-
tation, we determined an average vesicular volume of 1.014
± 0.018 fl (mean± SEM, n: 5061 vesicles). Therefore, a sin-
gle vesicle contains about 12 000 LNA-ASOmolecules after
72 h incubation. With 52 ± 9 vesicles (mean ± SD) per cell
(as determined from maximum projections of 3D images),
we estimate the number of LNA-ASO molecules within the
endosomal compartment to approximately 620,000/cell.
In addition to the bright vesicular signal, the logarithmi-
cally colour-coded heat map revealed low amounts of nu-
clear LNA. By manually selecting nuclear regions of in-
terests free of vesicular signals we determined the nuclear
LNA-ASO concentrations as 171 ± 68, 206 ± 82 and 296
± 111 nM after 24, 48 and 72 h, respectively (mean ± SD)
(Figure 7C). Assuming a nuclear volume of 1180 fl (50),
this corresponds to a total number of 210 000 ± 80 000
(mean ± SD) LNA-ASO molecules in the nucleus, in good
agreement with the number of molecules (∼105) required
for functional knock down determined by microinjection
experiments.
DISCUSSION
In this study, we determined the absolute number of LNA-
ASOmolecules required for knock downof two target genes
detected either at RNA or protein level. Intracellular LNA-
ASO levels were quantified by fluorescence microscopy,
comparing gymnotic uptake with direct cytosolic delivery
via microinjection. In parallel, we followed the subcellular
distribution of fluorescently labelled LNA-ASOs and mea-
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Figure 7. Detection of nuclear LNA-ASOs after gymnotic delivery. MCF-7 cells were incubated with 5 MHIF1A LNA-AF594 (LNA-AF594 oligonu-
cleotides) for 72 h. Live cell imaging was carried out on a confocal microscope set to photon counting mode. Using a standard curve, photons counts were
translated into concentrations and presented as false-color heat map. A logarithmic color scale was applied to visualize differences in the low concentration
range. Scale bar: 40m (A). Vesicular LNA-ASO concentrations were calculated using automated image segmentation (B). Nuclei were identifiedmanually
using transmission images. LNA-ASO concentrations were measured from average gray values in nuclear areas free of signal contamination originating
from vesicles (C). Bars represent mean values ± SD. Quantitative analysis of three independent experiments.
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sured themobility/diffusion constant of LNA-ASOswithin
the nucleus of living cells.
The amount of LNA required for knock down is substantially
higher than cellular RNA levels
Given the many variables determining LNA-ASO potency
in vitro, microinjection of LNA oligonucleotides into the
cells allowed us to focus on their activity at the subcellu-
lar site of action, leaving out variables such as stability and
protein binding in medium, and more importantly uptake
into cells via endocytosis and endosomal escape (51). De-
livery of a defined amount of unlabelled LNA-ASOs into
the cytosol and subsequent single cell knock down analysis
revealed that ∼105 LNA-ASO molecules are required for
efficient target knock down. The absolute number of LNA-
ASO molecules was established both at RNA and protein
level using the noncoding RNA MALAT1 and the nuclear
protein HIF1A as model targets.
Calculations on LNA-ASO molecules required for tar-
get gene suppression have been based on copy numbers of
RNA substrates, cellular RNaseH1 levels and cleavage rate
of the enzyme. Compared to relatively high cellular levels
of RNaseH1 (1,000 copies/cell) and a fast processing rate
of 7.1 cleavages/sec per RNase H1 molecule (51,52), the
amounts of catalytically active LNA-ASOs determined here
for efficient target knock downwere higher thanwhatwould
be expected from these numbers. The median copy num-
ber of a typical mRNA is 17 mRNAs per cell with a tran-
scription rate of 2 mRNAs/h and a median half-life of 9 h
(44). In this regard, the non-coding RNA used in this study,
MALAT1, is relatively abundant with a copy number of
2,500 RNAs per cell (43). For the second target, HIF1A, we
found comparablemRNA copy numbers inMCF-7 cells (as
determined by qPCR) consistent with high protein turnover
enabling fast adaption to changing oxygen conditions. Ef-
ficient down regulation of comparably abundant targets by
RNA interference was reported by applying <2000 siRNA
molecules per cell using lipid nanoparticle transfer (42,53).
Surprisingly, the number of LNA-ASO molecules required
for knock down is more than an order of magnitude higher
than the copy number of both investigated target RNAs,
indicating that only a small fraction might be available for
RNase H1 mediated RNA knock down.
A large fraction of LNA-ASO is bound to nuclear compo-
nents and might not be available for RNase H1 mediated tar-
get degradation
Investigating the underlying mechanism, we followed the
distribution of fluorescently labelled LNA-ASOs inside liv-
ing cells followingmicroinjection.While considerable atten-
tion has been given to the endosomal trafficking of anti-
sense oligonucleotides, little has been known about LNA-
ASO trafficking to and especially within the nucleus (28,29).
Our investigations on LNA-ASO trafficking after deliv-
ery by microinjection revealed that LNA oligonucleotides
rapidly redistributed from the cytosol to the nucleus, sug-
gesting that nuclear transport is not a bottleneck for sub-
cellular LNA-ASO delivery. This observation is consistent
with earlier reports on nuclear accumulation of microin-
jected single stranded oligonucleotides which has been ob-
served bothwith fluorescently tagged andBrdUrd-modified
oligomers, whose nuclear distribution was monitored by
indirect immunofluorescence with BrdUrd-specific anti-
bodies (54,55). In these studies, fluorescence microscopy
data showed that the bulk of single-stranded antisense-
oligonucleotides injected into the cytosol almost quanti-
tatively accumulated inside the nucleus. However, small
amounts of cytosolic LNA-ASOs might be missed due to
the detection limit (∼1000 molecules). Cytosolic antisense
effects through steric blocking or trapping of LNA-ASOs
by binding to cytosolic proteins should be considered when
low numbers of oligonucleotides are delivered to the cy-
tosol, i.e. after endosomal escape. The question how an-
tisense oligonucleotides are translocated and enriched in-
side the nucleus is still under debate. For oligonucleotides
modified with a phosphorothioate backbone, rapid nuclear
accumulation has been attributed to active nucleocytoplas-
mic shuttling whereas data obtained from phosphodiester
oligonucleotides argue for passive transport by diffusion
(54,56,57). Following depletion of the intracellular ATP
pool before microinjection, we found that LNA-ASO trans-
port to the nucleus was energy independent and mediated
by diffusion through the nuclear pore complexes, either in a
free formor bound to protein complexes.We cannot exclude
that active nuclear transport might play a role in the nat-
ural situation after unassisted endocytic uptake. However,
the observation of nuclear LNA-ASO accumulation after
microinjection together with passive nuclear transport via
diffusion clearly indicates that LNA oligonucleotides must
be retained inside the nucleus by binding to nuclear compo-
nents.
FRAP experiments in the nucleus of living cells revealed
that the diffusion of LNA-ASO is highly constrained, in-
dicating binding to less mobile macromolecular structures.
This is in contrast to diffusion measurements reported by
Politz et al. (48) using fluorescein-labelled oligo(dA) and
(dT) (43-mers) for which a significant fraction of freely dif-
fusing oligomers showed nuclear diffusion rates similar to
thosemeasured in aqueous solution. Although intracellular
‘fluid-phase’ viscosity, defined as the microviscosity sensed
by a small probe in the absence of molecular interactions,
is only 1.2–1.4 times greater than the viscosity of water
(58), translational diffusion of macromolecules on a larger
scale is hindered bymolecular crowding. Unreactive macro-
molecules such as dextrans show nuclear diffusion rates 3-
to 5-fold slower than in water while binding to immobile ob-
stacles further constrains themobility of nuclear solvents by
orders of magnitude (59–61). Thus, our finding that nuclear
LNA-ASO diffusion rates are by two orders of magnitude
reduced clearly indicates binding to immobile nuclear com-
ponents.
The high number of LNA-ASO molecules required for
knock down together with the strong binding to nuclear
components suggests that a large fraction of LNA oligonu-
cleotides might be sequestered and therefore not be avail-
able for RNase H1-mediated target knock down. This no-
tion is further supported by our competition experiments
with unrelated LNA.We found that co-injection of excess of
unrelated LNA-ASO increased the potency of the oligonu-
cleotides, presumably by saturating non-target RNA bind-
Nucleic Acids Research, 2019, Vol. 47, No. 2 967
ing sites. This is in line with competition experiments in
vivo: co-administration of ‘nonsense’ oligonucleotides sig-
nificantly improved target mRNA knockdown in liver sug-
gesting that the ‘nonsense’ oligonucleotides compete for up-
take into an apparent negative or non-productive sink (62).
Our results indicate that binding to nuclear components
might represent at least part of this sink and that the ac-
tivity of antisense oligonucleotides is influenced by com-
petition between RNA target and nuclear protein binding.
Indeed, a number of nuclear and cytosolic proteins have
been identified which can interact with the duplex formed
between LNA-ASO and target RNA and compete with
RNase H1 for binding (23,63,64). While interaction with
nucleic-acid binding proteins has been found for all phos-
phorothioated oligonucleotides, chemical modifications at
the 2′ position of the ribose ring seem to strongly influ-
ence binding to proteins (23). LNA oligonucleotides have
a strong tendency to bind Hsp90 which is reported to en-
hance their activity (65). As a possiblemode of action, chap-
erone proteins might modulate antisense activity by melt-
ing potential intramolecular structures or simply by pre-
venting binding to inhibitory proteins. Additionally, inter-
action with nuclear or cytosolic proteins can enhance or
reduce the activity of antisense oligonucleotides by influ-
encing their subcellular localization. Indeed, we observed
the formation of LNA-ASO nuclear foci upon microinjec-
tion. Interaction with the paraspeckle protein P54nrb was
reported to negatively affect antisense activity of oligonu-
cleotides via formation of paraspeckle-like structures (66).
In contrast, interaction with TCP1 in distinct nuclear struc-
tures of 0.15–2.0 m in diameter, termed phosphorothioate
bodies (PS-bodies), was related to increased knock down
activity (67). Given that interaction with different cellular
components seems to strongly influence LNA-ASO activ-
ity in both ways, screening for beneficial binding properties
will make a valuable contribution to increase the potency of
therapeutic LNA oligonucleotides.
Following gymnotic uptake, a substantial amount of LNA-
ASO can escape from endosomes and reach the nucleus
In a last set of experiments, we compared our results
from microinjection experiments with gymnotic delivery of
LNA-ASO and assessed the amount of LNA-ASO reaching
the nucleus. Quantification of nuclear LNA-ASO levels in
living cells was achieved for the first time by applying high
sensitivity fluorescence imaging. Since the fluorescence la-
belling had no effect on LNA-ASO potency, we expect that
our findings are transferable to unlabelled oligonucleotides.
This assumption is supported by the fact that the number
of labelled LNA-ASO molecules delivered to the nucleus
via free uptake is in good in line with the copy number re-
quired for knock down as determined by microinjection ex-
periments using unlabelled LNA.
When applying low micromolar extracellular LNA-ASO
concentrations, copy numbers in the range of 105 LNA-
ASOmolecules were detected in the nucleus. We found that
approximately a quarter of total cellular LNA-ASO can be
found in the nucleus, indicating that endosomal escape is
not a rare event for LNA-ASO. This is of significance for
therapeutic applications since endosomal escape rates for
siRNA and other antisense oligonucleotides have been esti-
mated to 0.01%, thereby representing the major bottleneck
for antisense oligonucleotide delivery (6).Having found that
the presence of high LNA-ASO copy numbers in the nu-
cleus is required for knock down activity, efficient endo-
somal escape and nuclear accumulation remain a critical
factor determining the potency of LNA oligonucleotides.
In addition, dynamic processes within the nucleus seem
to have a strong influence on LNA-ASO activity and re-
quire further investigations in order to increase the potency
of LNA oligonucleotides for therapeutic applications. This
could mean that a loading dose may be applied first, fol-
lowed by maintenance doses. In this situation, the first dose
might partially saturate unspecific binding sites.
Another major aspect for improving LNA-ASO delivery
includes strategies for efficient internalization into the endo-
somal compartment, given that endosomal LNA-ASO con-
centrations were found moderately enhanced by a factor of
4 compared to the extracellular space following gymnotic
uptake as shown in this study. Delivery approaches that tar-
get cell surface receptors, such as GalNAc- or antibody-
conjugation, provide more efficient internalization kinet-
ics, i.e. stronger endosomal enrichment of LNA oligonu-
cleotides in shorter time (6,26). In conclusion, our data pro-
vide a functional and quantitative basis for the development
of new strategies to efficiently deliver LNA oligonucleotides
to their desired cellular and subcellular target sites.
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